


**CUMULATIVE  
SUPPLEMENT 9  
September 2024**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

2024

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**Cumulative Supplement 9  
September 2024**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 9  
September 2024**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ACI HEALTHCARE LTD (ACI)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
AKORN OPERATING CO LLC (AKORN)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
EXTROVIS AG (EXTROVIS)	RISING PHARMA HOLDINGS INC (RISING)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC	NORVIUM BIOSCIENCE LLC

(MYLAN PHARMS INC)	(NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
SAPTALIS PHARMACEUTICALS LLC (SAPTALIS PHARMS)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
STERISCIENCE PTE LTD (STERISCIENCE)	STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

---

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.



Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with

approval for marketing by a firm under a particular generic or trade name.

### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

#### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 (12.1%)	23058 (12.2%)	23182 (11.9%)	23346 (11.7%)	
MULTISOURCE	20315 (87.9%)	20256 (87.8%)	20419 (88.1%)	20605 (88.3%)	
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)	20332 (87.7%)	20522 (87.9%)	
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)	87 (0.4%)	83 (0.4%)	
EXCEPTIONS <sup>4</sup>	46 (0.2%)	46 (0.2%)	47 (0.2%)	47 (0.2%)	
NEW MOLECULAR ENTITIES APPROVED	32	18	14	19	
NUMBER OF APPLICANTS	1214	1219	1214	1191	

### 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

	TABLET;ORAL								
	ABACAVIR SULFATE AND LAMIVUDINE								
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
	TABLET, FOR SUSPENSION;ORAL								
	ABACAVIR SULFATE AND LAMIVUDINE								
	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan	DISC	
	+	@ NORVIUM BIOSCIENCE	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Aug	CAHN	

ABIRATERONE ACETATE

	TABLET;ORAL								
	ABIRATERONE ACETATE								
AB		MSN	500MG	A210686	002	Apr 24, 2024	Apr	NEWA	

ACAMPROSATE CALCIUM

	TABLET, DELAYED RELEASE;ORAL								
	ACAMPROSATE CALCIUM								
		@ GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Aug	DISC	
AB	!	ZYDUS PHARMS	333MG	A205995	001	May 26, 2017	Aug	CHRS	

ACARBOSE

	TABLET;ORAL								
	ACARBOSE								
>A>	AB	SOMERSET THERAPS LLC	25MG	A091343	001	Oct 17, 2013	Sep	CAHN	
>A>	AB		50MG	A091343	002	Oct 17, 2013	Sep	CAHN	
>A>	AB		100MG	A091343	003	Oct 17, 2013	Sep	CAHN	
>D>	AB	VIRTUS PHARM	25MG	A091343	001	Oct 17, 2013	Sep	CAHN	
>D>	AB		50MG	A091343	002	Oct 17, 2013	Sep	CAHN	
>D>	AB		100MG	A091343	003	Oct 17, 2013	Sep	CAHN	

ACETAMINOPHEN; BUTALBITAL

	TABLET;ORAL								
	BUTALBITAL AND ACETAMINOPHEN								
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

	CAPSULE;ORAL								
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE								
		@ KEY THERAP	300MG;50MG;40MG	A206615	001	Aug 04, 2017	May	DISC	
AA			300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr	CAHN	
AA		QUAGEN	300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
AA			325MG;50MG;40MG	A216376	001	Mar 12, 2024	Mar	NEWA	
AA		SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
AA			325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
	TABLET;ORAL								
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE								
AA		QUAGEN	325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

	CAPSULE;ORAL								
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE								
		@ NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May	DISC	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

	CAPSULE;ORAL								
	TREZIX								
		@ KEY THERAP	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	May	DISC	
			320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Apr	CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

	SOLUTION;ORAL								
	ACETAMINOPHEN AND CODEINE PHOSPHATE								
>D>		@ ACI	120MG/5ML;12MG/5ML	A086366	001		Sep	CAHN	
		@ AKORN	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
		@ PAI HOLDINGS	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	May	CAHN	
>A>		@ STRIDES PHARMA	120MG/5ML;12MG/5ML	A086366	001		Sep	CAHN	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	!	SPECGX LLC	300MG;60MG	A 040419	003	May 31, 2001	Apr	CHRS
AA		STRIDES PHARMA	300MG;15MG	A 089990	001	Sep 30, 1988	Apr	CMFD
AA			300MG;30MG	A 089805	001	Sep 30, 1988	Apr	CMFD
AA			300MG;60MG	A 089828	001	Sep 30, 1988	Apr	CMFD
	@	SUN PHARM INDS LTD	300MG;30MG	A 085868	001		Jan	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	AMNEAL PHARMS	300MG;10MG	A 207137	001	Nov 29, 2016	Jul	DISC
	@	AMNEAL PHARMS NY	300MG;5MG	A 206869	001	Jun 23, 2017	Jul	DISC
>D>	@	CEROVENE INC	325MG;5MG	A 211690	001	Feb 07, 2020	Sep	CAHN
>D>	@		325MG;7.5MG	A 211690	002	Feb 07, 2020	Sep	CAHN
>D>	@		325MG;10MG	A 211690	003	Feb 07, 2020	Sep	CAHN
	@	ELITE LABS INC	325MG;2.5MG	A 209924	001	Nov 16, 2018	Jun	CAHN
	@		325MG;5MG	A 209924	002	Nov 16, 2018	Jun	CAHN
	@		325MG;7.5MG	A 209924	003	Nov 16, 2018	Jun	CAHN
	@		325MG;10MG	A 209924	004	Nov 16, 2018	Jun	CAHN
	@	ENDO OPERATIONS	300MG;5MG	A 090415	001	Jan 24, 2011	May	CAHN
	@		300MG;7.5MG	A 090415	002	Jan 24, 2011	May	CAHN
	@		300MG;10MG	A 090415	003	Jan 24, 2011	May	CAHN
AA		GRANULES	325MG;5MG	A 211729	001	Jan 03, 2020	Jul	CMFD
AA			325MG;7.5MG	A 211729	002	Jan 03, 2020	Jul	CMFD
AA			325MG;10MG	A 211729	003	Jan 03, 2020	Jul	CMFD
	@	PRINSTON INC	325MG;5MG	A 214928	001	Dec 30, 2021	Mar	DISC
	@		325MG;7.5MG	A 214928	002	Dec 30, 2021	Mar	DISC
	@		325MG;10MG	A 214928	003	Dec 30, 2021	Mar	DISC
>A>	@	SANALUZ	325MG;5MG	A 211690	001	Feb 07, 2020	Sep	CAHN
>A>	@		325MG;7.5MG	A 211690	002	Feb 07, 2020	Sep	CAHN
>A>	@		325MG;10MG	A 211690	003	Feb 07, 2020	Sep	CAHN

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

COMBOGESIC

>D>	+	@	AFT PHARMS LTD	325MG;97.5MG	N 209471	001	Mar 01, 2023	Sep	CMFD
>A>	+	!		325MG;97.5MG	N 209471	001	Mar 01, 2023	Sep	CMFD
>A>	+	!	AFT PHARMS US	325MG;97.5MG	N 209471	001	Mar 01, 2023	Sep	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

	@	ENDO OPERATIONS	325MG/5ML;5MG/5ML	A 203573	001	Dec 18, 2014	May	CAHN
--	---	-----------------	-------------------	----------	-----	--------------	-----	------

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	@	CEROVENE INC	325MG;5MG	A 207574	001	Dec 13, 2016	Sep	CAHN
AA		ELITE LABS INC	325MG;5MG	A 209385	001	Jul 02, 2018	Aug	CMFD
	@		325MG;5MG	A 209385	001	Jul 02, 2018	Jun	CAHN
AA			325MG;7.5MG	A 209385	002	Jul 02, 2018	Aug	CMFD
	@		325MG;7.5MG	A 209385	002	Jul 02, 2018	Jun	CAHN
AA			325MG;10MG	A 209385	003	Jul 02, 2018	Aug	CMFD
	@		325MG;10MG	A 209385	003	Jul 02, 2018	Jun	CAHN
	@	ENDO OPERATIONS	325MG;2.5MG	A 090733	001	Jul 11, 2013	May	CAHN
	@		325MG;5MG	A 040105	001	Jul 30, 1996	May	CAHN
	@		325MG;7.5MG	A 090734	001	Jul 11, 2013	May	CAHN
	@		325MG;10MG	A 090734	002	Jul 11, 2013	May	CAHN
AA		GRANULES	325MG;2.5MG	A 211708	001	Oct 31, 2019	Jul	CMFD
AA			325MG;5MG	A 211708	002	Oct 31, 2019	Jul	CMFD
AA			325MG;7.5MG	A 211708	003	Oct 31, 2019	Jul	CMFD
AA			325MG;10MG	A 211708	004	Oct 31, 2019	Jul	CMFD
>A>	@	SANALUZ	325MG;5MG	A 207574	001	Dec 13, 2016	Sep	CAHN
		PERCOCET						
AA	!	ENDO OPERATIONS	325MG;2.5MG	A 040330	001	Jun 25, 1999	Apr	CAHN
AA	!		325MG;5MG	A 040330	002	Jun 25, 1999	Apr	CAHN
	+	@	325MG;5MG	A 085106	002		May	CAHN
AA	!		325MG;7.5MG	A 040330	003	Nov 23, 2001	Apr	CAHN
AA	!		325MG;10MG	A 040330	004	Nov 23, 2001	Apr	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@ SUN PHARM INDS INC 325MG; 37.5MG A077184 001 Dec 16, 2005 Aug DISC

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

@ AJANTA PHARMA LTD 125MG A211151 001 Sep 11, 2023 Feb DISC  
 @ 250MG A211151 002 Sep 11, 2023 Feb DISC  
 AB EPIC PHARMA LLC 125MG A218023 001 May 14, 2024 May NEWA  
 AB 250MG A218023 002 May 14, 2024 May NEWA  
 BX EYWA PHARMA 125MG A211556 001 Oct 18, 2019 Jun CTEC  
 BX 250MG A211556 002 Oct 18, 2019 Jun CTEC  
 BX HIBROW HLTHCARE 125MG A211556 001 Oct 18, 2019 Jul CAHN  
 BX 250MG A211556 002 Oct 18, 2019 Jul CAHN  
 @ TORRENT 125MG A213706 001 Jan 26, 2024 Jan DISC  
 AB 125MG A213706 001 Jan 26, 2024 Jan NEWA  
 @ 250MG A213706 002 Jan 26, 2024 Jan DISC  
 AB 250MG A213706 002 Jan 26, 2024 Jan NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

@ ENDO OPERATIONS EQ 500MG BASE/VIAL A205358 001 Jun 20, 2017 May CAHN

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

VOSOL

+ @ HIKMA 2% N012179 001 Apr CRLD  
 @ 2% N012179 001 Apr DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

>D> AP ASPEN 6GM/30ML (200MG/ML) A213693 001 Feb 03, 2022 Sep CAHN  
 >A> AP GLENMARK PHARMS INC 6GM/30ML (200MG/ML) A213693 001 Feb 03, 2022 Sep CAHN  
 AP SOMERSET THERAPS LLC 6GM/30ML (200MG/ML) A218397 001 Jun 07, 2024 May NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

@ EXELA PHARMA 20% A205643 001 Nov 01, 2023 Feb DISC

ACETYLCYSTEINE LYSINE

FOR SOLUTION; ORAL

LEGUBETI

+ @ GALEPHAR EQ 500MG BASE/PACKET N215040 001 Feb 13, 2024 Jun DISC  
 +! EQ 500MG BASE/PACKET N215040 001 Feb 13, 2024 Feb NEWA  
 + @ EQ 2.5GM BASE/PACKET N215040 002 Feb 13, 2024 Jun DISC  
 +! EQ 2.5GM BASE/PACKET N215040 002 Feb 13, 2024 Feb NEWA

ACITRETIN

CAPSULE; ORAL

ACITRETIN

AB ALEMBIC 10MG A217774 001 Aug 05, 2024 Jul NEWA  
 AB 17.5MG A217774 002 Aug 05, 2024 Jul NEWA  
 AB 25MG A217774 003 Aug 05, 2024 Jul NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ @ ENDO OPERATIONS 8MG; 60MG N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>A> AB ADAPTIS 200MG A075090 001 Jan 26, 1999 Sep CAHN  
 >D> AB INDOCO 200MG A075090 001 Jan 26, 1999 Sep CAHN

CREAM; TOPICAL

ACYCLOVIR

AB TARO 5% A205470 001 Jun 12, 2024 Jul CAHN  
 AB 5% A205470 001 Jun 12, 2024 May NEWA

	OINTMENT; TOPICAL							
	ACYCLOVIR							
	@ COSETTE	5%		A205591	001	Nov 13, 2017	Mar	DISC
	SUSPENSION; ORAL							
	ACYCLOVIR							
	@ HIKMA	200MG/5ML		A077026	001	Jun 07, 2005	Mar	DISC
	@ VISTAPHARM LLC	200MG/5ML		A213951	001	Jan 11, 2021	Mar	CAHN
	<u>ACYCLOVIR SODIUM</u>							
	INJECTABLE; INJECTION							
	ACYCLOVIR SODIUM							
AP	DDREG PHARMA	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	Jun	NEWA
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	Jul	CAHN
>D>	AP	HAINAN POLY	EQ 50MG BASE/ML	A218111	001	Jan 08, 2024	Sep	CAHN
	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL		A203927	001	Mar 29, 2017	Jun	CAHN
	@	EQ 1GM BASE/VIAL		A203927	002	Mar 29, 2017	Jun	CAHN
>A>	AP	SLATE RUN PHARMA	EQ 50MG BASE/ML	A218111	001	Jan 08, 2024	Sep	CAHN
	<u>ADAGRASIB</u>							
	TABLET; ORAL							
	KRAZATI							
>A>	+!	BRISTOL	200MG	N216340	001	Dec 12, 2022	Sep	CAHN
>D>	+!	MIRATI THERAPS	200MG	N216340	001	Dec 12, 2022	Sep	CAHN
	<u>ADAPALENE</u>							
	LOTION; TOPICAL							
	DIFFERIN							
	+ @	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	May	DISC
	<u>ADEFOVIR DIPIVOXIL</u>							
	TABLET; ORAL							
	ADEFOVIR DIPIVOXIL							
AB	!	SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Jun	CHRS
		HEPSERA						
	+ @	GILEAD	10MG	N021449	001	Sep 20, 2002	Jun	DISC
	<u>ADENOSINE</u>							
	SOLUTION; INTRAVENOUS							
	ADENOSINE							
	@	HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb	DISC
	@		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb	DISC
	<u>ALBENDAZOLE</u>							
	TABLET; ORAL							
	ALBENDAZOLE							
AB		ALEMBIC	200MG	A215652	001	Sep 04, 2024	Aug	NEWA
>D>	AB	STRIDES PHARMA	200MG	A210011	001	Dec 07, 2018	Sep	DISC
>A>	@		200MG	A210011	001	Dec 07, 2018	Sep	DISC
	<u>ALBUTEROL SULFATE</u>							
	AEROSOL, METERED; INHALATION							
	ALBUTEROL SULFATE							
AB2		ARMSTRONG PHARMS	EQ 0.09MG BASE/INH	A212447	001	May 21, 2024	May	NEWA
	POWDER, METERED; INHALATION							
	PROAIR DIGIHALER							
	+ @	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jun	DISC
	SOLUTION; INHALATION							
	ACCUNEB							
	+ @	NORVIUM BIOSCIENCE	EQ 0.021% BASE	N020949	002	Apr 30, 2001	Jul	CAHN
	+ @		EQ 0.042% BASE	N020949	001	Apr 30, 2001	Jul	CAHN
	ALBUTEROL SULFATE							
AN		LEXENPHARM	EQ 0.021% BASE	A215571	001	May 03, 2024	Apr	NEWA
AN			EQ 0.042% BASE	A215571	002	May 03, 2024	Apr	NEWA
AN		LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Jun	CMFD
AN			EQ 0.042% BASE	A211888	002	Apr 20, 2020	Jun	CMFD
	@	NORVIUM BIOSCIENCE	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jun	CAHN
	@	WATSON LABS	EQ 0.021% BASE	A077772	001	Sep 25, 2007	Jun	DISC
	@		EQ 0.042% BASE	A077772	002	Sep 25, 2007	Jun	DISC
	SYRUP; ORAL							
	ALBUTEROL SULFATE							
	@	HIKMA	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998	Mar	DISC



<u>TABLET;ORAL</u>							
ALBUTEROL SULFATE							
BX	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jun	CTEC
BX		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jun	CTEC
>D>	@ EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020	Sep	CAHN
>D>	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Sep	CAHN
>A>	@ HIBROW HLTHCARE	EQ 2MG BASE	A213524	001	Oct 08, 2020	Sep	CAHN
>A>	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Sep	CAHN
<u>ALBUTEROL SULFATE; BUDESONIDE</u>							
AEROSOL, METERED; INHALATION							
AIRSUPRA							
+!	ASTRAZENECA	EQ 0.09MG BASE/INH;0.08MG/INH	N214070	001	Jan 10, 2023	Jan	CPOT
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
SOLUTION; INHALATION							
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
>A>	@ AIPING PHARM INC	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Sep	CAHN
>D>	@ FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Sep	CAHN
	DUONEB						
+ @	NORVIUM BIOSCIENCE	EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	Jul	CAHN
<u>ALCOHOL</u>							
SOLUTION; INTRA-ARTERIAL							
ABLYSINOL							
+ @	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jun	DISC
<u>ALENDRONATE SODIUM</u>							
TABLET;ORAL							
ALENDRONATE SODIUM							
AB	IPCA LABS LTD	EQ 10MG BASE	A206387	001	Jun 04, 2024	May	NEWA
AB		EQ 35MG BASE	A206387	002	Jun 04, 2024	May	NEWA
AB		EQ 40MG BASE	A206387	003	Jun 04, 2024	May	NEWA
AB		EQ 70MG BASE	A206387	004	Jun 04, 2024	May	NEWA
<u>ALFUZOSIN HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
ALFUZOSIN HYDROCHLORIDE							
@	NORVIUM BIOSCIENCE	10MG	A079014	001	Jul 18, 2011	Jun	CAHN
<u>ALISKIREN HEMIFUMARATE</u>							
TABLET;ORAL							
ALISKIREN HEMIFUMARATE							
AB	ENDO OPERATIONS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Apr	CAHN
AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Apr	CAHN
<u>ALLOPURINOL</u>							
TABLET;ORAL							
ALLOPURINOL							
AB	ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr	CAHN
AB		300MG	A075798	002	Jun 27, 2003	Apr	CAHN
AB	HARMAN FINOCHEM	200MG	A214443	003	Jun 17, 2024	Jun	NFTG
	@ LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr	DISC
	@	300MG	A211807	002	Dec 14, 2023	Apr	DISC
	ZYLOPRIM						
AB	+ CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Jun	CFTG
<u>ALOSETRON HYDROCHLORIDE</u>							
TABLET;ORAL							
ALOSETRON HYDROCHLORIDE							
	@ ENDO OPERATIONS	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	May	CAHN
	@	EQ 1MG BASE	A206113	002	Feb 23, 2018	May	CAHN
>A>	@ EYWA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN
>A>	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN
>D>	@ EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN
>D>	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN
>A>	@ HIBROW HLTHCARE	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN
>A>	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN

ALPELISIBGRANULES;ORAL  
VIJOICE

+! NOVARTIS 50MG/PACKET N218466 001 Apr 24, 2024 Apr NEWA

ALPRAZOLAMTABLET;ORAL  
ALPRAZOLAM

AB	CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
AB		0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
AB		1MG	A207507	003	Jul 09, 2018	Mar	CAHN
AB		2MG	A207507	004	Jul 09, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
@		1MG	A078469	002	Sep 29, 2011	Mar	DISC
@		2MG	A078469	003	Sep 29, 2011	Mar	DISC
@		3MG	A078469	004	Sep 29, 2011	Mar	DISC
@	ENDO OPERATIONS	0.5MG	A078442	001	Oct 15, 2007	May	CAHN
@		0.5MG	A078469	001	Sep 29, 2011	May	CAHN
@		1MG	A078442	002	Oct 15, 2007	May	CAHN
@		1MG	A078469	002	Sep 29, 2011	May	CAHN
@		2MG	A078442	003	Oct 15, 2007	May	CAHN
@		2MG	A078469	003	Sep 29, 2011	May	CAHN
@		3MG	A078442	004	Oct 15, 2007	May	CAHN
@		3MG	A078469	004	Sep 29, 2011	May	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB	ENDO OPERATIONS	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
AB		0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
AB	!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
AB		2MG	A078088	004	Jan 09, 2009	Apr	CAHN

ALPROSTADILINJECTABLE;INJECTION  
EDEX

@	ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
	+!	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
	+!	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP	+!	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
	+!	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

SUPPOSITORY;URETHRAL

MUSE

+	@	MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996	Jun	DISC
+	@		0.5MG	N020700	003	Nov 19, 1996	Jun	DISC
+	@		1MG	N020700	004	Nov 19, 1996	Jun	DISC

AMANTADINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
AMANTADINE HYDROCHLORIDE

AB	ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	Aug	NFTG	
	GOCOVRI							
AB	+	SUPERNUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	NFTG
	+		EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	CAHN
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@	CHARTWELL RX	50MG/5ML	A076352	001	Sep 10, 2004	Aug	CAHN
@	ENDO OPERATIONS	50MG/5ML	A077992	001	Dec 12, 2006	May	CAHN
@	GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Jan	CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

>A>	@	ADAPTIS	100MG	A212407	001	May 27, 2022	Sep	CAHN
>D>	@	EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022	Sep	CAHN
>A>	AB	ZHEJIANG JUTAI PHARM	100MG	A218598	001	Sep 26, 2024	Sep	NEWA

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

+	@	ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
+	@		EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL  
OSMOLEX ER

+ @	SUPERLUS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug	CAHN
+ @		EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug	CAHN
+ @		EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug	CAHN
+ @		EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug	CAHN

AMBRISENTAN

TABLET;ORAL  
AMBRISENTAN

@	ENDO OPERATIONS	5MG	A209509	001	Apr 10, 2019	May	CAHN
@		10MG	A209509	002	Apr 10, 2019	May	CAHN
@	PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Apr	DISC
@		10MG	A209509	002	Apr 10, 2019	Apr	DISC

AMCINONIDE

LOTION;TOPICAL  
AMCINONIDE

!	GENUS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN
---	-------	------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL  
AMCINONIDE

AB	!	GENUS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN
----	---	-------	------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE;INJECTION  
AMIKACIN SULFATE

AP		QILU	EQ 250MG BASE/ML	A218146	001	Mar 19, 2024	Mar	NEWA
----	--	------	------------------	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET;ORAL  
AMILORIDE HYDROCHLORIDE

AB	!	ENDO OPERATIONS	5MG	A070346	001	Jan 22, 1986	Apr	CAHN
----	---	-----------------	-----	---------	-----	--------------	-----	------

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION  
CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	8%;14GM/100ML	N020734	019	Apr 13, 2021	Apr	NEWA
--	-----------------	---------------	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SOLUTION;ORAL  
AMICAR

+ @	HIKMA	0.25GM/ML	N015230	002		Mar	DISC
-----	-------	-----------	---------	-----	--	-----	------

AMINOCAPROIC ACID

>A>	AA	MSN	0.25GM/ML	A215100	001	Sep 26, 2024	Sep	NEWA	
>A>	AA	!	TRUPHARMA	0.25GM/ML	A212494	001	Aug 11, 2020	Sep	CAHN
>D>	AA	!	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Sep	CAHN
	AA	!		0.25GM/ML	A212494	001	Aug 11, 2020	Mar	CHRS
		@	VISTAPHARM LLC	0.25GM/ML	A212814	001	Feb 26, 2020	Mar	CAHN

TABLET;ORAL  
AMICAR

+ @	HIKMA	500MG	N015197	001		Mar	DISC
+ @		1GM	N015197	002	Jun 24, 2004	Mar	DISC

AMINOCAPROIC ACID

>A>		@	ADAPTIS	500MG	A212110	001	Jun 14, 2021	Sep	CAHN
>A>	AB		APPCO	500MG	A213944	001	Sep 14, 2022	Sep	CAHN
>A>	AB			1GM	A213944	002	Sep 14, 2022	Sep	CAHN
>D>		@	EDENBRIDGE PHARMS	500MG	A212110	001	Jun 14, 2021	Sep	CAHN
>D>	AB		OPTIMUS	500MG	A213944	001	Sep 14, 2022	Sep	CAHN
>D>	AB			1GM	A213944	002	Sep 14, 2022	Sep	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION  
AMIODARONE HYDROCHLORIDE

	@	HOSPIRA	50MG/ML	A203884	001	Nov 25, 2013	May	DISC
AP		ZHEJIANG POLY PHARM	50MG/ML	A218253	001	Sep 11, 2024	Aug	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	AIPING PHARM INC	10MG	A212654	002	Sep 29, 2021	May	CMFD
AB		25MG	A212654	001	Apr 07, 2020	May	CMFD
AB		50MG	A212654	003	Sep 29, 2021	May	CMFD
AB		75MG	A212654	004	Sep 29, 2021	May	CMFD
AB		100MG	A212654	005	Sep 29, 2021	May	CMFD
AB		150MG	A212654	006	Sep 29, 2021	May	CMFD
>A>	BRECKENRIDGE	10MG	A216243	001	Jun 06, 2022	Sep	CAHN
>A>		25MG	A216243	002	Jun 06, 2022	Sep	CAHN
>A>		50MG	A216243	003	Jun 06, 2022	Sep	CAHN
>A>		75MG	A216243	004	Jun 06, 2022	Sep	CAHN
>A>		100MG	A216243	005	Jun 06, 2022	Sep	CAHN
>A>		150MG	A216243	006	Jun 06, 2022	Sep	CAHN
>D>	CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	Sep	CAHN
		10MG	A216243	001	Jun 06, 2022	Aug	CAHN
>D>		25MG	A216243	002	Jun 06, 2022	Sep	CAHN
		25MG	A216243	002	Jun 06, 2022	Aug	CAHN
>D>		50MG	A216243	003	Jun 06, 2022	Sep	CAHN
		50MG	A216243	003	Jun 06, 2022	Aug	CAHN
>D>		75MG	A216243	004	Jun 06, 2022	Sep	CAHN
		75MG	A216243	004	Jun 06, 2022	Aug	CAHN
>D>		100MG	A216243	005	Jun 06, 2022	Sep	CAHN
		100MG	A216243	005	Jun 06, 2022	Aug	CAHN
>D>		150MG	A216243	006	Jun 06, 2022	Sep	CAHN
		150MG	A216243	006	Jun 06, 2022	Aug	CAHN
	@ ENDO OPERATIONS	10MG	A040218	001	Sep 11, 1997	May	CAHN
	@	25MG	A040218	002	Sep 11, 1997	May	CAHN
	@	50MG	A040218	003	Sep 11, 1997	May	CAHN
	@	75MG	A040218	004	Sep 11, 1997	May	CAHN
	@	100MG	A040218	005	Sep 11, 1997	May	CAHN
	@	150MG	A040218	006	Sep 11, 1997	May	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

>D>	@ AIPING PHARM INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Sep	CAHN
	@	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Feb	CAHN
>D>	@	EQ 5MG BASE	A077759	002	Jul 09, 2007	Sep	CAHN
	@	EQ 5MG BASE	A077759	002	Jul 09, 2007	Feb	CAHN
>D>	@	EQ 10MG BASE	A077759	003	Jul 09, 2007	Sep	CAHN
	@	EQ 10MG BASE	A077759	003	Jul 09, 2007	Feb	CAHN
BX	LUPIN	EQ 2.5MG BASE	A078043	001	Jul 12, 2007	Jun	CTEC
BX		EQ 5MG BASE	A078043	002	Jul 12, 2007	Jun	CTEC
BX		EQ 10MG BASE	A078043	003	Jul 12, 2007	Jun	CTEC
>A>	@ SCIEGEN PHARMS INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Sep	CAHN
>A>	@	EQ 5MG BASE	A077759	002	Jul 09, 2007	Sep	CAHN
>A>	@	EQ 10MG BASE	A077759	003	Jul 09, 2007	Sep	CAHN
	@ SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Jan	DISC
	@	EQ 5MG BASE	A077974	002	Jul 09, 2007	Jan	DISC
	@	EQ 10MG BASE	A077974	003	Jul 09, 2007	Jan	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

	@ AMNEAL	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	Apr	CAHN
	@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	Apr	CAHN
	@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	Apr	CAHN
	@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	Apr	CAHN
>D>	APOTEX	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013	Sep	CAHN
>D>		EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013	Sep	CAHN
>D>		EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013	Sep	CAHN
>D>		EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013	Sep	CAHN
>D>		EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013	Sep	CAHN
>D>		EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013	Sep	CAHN
>A>	HERITAGE	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013	Sep	CAHN
>A>		EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013	Sep	CAHN
>A>		EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013	Sep	CAHN
>A>		EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013	Sep	CAHN
>A>		EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013	Sep	CAHN
>A>		EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013	Sep	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>D>	AB	GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Sep	DISC
>A>	@		EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Sep	DISC
>D>	AB		EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Sep	DISC
>A>	@		EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Sep	DISC
>D>	AB		EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Sep	DISC
>A>	@		EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Sep	DISC
>D>	AB		EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Sep	DISC
>A>	@		EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Sep	DISC
	AB	SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018	Feb	CMFD
	AB		EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018	Feb	CMFD
	AB		EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018	Feb	CMFD
	AB		EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018	Feb	CMFD

>D> AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

&gt;D&gt; TABLET; ORAL

&gt;D&gt; PRESTALIA

>D>	+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Sep	DISC
>A>	+ @		EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Sep	DISC
>D>	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Sep	DISC
>A>	+ @		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Sep	DISC
>D>	+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Sep	DISC
>A>	+ @		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Sep	DISC

AMOXAPINE

TABLET; ORAL

AMOXAPINE

	@	CHARTWELL RX	25MG	A072879	002	Jun 28, 1991	Jun	CMS1
	@		50MG	A072879	003	Jun 28, 1991	Jun	CMS1
	@		100MG	A072879	004	Jun 28, 1991	Jun	CMS1

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB		CHARTWELL RX	400MG/5ML	A065319	002	Jun 18, 2007	May	CAHN
	@	DAVA PHARMS INC	125MG/5ML	A062927	001	Nov 25, 1988	Mar	DISC
	@		250MG/5ML	A062927	002	Nov 25, 1988	Mar	DISC
	@	ENDO OPERATIONS	125MG/5ML	A062927	001	Nov 25, 1988	May	CAHN
	@		250MG/5ML	A062927	002	Nov 25, 1988	May	CAHN
		AMOXIL						
AB	+	US ANTIBIOTICS	400MG/5ML	N050760	002	Apr 15, 1999	Apr	CMFD

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

>A>		OMECLAMOX-PAK						
>A>	+	@ CUMBERLAND	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Sep	CTNA
>D>		OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN						
>D>	+	@ CUMBERLAND	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Sep	CTNA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		CIPLA	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Jul	CAHN
AB			600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Jul	CAHN
		TABLET, CHEWABLE; ORAL						
		AMOXICILLIN AND CLAVULANATE POTASSIUM						
	@	CHARTWELL RX	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	CAHN
	@		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB1	+	TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N021303	001	Oct 11, 2001	Jan	CTEC
		ADDERALL XR 15						
AB1	+	TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N021303	006	May 22, 2002	Jan	CTEC
		ADDERALL XR 20						
AB1	+	TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N021303	002	Oct 11, 2001	Jan	CTEC

CAPSULE, EXTENDED RELEASE;ORAL									
	ADDERALL XR 25								
AB1	+	TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N021303	004	May 22, 2002	Jan	CTEC	
	ADDERALL XR 30								
AB1	+!	TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N021303	003	Oct 11, 2001	Jan	CTEC	
	ADDERALL XR 5								
AB1	+	TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N021303	005	May 22, 2002	Jan	CTEC	
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE								
AB1		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302	001	Jun 22, 2012	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A077302	002	Jun 22, 2012	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A077302	003	Jun 22, 2012	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A077302	004	Jun 22, 2012	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A077302	005	Jun 22, 2012	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A077302	006	Jun 22, 2012	Jan	CTEC	
AB1		ANI PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	CTEC	
AB1		ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Jan	CTEC	
AB1		ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A212037	003	Dec 11, 2019	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A212037	004	Dec 11, 2019	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019	Jan	CTEC	
	@	ENDO OPERATIONS	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May	CAHN	
	@		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May	CAHN	
	@		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May	CAHN	
	@		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May	CAHN	
	@		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May	CAHN	
	@		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May	CAHN	
AB1		GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan	CTEC	
AB1		IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Jan	CTEC	
AB1		LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Jan	CTEC	
AB1		RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	Jan	CTEC	
AB1		SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Jan	CTEC	
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Jan	CTEC	
AB2			3.125MG;3.125MG;3.125MG;3.125MG	A211546	001	Aug 31, 2023	Jan	CTEC	
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Jan	CTEC	
AB1			5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Jan	CTEC	
AB2			6.25MG;6.25MG;6.25MG;6.25MG	A211546	002	Aug 31, 2023	Jan	CTEC	
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Jan	CTEC	
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Jan	CTEC	
AB2			9.375MG;9.375MG;9.375MG;9.375MG	A211546	003	Aug 31, 2023	Jan	CTEC	
AB2			12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023	Jan	CTEC	
AB2		SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A215997	001	Sep 27, 2023	Jan	CTEC	
AB2			6.25MG;6.25MG;6.25MG;6.25MG	A215997	002	Sep 27, 2023	Jan	CTEC	

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB2		9.375MG;9.375MG;9.375MG;9.375MG	A215997	003	Sep 27, 2023	Jan CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A215997	004	Sep 27, 2023	Jan CTEC
	@ SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Jul DISC
AB1		1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Jan CTEC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jul DISC
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jan CTEC
	@	3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jul DISC
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jan CTEC
	@	5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jul DISC
AB1		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jan CTEC
	@	6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jul DISC
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jan CTEC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jul DISC
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jan CTEC
AB2	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan CTEC
	MYDAYIS					
AB2	+ TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jan CTEC
AB2	+	6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jan CTEC
AB2	+	9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jan CTEC
AB2	+!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jan CTEC

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	ORYZA	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep CAHN
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep CAHN
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep CAHN
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep CAHN
>A>	AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep CAHN
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Sep CAHN
>D>	AB	USPHARMA WINDLAS	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep CAHN
>D>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep CAHN
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep CAHN
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep CAHN
>D>	AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep CAHN
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Sep CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>D>	AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Sep CAHN
>D>	AA		10MG	A212582	002	Feb 04, 2020	Sep CAHN
>A>	AA	SANALUZ	5MG	A212582	001	Feb 04, 2020	Sep CAHN
>A>	AA		10MG	A212582	002	Feb 04, 2020	Sep CAHN
	AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb CAHN
	AA		10MG	A212901	002	May 22, 2020	Feb CAHN
		@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar DISC
		@	10MG	A214574	002	Jan 27, 2021	Mar DISC
		EVEKEO					
AA		AZURITY	5MG	A200166	001	Aug 09, 2012	Mar CAHN
AA	!		10MG	A200166	002	Aug 09, 2012	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	@	AZURITY	5MG	N209905	001	Jan 30, 2019	Apr DISC
+	@		10MG	N209905	002	Jan 30, 2019	Apr DISC
+	@		15MG	N209905	003	Jan 30, 2019	Apr DISC
+	@		20MG	N209905	004	Jan 30, 2019	Apr DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

>A>	@	MEDIMETRIKS PHARMS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Sep CAHN
>A>	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep CAHN
>D>	@	PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Sep CAHN
>D>	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATEFOR SUSPENSION;ORAL  
AMPICILLIN TRIHYDRATE

@ ENDO OPERATIONS	EQ 125MG BASE/5ML	A 062982	001	Feb 10, 1989	May	CAHN
@	EQ 250MG BASE/5ML	A 062982	002	Feb 10, 1989	May	CAHN

APIXABANTABLET;ORAL  
APIXABAN

@ APOTEX	2.5MG	A 210091	001	Feb 16, 2024	May	DISC
AB	2.5MG	A 210091	001	Feb 16, 2024	Feb	NEWA
@	5MG	A 210091	002	Feb 16, 2024	May	DISC
AB	5MG	A 210091	002	Feb 16, 2024	Feb	NEWA

APOMORPHINE HYDROCHLORIDEINJECTABLE;SUBCUTANEOUS  
APOMORPHINE HYDROCHLORIDE

>D> AP	SAGE CHEMS	30MG/3ML (10MG/ML)	A 212025	001	Feb 23, 2022	Sep	CAHN
>A> AP	TRUPHARMA	30MG/3ML (10MG/ML)	A 212025	001	Feb 23, 2022	Sep	CAHN

APREMILASTTABLET;ORAL  
APREMILAST

AB	MANKIND PHARMA	10MG	A 211734	001	Feb 07, 2024	Jan	NEWA
AB		20MG	A 211734	002	Feb 07, 2024	Jan	NEWA
AB		30MG	A 211734	003	Feb 07, 2024	Jan	NEWA

APROCITENTANTABLET;ORAL  
TRYVIO

+! IDORSIA	12.5MG	N 217686	001	Mar 19, 2024	Mar	NEWA
------------	--------	----------	-----	--------------	-----	------

ARFORMOTEROL TARTRATESOLUTION;INHALATION  
ARFORMOTEROL TARTRATE

AN	AIPING PHARM INC	EQ 0.015MG BASE/2ML	A 214901	001	Apr 02, 2024	Aug	CAHN
AN	CF PHARMTECH	EQ 0.015MG BASE/2ML	A 216303	001	May 17, 2024	May	NEWA
AN	DR REDDYS	EQ 0.015MG BASE/2ML	A 215032	001	Jun 03, 2024	May	NEWA
AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A 214901	001	Apr 02, 2024	Mar	NEWA
AN	WILSHIRE PHARMS INC	EQ 0.015MG BASE/2ML	A 216815	001	Nov 25, 2022	Jul	CAHN

>A> ARIMOCLOMOL CITRATECAPSULE;ORAL  
MIPLYFFA

>A>	+ ZEVRA DENMARK	EQ 47MG BASE	N 214927	001	Sep 20, 2024	Sep	NEWA
>A>	+	EQ 62MG BASE	N 214927	002	Sep 20, 2024	Sep	NEWA
>A>	+	EQ 93MG BASE	N 214927	003	Sep 20, 2024	Sep	NEWA
>A>	+!	EQ 124MG BASE	N 214927	004	Sep 20, 2024	Sep	NEWA

ARIPIPRAZOLEFILM;ORAL  
OPIPZA

+ XIAMEN LP PHARM CO	2MG	N 216655	001	Jul 22, 2024	Jul	NEWA
+	5MG	N 216655	002	Jul 22, 2024	Jul	NEWA
+!	10MG	N 216655	003	Jul 22, 2024	Jul	NEWA

TABLET;ORAL

ARIPIPRAZOLE

@ BRECKENRIDGE	2MG	A 091279	001	Jan 09, 2017	Aug	DISC	
@	5MG	A 091279	002	Jan 09, 2017	Aug	DISC	
@	10MG	A 091279	003	Jan 09, 2017	Aug	DISC	
@	15MG	A 091279	004	Jan 09, 2017	Aug	DISC	
@	20MG	A 091279	005	Jan 09, 2017	Aug	DISC	
@	30MG	A 091279	006	Jan 09, 2017	Aug	DISC	
AB	LUPIN	2MG	A 205589	001	Mar 18, 2024	Mar	NEWA
AB		5MG	A 205589	002	Mar 18, 2024	Mar	NEWA
AB		10MG	A 205589	003	Mar 18, 2024	Mar	NEWA
AB		15MG	A 205589	004	Mar 18, 2024	Mar	NEWA
AB		20MG	A 205589	005	Mar 18, 2024	Mar	NEWA
AB		30MG	A 205589	006	Mar 18, 2024	Mar	NEWA



ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
ARISTADA INITIO KIT

+ ALKERMES INC 675MG/2.4ML (281.25MG/ML) N209830 001 Jun 29, 2018 Jan CPOT

ASCIMINIB HYDROCHLORIDE

TABLET; ORAL  
SCEMBLIX

+ NOVARTIS EQ 100MG BASE N215358 003 Apr 18, 2024 Apr NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID  
AA TARO 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM A207498 001 Jun 28, 2024 Jun NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
LANORINAL

AA ! SANDOZ 325MG; 50MG; 40MG A086996 002 Oct 11, 1985 Jan CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL  
CARISOPRODOL AND ASPIRIN  
@ GENUS

325MG; 200MG A040116 001 Apr 25, 1996 Aug CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL  
ASPIRIN AND DIPYRIDAMOLE

AB ENDO OPERATIONS 25MG; 200MG A207944 001 Jan 18, 2017 Apr CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL  
PERCODAN

AA +! ENDO OPERATIONS 325MG; 4.8355MG N007337 007 Aug 05, 2005 May CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL  
PERCODAN

@ ENDO OPERATIONS 325MG; 4.5MG; 0.38MG N007337 006 May CAHN

PERCODAN-DEMI  
@ ENDO OPERATIONS 325MG; 2.25MG; 0.19MG N007337 005 May CAHN

ATAZANAVIR SULFATE

CAPSULE; ORAL  
ATAZANAVIR SULFATE

>D> AB AMNEAL EQ 150MG BASE A209717 002 Jun 01, 2020 Sep DISC  
>A> @ EQ 150MG BASE A209717 002 Jun 01, 2020 Sep DISC  
>D> AB EQ 200MG BASE A209717 003 Jun 01, 2020 Sep DISC  
>A> @ EQ 200MG BASE A209717 003 Jun 01, 2020 Sep DISC  
>D> AB EQ 300MG BASE A209717 004 Jun 01, 2020 Sep DISC  
>A> @ EQ 300MG BASE A209717 004 Jun 01, 2020 Sep DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL  
ATOMOXETINE HYDROCHLORIDE

AB APOTEX EQ 10MG BASE A078983 001 May 30, 2017 Mar CPOT  
AB EQ 18MG BASE A078983 002 May 30, 2017 Mar CPOT  
AB EQ 25MG BASE A078983 003 May 30, 2017 Mar CPOT  
AB EQ 40MG BASE A078983 004 May 30, 2017 Mar CPOT  
AB EQ 60MG BASE A078983 005 May 30, 2017 Mar CPOT  
AB EQ 80MG BASE A078983 006 May 30, 2017 Mar CPOT  
AB EQ 100MG BASE A078983 007 May 30, 2017 Mar CPOT  
AB AUROBINDO PHARMA EQ 10MG BASE A079016 001 May 30, 2017 Mar CPOT  
AB EQ 18MG BASE A079016 002 May 30, 2017 Mar CPOT  
AB EQ 25MG BASE A079016 003 May 30, 2017 Mar CPOT  
AB EQ 40MG BASE A079016 004 May 30, 2017 Mar CPOT  
AB EQ 60MG BASE A079016 005 May 30, 2017 Mar CPOT  
AB EQ 80MG BASE A079016 006 May 30, 2017 Mar CPOT  
AB EQ 100MG BASE A079016 007 May 30, 2017 Mar CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	DR REDDYS	EQ 10MG BASE	A090609	001	Feb 23, 2018	Mar	CPOT
AB		EQ 18MG BASE	A090609	002	Feb 23, 2018	Mar	CPOT
AB		EQ 25MG BASE	A090609	003	Feb 23, 2018	Mar	CPOT
AB		EQ 40MG BASE	A090609	004	Feb 23, 2018	Mar	CPOT
AB		EQ 60MG BASE	A090609	005	Feb 23, 2018	Mar	CPOT
AB		EQ 80MG BASE	A090609	006	Feb 23, 2018	Mar	CPOT
AB		EQ 100MG BASE	A090609	007	Feb 23, 2018	Mar	CPOT
AB	GLENMARK PHARMS LTD	EQ 10MG BASE	A079019	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079019	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079019	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079019	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079019	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079019	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079019	007	May 30, 2017	Mar	CPOT
AB	HETERO LABS LTD V	EQ 10MG BASE	A202682	001	Mar 11, 2021	Mar	CPOT
AB		EQ 18MG BASE	A202682	002	Mar 11, 2021	Mar	CPOT
AB		EQ 25MG BASE	A202682	003	Mar 11, 2021	Mar	CPOT
AB		EQ 40MG BASE	A202682	004	Mar 11, 2021	Mar	CPOT
AB		EQ 60MG BASE	A202682	005	Mar 11, 2021	Mar	CPOT
AB		EQ 80MG BASE	A202682	006	Mar 11, 2021	Mar	CPOT
AB		EQ 100MG BASE	A202682	007	Mar 11, 2021	Mar	CPOT
AB	STRIDES PHARMA	EQ 10MG BASE	A079021	001	Feb 18, 2021	Aug	CMFD
AB	@	EQ 10MG BASE	A079021	001	Feb 18, 2021	Mar	CPOT
AB		EQ 18MG BASE	A079021	002	Feb 18, 2021	Aug	CMFD
AB	@	EQ 18MG BASE	A079021	002	Feb 18, 2021	Mar	CPOT
AB		EQ 25MG BASE	A079021	003	Feb 18, 2021	Aug	CMFD
AB	@	EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
AB		EQ 40MG BASE	A079021	004	Feb 18, 2021	Aug	CMFD
AB	@	EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
AB		EQ 60MG BASE	A079021	005	Feb 18, 2021	Aug	CMFD
AB	@	EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
AB		EQ 80MG BASE	A079021	006	Feb 18, 2021	Aug	CMFD
AB	@	EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
AB		EQ 100MG BASE	A079021	007	Feb 18, 2021	Aug	CMFD
AB	@	EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB	TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB	ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB		EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB		18MG	A079017	001	Sep 16, 2010	Jan	CMS1
AB		EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB		25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB		EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB		40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB		EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB		60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB		EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB		80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB		EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB		100MG	A079017	006	Sep 16, 2010	Jan	CMS1
	STRATTERA						
	@ LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+	EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+	EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+	EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+	EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+	EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+	EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+	EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA

## TABLET;ORAL

## ATORVASTATIN CALCIUM

AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
AB		EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
AB		EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
	@ CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
	@	EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
	@	EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
	@	EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
	@ INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
	@	EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
	@	EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
	@	EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB	LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
AB		EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB		EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB		EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
	@ LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Aug	DISC
BX		EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
	@	EQ 20MG BASE	A204991	002	Mar 06, 2019	Aug	DISC
BX		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
	@	EQ 40MG BASE	A204991	003	Mar 06, 2019	Aug	DISC
BX		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC
	@	EQ 80MG BASE	A204991	004	Mar 06, 2019	Aug	DISC
BX		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jun	CTEC
AB	MACLEODS PHARMS LTD	EQ 10MG BASE	A208480	001	Jun 03, 2024	May	NEWA
AB		EQ 20MG BASE	A208480	002	Jun 03, 2024	May	NEWA
AB		EQ 40MG BASE	A208480	003	Jun 03, 2024	May	NEWA
AB		EQ 80MG BASE	A208480	004	Jun 03, 2024	May	NEWA
AB	SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN
BX	UMEDICA	EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun	CTEC
BX		EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun	CTEC
BX		EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun	CTEC
BX		EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun	CTEC

ATRACURIUM BESYLATE

## INJECTABLE; INJECTION

## ATRACURIUM BESYLATE

@	NORVIUM BIOSCIENCE	10MG/ML	A206096	001	Jun 22, 2017	Jun	CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE						
@	NORVIUM BIOSCIENCE	10MG/ML	A206001	001	Apr 07, 2017	Jun	CAHN

ATROPINE SULFATE

## SOLUTION; INTRAVENOUS

## ATROPINE SULFATE

AP	SOMERSET THERAPS LLC	0.4MG/ML (0.4MG/ML)	A215969	001	Jul 03, 2024	Jun	NEWA
AP		1MG/ML (1MG/ML)	A215969	002	Jul 03, 2024	Jun	NEWA
	SOLUTION/DROPS; OPHTHALMIC						
	ATROPINE SULFATE						
AT1	! AMNEAL	1%	A214752	001	Jul 14, 2022	Apr	CTEC
AT1	APOTEX	1%	A215624	001	Nov 26, 2021	Apr	CTEC
AT1	MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr	CTEC
AT1	+ RISING	1%	N206289	001	Jul 18, 2014	Apr	CTEC
AT2	SOMERSET	1%	A217791	001	Apr 29, 2024	Apr	NFTG
AT1	SOMERSET THERAPS LLC	1%	A215618	001	Jul 01, 2024	Jun	NEWA
	ISOPTO ATROPINE						
AT2	+! ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

## TABLET;ORAL

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	ANI PHARMS	0.025MG; 2.5MG	A086727	001		Mar	DISC
@	MYLAN	0.025MG; 2.5MG	A085762	001		Apr	DISC

ATROPINE SULFATE; EDROPHONIUM CHLORIDEINJECTABLE; INJECTION  
ENLON-PLUS@ NORVIUM BIOSCIENCE 0.14MG/ML; 10MG/ML  
+ @ 0.14MG/ML; 10MG/MLN019677 001 Nov 06, 1991 Jul CAHN  
N019678 001 Nov 06, 1991 Jul CAHNAVACINCAPTAD PEGOL SODIUMSOLUTION; INTRAVITREAL  
IZERVAY+! ASTELLAS EQ 2MG BASE/0.1ML (EQ 2MG  
BASE/0.1ML)

N217225 001 Aug 04, 2023 Jan CAHN

AVANAFILTABLET; ORAL  
AVANAFILAB HETERO LABS LTD V 50MG  
AB 100MG  
AB 200MGA209266 001 Jun 14, 2024 Jun NFTG  
A209266 002 Jun 14, 2024 Jun NFTG  
A209266 003 Jun 14, 2024 Jun NFTG

STENDRA

AB + METUCHEN PHARMS 50MG  
AB + 100MG  
AB +! 200MGN202276 001 Apr 27, 2012 Jun CFTG  
N202276 002 Apr 27, 2012 Jun CFTG  
N202276 003 Apr 27, 2012 Jun CFTGAVIBACTAM SODIUM; CEFTAZIDIMEPOWDER; INTRAVENOUS  
AVYCAZ>A> +! ABBVIE EQ 0.5GM BASE; 2GM/VIAL  
>D> +! ALLERGAN EQ 0.5GM BASE; 2GM/VIALN206494 001 Feb 25, 2015 Sep CAHN  
N206494 001 Feb 25, 2015 Sep CAHNAZACITIDINEPOWDER; INTRAVENOUS, SUBCUTANEOUS  
AZACITIDINE

AP MSN LABS PVT LTD 100MG/VIAL

A212580 001 May 16, 2024 May NEWA

AZELAIC ACIDGEL; TOPICAL  
AZELAIC ACID

AB TARO 15%

A210549 001 Aug 23, 2019 Apr CAHN

AZELASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
OPTIVAR

+ @ NORVIUM BIOSCIENCE 0.05%

N021127 001 May 22, 2000 Jul CAHN

SPRAY, METERED; NASAL  
ASTELIN

+ @ NORVIUM BIOSCIENCE 0.137MG/SPRAY

N020114 001 Nov 01, 1996 Jul CAHN

AZELASTINE HYDROCHLORIDE

@ HIKMA 0.137MG/SPRAY

A091444 001 Oct 24, 2014 Mar DISC

AZITHROMYCININJECTABLE; INJECTION  
AZITHROMYCIN@ NORVIUM BIOSCIENCE EQ 500MG BASE/VIAL  
@ SUN PHARM INDS LTD EQ 500MG BASE/VIALA065506 001 Mar 24, 2009 Jun CAHN  
A090923 001 Apr 02, 2013 May DISC

TABLET; ORAL

AZITHROMYCIN

&gt;A&gt; @ PHARMOBEDIANT EQ 500MG BASE

A211318 001 Mar 17, 2021 Sep CAHN

&gt;D&gt; @ YUNG SHIN PHARM EQ 250MG BASE

A211317 001 Jul 26, 2022 Feb DISC

@ EQ 500MG BASE

A211318 001 Mar 17, 2021 Sep CAHN

BACLOFENINJECTABLE; INTRATHECAL  
BACLOFEN

&gt;D&gt; @ ACIC PHARMS 0.5MG/ML

A216309 001 Aug 10, 2023 Sep CAHN

&gt;D&gt; @ 0.5MG/ML

A216309 001 Aug 10, 2023 Jan DISC

&gt;D&gt; @ 2MG/ML

A216309 002 Aug 10, 2023 Sep CAHN

&gt;A&gt; @ 2MG/ML

A216309 002 Aug 10, 2023 Jan DISC

&gt;A&gt; @ HERITAGE 0.5MG/ML

A216309 001 Aug 10, 2023 Sep CAHN

&gt;A&gt; @ 2MG/ML

A216309 002 Aug 10, 2023 Sep CAHN

TABLET; ORAL

BACLOFEN

AB	ANDAS 5 HOLDING	5MG	A212378	003	Apr 30, 2021	Aug	CAHN
AB		10MG	A212378	001	Oct 09, 2020	Aug	CAHN
AB		20MG	A212378	002	Oct 09, 2020	Aug	CAHN
AB	ENDO OPERATIONS	10MG	A077068	002	Aug 30, 2005	Apr	CAHN
AB		20MG	A077068	001	Aug 30, 2005	Apr	CAHN
BX	EYWA	5MG	A211555	003	Nov 30, 2021	Jul	CAHN
BX		10MG	A211555	001	Feb 01, 2019	Jul	CAHN
BX		20MG	A211555	002	Feb 01, 2019	Jul	CAHN
BX	EYWA PHARMA	5MG	A211555	003	Nov 30, 2021	Jun	CTEC
BX		10MG	A211555	001	Feb 01, 2019	Jun	CTEC
BX		20MG	A211555	002	Feb 01, 2019	Jun	CTEC
	@ IMPAX	5MG	A077971	003	Jul 07, 2021	Mar	DISC
	@	10MG	A077971	001	Oct 26, 2007	Mar	DISC
	@	20MG	A077971	002	Oct 26, 2007	Mar	DISC
	@ NORVIUM BIOSCIENCE	20MG	A077121	002	Jul 29, 2005	Jul	CAHN
AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb	CTEC
		15MG	A209102	004	Feb 05, 2024	Jan	NEWA

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

AB	ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

BARICITINIB

TABLET; ORAL

BARICITINIB

	@ AUROBINDO PHARMA LTD	1MG	A217542	001	Jul 22, 2024	Aug	DISC
AB		1MG	A217542	001	Jul 22, 2024	Jul	NFTG
	@	2MG	A217542	002	Jul 22, 2024	Aug	DISC
AB		2MG	A217542	002	Jul 22, 2024	Jul	NFTG
	OLUMIANT						
	+ ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Aug	CTEC
AB		1MG	N207924	002	Oct 08, 2019	Jul	CFTG
		2MG	N207924	001	May 31, 2018	Aug	CTEC
AB		2MG	N207924	001	May 31, 2018	Jul	CFTG

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Jun	CAHN
AP		100MG/VIAL	A211001	002	Jun 05, 2023	Jun	CAHN
	@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Jun	CAHN
	@	100MG/VIAL	A204104	002	Apr 28, 2023	Jun	CAHN

SOLUTION; INTRAVENOUS

VIVIMUSTA

+!	AZURITY	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022	Jul	CAHN
----	---------	---------------------	---------	-----	--------------	-----	------

BENZGALANTAMINE GLUCONATE

TABLET, DELAYED RELEASE; ORAL

ZUNVEYL

+!	ALPHA COGNITION	EQ 5MG BASE	N218549	001	Jul 26, 2024	Jul	NEWA
+		EQ 10MG BASE	N218549	002	Jul 26, 2024	Jul	NEWA
+		EQ 15MG BASE	N218549	003	Jul 26, 2024	Jul	NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	PADAGIS ISRAEL	3.75%;EQ 1.2% BASE	A209610	001	Aug 20, 2024	Aug	NEWA
----	----------------	--------------------	---------	-----	--------------	-----	------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN AND BENZOYL PEROXIDE

>D>	AB	LYNE	5%;3%	A065385	001	Sep 18, 2015	Sep	CAHN
>A>	AB	RISING	5%;3%	A065385	001	Sep 18, 2015	Sep	CAHN

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	AIPING PHARM INC	0.5MG	A040103	001	Dec 12, 1996	Aug	CMFD
AA		1MG	A040103	002	Dec 12, 1996	Aug	CMFD
AA		2MG	A040103	003	Dec 12, 1996	Aug	CMFD
AA	ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN
AA		1MG	A040715	002	Aug 27, 2007	Apr	CAHN
AA		2MG	A040715	003	Aug 27, 2007	Apr	CAHN
	@ INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar	DISC
	@	1MG	A090294	002	Mar 29, 2010	Mar	DISC
	@	2MG	A090294	003	Mar 29, 2010	Mar	DISC
AA	! NUVO PHARM	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN
AA	!	1MG	A204713	002	Apr 14, 2015	Jul	CAHN
AA	!	2MG	A204713	003	Apr 14, 2015	Jul	CAHN

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

AT	SOMERSET THERAPS LLC	1.5%	A217770	001	Aug 14, 2024	Aug	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

BERDAZIMER SODIUM

GEL; TOPICAL

ZELSUVMI

+	! LNHC	EQ 10.3% BASE	N217424	001	Jan 05, 2024	Jan	NEWA
---	--------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

@ HIKMA EQ 0.05% BASE

A208849 001 Oct 11, 2019 Mar DISC

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	AUROBINDO PHARMA LTD	EQ 0.05% BASE	A218289	001	Apr 10, 2024	Mar	NEWA
	@ PADAGIS US	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Jan	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	! TARO	EQ 0.05% BASE; 1%	A075673	001	May 29, 2001	Apr	CAHN
----	--------	-------------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	ALEMBIC	0.12%	A215832	001	Aug 22, 2024	Aug	NEWA
----	---------	-------	---------	-----	--------------	-----	------

LOTION; TOPICAL

BETAMETHASONE VALERATE

>D>	AB	KANCHAN HLTHCARE	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Sep	CAHN
	AB		EQ 0.1% BASE	A070052	001	Jul 31, 1985	Aug	CAHN
>A>	AB	SCIENGEN PHARMS INC	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Sep	CAHN

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB	ASCENT PHARMS INC	75MG	A208628	001	Sep 06, 2024	Aug	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	CHARTWELL RX	50MG	A091011	001	Jun 10, 2015	Jan	CAHN
	@ RISING	50MG	A079185	001	Jul 06, 2009	Feb	CAHN

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

@ HIKMA 0.03%

A203051 001 Oct 09, 2018 Mar DISC

BIRCH TRITERPENES

GEL;TOPICAL  
FILSUVEZ

+! CHIESI 10% N215064 001 Dec 18, 2023 Jan CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

>A> AB NOVAST LABS 140MG;125MG;125MG A217511 001 Jul 03, 2023 Sep CAHN  
>D> AB RICONPHARMA LLC 140MG;125MG;125MG A217511 001 Jul 03, 2023 Sep CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB HARMAN FINOCHEM 5MG A217617 001 Jan 18, 2024 Jan NEWA  
AB A217617 002 Jan 18, 2024 Jan NEWA  
>A> AB TRUPHARMA 5MG A075474 001 Oct 25, 2002 Sep CAHN  
>A> AB 10MG A075474 002 Oct 25, 2002 Sep CAHN  
>D> AB UNITED RES LABS 5MG A075474 001 Oct 25, 2002 Sep CAHN  
>D> AB 10MG A075474 002 Oct 25, 2002 Sep CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

@ HOSPIRA 250MG/VIAL A090811 001 Jul 14, 2015 Aug DISC  
@ 250MG/VIAL A090816 001 Jul 14, 2015 May DISC

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

@ TEVA PHARMS USA EQ 15 UNITS BASE/VIAL A065033 001 Jun 27, 2000 Jan DISC  
@ EQ 30 UNITS BASE/VIAL A065033 002 Jun 27, 2000 Jan DISC

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP HETERO LABS LTD VI 3.5MG/VIAL A212204 001 May 03, 2024 Apr NEWA  
@ NORVIUM BIOSCIENCE 3.5MG/VIAL A205160 001 Oct 31, 2022 Jun CAHN  
AP RELIANCE LIFE SCI 3.5MG/VIAL A211898 001 Oct 11, 2022 May CAHN

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+! SHILPA 3.5MG/1.4ML (2.5MG/ML) N212782 001 Aug 26, 2024 Aug NEWA

BOSENTAN

TABLET;ORAL

BOSENTAN

@ ENDO OPERATIONS 62.5MG A205699 001 Apr 26, 2019 Apr CAHN  
@ 125MG A205699 002 Apr 26, 2019 Apr CAHN

BREMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+! COSETTE EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) N210557 001 Jun 21, 2019 Apr CAHN

BREXPIPIRAZOLE

TABLET;ORAL

BREXPIPIRAZOLE

>D> AB ALKEM LABS LTD 0.25MG A213782 001 Nov 28, 2023 Sep DISC  
>A> @ 0.25MG A213782 001 Nov 28, 2023 Sep DISC  
>D> AB 0.5MG A213782 002 Nov 28, 2023 Sep DISC  
>A> @ 0.5MG A213782 002 Nov 28, 2023 Sep DISC  
>D> AB 1MG A213782 003 Nov 28, 2023 Sep DISC  
>A> @ 1MG A213782 003 Nov 28, 2023 Sep DISC  
>D> AB 2MG A213782 004 Nov 28, 2023 Sep DISC  
>A> @ 2MG A213782 004 Nov 28, 2023 Sep DISC  
>D> AB 3MG A213782 005 Nov 28, 2023 Sep DISC  
>A> @ 3MG A213782 005 Nov 28, 2023 Sep DISC  
>D> AB 4MG A213782 006 Nov 28, 2023 Sep DISC  
>A> @ 4MG A213782 006 Nov 28, 2023 Sep DISC  
>A> @ ANDA REPOSITORY 0.25MG A213758 001 Oct 25, 2023 Sep CAHN

TABLET;ORAL

BREXPPIRAZOLE

>A>	@		0.5MG	A213758	002	Oct 25, 2023	Sep CAHN
>A>	@		1MG	A213758	003	Oct 25, 2023	Sep CAHN
>A>	@		2MG	A213758	004	Oct 25, 2023	Sep CAHN
>A>	@		3MG	A213758	005	Oct 25, 2023	Sep CAHN
>A>	@		4MG	A213758	006	Oct 25, 2023	Sep CAHN
>A>	@	CELLTRION	0.25MG	A213758	001	Oct 25, 2023	Sep CAHN
>A>	@		0.5MG	A213758	002	Oct 25, 2023	Sep CAHN
>A>	@		1MG	A213758	003	Oct 25, 2023	Sep CAHN
>A>	@		2MG	A213758	004	Oct 25, 2023	Sep CAHN
>A>	@		3MG	A213758	005	Oct 25, 2023	Sep CAHN
>A>	@		4MG	A213758	006	Oct 25, 2023	Sep CAHN
>D>	AB	HETERO LABS LTD V	0.25MG	A213669	001	Nov 20, 2023	Sep DISC
>A>	@		0.25MG	A213669	001	Nov 20, 2023	Sep DISC
>D>	AB		0.5MG	A213669	002	Nov 20, 2023	Sep DISC
>A>	@		0.5MG	A213669	002	Nov 20, 2023	Sep DISC
>D>	AB		1MG	A213669	003	Nov 20, 2023	Sep DISC
>A>	@		1MG	A213669	003	Nov 20, 2023	Sep DISC
>D>	AB		2MG	A213669	004	Nov 20, 2023	Sep DISC
>A>	@		2MG	A213669	004	Nov 20, 2023	Sep DISC
>D>	AB		3MG	A213669	005	Nov 20, 2023	Sep DISC
>A>	@		3MG	A213669	005	Nov 20, 2023	Sep DISC
>D>	AB		4MG	A213669	006	Nov 20, 2023	Sep DISC
>A>	@		4MG	A213669	006	Nov 20, 2023	Sep DISC
>D>	AB	OPTIMUS	0.25MG	A213758	001	Oct 25, 2023	Sep CAHN
>D>	AB		0.5MG	A213758	002	Oct 25, 2023	Sep CAHN
>D>	AB		1MG	A213758	003	Oct 25, 2023	Sep CAHN
>D>	AB		2MG	A213758	004	Oct 25, 2023	Sep CAHN
>D>	AB		3MG	A213758	005	Oct 25, 2023	Sep CAHN
>D>	AB		4MG	A213758	006	Oct 25, 2023	Sep CAHN

REXULTI

>D>	AB	+	OTSUKA			0.25MG	N205422	001	Jul 10, 2015	Sep CTEC
>A>		+				0.25MG	N205422	001	Jul 10, 2015	Sep CTEC
>D>	AB	+				0.5MG	N205422	002	Jul 10, 2015	Sep CTEC
>A>		+				0.5MG	N205422	002	Jul 10, 2015	Sep CTEC
>D>	AB	+				1MG	N205422	003	Jul 10, 2015	Sep CTEC
>A>		+				1MG	N205422	003	Jul 10, 2015	Sep CTEC
>D>	AB	+				2MG	N205422	004	Jul 10, 2015	Sep CTEC
>A>		+				2MG	N205422	004	Jul 10, 2015	Sep CTEC
>D>	AB	+				3MG	N205422	005	Jul 10, 2015	Sep CTEC
>A>		+				3MG	N205422	005	Jul 10, 2015	Sep CTEC
>D>	AB	+				4MG	N205422	006	Jul 10, 2015	Sep CTEC
>A>		+				4MG	N205422	006	Jul 10, 2015	Sep CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AB	LUPIN LTD		0.1%	A213215	001	Aug 26, 2024	Aug NEWA
AB	SANDOZ		0.1%	A203172	001	Mar 04, 2024	Feb NEWA
AB	SOMERSET THERAPS LLC		0.1%	A216906	001	Aug 09, 2024	Aug NEWA
AT	UPSHER SMITH LABS		0.15%	A216772	001	Jun 12, 2024	May NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB	GLENMARK PHARMS LTD		0.2%;EQ 0.5% BASE	A214987	001	May 16, 2024	May NEWA
AB	SOMERSET		0.2%;EQ 0.5% BASE	A216114	001	Sep 10, 2024	Aug NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AB	ALEMBIC		EQ 0.07% ACID	A214340	001	Jul 08, 2024	Jun NEWA
AB	AMNEAL		EQ 0.07% ACID	A210962	001	Jul 29, 2024	Jul NEWA
AB	APOTEX		EQ 0.07% ACID	A207334	001	Jul 08, 2024	Jun NEWA
AB	LUPIN LTD		EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan NFTG
			BROMSITE				
AB	+	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan CFTG



BUDESONIDEAEROSOL, FOAM;RECTAL  
BUDESONIDE

AB	!	PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Jun	CHRS
		UCERIS						
AB	+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Jun	CHRS
		POWDER, METERED; INHALATION						
		PULMICORT FLEXHALER						
	+	CHEFLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006	Jun	CAHN
	+	!	0.16MG/INH	N021949	002	Jul 12, 2006	Jun	CAHN
		SUSPENSION; INHALATION						
		BUDESONIDE						
	@	EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	May	DISC
		SUSPENSION; ORAL						
		EOHILIA						
	+	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb	NEWA

BUMETANIDEINJECTABLE; INJECTION  
BUMETANIDE

	@	HOSPIRA	0.25MG/ML	A074332	001	Oct 31, 1994	May	DISC
>A>	AP	LUPIN LTD	0.25MG/ML	A217153	001	Sep 17, 2024	Sep	NEWA
>A>	AP	QILU PHARM HAINAN	0.25MG/ML	A219116	001	Sep 19, 2024	Sep	NEWA
		TABLET; ORAL						
		BUMETANIDE						
>A>	AB	APPCO	0.5MG	A212931	001	Sep 18, 2024	Sep	NEWA
>A>	AB		1MG	A212931	002	Sep 18, 2024	Sep	NEWA
>A>	AB		2MG	A212931	003	Sep 18, 2024	Sep	NEWA
	AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jun	CTEC
	AB		1MG	A212019	002	Dec 12, 2019	Jun	CTEC
	AB		2MG	A212019	003	Dec 12, 2019	Jun	CTEC

BUPIVACAINEINJECTABLE, LIPOSOMAL; INJECTION  
BUPIVACAINE LIPOSOME

AP		HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Jun	NFTG
AP			266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Jun	NFTG
		EXPAREL						
AP	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jun	CFTG
AP	+	!	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Jun	CFTG
		SOLUTION; INFILTRATION						
		POSIMIR						
	+	INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Aug	CDFR

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION  
BUPIVACAINE HYDROCHLORIDE

AP		ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA
AP			0.5%	A217821	002	Mar 27, 2024	Mar	NEWA
AP			0.75%	A217821	003	Mar 27, 2024	Mar	NEWA
AP		MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN
AP			0.25%	A216040	001	Dec 27, 2023	Jun	CAHN
AP			0.5%	A216039	002	Jun 23, 2023	Jun	CAHN
AP			0.5%	A216040	002	Dec 27, 2023	Jun	CAHN
AP			0.75%	A216040	003	Dec 27, 2023	Jun	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE; INJECTION  
VIVACAINE

!		SEPTODONT	0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Jan	CTNA
---	--	-----------	-------------------	---------	-----	--------------	-----	------

BUPRENORPHINEFILM, EXTENDED RELEASE; TRANSDERMAL  
BUPRENORPHINE

>D>	AB	AVEVA	5MCG/HR	A210272	001	Sep 23, 2021	Sep	CAHN
>D>	AB		7.5MCG/HR	A210272	002	Sep 23, 2021	Sep	CAHN
>D>	AB		10MCG/HR	A210272	003	Sep 23, 2021	Sep	CAHN
>D>	AB		15MCG/HR	A210272	004	Sep 23, 2021	Sep	CAHN
>D>	AB		20MCG/HR	A210272	005	Sep 23, 2021	Sep	CAHN
>A>	AB	DIFGEN PHARMS	5MCG/HR	A210272	001	Sep 23, 2021	Sep	CAHN
>A>	AB		7.5MCG/HR	A210272	002	Sep 23, 2021	Sep	CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL  
BUPRENORPHINE

>A>	AB		10MCG/HR	A210272	003	Sep 23, 2021	Sep CAHN
>A>	AB		15MCG/HR	A210272	004	Sep 23, 2021	Sep CAHN
>A>	AB		20MCG/HR	A210272	005	Sep 23, 2021	Sep CAHN

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION  
PROBUPHINE

+	@ REACX PHARMS		EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Apr CAHN
---	----------------	--	----------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

@	AM REGENT		EQ 0.3MG BASE/ML	A078331	001	Mar 27, 2007	Jan DISC
---	-----------	--	------------------	---------	-----	--------------	----------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@	NORVIUM BIOSCIENCE		EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun CAHN
---	--------------------	--	-------------	---------	-----	--------------	----------

@			EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun CAHN
---	--	--	-------------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>D>	AB	AVEVA	EQ 8MG BASE;EQ 2MG BASE	A212756	001	Jun 02, 2022	Sep CAHN
>D>	AB		EQ 12MG BASE;EQ 3MG BASE	A212756	002	Jun 02, 2022	Sep CAHN
>A>	AB	DIFGEN PHARMS	EQ 8MG BASE;EQ 2MG BASE	A212756	001	Jun 02, 2022	Sep CAHN
>A>	AB		EQ 12MG BASE;EQ 3MG BASE	A212756	002	Jun 02, 2022	Sep CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB	AUROBINDO PHARMA USA		75MG	A075491	001	Apr 17, 2000	Apr CMFD
AB			100MG	A075491	002	Apr 17, 2000	Apr CMFD
	@ INVAGEN PHARMS		75MG	A207389	001	Sep 18, 2017	Mar DISC
	@		100MG	A207389	002	Sep 18, 2017	Mar DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

	@ ANCHEN PHARMS		100MG	A091459	001	Jun 09, 2011	Feb DISC
	@		150MG	A091459	002	Jun 09, 2011	Feb DISC
	@		150MG	A091520	001	Jun 09, 2011	Feb DISC
	@		200MG	A091459	003	Jun 09, 2011	Feb DISC
	@ ENDO OPERATIONS		100MG	A091459	001	Jun 09, 2011	May CAHN
	@		150MG	A077284	001	Dec 14, 2006	May CAHN
	@		150MG	A091459	002	Jun 09, 2011	May CAHN
	@		150MG	A091520	001	Jun 09, 2011	May CAHN
	@		200MG	A091459	003	Jun 09, 2011	May CAHN
	@		300MG	A077284	002	Dec 14, 2006	May CAHN
	@ INVAGEN PHARMS		100MG	A206674	001	Feb 09, 2016	Mar DISC
	@		150MG	A206556	001	Aug 26, 2016	Mar DISC
	@		150MG	A206674	002	Feb 09, 2016	Mar DISC
	@		200MG	A206674	003	Feb 09, 2016	Mar DISC
	@		300MG	A206556	002	Aug 26, 2016	Mar DISC
	@ RISING		150MG	A090941	001	May 03, 2010	Feb CAHN
	@ SUN PHARM		150MG	A078866	002	Apr 06, 2010	Jul DISC
	@		200MG	A078866	003	Apr 06, 2010	May DISC
AB3	TWI PHARMS		150MG	A210081	001	Nov 03, 2017	Mar CAHN
AB3			300MG	A210081	002	Nov 03, 2017	Mar CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	AIPING PHARM INC		5MG	A202087	001	Dec 16, 2015	Jan CAHN
AB			10MG	A202087	002	Dec 16, 2015	Jan CAHN
AB			15MG	A202087	003	Dec 16, 2015	Jan CAHN
AB			30MG	A202087	004	Dec 16, 2015	Jan CAHN
	@ AMNEAL PHARMS CO		5MG	A208829	001	May 24, 2017	Mar DISC
	@		7.5MG	A208829	002	May 24, 2017	Mar DISC
	@		10MG	A208829	003	May 24, 2017	Mar DISC
	@		15MG	A208829	004	May 24, 2017	Mar DISC
	@		30MG	A208829	005	May 24, 2017	Mar DISC

BUSULFAN

	INJECTABLE; INJECTION						
	BUSULFAN						
AP	EUGIA PHARMA	6MG/ML	A215102	001	Jun 25, 2024	Jun	NEWA
	@ NORVIUM BIOSCIENCE	6MG/ML	A205184	001	Jul 13, 2018	Jun	CAHN
AP	PRINSTON INC	6MG/ML	A215235	001	Sep 11, 2024	Aug	NEWA

BUTABARBITAL SODIUM

	TABLET; ORAL						
	BUTISOL SODIUM						
	@ NORVIUM BIOSCIENCE	15MG	N000793	002		Jun	CAHN
	+ @	30MG	N000793	004		Jun	CAHN
	@	50MG	N000793	003		Jun	CAHN
	@	100MG	N000793	005		Jun	CAHN

CABAZITAXEL

	SOLUTION; INTRAVENOUS						
	CABAZITAXEL						
	+ @ ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jun	DISC
>D>	+! ACTAVIS	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Sep	DISC
>A>	+ @	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Sep	DISC
	+!	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Mar	NEWA

CABERGOLINE

	TABLET; ORAL						
	CABERGOLINE						
	@ NORVIUM BIOSCIENCE	0.5MG	A202947	001	Dec 02, 2013	Jun	CAHN
AB	SKG PHARMA	0.5MG	A218618	001	Jun 26, 2024	Jun	NEWA
AB	WELDING	0.5MG	A218109	001	Sep 09, 2024	Aug	NEWA

CALCIPOTRIENE

	SOLUTION; TOPICAL						
	CALCIPOTRIENE						
	@ HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar	DISC

CALCITONIN SALMON

	INJECTABLE; INJECTION							
	CALCITONIN-SALMON							
>A>	AP	CIPLA	200 IU/ML	A213766	001	Sep 20, 2024	Sep	NEWA
	AP	DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr	NEWA
	SPRAY, METERED; NASAL							
	CALCITONIN-SALMON							
	AB	! APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul	CTEC
	AB	ENDO OPERATIONS	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul	CMFD
		@	200 IU/SPRAY	A076979	001	Jun 08, 2009	May	CAHN
		MIACALCIN						
	+ @	NORVIUM BIOSCIENCE	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul	CAHN

CALCITRIOL

	SOLUTION; ORAL							
	CALCITRIOL							
>A>	AA	ANDA REPOSITORY	1MCG/ML	A203973	001	Jul 28, 2023	Sep	CAHN
>D>	AA	PATRIN	1MCG/ML	A203973	001	Jul 28, 2023	Sep	CAHN

CALCIUM ACETATE

	CAPSULE; ORAL							
	CALCIUM ACETATE							
	AB	! INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr	CHRS
		PHOSLO GELCAPS						
	+ @	FRESENIUS MEDCL	667MG	N021160	003	Apr 02, 2001	Apr	DISC

CALCIUM CHLORIDE

	INJECTABLE; INJECTION						
	CALCIUM CHLORIDE						
AP	AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Jun	NEWA

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS  
CALCIUM GLUCONATE

AP	AMNEAL	1GM/10ML (100MG/ML)	A216611	001	May 10, 2024	May	NEWA
AP		5GM/50ML (100MG/ML)	A216611	002	May 10, 2024	May	NEWA
AP		10GM/100ML (100MG/ML)	A216611	003	May 10, 2024	May	NEWA
AP	NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr	NEWA

CAPECITABINE

TABLET; ORAL  
CAPECITABINE

AB	HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
AB		500MG	A210203	002	Mar 05, 2024	Feb	NEWA
>D>	AB	HIKMA	A200483	001	Jul 14, 2016	Sep	DISC
>A>	@	150MG	A200483	001	Jul 14, 2016	Sep	DISC
>D>	AB		A200483	002	Jul 14, 2016	Sep	DISC
>A>	@	500MG	A200483	002	Jul 14, 2016	Sep	DISC

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION  
CAPREOMYCIN SULFATE

@	NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Jun	CAHN
---	--------------------	------------------	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET; ORAL  
CAPTOPRIL

AB	ANDAS 5 HOLDING	12.5MG	A074677	004	May 30, 1997	Aug	CAHN
AB		25MG	A074677	002	May 30, 1997	Aug	CAHN
AB		50MG	A074677	001	May 30, 1997	Aug	CAHN
AB		100MG	A074677	003	May 30, 1997	Aug	CAHN
AB	INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar	CAHN
AB		25MG	A074677	002	May 30, 1997	Mar	CAHN
AB		50MG	A074677	001	May 30, 1997	Mar	CAHN
AB		100MG	A074677	003	May 30, 1997	Mar	CAHN
AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb	CAHN
AB		25MG	A074677	002	May 30, 1997	Feb	CAHN
AB		50MG	A074677	001	May 30, 1997	Feb	CAHN
AB		100MG	A074677	003	May 30, 1997	Feb	CAHN

CARBAMAZEPINE

TABLET; ORAL  
CARBAMAZEPINE

AB	BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb	NEWA
BX	UMEDICA	100MG	A207798	001	Apr 15, 2020	Jun	CTEC
BX		200MG	A207798	002	Apr 15, 2020	Jun	CTEC

TABLET, EXTENDED RELEASE; ORAL  
CARBAMAZEPINE

@	AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb	DISC
@		200MG	A212704	002	Sep 22, 2023	Feb	DISC
@		400MG	A212704	003	Sep 22, 2023	Feb	DISC
@	APOTEX	100MG	A213159	001	Mar 08, 2024	May	DISC
AB		100MG	A213159	001	Mar 08, 2024	Mar	NEWA
	@	200MG	A213159	002	Mar 08, 2024	May	DISC
AB		200MG	A213159	002	Mar 08, 2024	Mar	NEWA
	@	400MG	A213159	003	Mar 08, 2024	May	DISC
AB		400MG	A213159	003	Mar 08, 2024	Mar	NEWA
>A>	AB	EPIC PHARMA LLC	A216235	001	Mar 02, 2023	Sep	CAHN
>A>	AB		A216235	002	Mar 02, 2023	Sep	CAHN
>A>	AB		A216235	003	Mar 02, 2023	Sep	CAHN
>A>	AB	NOVAST LABS	A216404	001	Dec 02, 2022	Sep	CAHN
>A>	AB		A216404	002	Dec 02, 2022	Sep	CAHN
>A>	AB		A216404	003	Dec 02, 2022	Sep	CAHN
>D>	AB	RICONPHARMA LLC	A216404	001	Dec 02, 2022	Sep	CAHN
>D>	AB		A216404	002	Dec 02, 2022	Sep	CAHN
>D>	AB		A216404	003	Dec 02, 2022	Sep	CAHN
>D>	AB	SCIECURE PHARMA INC	A216235	001	Mar 02, 2023	Sep	CAHN
>D>	AB		A216235	002	Mar 02, 2023	Sep	CAHN
>D>	AB		A216235	003	Mar 02, 2023	Sep	CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

@ NORVIUM BIOSCIENCE	12.5MG;200MG;50MG	A203424	001	Aug 13, 2020	Jun CAHN
@	18.75MG;200MG;75MG	A203424	002	Aug 13, 2020	Jun CAHN
@	25MG;200MG;100MG	A203424	003	Aug 13, 2020	Jun CAHN
@	31.25MG;200MG;125MG	A203424	004	Aug 13, 2020	Jun CAHN
@	37.5MG;200MG;150MG	A203424	005	Aug 13, 2020	Jun CAHN
@	50MG;200MG;200MG	A203424	006	Aug 13, 2020	Jun CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

CREXONT

+ IMPAX	35MG;140MG	N217186	001	Aug 07, 2024	Aug NEWA
+	52.5MG;210MG	N217186	002	Aug 07, 2024	Aug NEWA
+	70MG;280MG	N217186	003	Aug 07, 2024	Aug NEWA
+!	87.5MG;350MG	N217186	004	Aug 07, 2024	Aug NEWA

RYTARY

+ IMPAX	23.75MG;95MG	N203312	001	Jan 07, 2015	May CAHN
+	36.25MG;145MG	N203312	002	Jan 07, 2015	May CAHN
+	48.75MG;195MG	N203312	003	Jan 07, 2015	May CAHN
+!	61.25MG;245MG	N203312	004	Jan 07, 2015	May CAHN

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB RUBICON	25MG;100MG	A217482	001	Jun 04, 2024	May NEWA
AB	50MG;200MG	A217482	002	Jun 04, 2024	May NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

@ ENDO OPERATIONS	4MG/5ML	A040814	001	Feb 26, 2008	May CAHN
-------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

CARBINOXAMINE MALEATE

@ INVAGEN PHARMS	4MG	A090435	001	Apr 15, 2010	Mar DISC
------------------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

@ NORVIUM BIOSCIENCE	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Jul CAHN
@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Jul CAHN
@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Jul CAHN

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

@ ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jul DISC
AP	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan NEWA
AP MICRO LABS	EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar NEWA
AP STERISCIENCE SPECLTS	EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Aug CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

@ ALLIED	350MG	A211789	001	Oct 20, 2021	Aug CAHN
>A> AB CHARTWELL RX	250MG	A205126	001	Jul 08, 2015	Sep CAHN
>A> AA	350MG	A205126	002	Jul 08, 2015	Sep CAHN
@ MLV	350MG	A211789	001	Oct 20, 2021	Jul DISC
>D> AB WILSHIRE PHARMS INC	250MG	A205126	001	Jul 08, 2015	Sep CAHN
>D> AA	350MG	A205126	002	Jul 08, 2015	Sep CAHN

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

@ NORVIUM BIOSCIENCE	100MG/VIAL	A215368	001	Mar 03, 2023	Jun CAHN
----------------------	------------	---------	-----	--------------	----------

POWDER; INTRAVENOUS

CARMUSTINE

+ @ ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May DISC
+ @	300MG/VIAL	N215000	002	May 16, 2022	May DISC

CARVEDILOL

## TABLET; ORAL

CARVEDILOL							
	@ MLV	3.125MG	A078786	001	Dec 22, 2009	Aug	CAHN
	@	6.25MG	A078786	002	Dec 22, 2009	Aug	CAHN
	@	12.5MG	A078786	003	Dec 22, 2009	Aug	CAHN
	@	25MG	A078786	004	Dec 22, 2009	Aug	CAHN
	@ MYLAN	3.125MG	A077316	001	Sep 05, 2007	Apr	DISC
	@ SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Jan	DISC
	@	6.25MG	A076989	002	Sep 05, 2007	Jan	DISC
	@	12.5MG	A076989	003	Sep 05, 2007	Jan	DISC
	@	25MG	A076989	004	Sep 05, 2007	Jan	DISC
COREG							
AB	+ WAYLIS THERAP	3.125MG	N020297	004	May 29, 1997	Apr	CAHN
AB	+	6.25MG	N020297	003	Sep 14, 1995	Apr	CAHN
AB	+!	12.5MG	N020297	002	Sep 14, 1995	Apr	CAHN
AB	+	25MG	N020297	001	Sep 14, 1995	Apr	CAHN

CARVEDILOL PHOSPHATE

## CAPSULE, EXTENDED RELEASE; ORAL

COREG CR							
AB	+ WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Apr	CAHN
AB	+	20MG	N022012	002	Oct 20, 2006	Apr	CAHN
AB	+!	40MG	N022012	003	Oct 20, 2006	Apr	CAHN
AB	+	80MG	N022012	004	Oct 20, 2006	Apr	CAHN

CASPOFUNGIN ACETATE

## POWDER; INTRAVENOUS

CASPOFUNGIN ACETATE							
AP	AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
AP		70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN

CEFAZOLIN SODIUM

## INJECTABLE; INJECTION

CEFAZOLIN SODIUM							
	QILU	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	NEWA
SOLUTION; INTRAVENOUS							
CEFAZOLIN IN DEXTROSE							
+!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	May	CTNA
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	May	CTNA
+!		EQ 3GM BASE/150ML (EQ 20MG BASE/ML)	N207131	003	May 31, 2024	May	NEWA

CEFEPIME HYDROCHLORIDE

## INJECTABLE; INJECTION

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER							
+!	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CHRS
+		EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CRLD
+!		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CHRS
+		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CRLD
CEFEPIME HYDROCHLORIDE							
	@ CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun	CAHN
	@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun	CAHN
AP	HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May	NEWA
AP		EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May	NEWA
POWDER; INTRAVENOUS							
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER							
!	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

## POWDER; INTRAVENOUS

EXBLIFEP							
+	@ ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May	DISC
+!		EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Feb	NEWA

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

@	CHARTWELL RX	100MG/5ML	A206144	001	Nov 17, 2017	Jul	CAHN
@		200MG/5ML	A206144	002	Nov 17, 2017	Jul	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

+	@	STERIMAX	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
+	@		EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
+	@		EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
+	@		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN	
@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN	
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
@	STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN	
@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN	

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

AP	+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
CEFOTETAN								
AP	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Feb	CTEC
AP	!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Feb	CTEC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN

@	NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987	Jul	CAHN	
+	@	EQ 1GM BASE/VIAL	N050517	001		Jul	CAHN	
	@	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987	Jul	CAHN	
+	@	EQ 2GM BASE/VIAL	N050517	002		Jul	CAHN	
+	@	EQ 10GM BASE/VIAL	N050517	003		Jul	CAHN	
MEFOXIN IN PLASTIC CONTAINER								
@	NORVIUM BIOSCIENCE	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Jul	CAHN	
@		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Jul	CAHN	

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

@	CHARTWELL RX	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jul	CAHN
@		EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jul	CAHN

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB		ALKEM LABS LTD	250MG	A090857	001	Apr 09, 2024	Mar	NEWA
AB			500MG	A090857	002	Apr 09, 2024	Mar	NEWA

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS

ZEVTERA

+	@	BASILEA PHARM ALLSCH	667MG/VIAL	N218275	001	Apr 03, 2024	Aug	DISC
+	!		667MG/VIAL	N218275	001	Apr 03, 2024	Apr	NEWA

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

@	DEVA HOLDING AS	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jul	DISC
AP		EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jan	NEWA
	@	EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jul	DISC
AP		EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jan	NEWA
	@	EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jul	DISC
AP		EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jan	NEWA
	@	EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jul	DISC
AP		EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jan	NEWA

CELECOXIBSOLUTION;ORAL  
ELYXYB

+! SCILEX PHARMS 25MG/ML N212157 001 May 05, 2020 Jun CAHN

CEPHALEXINTABLET;ORAL  
CEPHALEXIN

>A>	AB	ALKEM LABS LTD	EQ 250MG BASE	A218947	001	Sep 27, 2024	Sep NEWA
>A>	AB		EQ 500MG BASE	A218947	002	Sep 27, 2024	Sep NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A218817	001	Sep 27, 2024	Sep NEWA
>A>	AB		EQ 500MG BASE	A218817	002	Sep 27, 2024	Sep NEWA
		KEFLET					
>D>		@ LILLY	EQ 250MG BASE	N050440	003	Feb 26, 1987	Sep CRLD
>A>		+ @	EQ 250MG BASE	N050440	003	Feb 26, 1987	Sep CRLD
>D>		@	EQ 500MG BASE	N050440	001		Sep CRLD
>A>		+ @	EQ 500MG BASE	N050440	001		Sep CRLD

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

		@ ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Feb CDFR
AA		AMNEAL PHARMS	5MG/5ML	A090766	001	Oct 07, 2009	Feb CDFR
AA		APOZEAL PHARMS	5MG/5ML	A078870	001	Apr 27, 2009	Jul CMFD
		@	5MG/5ML	A078870	001	Apr 27, 2009	Feb CDFR
		@ AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb CDFR
AA		BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Feb CDFR
AA		BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Feb CDFR
AA		CHARTWELL MOLECULAR	5MG/5ML	A078876	001	May 11, 2012	Feb CDFR
		@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	Feb CDFR
AA	!	PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Feb CDFR
AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Feb CDFR
		@ RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Feb CDFR
AA		TARO	5MG/5ML	A076601	001	Jun 20, 2008	Feb CDFR
		@ TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008	Mar DISC
AA			5MG/5ML	A077279	001	May 27, 2008	Feb CDFR
		@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Feb CDFR
		ZYRTEC					
		@ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb CDFR

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA PHARM ASSOC 5MG/5ML A078412 001 Jun 18, 2008 Jan CMFD

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP		GLAND	EQ 0.25MG BASE/VIAL	A218150	001	Apr 25, 2024	Apr NEWA
AP		LIVZON GRP	EQ 0.25MG BASE/VIAL	A214540	001	Apr 24, 2024	Apr NEWA
AP		QILU	EQ 0.25MG BASE/VIAL	A217776	001	Apr 16, 2024	Apr NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

&gt;A&gt; AB MACLEODS PHARMS LTD 30MG A206808 001 Sep 20, 2024 Sep NEWA

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

@ FRESENIUS KABI USA EQ 1GM BASE/VIAL A062365 001 Aug 25, 1982 Feb DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB WINDER LABS LLC 5MG;2.5MG A212344 001 Jul 08, 2024 Jun NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

		@ SAPTALIS PHARMS	0.12%	A074356	001	May 07, 1996	Jun CAHN
		@ SCIEGEN PHARMS INC	0.12%	A074356	001	May 07, 1996	Aug CAHN



CHLOROTHIAZIDE SODIUMINJECTABLE; INJECTION  
CHLOROTHIAZIDE SODIUM

>A>	AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A218630	001	Oct 03, 2024	Sep NEWA
		@ RK PHARMA	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Mar DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>		@ APOZEAL PHARMS	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Sep CAHN
>A>		@ SCIEGEN PHARMS INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Sep CAHN

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

>A>	AP	DEVA HLDING	25MG/ML	A218229	001	Sep 24, 2024	Sep NEWA
	AP	DR REDDYS	25MG/ML	A080365	001		Apr CMFD
>A>	AP	GLAND PHARMA LTD	25MG/ML	A216911	001	Oct 04, 2024	Sep NEWA
	AP	+! HIKMA	25MG/ML	A083329	001		Jun CAHN
	AP	ZYDUS PHARMS	25MG/ML	A217275	001	Mar 13, 2024	Mar NEWA

SYRUP; ORAL

SONAZINE

		@ CHARTWELL RX	10MG/5ML	A083040	001		May CAHN
--	--	----------------	----------	---------	-----	--	----------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

		@ CHARTWELL RX	10MG	A080439	001		Jul CAHN
>A>	AB		10MG	A212630	001	Nov 29, 2021	Sep CAHN
		@	25MG	A080439	002		Jul CAHN
>A>	AB		25MG	A212630	002	Nov 29, 2021	Sep CAHN
		@	50MG	A080439	003		Jul CAHN
>A>	AB		50MG	A212630	003	Nov 29, 2021	Sep CAHN
		@	100MG	A080439	004		Jul CAHN
>A>	AB		100MG	A212630	004	Nov 29, 2021	Sep CAHN
		@	200MG	A080439	005		Jul CAHN
>A>	AB		200MG	A212630	005	Nov 29, 2021	Sep CAHN
>D>	AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Sep CAHN
	AB		10MG	A212630	001	Nov 29, 2021	Feb CAHN
>D>	AB		25MG	A212630	002	Nov 29, 2021	Sep CAHN
	AB		25MG	A212630	002	Nov 29, 2021	Feb CAHN
>D>	AB		50MG	A212630	003	Nov 29, 2021	Sep CAHN
	AB		50MG	A212630	003	Nov 29, 2021	Feb CAHN
>D>	AB		100MG	A212630	004	Nov 29, 2021	Sep CAHN
	AB		100MG	A212630	004	Nov 29, 2021	Feb CAHN
>D>	AB		200MG	A212630	005	Nov 29, 2021	Sep CAHN
	AB		200MG	A212630	005	Nov 29, 2021	Feb CAHN
	AB	ZYDUS LIFESCIENCES	10MG	A213368	001	Jan 17, 2020	Aug CAHN
	AB		25MG	A213368	002	Jan 17, 2020	Aug CAHN
	AB		50MG	A213368	003	Jan 17, 2020	Aug CAHN
	AB		100MG	A213368	004	Jan 17, 2020	Aug CAHN
	AB		200MG	A213368	005	Jan 17, 2020	Aug CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

>A>	AB	PHARMOBEDIENT	25MG	A212878	001	Feb 24, 2022	Sep CAHN
>A>	AB		50MG	A212875	001	Feb 24, 2022	Sep CAHN
>D>	AB	TAGI	25MG	A212878	001	Feb 24, 2022	Sep CAHN
>D>	AB		50MG	A212875	001	Feb 24, 2022	Sep CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

		@ APTAPHARMA INC	375MG	A212053	001	Sep 14, 2020	Apr DISC
		@	750MG	A212053	002	Sep 14, 2020	Apr DISC
>A>		@ CHARTWELL RX	375MG	A212053	001	Sep 14, 2020	Sep CAHN
>A>		@	750MG	A212053	002	Sep 14, 2020	Sep CAHN
	AB	ENDO OPERATIONS	375MG	A212743	002	Apr 29, 2021	Apr CAHN
	AB		750MG	A212743	001	Nov 02, 2020	Apr CAHN
	AA	HAVIX	500MG	A210961	001	Jan 22, 2024	Jan NEWA
>D>		@ I3 PHARMS	375MG	A212053	001	Sep 14, 2020	Sep CAHN
		@	375MG	A212053	001	Sep 14, 2020	Aug CAHN
>D>		@	750MG	A212053	002	Sep 14, 2020	Sep CAHN

TABLET;ORAL

CHLORZOAZONE

	@		750MG	A212053	002	Sep 14, 2020	Aug	CAHN
AA	RISING		250MG	A216925	001	Aug 09, 2023	Aug	CAHN
AA	SENORES PHARMS		250MG	A215158	001	Jul 29, 2021	Feb	CAHN
AA			500MG	A210961	001	Jan 22, 2024	Feb	CAHN
>D>	AB	TEVA PHARMS USA INC	375MG	A212898	001	Jun 17, 2020	Sep	DISC
>A>	@		375MG	A212898	001	Jun 17, 2020	Sep	DISC
>D>	AB		750MG	A212898	002	Jun 17, 2020	Sep	DISC
>A>	@		750MG	A212898	002	Jun 17, 2020	Sep	DISC

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE LIGHT

AB		ENDO OPERATIONS	EQ 4GM RESIN/PACKET	A077203	001	Aug 26, 2005	May	CAHN
AB			EQ 4GM RESIN/SCOOPFUL	A077203	002	Aug 26, 2005	May	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

	@	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Mar	DISC
	@		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Mar	DISC
	@	ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	May	CAHN
	@		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	May	CAHN
	@	MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Aug	DISC
AB			EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Feb	NEWA
	@		EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Aug	DISC
AB			EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Feb	NEWA
AB	RISING		EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN
AB			EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN
	@	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Aug	DISC
AB			EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CAHN
	@		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Aug	DISC
AB			EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CAHN

CICLESONIDE

AEROSOL, METERED;NASAL

ZETONNA

	+ @	COVIS	0.037MG/INH	N202129	001	Jan 20, 2012	Aug	DISC
--	-----	-------	-------------	---------	-----	--------------	-----	------

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

AB		TARO	0.77%	A076790	001	Apr 12, 2005	Jan	CAHN
----	--	------	-------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CICLOPIROX

@ COSETTE

@ HIKMA

			8%	A078233	001	Sep 18, 2007	Jul	DISC
			8%	A078270	001	Sep 18, 2007	Mar	DISC

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

@ RISING

@

			50MG	A077323	002	Apr 20, 2006	Feb	CAHN
			100MG	A077323	001	Apr 20, 2006	Feb	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

@ COSETTE

@ ENDO OPERATIONS

@

			EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997	Jun	CAHN
			EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994	May	CAHN
			EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	May	CAHN

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM

>D>			EQ 300MG BASE/5ML	A074664	001	Oct 28, 1997	Sep	CMFD
>A>	!		EQ 300MG BASE/5ML	A074664	001	Oct 28, 1997	Sep	CMFD
	@		EQ 300MG BASE/5ML	A074664	001	Oct 28, 1997	Feb	DISC
	@	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	Feb	DISC

CIPROFLOXACIN HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC							
	CIPROFLOXACIN HYDROCHLORIDE							
	@ THE J MOLNER	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jun	CAHN	
	SOLUTION/DROPS;OTIC							
	CETRAXAL							
	+! KEY THERAP	EQ 0.2% BASE	N021918	001	May 01, 2009	Apr	CAHN	
	TABLET;ORAL							
	CIPROFLOXACIN HYDROCHLORIDE							
AB	AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Apr	CMFD	
AB		EQ 500MG BASE	A076593	003	Jun 09, 2004	Apr	CMFD	
AB		EQ 750MG BASE	A076593	004	Jun 09, 2004	Apr	CMFD	

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL							
	CIPROFLOXACIN EXTENDED RELEASE							
	@ ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Mar	DISC	
	@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Mar	DISC	
	! DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CTEC	
AB	!	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CHRS	
	@ ENDO OPERATIONS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May	CAHN	
	@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May	CAHN	

CIPROFLOXACIN; DEXAMETHASONE

	SUSPENSION/DROPS;OTIC							
	CIPROFLOXACIN; DEXAMETHASONE							
AB	AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Mar	NEWA	

CISATRACURIUM BESYLATE

	INJECTABLE;INJECTION							
	CISATRACURIUM BESYLATE							
	@ CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Apr	DISC	
	@	EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Apr	DISC	
AP	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Mar	NEWA	
AP	! METHEAL	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr	CHRS	
AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CMS1	
	CISATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Aug	NEWA	
AP		EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Aug	NEWA	
	NIMBEX							
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Apr	DISC	
	NIMBEX PRESERVATIVE FREE							
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Apr	DISC	
	+ @	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Apr	DISC	

CISPLATIN

	INJECTABLE;INJECTION							
	CISPLATIN							
AP	QILU	1MG/ML	A218868	001	May 10, 2024	May	NEWA	

CITALOPRAM HYDROBROMIDE

	TABLET;ORAL							
	CITALOPRAM HYDROBROMIDE							
AB	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Jan	CAHN	
AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Jan	CAHN	
AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Jan	CAHN	
	@ CHARTWELL RX	EQ 10MG BASE	A077040	001	Aug 17, 2005	Aug	CAHN	
	@	EQ 20MG BASE	A077040	002	Aug 17, 2005	Aug	CAHN	
	@	EQ 40MG BASE	A077040	003	Aug 17, 2005	Aug	CAHN	
	@ COSETTE	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	DISC	
	@	EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	DISC	
	@	EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	DISC	
	@ TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006	Jan	CAHN	
	@	EQ 20MG BASE	A077278	002	Mar 22, 2006	Jan	CAHN	
	@	EQ 40MG BASE	A077278	003	Mar 22, 2006	Jan	CAHN	

CLADRIBINEINJECTABLE; INJECTION  
CLADRIBINE

@ NORVIUM BIOSCIENCE	1MG/ML	A200510	001	Oct 06, 2011	Jun	CAHN
----------------------	--------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATESYRUP; ORAL  
CLEMASTINE FUMARATE

AA	!	GENUS	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	Aug	CTEC
	@	NEW HEIGHTS	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jan	CAHN
AA		NEW HEIGHTSRX	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Aug	CMFD
	@		EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jul	CAHN

TABLET; ORAL  
CLEMASTINE FUMARATE  
@ OMNIVIUM PHARMS

2.68MG	A073459	001	Oct 31, 1993	Jun	CAHN
--------	---------	-----	--------------	-----	------

CLINDAMYCIN HYDROCHLORIDECAPSULE; ORAL  
CLINDAMYCIN HYDROCHLORIDE

@ COSETTE	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	DISC
@	EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL  
CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D> AA		LYNE	EQ 75MG BASE/5ML	A201821	001	Aug 28, 2012	Sep	CAHN
>A> AA		RISING	EQ 75MG BASE/5ML	A201821	001	Aug 28, 2012	Sep	CAHN

CLINDAMYCIN PHOSPHATEGEL; TOPICAL  
CLINDAMYCIN PHOSPHATE

AB1		ALEMBIC	EQ 1% BASE	A212466	001	Apr 02, 2024	Mar	NEWA
	@	AMNEAL	EQ 1% BASE	A215219	001	Nov 03, 2022	Feb	DISC
>A> AB1		QUAGEN	EQ 1% BASE	A211872	001	Jul 29, 2020	Sep	CAHN
>D> AB1		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Sep	CAHN

GEL; VAGINAL  
XACIATO

+!	ORGANON LLC	EQ 2% BASE	N215650	001	Dec 07, 2021	Jan	CAHN
----	-------------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL  
CLINDAMYCIN PHOSPHATE  
@ ENDO OPERATIONS

EQ 1% BASE	A203343	001	May 29, 2015	Apr	CAHN
------------	---------	-----	--------------	-----	------

CLOBAZAMTABLET; ORAL  
CLOBAZAM

>A>	@	ANDA REPOSITORY	10MG	A211959	001	Dec 09, 2020	Sep	CAHN
>A>	@		20MG	A211959	002	Dec 09, 2020	Sep	CAHN
	@	BRECKENRIDGE	20MG	A209308	002	Oct 22, 2018	Jan	DISC
>D>	@	CELLTRION	10MG	A211959	001	Dec 09, 2020	Sep	CAHN
>D>	@		20MG	A211959	002	Dec 09, 2020	Sep	CAHN

CLOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL  
CLOBETASOL PROPIONATE

AB2		TARO	0.05%	A208563	001	Mar 14, 2024	Mar	NEWA
-----	--	------	-------	---------	-----	--------------	-----	------

CREAM; TOPICAL  
CLOBETASOL PROPIONATE

@ COSETTE	0.05%	A074139	001	Aug 03, 1994	Apr	DISC
CORMAX						
@ HIKMA	0.05%	A074220	001	May 16, 1997	Mar	DISC

GEL; TOPICAL  
EMBELINE

@ HIKMA	0.05%	A076141	001	Apr 12, 2002	Mar	DISC
---------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL  
EMBELINE

@ HIKMA	0.05%	A074221	001	Mar 31, 1995	Mar	DISC
---------	-------	---------	-----	--------------	-----	------

SHAMPOO; TOPICAL  
CLOBETASOL PROPIONATE

@ HIKMA	0.05%	A209871	001	Oct 27, 2017	Mar	DISC
---------	-------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL									
CLOBETASOL PROPIONATE									
	@	COSETTE	0.05%	A074331	001	Dec 15, 1995	Apr	DISC	
AT		ENCUBE	0.05%	A076977	001	Aug 05, 2005	May	CMFD	
EMBELINE									
	@	HIKMA	0.05%	A074222	001	Dec 06, 1995	Mar	DISC	
SUSPENSION/DROPS;OPHTHALMIC									
CLOBETASOL PROPIONATE									
	+	EYENOVIA	0.05%	N218158	001	Mar 04, 2024	May	CAHN	
	+	FORMOSA	0.05%	N218158	001	Mar 04, 2024	Mar	NEWA	
<u>CLOCORTOLONE PIVALATE</u>									
CREAM;TOPICAL									
CLODERM									
AB	+	LEGACY PHARMA	0.1%	N017765	001		Apr	CAHN	
<u>CLOMIPRAMINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
CLOMIPRAMINE HYDROCHLORIDE									
AB		CHARTWELL RX	25MG	A074364	001	Mar 29, 1996	Mar	CAHN	
AB			50MG	A074364	002	Mar 29, 1996	Mar	CAHN	
AB			75MG	A074364	003	Mar 29, 1996	Mar	CAHN	
	@	MYLAN	25MG	A074947	001	Apr 30, 1998	May	DISC	
	@		50MG	A074947	002	Apr 30, 1998	May	DISC	
	@		75MG	A074947	003	Apr 30, 1998	May	DISC	
	@	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar	DISC	
	@		50MG	A213221	002	Jun 22, 2020	Mar	DISC	
	@		75MG	A213221	003	Jun 22, 2020	Mar	DISC	
>A>	AB	TRUPHARMA	25MG	A210653	001	Apr 03, 2020	Sep	CAHN	
>A>	AB		50MG	A210653	002	Apr 03, 2020	Sep	CAHN	
>A>	AB		75MG	A210653	003	Apr 03, 2020	Sep	CAHN	
>D>	AB	TULEX PHARMS INC	25MG	A210653	001	Apr 03, 2020	Sep	CAHN	
>D>	AB		50MG	A210653	002	Apr 03, 2020	Sep	CAHN	
>D>	AB		75MG	A210653	003	Apr 03, 2020	Sep	CAHN	
<u>CLONAZEPAM</u>									
TABLET, ORALLY DISINTEGRATING;ORAL									
CLONAZEPAM									
AB		ENDO OPERATIONS	0.125MG	A077171	001	Aug 03, 2005	Apr	CAHN	
AB			0.25MG	A077171	002	Aug 03, 2005	Apr	CAHN	
AB			0.5MG	A077171	003	Aug 03, 2005	Apr	CAHN	
AB	!		1MG	A077171	004	Aug 03, 2005	Apr	CAHN	
AB			2MG	A077171	005	Aug 03, 2005	Apr	CAHN	
<u>CLONIDINE</u>									
SYSTEM;TRANSDERMAL									
CLONIDINE									
>D>	AB	AVEVA	0.1MG/24HR	A076157	001	Aug 18, 2009	Sep	CAHN	
>D>	AB		0.2MG/24HR	A076157	002	Aug 18, 2009	Sep	CAHN	
>D>	AB		0.3MG/24HR	A076157	003	Aug 18, 2009	Sep	CAHN	
>A>	AB	DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Sep	CAHN	
>A>	AB		0.2MG/24HR	A076157	002	Aug 18, 2009	Sep	CAHN	
>A>	AB		0.3MG/24HR	A076157	003	Aug 18, 2009	Sep	CAHN	
<u>CLONIDINE HYDROCHLORIDE</u>									
SUSPENSION, EXTENDED RELEASE;ORAL									
ONYDA XR									
	+	TRIS PHARMA INC	0.1MG/ML	N217645	001	May 24, 2024	May	NEWA	
TABLET;ORAL									
CLONIDINE HYDROCHLORIDE									
>A>	AB	TRUPHARMA	0.1MG	A070923	003	Sep 04, 1987	Sep	CAHN	
>A>	AB		0.2MG	A070923	002	Sep 04, 1987	Sep	CAHN	
>A>	AB		0.3MG	A070923	001	Sep 04, 1987	Sep	CAHN	
>D>	AB	URL LABS	0.1MG	A070923	003	Sep 04, 1987	Sep	CAHN	
>D>	AB		0.2MG	A070923	002	Sep 04, 1987	Sep	CAHN	
>D>	AB		0.3MG	A070923	001	Sep 04, 1987	Sep	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
CLONIDINE HYDROCHLORIDE									
	@	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Mar	DISC	
	@	BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	Jan	CAHN	
	@	ENDO OPERATIONS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN	
	@		0.1MG	A202984	001	Sep 30, 2013	May	CAHN	

TABLET, EXTENDED RELEASE;ORAL  
CLONIDINE HYDROCHLORIDE

@		0.2MG	A202983	002	Apr 02, 2014	May	CAHN
@		0.2MG	A202984	002	Sep 30, 2013	May	CAHN
@	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	May	CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL  
CLOPIDOGREL BISULFATE

	@	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	May	DISC
	@		EQ 300MG BASE	A202925	002	Mar 27, 2013	May	DISC
AB		DR REDDYS LABS LTD	EQ 75MG BASE	A091023	002	Aug 05, 2024	Jul	NEWA
>A>	AB	MSN	EQ 75MG BASE	A215388	001	Sep 20, 2024	Sep	NEWA

CLOTRIMAZOLE

SOLUTION;TOPICAL  
CLOTRIMAZOLE

AT		TRUPHARMA	1%	A212281	001	Jul 25, 2019	Aug	CAHN
----	--	-----------	----	---------	-----	--------------	-----	------

TROCHE/LOZENGE;ORAL  
CLOTRIMAZOLE

AB		THINQ PHARM-CRO PVT	10MG	A215641	001	Feb 29, 2024	Feb	NEWA
----	--	---------------------	------	---------	-----	--------------	-----	------

CLOZAPINE

TABLET;ORAL  
CLOZARIL

	+ @	HERITAGE LIFE	50MG	N019758	003	May 20, 2019	Aug	DISC
	+ @		200MG	N019758	004	May 20, 2019	Aug	DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
CLOZAPINE

AB		BARR LABS INC	150MG	A090308	004	Nov 25, 2015	Jun	CMS1
AB			200MG	A090308	005	Nov 25, 2015	Jun	CMS1

COBICISTAT

TABLET;ORAL  
COBICISTAT

AB		MYLAN LABS LTD	150MG	A209986	001	Feb 07, 2024	Jan	NFTG
AB	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Jan	CFTG

COCAINE HYDROCHLORIDE

SOLUTION;NASAL  
GOPRELTO

+!		NODEN PHARMA	4%	N209963	001	Dec 14, 2017	Jan	CAHN
----	--	--------------	----	---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

AA	!	GENUS	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	Apr	CAHN
			PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE					
	@	HIKMA	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Mar	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

	@	HIKMA	10MG/5ML;6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC
--	---	-------	---------------------	---------	-----	--------------	-----	------

COLCHICINE

CAPSULE;ORAL  
COLCHICINE

AB		ANNORA PHARMA	0.6MG	A217620	001	Apr 29, 2024	Apr	NEWA
AB		AUROBINDO PHARMA LTD	0.6MG	A215463	001	Apr 29, 2024	Apr	NEWA
AB		GRANULES	0.6MG	A210757	001	Apr 29, 2024	Apr	NEWA

TABLET;ORAL  
COLCHICINE

AB	!	ENDO OPERATIONS	0.6MG	A203976	001	Aug 12, 2021	May	CHRS
	@	MYLAN	0.6MG	A209470	001	Sep 16, 2019	Apr	DISC
	+ @	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	May	DISC

<u>COLESEVELAM HYDROCHLORIDE</u>							
FOR SUSPENSION;ORAL							
COLESEVELAM HYDROCHLORIDE							
	@ IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	May	DISC
<u>COLESTIPOL HYDROCHLORIDE</u>							
GRANULE;ORAL							
FLAVORED COLESTID							
	+ @ PFIZER	5GM/PACKET	N017563	001		Jun	DISC
	+ @	5GM/SCOOPFUL	N017563	002		Jun	DISC
TABLET;ORAL							
COLESTIPOL HYDROCHLORIDE							
AB	EDENBRIDGE PHARMS	1GM	A217667	001	Aug 16, 2024	Aug	NEWA
<u>COLISTIMETHATE SODIUM</u>							
INJECTABLE;INJECTION							
COLISTIMETHATE SODIUM							
AP	ADRASTEIA PHARMA	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Jul	CAHN
<u>COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE</u>							
SUSPENSION/DROPS;OTIC							
COLY-MYCIN S							
	+! ENDO OPERATIONS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		Apr	CAHN
<u>COPPER</u>							
SYSTEM;INTRAUTERINE							
PARAGARD T 380A							
	+! COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984	Jun	CDFR
<u>CORTICOTROPIN</u>							
INJECTABLE;INJECTION							
ACTHAR GEL (AUTOINJECTOR)							
	+! MALLINCKRODT ARD	40 UNITS/0.5ML	N008372	003	Feb 29, 2024	Mar	NEWA
	+!	80 UNITS/ML	N008372	004	Feb 29, 2024	Mar	NEWA
<u>COSYNTROPIN</u>							
INJECTABLE;INJECTION							
COSYNTROPIN							
	@ MYLAN INSTITUTIONAL	0.25MG/VIAL	A090574	001	Dec 17, 2009	May	DISC
<u>CUPRIC CHLORIDE</u>							
INJECTABLE;INJECTION							
CUPRIC CHLORIDE							
AP	RK PHARMA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	May	CAHN
AP	SOMERSET	EQ 0.4MG COPPER/ML	A216113	001	Apr 30, 2024	Apr	NEWA
AP	STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	Apr	NEWA
<u>CUPRIC SULFATE</u>							
INJECTABLE;INJECTION							
CUPRIC SULFATE							
AP	! AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Aug	CTEC
AP	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Aug	NEWA
<u>CYANOCOBALAMIN</u>							
GEL, METERED;NASAL							
NASCOBAL							
	@ ENDO OPERATIONS	0.5MG/INH	N019722	001	Nov 05, 1996	May	CAHN
INJECTABLE;INJECTION							
CYANOCOBALAMIN							
	@ EUGIA PHARMA	1MG/ML	A213874	001	Dec 08, 2020	Jun	DISC
AP	MANKIND PHARMA	1MG/ML	A217839	001	Jul 10, 2024	Jun	NEWA
SPRAY, METERED;NASAL							
CALOMIST							
	@ ENDO OPERATIONS	25MCG/SPRAY	N022102	001	Jul 27, 2007	May	CAHN
CYANOCOBALAMIN							
AB	! PADAGIS ISRAEL	0.5MG/SPRAY	A212458	001	Sep 09, 2020	Jul	CHRS
NASCOBAL							
	+ @ ENDO OPERATIONS	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Jul	DISC
AB	+!	0.5MG/SPRAY	N021642	001	Jan 31, 2005	May	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL		CYCLOBENZAPRINE HYDROCHLORIDE					
AB	MACLEODS PHARMS LTD	15MG		A207314	001	Jul 22, 2024	Jul NEWA
AB		30MG		A207314	002	Jul 22, 2024	Jul NEWA
AB	NOVAST LABS	15MG		A214732	001	Aug 27, 2024	Aug NEWA
AB		30MG		A214732	002	Aug 27, 2024	Aug NEWA
TABLET;ORAL		CYCLOBENZAPRINE HYDROCHLORIDE					
	@ AIPING PHARM INC	5MG		A072854	002	Feb 03, 2006	Jun CAHN
	@	10MG		A072854	001	Nov 19, 1991	Jun CAHN
>A>	AB GRAVITI PHARMS	5MG		A218936	001	Sep 12, 2024	Sep NEWA
>A>	AB	7.5MG		A218936	002	Sep 12, 2024	Sep NEWA
>A>	AB	10MG		A218936	003	Sep 12, 2024	Sep NEWA

CYCLOPHOSPHAMIDE

CAPSULE;ORAL		CYCLOPHOSPHAMIDE					
AB	KANCHAN HLTHCARE	25MG		A209872	001	May 07, 2018	Aug CAHN
AB		50MG		A209872	002	May 07, 2018	Aug CAHN
INJECTABLE;INJECTION		CYCLOPHOSPHAMIDE					
AP	HIKMA	500MG/VIAL		A216958	001	Dec 18, 2023	Jan CAHN
AP		1GM/VIAL		A216958	002	Dec 18, 2023	Jan CAHN
AP		2GM/VIAL		A216958	003	Dec 18, 2023	Jan CAHN
SOLUTION;INTRAVENOUS		CYCLOPHOSPHAMIDE					
+	AVYXA HOLDINGS	500MG/ML (500MG/ML)		N210852	001	Jun 07, 2023	Jun CAHN
+		1GM/2ML (500MG/ML)		N210852	002	Jun 07, 2023	Jun CAHN
+		2GM/4ML (500MG/ML)		N210852	003	Jun 07, 2023	Jun CAHN
+	@ BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)		N217651	001	Jun 28, 2023	Jan CAHN
+	@	1GM/5ML (200MG/ML)		N217651	002	Jun 28, 2023	Jan CAHN
+	DR REDDYS	500MG/2.5ML (200MG/ML)		N212501	001	Jul 30, 2020	Jun CAHN
+		1GM/5ML (200MG/ML)		N212501	002	Jul 30, 2020	Jun CAHN
+		2GM/10ML (200MG/ML)		N212501	003	Nov 19, 2021	Jun CAHN

CYCLOSERINE

CAPSULE;ORAL		SEROMYCIN					
>D>	! CEROVENE INC	250MG		A060593	001		Sep CAHN
>A>	! SANALUZ	250MG		A060593	001		Sep CAHN

CYCLOSPORINE

EMULSION;OPHTHALMIC		CYCLOSPORINE					
AB	DEVA HOLDING AS	0.05%		A209811	001	May 21, 2024	May NEWA
AB	SAPTALIS PHARMS	0.05%		A211943	001	Jul 05, 2024	Jun NEWA
	@ TEVA PHARMS USA INC	0.05%		A203880	001	Dec 14, 2023	Jun DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL		CYPROHEPTADINE HYDROCHLORIDE					
>D>	AA ! LYNE	2MG/5ML		A040668	001	Jun 28, 2006	Sep CAHN
	@ PATRIN	2MG/5ML		A204823	001	Dec 27, 2016	Apr DISC
	@ PHARM ASSOC	2MG/5ML		A091295	001	Mar 28, 2013	Feb DISC
>A>	AA ! RISING	2MG/5ML		A040668	001	Jun 28, 2006	Sep CAHN
TABLET;ORAL		CYPROHEPTADINE HYDROCHLORIDE					
	@ CHARTWELL RX	4MG		A086808	001		Aug CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS		ELCYS					
+	@ EXELA PHARMA	2500MG/50ML (50MG/ML)		N210660	002	Dec 04, 2023	Jan DISC

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL		DABIGATRAN ETEXILATE MESYLATE					
AB	ALEMBIC	EQ 75MG BASE		A215233	001	Jun 14, 2024	Jun NEWA
AB		EQ 110MG BASE		A215233	003	Aug 12, 2024	Aug NEWA
AB		EQ 150MG BASE		A215233	002	Jun 14, 2024	Jun NEWA



CAPSULE;ORALDABIGATRAN ETEXILATE MESYLATE

AB	ALKEM LABS LTD	EQ 110MG BASE	A208040	003	Sep 11, 2024	Aug	NEWA
AB	HETERO LABS LTD III	EQ 110MG BASE	A207961	003	Aug 13, 2024	Aug	NEWA
AB	MSN	EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA
AB		EQ 110MG BASE	A213879	003	Aug 12, 2024	Aug	NEWA
AB		EQ 150MG BASE	A213879	002	May 22, 2024	May	NEWA

DACTINOMYCININJECTABLE;INJECTIONCOSMEGEN

	+ @ RECORDATI RARE	0.5MG/VIAL	N050682	001		Jan	DISC
	DACTINOMYCIN						
AP	! EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CHRS

>D> DALFOPRISTIN; QUINUPRISTIN>D> INJECTABLE;INTRAVENOUS>D> SYNERCID

>D>	+! KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999	Sep	DISC
>A>	+ @	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999	Sep	DISC

DANICOPANTABLET;ORALVOYDEYA

	+ ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024	Mar	NEWA
	+!	100MG	N218037	002	Mar 29, 2024	Mar	NEWA

DAPIPRAZOLE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMICDAPIPRAZOLE HYDROCHLORIDE

	@ BARADAINA LLC	0.5%	A204902	001	May 30, 2019	Aug	CAHN
--	-----------------	------	---------	-----	--------------	-----	------

DAPRODUSTATTABLET;ORALJESDUVROQ

	+ @ GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	May	DISC
	+ @	2MG	N216951	002	Feb 01, 2023	May	DISC
	+ @	4MG	N216951	003	Feb 01, 2023	May	DISC
	+ @	6MG	N216951	004	Feb 01, 2023	May	DISC
	+ @	8MG	N216951	005	Feb 01, 2023	May	DISC

DAPSONEGEL;TOPICALDAPSONE

>D>	AB	ACRUX DDS	7.5%	A213636	001	Aug 26, 2024	Sep	CAHN
	AB		7.5%	A213636	001	Aug 26, 2024	Aug	NEWA
>D>	AB	BELOTECA	5%	A213907	001	Jun 06, 2023	Sep	CAHN
	@	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC
	@		7.5%	A212657	001	Nov 01, 2023	Jan	DISC
	AB	TARO	5%	A209506	001	Oct 16, 2017	Jun	CAHN
>A>	AB	TRUPHARMA	5%	A213907	001	Jun 06, 2023	Sep	CAHN
>A>	AB		7.5%	A213636	001	Aug 26, 2024	Sep	CAHN
	AB	ZYDUS	7.5%	A214019	001	May 08, 2024	Apr	NEWA
	AB	ZYDUS LIFESCIENCES	7.5%	A214019	001	May 08, 2024	May	CAHN

DAPTOMYCINPOWDER;INTRAVENOUSDAPTOMYCIN

AP	BIOCON PHARMA	500MG/VIAL	A217215	001	Aug 29, 2024	Aug	NEWA
AP	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jul	NEWA

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE;ORALDARIFENACIN HYDROBROMIDE

	@ ENDO OPERATIONS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	May	CAHN
	@	EQ 15MG BASE	A091190	002	Mar 13, 2015	May	CAHN

DARUNAVIR

TABLET; ORAL

DARUNAVIR

AB	ZYDUS LIFESCIENCES	600MG	A214085	001	Dec 13, 2023	May	CAHN
AB		800MG	A214085	002	Dec 13, 2023	May	CAHN

DASATINIB

TABLET; ORAL

DASATINIB

AB	APOTEX	20MG	A202103	001	Jun 10, 2016	Aug	CMFD
AB		50MG	A202103	002	Jun 10, 2016	Aug	CMFD
AB		70MG	A202103	003	Jun 10, 2016	Aug	CMFD
AB		80MG	A203180	001	Nov 23, 2021	Aug	CMFD
AB		100MG	A202103	004	Jun 10, 2016	Aug	CMFD
AB		140MG	A203180	002	Nov 23, 2021	Aug	CMFD

SPRYCEL

AB	+ BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	Aug	CTEC
AB	+	50MG	N021986	002	Jun 28, 2006	Aug	CTEC
AB	+	70MG	N021986	003	Jun 28, 2006	Aug	CTEC
AB	+	80MG	N021986	005	Oct 28, 2010	Aug	CTEC
AB	+!	100MG	N021986	004	May 30, 2008	Aug	CTEC
AB	+	140MG	N021986	006	Oct 28, 2010	Aug	CTEC

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

AP	HETERO LABS LTD VI	50MG/VIAL	A215355	001	May 10, 2024	May	NEWA
----	--------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

AB	GLENMARK SPECLT	125MG	A209433	001	Jan 06, 2020	May	CAHN
AB		250MG	A209433	002	Jan 06, 2020	May	CAHN
AB		500MG	A209433	003	Jan 06, 2020	May	CAHN
AB	TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Jul	CMFD
AB		250MG	A207124	002	Sep 23, 2022	Jul	CMFD
AB		500MG	A207124	003	Sep 23, 2022	Jul	CMFD

DEFLAZACORT

SUSPENSION; ORAL

DEFLAZACORT

AB	TRIS PHARMA INC	22.75MG/ML	A217813	001	Apr 25, 2024	Apr	NFTG
	EMFLAZA						
AB	+! PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CFTG
	TABLET; ORAL						
	DEFLAZACORT						
AB	AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb	NFTG
AB		18MG	A217123	002	Feb 09, 2024	Feb	NFTG
AB		30MG	A217123	003	Feb 09, 2024	Feb	NFTG
AB		36MG	A217123	004	Feb 09, 2024	Feb	NFTG
	EMFLAZA						
AB	+ PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb	CFTG
AB	+	18MG	N208684	002	Feb 09, 2017	Feb	CFTG
AB	+	30MG	N208684	003	Feb 09, 2017	Feb	CFTG
AB	+!	36MG	N208684	004	Feb 09, 2017	Feb	CFTG

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS

DEOXYCHOLIC ACID

AP	WILSHIRE PHARMS INC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Jul	CAHN
	KYBELLA						
AP	+! ABBVIE	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Jan	CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar	CAHN
AB		25MG	A072103	003	May 24, 1988	Mar	CAHN
AB		50MG	A072103	004	May 24, 1988	Mar	CAHN
AB		75MG	A072103	005	Jun 20, 1988	Mar	CAHN
AB		100MG	A072103	001	Jun 20, 1988	Mar	CAHN

TABLET;ORAL		DESIPRAMINE HYDROCHLORIDE							
AB		150MG		A072103	006	Jun 20, 1988	Mar	CAHN	
<u>DESLORATADINE</u>									
TABLET;ORAL		DESLORATADINE							
	@ CHARTWELL RX	5MG		A078364	001	Dec 03, 2010	Jan	CAHN	
<u>DESMOPRESSIN ACETATE</u>									
TABLET;ORAL		DESMOPRESSIN ACETATE							
	@ ACTAVIS LABS FL INC	0.1MG		A076470	001	Jul 01, 2005	Feb	DISC	
	@	0.2MG		A076470	002	Jul 01, 2005	Feb	DISC	
AB	AUROBINDO PHARMA	0.1MG		A213095	001	Mar 21, 2024	Mar	NEWA	
AB		0.2MG		A213095	002	Mar 21, 2024	Mar	NEWA	
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>									
TABLET;ORAL-28		DESOGESTREL AND ETHINYL ESTRADIOL							
AB	NAARI PTE LTD	0.15MG;0.03MG		A207067	001	Sep 13, 2018	Apr	CMFD	
	@ XIROMED	0.15MG;0.03MG		A202085	001	May 20, 2015	Apr	CAHN	
		EMOQUETTE							
	@ ENDO OPERATIONS	0.15MG;0.03MG		A076675	001	Feb 25, 2011	May	CAHN	
		KIMIDESS							
	@ ENDO OPERATIONS	0.15MG,N/A;0.02MG,0.01MG		A076681	001	Apr 30, 2015	Aug	DISC	
AB		0.15MG,N/A;0.02MG,0.01MG		A076681	001	Apr 30, 2015	May	CAHN	
<u>DESONIDE</u>									
OINTMENT;TOPICAL		DESONIDE							
	@ HIKMA	0.05%		A208836	001	Mar 27, 2017	Mar	DISC	
<u>DESOXIMETASONE</u>									
CREAM;TOPICAL		DESOXIMETASONE							
	@ COSETTE	0.25%		A209595	001	Mar 04, 2020	Mar	DISC	
OINTMENT;TOPICAL		DESOXIMETASONE							
	@ COSETTE	0.25%		A206740	001	Dec 23, 2016	Apr	DISC	
<u>DESVENLAFAXINE SUCCINATE</u>									
TABLET, EXTENDED RELEASE;ORAL		DESVENLAFAXINE SUCCINATE							
	@ NORVIUM BIOSCIENCE	EQ 50MG BASE		A204095	001	Jun 29, 2015	Jun	CAHN	
	@	EQ 100MG BASE		A204095	002	Jun 29, 2015	Jun	CAHN	
<u>DEURUXOLITINIB PHOSPHATE</u>									
TABLET;ORAL		LEQSELVI							
+	! SUN PHARM INDS INC	EQ 8MG BASE		N217900	001	Jul 25, 2024	Jul	NEWA	
<u>DEUTETRABENAZINE</u>									
TABLET, EXTENDED RELEASE;ORAL		AUSTEDO XR							
+	TEVA	18MG		N216354	008	Jul 01, 2024	Jul	NEWA	
+		30MG		N216354	004	May 29, 2024	May	NEWA	
+		36MG		N216354	005	May 29, 2024	May	NEWA	
+		42MG		N216354	006	May 29, 2024	May	NEWA	
<u>DEXAMETHASONE</u>									
ELIXIR;ORAL		DEXAMETHASONE							
AA	! KANCHAN HLTHCARE	0.5MG/5ML		A084754	001		Aug	CAHN	
>D>	AA LYNE	0.5MG/5ML		A090891	001	Jul 12, 2011	Sep	CAHN	
>A>	AA RISING	0.5MG/5ML		A090891	001	Jul 12, 2011	Sep	CAHN	
TABLET;ORAL		DEXAMETHASONE							
>A>	@ ABRAXEOLUS	0.25MG		A088149	001	Apr 28, 1983	Sep	CAHN	
>A>	AB COREPHARMA	0.5MG		A218372	001	Sep 17, 2024	Sep	NEWA	
>A>	AB	0.75MG		A218372	002	Sep 17, 2024	Sep	NEWA	

TABLET; ORAL

DEXAMETHASONE

>A>	AB		1MG	A218372	003	Sep 17, 2024	Sep	NEWA
>A>	AB		1.5MG	A218372	004	Sep 17, 2024	Sep	NEWA
>A>	AB		2MG	A218372	005	Sep 17, 2024	Sep	NEWA
>A>	AB		4MG	A218372	006	Sep 17, 2024	Sep	NEWA
>A>	AB		6MG	A218372	007	Sep 17, 2024	Sep	NEWA
		@ KEY THERAP	1.5MG	A088237	001	Apr 28, 1983	May	DISC
BP			1.5MG	A088237	001	Apr 28, 1983	Apr	CAHN
>D>		@ PANGEA	0.25MG	A088149	001	Apr 28, 1983	Sep	CAHN
		@	0.25MG	A088149	001	Apr 28, 1983	Jan	CAHN
	AB	ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar	CAHN
	AB		0.75MG	A216282	002	Feb 07, 2024	Mar	CAHN
	AB		1MG	A216284	001	May 09, 2024	May	CAHN
	AB		1.5MG	A216282	003	Feb 07, 2024	Mar	CAHN
	AB		2MG	A216283	001	Feb 07, 2024	Mar	CAHN
	AB		4MG	A216282	004	Feb 07, 2024	Mar	CAHN
	AB		6MG	A216282	005	Feb 07, 2024	Mar	CAHN
	AB	ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan	NEWA
	AB		0.75MG	A216282	002	Feb 07, 2024	Jan	NEWA
	AB		1MG	A216284	001	May 09, 2024	May	NEWA
	AB		1.5MG	A216282	003	Feb 07, 2024	Jan	NEWA
	AB		2MG	A216283	001	Feb 07, 2024	Jan	NEWA
	AB		4MG	A216282	004	Feb 07, 2024	Jan	NEWA
	AB		6MG	A216282	005	Feb 07, 2024	Jan	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

		@ GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214890	002	Jul 28, 2023	Jul	CMS1
		@	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC
AP		HIKMA	EQ 4MG PHOSPHATE/ML	A084282	001		Jun	CAHN
		@	EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul	DISC
AP	!		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Jun	CAHN
AP		MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar	NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

	+	@ PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Mar	DISC
		POLMON						
	!	CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CTEC
AA	!		2MG/5ML	A202520	001	Jul 16, 2018	Mar	CHRS

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXLANSOPRAZOLE

AB		MYLAN	30MG	A205205	001	Jan 19, 2024	Jan	NEWA
AB			60MG	A205205	002	Jan 19, 2024	Jan	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

		@ WILSHIRE PHARMS INC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A212791	003	May 08, 2020	Jul	CAHN
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212791	001	Dec 04, 2019	Jul	CAHN
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A212791	002	Dec 04, 2019	Jul	CAHN

SOLUTION; INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

>D>	+	! HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015	Sep	CFTG
>A>	AP	+	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015	Sep	CFTG
>D>	+		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Sep	CFTG
>A>	AP	+	EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Sep	CFTG
>A>	AP	SOMERSET	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	A218112	002	Sep 24, 2024	Sep	NFTG
>A>	AP		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	A218112	001	Sep 24, 2024	Sep	NFTG

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL  
DEXEDRINE SPANSULE

AB	+	IMPAX LABS INC	5MG	N017078	001		Aug	CTNA
AB	+		10MG	N017078	002		Aug	CTNA
AB	+	!	15MG	N017078	003		Aug	CTNA
		DEXTROAMPHETAMINE SULFATE						
		@	NORVIUM BIOSCIENCE	5MG	A206735	001	Jan 27, 2016	Jun CAHN
		@		10MG	A206735	002	Jan 27, 2016	Jun CAHN
		@		15MG	A206735	003	Jan 27, 2016	Jun CAHN

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		AZURITY	2.5MG	A090533	001	Oct 25, 2011	Mar	CAHN
AA			5MG	A090533	002	Oct 25, 2011	Mar	CAHN
AA			7.5MG	A090533	003	Oct 25, 2011	Mar	CAHN
AA			10MG	A090533	004	Oct 25, 2011	Mar	CAHN
AA			15MG	A090533	005	Oct 25, 2011	Mar	CAHN
AA			20MG	A090533	006	Oct 25, 2011	Mar	CAHN
AA			30MG	A090533	007	Oct 25, 2011	Mar	CAHN
		@	TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Jan DISC
		@		10MG	A206095	002	Aug 18, 2022	Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>D>	+	@ ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984	Sep	CMFD
>A>	AA	+	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984	Sep	CMFD

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		HETERO LABS LTD III	20MG;10MG	A218426	001	Aug 28, 2024	Aug	NEWA
----	--	---------------------	-----------	---------	-----	--------------	-----	------

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5%

AP		AM REGENT	50MG/ML	A217263	001	Apr 08, 2024	Apr	CTNA
AP			50MG/ML	A217263	001	Apr 08, 2024	Mar	NEWA

DIAZEPAM

FILM;BUCCAL

LIBERVANT

+	AQUESTIVE	5MG	N218623	001	Apr 26, 2024	Apr	NEWA
+		7.5MG	N218623	002	Apr 26, 2024	Apr	NEWA
+		10MG	N218623	003	Apr 26, 2024	Apr	NEWA
+		12.5MG	N218623	004	Apr 26, 2024	Apr	NEWA
+	!	15MG	N218623	005	Apr 26, 2024	Apr	NEWA

INJECTABLE;INJECTION

DIAZEPAM

AP		ALEMBIC	10MG/2ML (5MG/ML)	A218450	001	Apr 25, 2024	Apr	NEWA
AP		DR REDDYS	10MG/2ML (5MG/ML)	A218422	001	Jul 18, 2024	Jul	NEWA
		@	HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985	Jan NEWA
		@		10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985	Jan NEWA
AP			50MG/10ML (5MG/ML)	A070311	001	Dec 16, 1985	Jan	CPOT

TABLET;ORAL

DIAZEPAM

		@	ENDO OPERATIONS	2MG	A070228	002	Sep 26, 1985	May CAHN
		@		5MG	A070228	003	Sep 26, 1985	May CAHN
		@		10MG	A070228	001	Sep 26, 1985	May CAHN
AB			NUVO PHARM	2MG	A070464	002	Sep 10, 2024	Aug NEWA
AB				5MG	A070464	003	Sep 10, 2024	Aug NEWA

DICHLORPHENAMIDE

TABLET;ORAL

ORMALVI

AB		TORRENT	50MG	A215924	001	Dec 29, 2022	Feb	CTNA
----	--	---------	------	---------	-----	--------------	-----	------

DICLOFENAC POTASSIUMFOR SOLUTION;ORAL  
DICLOFENAC POTASSIUM

AB	ENDO OPERATIONS	50MG	A202964	001	May 02, 2016	May	CAHN
AB	TARO	50MG	A218011	001	Jun 14, 2024	Jun	NEWA

DICLOFENAC SODIUMSOLUTION;TOPICAL  
DICLOFENAC SODIUM

AB	!	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Mar	CHRS
----	---	--------------	----	---------	-----	--------------	-----	------

DICLOFENAC SODIUM; MISOPROSTOLTABLET, DELAYED RELEASE;ORAL  
DICLOFENAC SODIUM AND MISOPROSTOL  
@ SANDOZ 50MG;0.2MG  
@ 75MG;0.2MG

A200158	001	May 09, 2013	Jul	DISC
A200158	002	May 09, 2013	Jul	DISC

DICLOXACILLIN SODIUMCAPSULE;ORAL  
DICLOXACILLIN SODIUM@ CHARTWELL RX EQ 125MG BASE  
@ EQ 250MG BASE  
@ EQ 500MG BASE

A061454	002		Jul	CAHN
A061454	001		Jul	CAHN
A061454	003		Jul	CAHN

DICYCLOMINE HYDROCHLORIDECAPSULE;ORAL  
DICYCLOMINE HYDROCHLORIDE

AB	ANNORA PHARMA	10MG	A218018	001	Jul 01, 2024	Jun	NEWA
----	---------------	------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION  
BENTYL+ @ ABBVIE 10MG/ML  
BENTYL PRESERVATIVE FREE

N008370	001	Oct 15, 1984	Apr	DISC
---------	-----	--------------	-----	------

+ @ ABBVIE 10MG/ML  
DICYCLOMINE HYDROCHLORIDE

N008370	002	Oct 15, 1984	Aug	DISC
---------	-----	--------------	-----	------

AP	!	FOSUN PHARMA	10MG/ML	A210979	001	Jul 02, 2018	Apr	CHRS
----	---	--------------	---------	---------	-----	--------------	-----	------

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP	!	HIKMA	10MG/ML	A040465	001	Jun 30, 2003	Aug	CHRS
----	---	-------	---------	---------	-----	--------------	-----	------

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

AA	!	ENDO OPERATIONS	10MG/5ML	A040169	001	Mar 24, 2005	Apr	CAHN
----	---	-----------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	ANNORA PHARMA	20MG	A217566	001	May 07, 2024	Apr	NEWA
----	---------------	------	---------	-----	--------------	-----	------

DIFLORASONE DIACETATECREAM;TOPICAL  
DIFLORASONE DIACETATE

>D>	BX	!	ANI PHARMS	0.05%	A076263	001	Dec 20, 2002	Sep	DISC
-----	----	---	------------	-------	---------	-----	--------------	-----	------

>A>		@		0.05%	A076263	001	Dec 20, 2002	Sep	DISC
-----	--	---	--	-------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

@ SAPTALIS PHARMS 0.05%  
@ SCIEGEN PHARMS INC 0.05%

A206572	001	Jul 24, 2015	Jun	CAHN
A206572	001	Jul 24, 2015	Aug	CAHN

DIFLUNISALTABLET;ORAL  
DIFLUNISALHERITAGE PHARMA 250MG  
375MG

A202845	002	Aug 16, 2024	Aug	NEWA
A202845	003	Aug 16, 2024	Aug	NFTG

DIFLUPREDNATEEMULSION;OPHTHALMIC  
DIFLUPREDNATE

AB	EPIC PHARMA LLC	0.05%	A207284	001	May 14, 2024	May	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

DIGOXIN

	ELIXIR;ORAL								
	DIGOXIN								
AA	VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN		
	INJECTABLE;INJECTION								
	DIGOXIN								
AP	HIKMA	0.25MG/ML	A083391	001		Jun	CAHN		

DIHYDROERGOTAMINE MESYLATE

	INJECTABLE;INJECTION								
	DIHYDROERGOTAMINE MESYLATE								
>A> AP	CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Sep	NEWA		
	SPRAY, METERED;NASAL								
	DIHYDROERGOTAMINE MESYLATE								
	@ AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar	DISC		
	TRUDHESA								
	+! IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Jun	CAHN		
	+! JN BIDCO	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN		

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL								
	DILTIAZEM HYDROCHLORIDE								
>D> AB2	AMTA	120MG	A216304	001	Aug 08, 2022	Sep	CAHN		
>D> AB2		180MG	A216304	002	Aug 08, 2022	Sep	CAHN		
>D> AB2		240MG	A216304	003	Aug 08, 2022	Sep	CAHN		
AB3	ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr	CAHN		
AB3		180MG	A074984	002	Dec 20, 1999	Apr	CAHN		
AB3		240MG	A074984	003	Dec 20, 1999	Apr	CAHN		
AB3		300MG	A074984	004	Dec 20, 1999	Apr	CAHN		
	@	360MG	A209766	001	May 30, 2018	May	CAHN		
	@ SUN PHARM	360MG	A090492	005	Oct 28, 2011	Feb	DISC		
>A> AB2	UTOPIC PHARMS	120MG	A216304	001	Aug 08, 2022	Sep	CAHN		
>A> AB2		180MG	A216304	002	Aug 08, 2022	Sep	CAHN		
>A> AB2		240MG	A216304	003	Aug 08, 2022	Sep	CAHN		
	TAZTIA XT								
	@ ACTAVIS LABS FL INC	120MG	A075401	001	Apr 10, 2003	Jul	DISC		
	@	180MG	A075401	002	Apr 10, 2003	Jul	DISC		
	@	240MG	A075401	003	Apr 10, 2003	Jul	DISC		
	@	300MG	A075401	004	Apr 10, 2003	Jul	DISC		
	@	360MG	A075401	005	Apr 10, 2003	Jul	DISC		
	INJECTABLE;INJECTION								
	DILTIAZEM HYDROCHLORIDE								
AP	HIKMA	5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN		
	@ HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC		

DIMETHYL FUMARATE

	CAPSULE, DELAYED RELEASE;ORAL								
	DIMETHYL FUMARATE								
AB	MACLEODS PHARMS LTD	120MG	A210377	001	Jun 26, 2024	Jun	NEWA		
AB		240MG	A210377	002	Jun 26, 2024	Jun	NEWA		

DIPHENHYDRAMINE HYDROCHLORIDE

	INJECTABLE;INJECTION								
	DIPHENHYDRAMINE HYDROCHLORIDE								
AP	GLAND PHARMA LTD	50MG/ML	A218448	001	Mar 20, 2024	Mar	NEWA		
	@ HIKMA	50MG/ML	A083183	001		Jun	CAHN		
AP	! MYLAN INSTITUTIONAL	50MG/ML	A040498	001	Jul 12, 2005	May	CHRS		

DIPYRIDAMOLE

	TABLET;ORAL								
	DIPYRIDAMOLE								
	@ CHARTWELL RX	25MG	A040898	001	Apr 23, 2008	Aug	CAHN		
	@	50MG	A040898	002	Apr 23, 2008	Aug	CAHN		
	@	75MG	A040898	003	Apr 23, 2008	Aug	CAHN		
	@ GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN		
	@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN		
	@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN		
AB	! IMPAX LABS	75MG	A040782	003	Jul 18, 2007	May	CHRS		
	PERSANTINE								
	+ @ BOEHRINGER INGELHEIM	25MG	N012836	003	Dec 22, 1986	May	DISC		
	+ @	50MG	N012836	004	Feb 06, 1987	May	DISC		

TABLET; ORAL  
PERSANTINE

+ @ 75MG N012836 005 Feb 06, 1987 May DISC

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL  
DIVALPROEX SODIUM

@ ENDO OPERATIONS EQ 500MG VALPROIC ACID A078411 001 Nov 03, 2008 May CAHN  
@ NORVIUM BIOSCIENCE EQ 125MG VALPROIC ACID A090062 001 Mar 17, 2009 Jun CAHN  
@ EQ 250MG VALPROIC ACID A090062 002 Mar 17, 2009 Jun CAHN  
@ EQ 500MG VALPROIC ACID A090062 003 Mar 17, 2009 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL  
DIVALPROEX SODIUM

>D> @ AMTA EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Sep CAHN  
>D> @ EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Sep CAHN  
@ ENDO OPERATIONS EQ 250MG VALPROIC ACID A078445 001 Feb 26, 2009 May CAHN  
@ EQ 500MG VALPROIC ACID A078445 002 Aug 04, 2009 May CAHN  
>A> @ UTOPIC PHARMS EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Sep CAHN  
>A> @ EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Sep CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DOBUTAMINE HYDROCHLORIDE

>D> AP HAINAN POLY EQ 12.5MG BASE/ML A216131 001 Dec 21, 2022 Sep CAHN  
>A> AP SLATE RUN PHARMA EQ 12.5MG BASE/ML A216131 001 Dec 21, 2022 Sep CAHN

DOCETAXEL

INJECTABLE; INJECTION  
DOCETAXEL

>D> AP ACIC PHARMS 80MG/4ML (20MG/ML) A216677 002 Feb 28, 2024 Sep CAHN  
AP 80MG/4ML (20MG/ML) A216677 002 Feb 28, 2024 Feb NEWA  
>D> AP 20MG/ML (20MG/ML) A216677 001 Feb 28, 2024 Sep CAHN  
AP 20MG/ML (20MG/ML) A216677 001 Feb 28, 2024 Feb NEWA  
>A> AP HERITAGE 80MG/4ML (20MG/ML) A216677 002 Feb 28, 2024 Sep CAHN  
>A> AP 20MG/ML (20MG/ML) A216677 001 Feb 28, 2024 Sep CAHN  
@ NORVIUM BIOSCIENCE 20MG/ML (20MG/ML) A203892 001 May 11, 2023 Jun CAHN  
@ 80MG/4ML (20MG/ML) A203892 002 May 11, 2023 Jun CAHN

SOLUTION; INTRAVENOUS  
DOCIVYX

+! AVYXA HOLDINGS 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Apr CMFD  
+ @ 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Apr CTNA  
+ @ 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Jan CAHN  
+! 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Apr CMFD  
+ @ 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Apr CTNA  
+ @ 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Jan CAHN  
+! 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Apr CMFD  
+ @ 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Apr CTNA  
+ @ 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Jan CAHN

DOLASETRON MESYLATE

TABLET; ORAL  
ANZEMET

+ @ VALIDUS PHARMS 50MG N020623 001 Sep 11, 1997 Jun DISC

DOLUTEGRAVIR SODIUM

TABLET; ORAL  
TIVICAY

+ @ VIIV HLTHCARE EQ 10MG BASE N204790 002 Jun 09, 2016 Jan DISC  
+ @ EQ 25MG BASE N204790 003 Jun 09, 2016 Jan DISC

DONEPEZIL HYDROCHLORIDE

SYSTEM; TRANSDERMAL  
ADLARITY

+ CORIUM 5MG/DAY N212304 001 Mar 11, 2022 Jun CAHN  
+! 10MG/DAY N212304 002 Mar 11, 2022 Jun CAHN

## TABLET; ORAL

## DONEPEZIL HYDROCHLORIDE

@ ENDO OPERATIONS 23MG A202542 001 Jul 24, 2013 May CAHN  
@ SUN PHARM INDS 5MG A090493 001 May 31, 2011 May DISC  
@ 10MG A090493 002 May 31, 2011 May DISC



TABLET, ORALLY DISINTEGRATING;ORAL  
DONEPEZIL HYDROCHLORIDE

AB	!	MACLEODS PHARMS LTD	10MG	A201787	002	Dec 14, 2012	Mar	CHRS
	@	SANDOZ	5MG	A091198	001	May 10, 2011	Mar	DISC
	@		10MG	A091198	002	May 10, 2011	Mar	DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

	@	HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar	DISC
--	---	-------	------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

	@	HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar	DISC
--	---	-------	-------------------------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB		AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
AB			EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
AB			EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
AB			EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Sep	CAHN
>A>	AB	AIPING PHARM INC	EQ 10MG BASE	A213474	001	Jul 28, 2020	Sep	CAHN
>A>	AB		EQ 25MG BASE	A213474	002	Jul 28, 2020	Sep	CAHN
>A>	AB		EQ 50MG BASE	A213474	003	Jul 28, 2020	Sep	CAHN
>A>	AB		EQ 75MG BASE	A213474	004	Jul 28, 2020	Sep	CAHN
>A>	AB		EQ 100MG BASE	A213474	005	Jul 28, 2020	Sep	CAHN
>D>	AB	CONTRACT PHARMACAL	EQ 10MG BASE	A213474	001	Jul 28, 2020	Sep	CAHN
>D>	AB		EQ 25MG BASE	A213474	002	Jul 28, 2020	Sep	CAHN
>D>	AB		EQ 50MG BASE	A213474	003	Jul 28, 2020	Sep	CAHN
>D>	AB		EQ 75MG BASE	A213474	004	Jul 28, 2020	Sep	CAHN
>D>	AB		EQ 100MG BASE	A213474	005	Jul 28, 2020	Sep	CAHN
>D>	AB	EDENBRIDGE PHARMS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Sep	CAHN
	@	ENDO OPERATIONS	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr	CAHN
	@		EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr	CAHN
	@		EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr	CAHN
	@		EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr	CAHN
	@		EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr	CAHN
AB	!		EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CAHN
AB		LEADING	EQ 10MG BASE	A211619	001	Mar 09, 2021	Aug	CAHN
AB			EQ 25MG BASE	A211619	002	Mar 09, 2021	Aug	CAHN
AB			EQ 50MG BASE	A211619	003	Mar 09, 2021	Aug	CAHN
AB			EQ 75MG BASE	A211619	004	Mar 09, 2021	Aug	CAHN
AB			EQ 100MG BASE	A211619	005	Mar 09, 2021	Aug	CAHN
AB		VELZEN PHARMA PVT	EQ 150MG BASE	A211618	001	Mar 01, 2021	Aug	CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Jun	NEWA
AB			EQ 6MG BASE	A218564	002	Jul 01, 2024	Jun	NEWA
	@	AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Aug	DISC
AB			EQ 3MG BASE	A216041	001	Jul 25, 2024	Jul	NEWA
	@		EQ 6MG BASE	A216041	002	Jul 25, 2024	Aug	DISC
AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Jul	NEWA
>D>	@	ZYDUS LIFESCIENCES	EQ 3MG BASE	A202761	001	Aug 16, 2023	Sep	CMFD
>A>	AB		EQ 3MG BASE	A202761	001	Aug 16, 2023	Sep	CMFD
	@		EQ 3MG BASE	A202761	001	Aug 16, 2023	Jun	CAHN
>D>	@		EQ 6MG BASE	A202761	002	Aug 16, 2023	Sep	CMFD
>A>	AB		EQ 6MG BASE	A202761	002	Aug 16, 2023	Sep	CMFD
	@		EQ 6MG BASE	A202761	002	Aug 16, 2023	Jun	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

	@	AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
	@		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jul	DISC
AP			4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

>D>	AB	FORDOZ	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Sep CAHN
	AB		20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Jul NEWA
>D>	AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Sep CAHN
	AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Jul NEWA
>A>	AB	LUPIN	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Sep CAHN
>A>	AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Sep CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB		ALEMBIC	40MG	A217674	001	Jun 27, 2024	Jun NEWA
AB		APOTEX	40MG	A217170	001	Jul 11, 2024	Jul NEWA
		@ COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr DISC
		@	EQ 75MG BASE	A204446	002	May 28, 2015	Apr DISC
		@	EQ 100MG BASE	A204446	003	May 28, 2015	Apr DISC
AB		DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar NFTG
AB		LUPIN	40MG	A216631	001	Apr 08, 2024	Mar NFTG

ORACEA

AB	+	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar CFTG
----	---	------------------	------	---------	-----	--------------	----------

FOR SUSPENSION; ORAL

DOXYCYCLINE

AB	!	LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun CHRS
		VIBRAMYCIN					
	+	@ PFIZER	EQ 25MG BASE/5ML	N050006	001		Jun DISC

TABLET; ORAL

DOXYCYCLINE

>D>		@ APPCO	EQ 50MG BASE	A065377	001	Nov 07, 2006	Sep CAHN
>D>		@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Sep CAHN
>D>		@	EQ 100MG BASE	A065377	003	Nov 07, 2006	Sep CAHN
>D>		@	EQ 150MG BASE	A065427	001	Jun 07, 2007	Sep CAHN
>A>		@ SOMERSET THERAPS LLC	EQ 50MG BASE	A065377	001	Nov 07, 2006	Sep CAHN
>A>		@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Sep CAHN
>A>		@	EQ 100MG BASE	A065377	003	Nov 07, 2006	Sep CAHN
>A>		@	EQ 150MG BASE	A065427	001	Jun 07, 2007	Sep CAHN

>D> DOXYCYCLINE CALCIUM

>D> SUSPENSION; ORAL

>D> VIBRAMYCIN

>D>	+	!	PFIZER	EQ 50MG BASE/5ML	N050480	001	Sep DISC
>A>	+	@		EQ 50MG BASE/5ML	N050480	001	Sep DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

	+	@	CHARTWELL RX	EQ 75MG BASE	N208253	001	Apr 26, 2016	Jan CAHN
--	---	---	--------------	--------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

DOXYCYCLINE HYCLATE

>D>	AP	ACIC PHARMS	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Sep CAHN
	AP		EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Jul NEWA
>D>	AP	HAINAN POLY	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Sep CAHN
	AP		EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jun NEWA
>D>	AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Sep CAHN
	AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jun NEWA
>A>	AP	HERITAGE	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Sep CAHN
	AP	LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar NEWA
>A>	AP	SLATE RUN PHARMA	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Sep CAHN
>A>	AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Sep CAHN

TABLET; ORAL

ACTICLATE

AB	+		CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan CAHN
AB	+	!		EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan CAHN

DOXYCYCLINE HYCLATE

		@	NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May DISC
AB		@	ORYZA	EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr NEWA
		@	TORRENT	EQ 75MG BASE	A213475	001	Mar 10, 2021	Aug CAHN
		@		EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr DISC
AB		@		EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr NEWA
		@		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr DISC

TABLET;ORAL							
DOXYCYCLINE HYCLATE							
AB		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr NEWA	
TABLET, DELAYED RELEASE;ORAL							
DORYX							
	+ @	MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb DISC
	+ @		EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb DISC
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>							
TABLET, DELAYED RELEASE;ORAL							
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE							
AB		ENDO OPERATIONS	10MG;10MG	A208518	001	Dec 06, 2017	Apr CAHN
<u>DRONABINOL</u>							
CAPSULE;ORAL							
DRONABINOL							
	@	HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar DISC
	@		5MG	A079217	002	Jun 20, 2014	Mar DISC
	@		10MG	A079217	003	Jun 20, 2014	Mar DISC
	@	SVC PHARMA	2.5MG	A078292	001	Jun 27, 2008	Aug DISC
	@		5MG	A078292	002	Jun 27, 2008	Aug DISC
	@		10MG	A078292	003	Jun 27, 2008	Aug DISC
SOLUTION;ORAL							
SYNDROS							
	+ @	BENUVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017	Aug DISC
<u>DRONEDARONE HYDROCHLORIDE</u>							
TABLET;ORAL							
DRONEDARONE HYDROCHLORIDE							
AB		LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan NFTG
AB	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan CFTG
<u>DROSPIRENONE</u>							
TABLET;ORAL							
>A>							
>A>	AB	LUPIN LTD	4MG	A216936	001	Sep 30, 2024	Sep NFTG
>D>		SLYND					
>D>	+!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019	Sep CFTG
>A>	AB	+!	4MG	N211367	001	May 23, 2019	Sep CFTG
<u>DROXIDOPA</u>							
CAPSULE;ORAL							
DROXIDOPA							
>D>	AB	BLUEPHARMA INDUSTRIA	100MG	A214543	001	May 05, 2021	Sep CAHN
>D>	AB		200MG	A214543	002	May 05, 2021	Sep CAHN
>D>	AB		300MG	A214543	003	May 05, 2021	Sep CAHN
>D>	AB	SLATE RUN PHARMA	100MG	A215265	001	Nov 01, 2021	Sep CAHN
>D>	AB		200MG	A215265	002	Nov 01, 2021	Sep CAHN
>D>	AB		300MG	A215265	003	Nov 01, 2021	Sep CAHN
>A>	AB	SOMERSET THERAPS LLC	100MG	A214543	001	May 05, 2021	Sep CAHN
>A>	AB		200MG	A214543	002	May 05, 2021	Sep CAHN
>A>	AB		300MG	A214543	003	May 05, 2021	Sep CAHN
	@	UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Apr DISC
	@		200MG	A213661	002	Feb 18, 2021	Apr DISC
	@		300MG	A213661	003	Feb 18, 2021	Apr DISC
>A>	AB	YAMPA	100MG	A215265	001	Nov 01, 2021	Sep CAHN
>A>	AB		200MG	A215265	002	Nov 01, 2021	Sep CAHN
>A>	AB		300MG	A215265	003	Nov 01, 2021	Sep CAHN
<u>DULOXETINE HYDROCHLORIDE</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
DRIZALMA SPRINKLE							
	+!	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr CMFD
	+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr CMFD
	+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr CMFD
	+		EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr CMFD
DULOXETINE HYDROCHLORIDE							
	@	ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb DISC
	@		EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb DISC
	@		EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb DISC
	@	ENDO OPERATIONS	EQ 20MG BASE	A090780	001	Oct 28, 2015	May CAHN

CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

@	EQ 30MG BASE	A090780	002	Oct 28, 2015	May CAHN
@	EQ 60MG BASE	A090780	003	Oct 28, 2015	May CAHN

DUTASTERIDE

CAPSULE;ORAL  
AVODART

AB	+!	WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar CAHN
AB		CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar CAHN
	@	NORVIUM BIOSCIENCE	0.5MG	A203241	001	Jun 14, 2016	Jun CAHN
	@	VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL  
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA	0.5MG;0.4MG	A213300	001	Jul 18, 2024	Jul NEWA
AB		ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr CAHN
AB	+!	WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Apr CAHN

DYPHYLLINE

TABLET;ORAL  
LUFYLLIN

@	NORVIUM BIOSCIENCE	200MG	A084566	001	Jul CAHN
@		400MG	A084566	002	Jul CAHN

EDARAVONE

SOLUTION;INTRAVENOUS  
EDARAVONE

AP		DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr NEWA
AP		GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr NFTG
AP			60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr NFTG
AP		HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr NFTG
AP		LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr NEWA
AP	+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr CFTG
AP	+!		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr CFTG

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION  
ENLON

@	NORVIUM BIOSCIENCE	10MG/ML	A088873	001	Aug 06, 1985	Jul CAHN
---	--------------------	---------	---------	-----	--------------	----------

EFAVIRENZ

TABLET;ORAL  
EFAVIRENZ

AB		MACLEODS PHARMS LTD	600MG	A091579	001	May 10, 2024	May NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

>D>		ATRIPLA						
>D>	AB	+!	GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Sep DISC
>A>		+ @		600MG;200MG;300MG	N021937	001	Jul 12, 2006	Sep DISC
			EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE					
>D>	AB		AUROBINDO PHARMA	600MG;200MG;300MG	A203041	001	Sep 04, 2018	Sep CHRS
>A>	AB	!		600MG;200MG;300MG	A203041	001	Sep 04, 2018	Sep CHRS
			EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE					
		@	STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar DISC
			EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE					
>D>	AB		MYLAN	600MG;200MG;300MG	A209061	001	Sep 05, 2024	Sep DISC
>A>		@		600MG;200MG;300MG	A209061	001	Sep 05, 2024	Sep DISC
	AB			600MG;200MG;300MG	A209061	001	Sep 05, 2024	Aug NEWA

EFINACONAZOLE

SOLUTION;TOPICAL  
EFINACONAZOLE

AB		UMEDICA	10%	A211969	001	Jun 21, 2021	Aug CAHN
	@	ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022	May CAHN

ELAFIBRANORTABLET;ORAL  
IQIRVO

+! IPSEN 80MG N218860 001 Jun 10, 2024 Jun NEWA

ELIGLUSTAT TARTRATECAPSULE;ORAL  
ELIGLUSTAT TARTRATE

AB APOTEX EQ 84MG BASE A212425 001 Jul 10, 2024 Jun NEWA

ELTROMBOPAG OLAMINEFOR SUSPENSION;ORAL  
ELTROMBOPAG OLAMINE

AB ANNORA PHARMA EQ 12.5MG ACID/PACKET A216620 001 Apr 18, 2024 Apr NFTG

AB EQ 25MG ACID/PACKET A216620 002 Apr 18, 2024 Apr NFTG

PROMACTA KIT

AB + NOVARTIS EQ 12.5MG ACID/PACKET N207027 002 Sep 27, 2018 Apr CFTG

AB +! EQ 25MG ACID/PACKET N207027 001 Aug 24, 2015 Apr CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET;ORAL  
DESCOVY

&gt;D&gt; AB + GILEAD SCIENCES INC 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022 Sep CTEC

&gt;A&gt; + 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022 Sep CTEC

AB + 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022 May CFTG

&gt;D&gt; AB +! 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 Sep CTEC

&gt;A&gt; +! 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 Sep CTEC

AB +! 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 May CFTG

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

&gt;D&gt; AB APOTEX 120MG;EQ 15MG BASE A214053 001 May 17, 2024 Sep DISC

&gt;A&gt; @ 120MG;EQ 15MG BASE A214053 001 May 17, 2024 Sep DISC

AB 120MG;EQ 15MG BASE A214053 001 May 17, 2024 May NFTG

&gt;D&gt; AB 200MG;EQ 25MG BASE A214053 002 May 17, 2024 Sep DISC

&gt;A&gt; @ 200MG;EQ 25MG BASE A214053 002 May 17, 2024 Sep DISC

AB 200MG;EQ 25MG BASE A214053 002 May 17, 2024 May NFTG

ENALAPRIL MALEATEFOR SOLUTION;ORAL  
EPANED KIT

+ @ AZURITY 1MG/ML N204308 001 Aug 13, 2013 Mar CAHN

SOLUTION;ORAL  
ENALAPRIL MALEATE

AB AMNEAL 1MG/ML A212894 001 Jun 29, 2022 Mar CMFD

TABLET;ORAL  
ENALAPRIL MALEATE

&gt;A&gt; AB UNIQUE PHARM 2.5MG A218531 001 Sep 19, 2024 Sep NEWA

&gt;A&gt; AB 5MG A218531 002 Sep 19, 2024 Sep NEWA

&gt;A&gt; AB 10MG A218531 003 Sep 19, 2024 Sep NEWA

&gt;A&gt; AB 20MG A218531 004 Sep 19, 2024 Sep NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDETABLET;ORAL  
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE  
@ COSETTE 5MG;12.5MG  
@ 10MG;25MG

A075727 001 Sep 18, 2001 Apr DISC

A075727 002 Sep 18, 2001 Apr DISC

ENSIFENTRINESUSPENSION;INHALATION  
OHTUVAYRE

+! VERONA PHARMA 3MG/2.5ML N217389 001 Jun 26, 2024 Jun NEWA

ENTECAVIRTABLET;ORAL  
ENTECAVIR

&gt;D&gt; AB PRINSTON INC 0.5MG A208782 001 Oct 10, 2017 Sep DISC

&gt;A&gt; @ 0.5MG A208782 001 Oct 10, 2017 Sep DISC

&gt;D&gt; AB 1MG A208782 002 Oct 10, 2017 Sep DISC

&gt;A&gt; @ 1MG A208782 002 Oct 10, 2017 Sep DISC

@ SWISS PHARM 0.5MG A212106 001 Aug 10, 2020 Jul CAHN

@ 1MG A212106 002 Aug 10, 2020 Jul CAHN

@ VITRUVIAS 0.5MG A212106 001 Aug 10, 2020 Jun DISC

	TABLET;ORAL								
	ENTECAVIR								
	@	1MG	A212106	002	Aug 10, 2020	Jun	DISC		
AB	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	Jun	CMFD		
AB		1MG	A208195	002	Nov 10, 2021	Jun	CMFD		
	<u>ENZALUTAMIDE</u>								
	CAPSULE;ORAL								
	ENZALUTAMIDE								
>A>	AB ZYDUS PHARMS	40MG	A209667	001	Sep 26, 2024	Sep	NEWA		
	XTANDI								
>D>	+! ASTELLAS	40MG	N203415	001	Aug 31, 2012	Sep	CTEC		
>A>	AB +!	40MG	N203415	001	Aug 31, 2012	Sep	CTEC		
	<u>EPHEDRINE HYDROCHLORIDE</u>								
	SOLUTION;INTRAVENOUS								
	REZIPRES								
	+ @ DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	May	DISC		
	<u>EPHEDRINE SULFATE</u>								
	SOLUTION;INTRAVENOUS								
	EPHEDRINE SULFATE								
AP	CAPLIN	50MG/ML (50MG/ML)	A219050	001	Jul 18, 2024	Jul	NEWA		
	+! ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN		
	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN		
	<u>EPINEPHRINE</u>								
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS								
	EPINEPHRINE								
AP	AM REGENT	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A217192	001	Sep 06, 2024	Aug	NEWA		
	+! BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	Apr	NEWA		
	+!	30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA		
	SOLUTION;INTRAVENOUS								
	EPINEPHRINE								
	+ @ BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun	DISC		
	SPRAY;NASAL								
	NEFFY								
	+! ARS PHARMS OPERATION	2MG/SPRAY	N214697	001	Aug 09, 2024	Aug	NEWA		
	<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	XYLOCAINE W/ EPINEPHRINE								
	+ @ FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003		Feb	CRLD		
	<u>EPIRUBICIN HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	EPIRUBICIN HYDROCHLORIDE								
	@ NORVIUM BIOSCIENCE	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Jul	CAHN		
	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Jul	CAHN		
	<u>EPLERENONE</u>								
	TABLET;ORAL								
	EPLERENONE								
	@ PRASCO	25MG	A203896	001	Feb 02, 2017	Mar	DISC		
	@	50MG	A203896	002	Feb 02, 2017	Mar	DISC		
AB	SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb	CAHN		
AB		50MG	A212765	002	Aug 10, 2020	Feb	CAHN		
	<u>EPLONTERSEN SODIUM</u>								
	SOLUTION;SUBCUTANEOUS								
	WAINUA (AUTOINJECTOR)								
	+! ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb	CTNA		
	+!	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan	CAHN		
	<u>EPOPROSTENOL SODIUM</u>								
	INJECTABLE;INJECTION								
	EPOPROSTENOL SODIUM								
AP1	MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jan	CAHN		
AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jan	CAHN		
AP2	MYLAN	EQ 0.5MG BASE/VIAL	A213913	001	Jun 12, 2024	May	NEWA		

INJECTABLE; INJECTION  
EPOPROSTENOL SODIUM

AP2 EQ 1.5MG BASE/VIAL A213913 002 Jun 12, 2024 May NEWA

EPTIFIBATIDE

INJECTABLE; INJECTION  
EPTIFIBATIDE

@ ACCORD HLTHCARE 2MG/ML A205557 001 Nov 06, 2017 May DISC  
 @ 75MG/100ML A205557 002 Nov 06, 2017 May DISC  
 AP HONG KONG 2MG/ML A213599 001 May 09, 2024 May NEWA  
 AP 75MG/100ML A213599 002 May 09, 2024 May NEWA

ERGOLOID MESYLATES

TABLET; ORAL  
ERGOLOID MESYLATES

@ SUN PHARM INDUSTRIES 1MG A081113 001 Oct 31, 1991 Jul DISC

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL  
ERGOMAR

>D> ! PANGEA 2MG A087693 001 Feb 24, 1983 Sep CAHN  
 ! 2MG A087693 001 Feb 24, 1983 Feb CAHN  
 >A> ! PHARMOBEDIENT 2MG A087693 001 Feb 24, 1983 Sep CAHN

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS  
ERIBULIN MESYLATE

>A> AP BAXTER HLTHCARE CORP 1MG/2ML (0.5MG/ML) A217250 001 Oct 01, 2024 Sep NEWA  
 AP GLAND PHARMA LTD 1MG/2ML (0.5MG/ML) A218047 001 Apr 05, 2024 Mar NFTG  
 AP JIANGXI QINGFENG 1MG/2ML (0.5MG/ML) A218281 001 Jun 28, 2024 Jun NEWA  
 AP LONG GROVE PHARMS 1MG/2ML (0.5MG/ML) A214850 001 Jul 18, 2024 Jul NEWA  
 HALAVEN  
 AP +! EISAI INC 1MG/2ML (0.5MG/ML) N201532 001 Nov 15, 2010 Mar CFTG

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

>A> AB CHARTWELL RX EQ 25MG BASE A203843 001 Sep 13, 2024 Sep CAHN  
 >A> AB EQ 150MG BASE A203843 002 Sep 13, 2024 Sep CAHN  
 AB HETERO LABS LTD V EQ 25MG BASE A209267 001 May 24, 2024 May NEWA  
 AB EQ 100MG BASE A209267 002 May 24, 2024 May NEWA  
 AB EQ 150MG BASE A209267 003 May 24, 2024 May NEWA  
 >A> AB HIKMA EQ 25MG BASE A203843 001 Sep 13, 2024 Sep NEWA  
 >A> AB EQ 150MG BASE A203843 002 Sep 13, 2024 Sep NEWA  
 @ NATCO PHARMA LTD EQ 25MG BASE A208488 001 Nov 05, 2019 Apr DISC  
 @ EQ 150MG BASE A208488 003 Nov 05, 2019 Aug DISC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ERTAPENEM SODIUM

@ SUN PHARM EQ 1GM BASE/VIAL A209145 001 May 02, 2023 Jan DISC

ERTUGLIFLOZIN

TABLET; ORAL  
ERTUGLIFLOZIN

>A> AB HETERO LABS LTD V 5MG A217071 001 Sep 17, 2024 Sep NEWA  
 >A> AB 15MG A217071 002 Sep 17, 2024 Sep NEWA  
 STEGLATRO  
 >D> + MSD SUB MERCK 5MG N209803 001 Dec 19, 2017 Sep CTEC  
 >A> AB + 5MG N209803 001 Dec 19, 2017 Sep CTEC  
 >D> +! 15MG N209803 002 Dec 19, 2017 Sep CTEC  
 >A> AB +! 15MG N209803 002 Dec 19, 2017 Sep CTEC

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL  
ERYTHROMYCIN

AB AZURITY 250MG A062746 001 Dec 22, 1986 Mar CAHN

OINTMENT; OPHTHALMIC  
ERYTHROMYCIN

AT ! BAUSCH AND LOMB 0.5% A064067 001 Jul 29, 1994 Mar CHRS  
 @ PADAGIS US 0.5% A062447 001 Sep 26, 1983 Mar DISC

TABLET;ORAL  
ERYTHROMYCIN

AB	AZURITY	250MG	A 061621	001		Mar	CAHN
AB		500MG	A 061621	002		Mar	CAHN
TABLET, DELAYED RELEASE;ORAL							
ERY-TAB							
AB	AZURITY	250MG	A 062298	001		Mar	CAHN
AB		333MG	A 062298	003	Mar 29, 1982	Mar	CAHN
AB	!	500MG	A 062298	002		Mar	CAHN
ERYTHROMYCIN							
AB	TORRENT	333MG	A 211975	003	Aug 13, 2024	Aug	NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL  
ERYTHROMYCIN ETHYLSUCCINATE

	@ ENDO OPERATIONS	EQ 200MG BASE/5ML	A 211991	001	Oct 23, 2019	May	CAHN
	@	EQ 400MG BASE/5ML	A 211991	002	Oct 23, 2019	May	CAHN
TABLET;ORAL							
E.E.S. 400							
	@ AZURITY	EQ 400MG BASE	A 061905	001		Mar	CAHN
BX	!	EQ 400MG BASE	A 061905	002	Aug 12, 1982	Mar	CAHN
ERYTHROMYCIN ETHYLSUCCINATE							
BX	!	AZURITY EQ 400MG BASE	A 061904	001		Mar	CAHN

ERYTHROMYCIN STEARATE

TABLET;ORAL  
ERYTHROCIN STEARATE

	@ AZURITY	EQ 125MG BASE	A 060359	002		Mar	CAHN
	!	EQ 250MG BASE	A 060359	001		Mar	CAHN
	@	EQ 500MG BASE	A 060359	003		Mar	CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL  
ESCITALOPRAM OXALATE

>A>	@ ANIMA	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Sep	CAHN
>A>	@	EQ 10MG BASE	A 077512	002	Sep 12, 2012	Sep	CAHN
>A>	@	EQ 20MG BASE	A 077512	003	Sep 12, 2012	Sep	CAHN
>D>	@ PHARM ASSOC	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Sep	CAHN
	@	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Mar	DISC
>D>	@	EQ 10MG BASE	A 077512	002	Sep 12, 2012	Sep	CAHN
	@	EQ 10MG BASE	A 077512	002	Sep 12, 2012	Mar	DISC
>D>	@	EQ 20MG BASE	A 077512	003	Sep 12, 2012	Sep	CAHN
	@	EQ 20MG BASE	A 077512	003	Sep 12, 2012	Mar	DISC

ESLICARBAZEPINE ACETATE

TABLET;ORAL  
ESLICARBAZEPINE ACETATE

	@ APOTEX	200MG	A 211236	001	Dec 07, 2023	Apr	DISC
	@	400MG	A 211236	002	Dec 07, 2023	Apr	DISC
	@	600MG	A 211236	003	Dec 07, 2023	Apr	DISC
	@	800MG	A 211236	004	Dec 07, 2023	Apr	DISC
>D>	AB LUPIN LTD	200MG	A 211246	001	Mar 27, 2024	Sep	DISC
>A>	@	200MG	A 211246	001	Mar 27, 2024	Sep	DISC
	AB	200MG	A 211246	001	Mar 27, 2024	Mar	NEWA
>D>	AB	400MG	A 211246	002	Mar 27, 2024	Sep	DISC
>A>	@	400MG	A 211246	002	Mar 27, 2024	Sep	DISC
	AB	400MG	A 211246	002	Mar 27, 2024	Mar	NEWA
>D>	AB	600MG	A 211246	003	Mar 27, 2024	Sep	DISC
>A>	@	600MG	A 211246	003	Mar 27, 2024	Sep	DISC
	AB	600MG	A 211246	003	Mar 27, 2024	Mar	NEWA
>D>	AB	800MG	A 211246	004	Mar 27, 2024	Sep	DISC
>A>	@	800MG	A 211246	004	Mar 27, 2024	Sep	DISC
	AB	800MG	A 211246	004	Mar 27, 2024	Mar	NEWA
	@ TORRENT	200MG	A 211227	001	Feb 27, 2024	Mar	DISC
	AB	200MG	A 211227	001	Feb 27, 2024	Feb	NEWA
	@	400MG	A 211227	002	Feb 27, 2024	Mar	DISC
	AB	400MG	A 211227	002	Feb 27, 2024	Feb	NEWA
	@	600MG	A 211227	003	Feb 27, 2024	Mar	DISC
	AB	600MG	A 211227	003	Feb 27, 2024	Feb	NEWA
	@	800MG	A 211227	004	Feb 27, 2024	Mar	DISC
	AB	800MG	A 211227	004	Feb 27, 2024	Feb	NEWA



ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL  
ESOMEPRAZOLE MAGNESIUM

>D>	AB	GLENMARK SPECLT	EQ 20MG BASE	A209495	001	May 10, 2019	Sep	DISC
>A>		@	EQ 20MG BASE	A209495	001	May 10, 2019	Sep	DISC
>D>	AB		EQ 40MG BASE	A209495	002	May 10, 2019	Sep	DISC
>A>		@	EQ 40MG BASE	A209495	002	May 10, 2019	Sep	DISC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS  
ESOMEPRAZOLE SODIUM

		@ ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	May	DISC
		! GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	May	CHRS
>D>	AP	! HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Sep	CAHN
	AP	!	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Aug	CHRS
>A>	AP	! SLATE RUN PHARMA	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Sep	CAHN
		@ SUN PHARM	EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	May	DISC
		NEXIUM IV						
		+ @ ASTRAZENECA	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug	DISC

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL  
CLIMARA

>D>	AB	+ BAYER HLTHCARE	0.06MG/24HR	N020375	006	May 27, 2003	Sep	CTEC
>A>	AB2	+	0.06MG/24HR	N020375	006	May 27, 2003	Sep	CTEC
		ESTRADIOL						
>D>		@ ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Sep	CMFD
>A>	AB2		0.025MG/24HR	A202985	001	Mar 29, 2023	Sep	CMFD
>D>		@	0.0375MG/24HR	A202985	002	Mar 29, 2023	Sep	CMFD
>A>	AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Sep	CMFD
>D>		@	0.05MG/24HR	A202985	003	Mar 29, 2023	Sep	CMFD
>A>	AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Sep	CMFD
>D>		@	0.06MG/24HR	A202985	004	Mar 29, 2023	Sep	CMFD
>A>	AB2		0.06MG/24HR	A202985	004	Mar 29, 2023	Sep	CMFD
>D>		@	0.075MG/24HR	A202985	005	Mar 29, 2023	Sep	CMFD
>A>	AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Sep	CMFD
>D>		@	0.1MG/24HR	A202985	006	Mar 29, 2023	Sep	CMFD
>A>	AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Sep	CMFD

GEL;TRANSDERMAL

DIVIGEL

AB	+	VERTICAL PHARMS	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Jul	CPOT
AB	+		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Jul	NEWA
AB	+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Jul	NEWA
AB	+		0.1% (0.75GM/PACKET)	N022038	004	Aug 17, 2018	Jul	NEWA
AB	+		0.1% (1.25GM/PACKET)	N022038	005	Dec 12, 2019	Jul	NEWA

ESTRADIOL

AB		AMNEAL	0.1% (0.25GM/PACKET)	A216055	001	Jul 12, 2024	Jul	NEWA
AB			0.1% (0.5GM/PACKET)	A216055	002	Jul 12, 2024	Jul	NEWA
AB			0.1% (0.75GM/PACKET)	A216055	003	Jul 12, 2024	Jul	NEWA
AB			0.1% (1GM/PACKET)	A216055	004	Jul 12, 2024	Jul	NEWA
AB			0.1% (1.25GM/PACKET)	A216055	005	Jul 12, 2024	Jul	NEWA
AB		CHEMO RESEARCH SL	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jul	CPOT
AB			0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jul	NEWA
AB			0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022	Jul	NEWA
AB		NOVITIUM PHARMA	0.1% (0.25GM/PACKET)	A217610	001	Aug 24, 2023	Jul	CPOT
AB			0.1% (0.5GM/PACKET)	A217610	002	Aug 24, 2023	Jul	NEWA
AB			0.1% (0.75GM/PACKET)	A217610	003	Aug 24, 2023	Jul	NEWA
AB			0.1% (1GM/PACKET)	A217610	004	Aug 24, 2023	Jul	NEWA
AB			0.1% (1.25GM/PACKET)	A217610	005	Aug 24, 2023	Jul	NEWA
AB		PADAGIS ISRAEL	0.1% (0.25GM/PACKET)	A216524	001	Nov 14, 2023	Jul	CPOT
AB			0.1% (0.5GM/PACKET)	A216524	002	Nov 14, 2023	Jul	NEWA
AB			0.1% (0.75GM/PACKET)	A216524	003	Nov 14, 2023	Jul	NEWA
AB			0.1% (1GM/PACKET)	A216524	004	Nov 14, 2023	Jul	NEWA
AB			0.1% (1.25GM/PACKET)	A216524	005	Nov 14, 2023	Jul	NEWA
>A>	AB	QUAGEN	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Sep	CAHN
>A>	AB		0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Sep	CAHN
>A>	AB		0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Sep	CAHN
>A>	AB		0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Sep	CAHN
>A>	AB		0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Sep	CAHN
>D>	AB	SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Sep	CAHN
	AB		0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Jul	NEWA
>D>	AB		0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Sep	CAHN

	GEL; TRANSDERMAL							
	ESTRADIOL							
	AB	0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Jul	NEWA	
>D>	AB	0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Sep	CAHN	
	AB	0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Jul	NEWA	
>D>	AB	0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Sep	CAHN	
	AB	0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Jul	NEWA	
>D>	AB	0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Sep	CAHN	
	AB	0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Jul	NEWA	
	GEL, METERED; TRANSDERMAL							
	ESTRADIOL							
	AB	SOLARIS PHARMA CORP ESTROGEL	0.06% (1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr	NFTG
	AB	+! ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr	CFTG
	TABLET; VAGINAL							
	ESTRADIOL							
	AB	AUROBINDO PHARMA	10MCG	A216550	001	Aug 02, 2024	Jul	NEWA
	<u>ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE</u>							
	INJECTABLE; INTRAMUSCULAR							
	LUNELLE							
	+ @	PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000	Feb	CRLD
	<u>ESTRADIOL VALERATE</u>							
	INJECTABLE; INJECTION							
	DELESTROGEN							
	AO	+! ENDO OPERATIONS	10MG/ML	N009402	002		Apr	CAHN
	AO	+!	20MG/ML	N009402	004		Apr	CAHN
>D>	AO	+!	40MG/ML	N009402	003		Sep	DISC
>A>	+ @		40MG/ML	N009402	003		Sep	DISC
	AO	+!	40MG/ML	N009402	003		Apr	CAHN
	ESTRADIOL VALERATE							
>D>	AO	XIROMED	40MG/ML	A216656	003	Apr 28, 2023	Sep	CHRS
>A>	AO	!	40MG/ML	A216656	003	Apr 28, 2023	Sep	CHRS
	<u>ESTRADIOL; NORETHINDRONE ACETATE</u>							
	TABLET; ORAL							
	ESTRADIOL AND NORETHINDRONE ACETATE							
	AB	NAARI PTE LTD	1MG; 0.5MG	A210233	001	Feb 28, 2018	Apr	CMFD
	<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX</u>							
	TABLET; ORAL							
	MYFEMBREE							
>D>	+!	MYOVANT SCIENCES	1MG; 0.5MG; 40MG	N214846	001	May 26, 2021	Sep	CAHN
>A>	+!	SUMITOMO PHARMA	1MG; 0.5MG; 40MG	N214846	001	May 26, 2021	Sep	CAHN
	<u>ESTRADIOL; NORGESTIMATE</u>							
	TABLET; ORAL							
	ESTRADIOL AND NORGESTIMATE							
	@	BARR	1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Aug	DISC
	<u>ESTRAMUSTINE PHOSPHATE SODIUM</u>							
	CAPSULE; ORAL							
	EMCYT							
	+ @	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001		Jun	DISC
	<u>ESTROGENS, ESTERIFIED</u>							
	TABLET; ORAL							
	MENEST							
	@	MONARCH PHARMS	0.3MG	A084951	001		Jul	DISC
	@		0.625MG	A084948	001		Jul	DISC
	@		1.25MG	A084950	001		Jul	DISC
	@		2.5MG	A084949	001		Jul	DISC
	<u>ESZOPICLONE</u>							
	TABLET; ORAL							
	LUNESTA							
	AB	+ WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr	CAHN
	AB	+	2MG	N021476	002	Dec 15, 2004	Apr	CAHN
	AB	+!	3MG	N021476	003	Dec 15, 2004	Apr	CAHN

ETHACRYNATE SODIUMINJECTABLE; INJECTION  
ETHACRYNATE SODIUM

AP	ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr	CAHN
AP	STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar	CAHN

ETHACRYNIC ACIDTABLET; ORAL  
ETHACRYNIC ACID

>A>	AB	ADAPTIS	25MG	A205609	001	Jun 30, 2016	Sep	CAHN
>D>	AB	EDENBRIDGE PHARMS	25MG	A205609	001	Jun 30, 2016	Sep	CAHN
		@ ENDO OPERATIONS	25MG	A208501	001	Jul 21, 2017	May	CAHN
		@ PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Apr	DISC

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL  
MYAMBUTOL

AB	+	KANCHAN HLTHCARE	100MG	N016320	001		Aug	CAHN
		@	200MG	N016320	002		Aug	CAHN
AB	+	!	400MG	N016320	003		Aug	CAHN
		@	500MG	N016320	004		Aug	CAHN

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL  
LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		XIROMED	0.03MG; 0.15MG	A200490	001	Apr 21, 2015	Apr	CAHN
		MINZOYA						
AB3		LUPIN LTD	0.02MG; 0.1MG	A217087	001	Feb 15, 2024	Feb	NEWA
		TABLET; ORAL-28						
		LEVONORGESTREL AND ETHINYL ESTRADIOL						
		@ XIROMED	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Apr	CAHN
		@	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	May	CAHN
		MYZILRA						
AB		ENDO OPERATIONS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A077502	001	Nov 23, 2011	May	CAHN
		ORSYTHIA						
		@ ENDO OPERATIONS	0.02MG; 0.1MG	A077099	001	May 11, 2011	May	CAHN

ETHINYL ESTRADIOL; NORETHINDRONETABLET; ORAL-28  
CYCLAFEM 0.5/35

		@ ENDO OPERATIONS	0.035MG; 0.5MG	A203413	001	Dec 16, 2015	Apr	CAHN
		CYCLAFEM 1/35						
		@ ENDO OPERATIONS	0.035MG; 1MG	A076337	001	Nov 12, 2010	May	CAHN
		CYCLAFEM 7/7/7						
		@ ENDO OPERATIONS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	A076338	001	Nov 16, 2010	May	CAHN
		GILDAGIA						
AB		ENDO OPERATIONS	0.035MG; 0.4MG	A078376	001	Nov 06, 2012	May	CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL						
		@ XIROMED	0.035MG; 0.4MG	A200897	001	May 11, 2015	Apr	CAHN
		@	0.05MG; 1MG	A203006	001	Aug 05, 2013	Apr	CAHN
		TABLET, CHEWABLE; ORAL						
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	+	!	TEVA BRANDED PHARM	N022573	001	Dec 22, 2010	Mar	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATECAPSULE; ORAL  
MERZEE

AB		WILSHIRE PHARMS INC	0.02MG; 1MG	A212706	001	Dec 18, 2020	Jul	CAHN
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
		@ AMNEAL PHARMS	0.02MG; 1MG	A214292	001	Jul 20, 2021	Feb	DISC
		TABLET; ORAL						
		GILDESS 24 FE						
AB		ENDO OPERATIONS	0.02MG; 1MG	A090293	001	Dec 01, 2014	May	CAHN
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
		@ XIROMED	0.0025MG; 0.5MG	A207260	001	Feb 02, 2017	Apr	CAHN
		@	0.005MG; 1MG	A207259	001	Dec 27, 2016	Apr	CAHN

## TABLET;ORAL

	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
	@ XIROMED	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May	CAHN		
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
	@ XIROMED	0.02MG;1MG	A206120	001	Sep 12, 2017	May	CAHN		
	OSHIH								
	@ AUROBINDO PHARMA	0.02MG;1MG	A216558	001	Dec 06, 2023	May	DISC		
	TABLET;ORAL-21								
	GILDESS 1.5/30								
	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	002	Jul 24, 2012	May	CAHN		
	GILDESS 1/20								
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	002	Jul 24, 2012	May	CAHN		
	TABLET;ORAL-28								
	GILDESS FE 1.5/30								
	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	001	Apr 28, 2005	May	CAHN		
	GILDESS FE 1/20								
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	001	May 20, 2005	May	CAHN		
AB	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL								
	XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr	CAHN		
	TABLET, ORALLY DISINTEGRATING;ORAL								
	FEMLYV								
	+! MILLICENT PR	0.02MG;1MG	N218718	001	Jul 22, 2024	Jul	NEWA		

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET;ORAL-28								
	NORGESTIMATE AND ETHINYL ESTRADIOL								
	@ XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A202132	001	Sep 09, 2015	May	CAHN		
		15MG,0.25MG							
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A201897	001	Jan 27, 2016	May	CAHN		
		15MG,0.25MG							
	PREVIFEM								
AB	ENDO OPERATIONS	0.035MG;0.25MG	A076334	001	Jan 09, 2004	May	CAHN		
	TRI-PREVIFEM								
	@ ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A076335	001	Mar 26, 2004	May	CAHN		
		15MG,0.25MG							

ETHOSUXIMIDE

	CAPSULE;ORAL								
	ETHOSUXIMIDE								
AB	EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan	CAHN		

ETODOLAC

	CAPSULE;ORAL								
	ETODOLAC								
AB	IPCA LABS LTD	200MG	A205448	001	Aug 01, 2024	Jul	NEWA		
AB		300MG	A205448	002	Aug 01, 2024	Jul	NEWA		
	TABLET;ORAL								
	ETODOLAC								
>A>	AB	ABRAXEOLUS	400MG	A074903	001	Apr 11, 1997	Sep	CAHN	
>A>	AB		500MG	A074903	002	Apr 19, 1999	Sep	CAHN	
>A>	AB	ADAPTIS	400MG	A209888	001	Nov 30, 2018	Sep	CAHN	
>A>	AB		500MG	A209888	002	Nov 30, 2018	Sep	CAHN	
>D>	AB	EDENBRIDGE PHARMS	400MG	A209888	001	Nov 30, 2018	Sep	CAHN	
	AB		400MG	A209888	001	Nov 30, 2018	Jul	CMFD	
>D>	AB		500MG	A209888	002	Nov 30, 2018	Sep	CAHN	
	AB		500MG	A209888	002	Nov 30, 2018	Jul	CMFD	
	AB	IPCA LABS LTD	400MG	A204729	001	May 01, 2024	Apr	NEWA	
	AB		500MG	A204729	002	May 01, 2024	Apr	NEWA	
>D>	AB	PANGEA	400MG	A074903	001	Apr 11, 1997	Sep	CAHN	
	AB		400MG	A074903	001	Apr 11, 1997	Jun	CAHN	
>D>	AB		500MG	A074903	002	Apr 19, 1999	Sep	CAHN	
	AB		500MG	A074903	002	Apr 19, 1999	Jun	CAHN	

ETOMIDATE

	INJECTABLE;INJECTION								
	ETOMIDATE								
	@ ENDO OPERATIONS	2MG/ML	A091297	001	Jun 20, 2012	May	CAHN		

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB	MACLEODS PHARMS LTD	10MG	A211159	001	Apr 29, 2024	Apr	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB	AUROBINDO PHARMA USA	10MG;10MG	A200082	001	Dec 17, 2020	Mar	CMFD
AB		10MG;20MG	A200082	002	Dec 17, 2020	Mar	CMFD
AB		10MG;40MG	A200082	003	Dec 17, 2020	Mar	CMFD
AB		10MG;80MG	A200082	004	Dec 17, 2020	Mar	CMFD

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

>D>	AB	CEROVENE INC	40MG/5ML	A217605	001	Jan 16, 2024	Sep	CAHN
	AB		40MG/5ML	A217605	001	Jan 16, 2024	Jan	NEWA
>A>	AB	UNICHEM	40MG/5ML	A217605	001	Jan 16, 2024	Sep	CAHN

TABLET; ORAL

FAMOTIDINE

AB	MSN	20MG	A217400	001	Aug 06, 2024	Jul	NEWA
AB		40MG	A217400	002	Aug 06, 2024	Jul	NEWA
AB	RISING	20MG	A218181	001	Dec 22, 2023	Aug	CAHN
AB		40MG	A218181	002	Dec 22, 2023	Aug	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

FAMOTIDINE AND IBUPROFEN

@ TORRENT 26.6MG;800MG

IBUPROFEN AND FAMOTIDINE

AB	!	ALKEM LABS LTD	26.6MG;800MG	A215925	001	Mar 18, 2024	Mar	NEWA
				A211890	001	Aug 03, 2021	Feb	CHRS

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

@ LUPIN LTD

AB		40MG	A205406	001	Jan 17, 2024	Apr	DISC
		40MG	A205406	001	Jan 17, 2024	Jan	NEWA
	@	80MG	A205406	002	Jan 17, 2024	Apr	DISC
AB		80MG	A205406	002	Jan 17, 2024	Jan	NEWA
BX	MSN	40MG	A210461	001	Dec 30, 2019	Jun	CTEC
BX		80MG	A210461	002	Dec 30, 2019	Jun	CTEC

FEDRATINIB HYDROCHLORIDE

CAPSULE; ORAL

INREBIC

+	!	BRISTOL-MYERS	EQ 100MG BASE	N212327	001	Aug 16, 2019	Feb	CAHN
---	---	---------------	---------------	---------	-----	--------------	-----	------

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	ENDO OPERATIONS	2.5MG	A200815	001	Oct 28, 2011	Apr	CAHN
AB		5MG	A200815	002	Oct 28, 2011	Apr	CAHN
AB		10MG	A200815	003	Oct 28, 2011	Apr	CAHN

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB	CHARTWELL	67MG	A211407	001	Jan 31, 2024	Mar	CAHN	
AB		134MG	A211407	002	Jan 31, 2024	Mar	CAHN	
AB		200MG	A211407	003	Jan 31, 2024	Mar	CAHN	
	@	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	DISC
	@		134MG	A207378	002	Mar 28, 2017	Mar	DISC
	@		200MG	A207378	003	Mar 28, 2017	Mar	DISC
AB	YOUNGTECH PHARMS INC	67MG	A211407	001	Jan 31, 2024	Jan	NEWA	
AB		134MG	A211407	002	Jan 31, 2024	Jan	NEWA	
AB		200MG	A211407	003	Jan 31, 2024	Jan	NEWA	

TABLET; ORAL

FENOFIBRATE

AB	!	AUROBINDO PHARMA	145MG	A205118	002	May 05, 2016	Mar	CHRS
BX		CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Jun	CTEC

TABLET;ORAL  
FENOFIBRATE

BX		120MG	A217732	002	Sep 07, 2023	Jun	CTEC	
AB	!	MYLAN PHARMS INC	120MG	A204475	002	Jun 23, 2016	May	CHRS
AB		RISING	48MG	A211122	001	Mar 18, 2020	Aug	CAHN
AB			54MG	A210606	001	Aug 17, 2018	Aug	CAHN
AB			145MG	A211122	002	Mar 18, 2020	Aug	CAHN
AB			160MG	A210606	002	Aug 17, 2018	Aug	CAHN
AB		YICHANG HUMANWELL	54MG	A218548	001	Apr 24, 2024	Apr	NEWA
AB			160MG	A218548	002	Apr 24, 2024	Apr	NEWA

FENOGLIDE

+	@	SALIX	40MG	N022118	001	Aug 10, 2007	May	DISC
+	@		120MG	N022118	002	Aug 10, 2007	May	DISC
		TRICOR						
+	@	ABBVIE	48MG	N021656	001	Nov 05, 2004	Aug	DISC
+	@		145MG	N021656	002	Nov 05, 2004	Mar	DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION  
CORLOPAM

+	@	HOSPIRA	EQ 10MG BASE/ML	N019922	001	Sep 23, 1997	May	DISC
		FENOLDOPAM MESYLATE						
	@	HIKMA	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	May	DISC
	@	SANDOZ	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	May	DISC

FENOPROFEN CALCIUM

CAPSULE;ORAL  
FENOPROFEN CALCIUM

	@	MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	Aug	DISC
			EQ 200MG BASE	A215548	001	May 16, 2023	May	CTEC
	@		EQ 300MG BASE	A215548	002	May 16, 2023	Aug	DISC
	@		EQ 400MG BASE	A215548	003	May 16, 2023	Aug	DISC
>A>		RISING	EQ 200MG BASE	A214475	002	Jul 26, 2024	Sep	NEWA
>A>			EQ 300MG BASE	A214475	003	Jul 26, 2024	Sep	NEWA
	!		EQ 400MG BASE	A214475	001	Jul 18, 2022	Aug	CTEC
AB	!		EQ 400MG BASE	A214475	001	Jul 18, 2022	May	CHRS
		NALFON						
	+	KEY THERAP	EQ 200MG BASE	N017604	003		May	DISC
AB	+		EQ 200MG BASE	N017604	003		Apr	CAHN
	+	@	EQ 400MG BASE	N017604	004	Jul 21, 2009	May	DISC
AB	+	!	EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr	CAHN

TABLET;ORAL  
FENOPROFEN CALCIUM

	@	KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	May	DISC
	!		EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

		FENTANYL-100						
>D>	AB	AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Sep	CAHN
>A>	AB	DIFGEN PHARMS	100MCG/HR	A077449	004	Oct 20, 2008	Sep	CAHN
		FENTANYL-12						
>D>	AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Sep	CAHN
>A>	AB	DIFGEN PHARMS	12.5MCG/HR	A077449	005	Sep 11, 2015	Sep	CAHN
		FENTANYL-25						
>D>	AB	AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Sep	CAHN
>A>	AB	DIFGEN PHARMS	25MCG/HR	A077449	001	Oct 20, 2008	Sep	CAHN
		FENTANYL-37						
>D>	AB	AVEVA	37.5MCG/HR	A077449	006	Dec 06, 2017	Sep	CAHN
>A>	AB	DIFGEN PHARMS	37.5MCG/HR	A077449	006	Dec 06, 2017	Sep	CAHN
		FENTANYL-50						
>D>	AB	AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Sep	CAHN
>A>	AB	DIFGEN PHARMS	50MCG/HR	A077449	002	Oct 20, 2008	Sep	CAHN
		FENTANYL-62						
>D>	AB	AVEVA	62.5MCG/HR	A077449	007	Dec 06, 2017	Sep	CAHN
>A>	AB	DIFGEN PHARMS	62.5MCG/HR	A077449	007	Dec 06, 2017	Sep	CAHN
		FENTANYL-75						
>D>	AB	AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Sep	CAHN
>A>	AB	DIFGEN PHARMS	75MCG/HR	A077449	003	Oct 20, 2008	Sep	CAHN
		FENTANYL-87						
>D>	AB	AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017	Sep	CAHN
>A>	AB	DIFGEN PHARMS	87.5MCG/HR	A077449	008	Dec 06, 2017	Sep	CAHN

>D>	<u>FENTANYL CITRATE</u>						
>D>	TABLET;BUCCAL, SUBLINGUAL						
>D>	FENTORA						
>D>	+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Sep DISC
>A>	+	@	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Sep DISC
>D>	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Sep DISC
>A>	+	@	EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Sep DISC
>D>	+	!	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Sep DISC
>A>	+	@	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Sep DISC
>D>	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Sep DISC
>A>	+	@	EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Sep DISC
>D>	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Sep DISC
>A>	+	@	EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Sep DISC
>D>	TROCHE/LOZENGE;TRANSMUCOSAL						
>D>	ACTIQ						
>D>	+	CEPHALON	EQ 0.2MG BASE	N020747	001	Nov 04, 1998	Sep DISC
>A>	+	@	EQ 0.2MG BASE	N020747	001	Nov 04, 1998	Sep DISC
>D>	+	!	EQ 0.4MG BASE	N020747	002	Nov 04, 1998	Sep DISC
>A>	+	@	EQ 0.4MG BASE	N020747	002	Nov 04, 1998	Sep DISC
>D>	+		EQ 0.6MG BASE	N020747	003	Nov 04, 1998	Sep DISC
>A>	+	@	EQ 0.6MG BASE	N020747	003	Nov 04, 1998	Sep DISC
>D>	+		EQ 0.8MG BASE	N020747	004	Nov 04, 1998	Sep DISC
>A>	+	@	EQ 0.8MG BASE	N020747	004	Nov 04, 1998	Sep DISC
>D>	+		EQ 1.2MG BASE	N020747	005	Nov 04, 1998	Sep DISC
>A>	+	@	EQ 1.2MG BASE	N020747	005	Nov 04, 1998	Sep DISC
>D>	+		EQ 1.6MG BASE	N020747	006	Nov 04, 1998	Sep DISC
>A>	+	@	EQ 1.6MG BASE	N020747	006	Nov 04, 1998	Sep DISC

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
FESOTERODINE FUMARATE

@	ANI PHARMS	4MG	A204504	001	Jan 04, 2023	Apr DISC
@		8MG	A204504	002	Jan 04, 2023	Apr DISC

FIDAXOMICIN

TABLET;ORAL  
DIFICID

AB	+	!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul CTEC
	+	!		200MG	N201699	001	May 27, 2011	Jan CFTG
			FIDAXOMICIN					
AB	@		ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul DISC
				200MG	A208443	001	Jan 16, 2024	Jan NEWA

FINASTERIDE

TABLET;ORAL  
FINASTERIDE

@	CIPLA	1MG	A077335	001	Nov 20, 2014	Mar DISC
---	-------	-----	---------	-----	--------------	----------

>D> FINASTERIDE; TADALAFIL

>D> CAPSULE;ORAL  
>D> ENTADFI

>D>	AB	+	!	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Sep DISC
>A>		+	@		5MG;5MG	N215423	001	Dec 09, 2021	Sep DISC
	AB	+	!		5MG;5MG	N215423	001	Dec 09, 2021	Mar CFTG
				FINASTERIDE AND TADALAFIL					
	AB			ZYDUS	5MG;5MG	A218232	001	Mar 15, 2024	Mar NFTG
>D>	AB			ZYDUS LIFESCIENCES	5MG;5MG	A218232	001	Mar 15, 2024	Sep DISC
>A>			@		5MG;5MG	A218232	001	Mar 15, 2024	Sep DISC
	AB				5MG;5MG	A218232	001	Mar 15, 2024	May CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL  
FINGOLIMOD HYDROCHLORIDE

AB			AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A207983	001	Feb 28, 2024	Feb NEWA
AB			BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Feb CMFD

FLORTAUCIPIR F-18

SOLUTION; INTRAVENOUS

TAUVID

+ @	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	Jun	DISC
+ @		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	Jun	DISC

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ NORVIUM BIOSCIENCE 200MG/100ML (2MG/ML)

A076888 001 Mar 25, 2005 Jul CAHN

@ 400MG/200ML (2MG/ML)

A076888 002 Mar 25, 2005 Jul CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

@ RISING 50MG/VIAL

A200648 001 Oct 16, 2012 Feb CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP ! CARDINAL HEALTH 414 20-500mCi/ML

A203603 002 Sep 27, 2018 May CHRS

@ SOFIE 20-500mCi/ML

A203665 001 Feb 14, 2013 May DISC

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

&gt;A&gt; @ CHARTWELL RX 0.1MG

A216013 001 Oct 27, 2022 Sep CAHN

&gt;D&gt; @ HIKMA 0.1MG

A216013 001 Oct 27, 2022 Sep CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

&gt;D&gt; AT LYNE 0.01%

A090982 001 Apr 25, 2016 Sep CAHN

&gt;D&gt; AT 0.01%

A203377 001 Apr 25, 2016 Sep CAHN

&gt;A&gt; AT RISING 0.01%

A090982 001 Apr 25, 2016 Sep CAHN

&gt;A&gt; AT 0.01%

A203377 001 Apr 25, 2016 Sep CAHN

AT TARO 0.01%

A209336 001 May 19, 2016 Jan CAHN

OIL/DROPS; OTIC

FLAC

&gt;A&gt; AT ANDA REPOSITORY 0.01%

A210736 001 Apr 11, 2018 Sep CAHN

&gt;D&gt; AT PATRIN 0.01%

A210736 001 Apr 11, 2018 Sep CAHN

FLUOCINOLONE ACETONIDE

&gt;D&gt; AT LYNE 0.01%

A203378 001 Apr 25, 2016 Sep CAHN

&gt;A&gt; AT RISING 0.01%

A203378 001 Apr 25, 2016 Sep CAHN

AT TRUPHARMA 0.01%

A213264 001 Feb 05, 2021 Aug CAHN

SHAMPOO; TOPICAL

CAPEX

+ @ GALDERMA LABS LP 0.01%

N020001 001 Aug 27, 1990 May DISC

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

@ AMNEAL 0.1%

A211111 001 Jun 04, 2018 Jul DISC

@ PADAGIS ISRAEL 0.1%

A090256 001 Jan 14, 2014 Jan DISC

+ @ TARO 0.05%

N019117 001 Jun 26, 1984 Aug CAHN

GEL; TOPICAL

FLUOCINONIDE

+ @ ALVOGEN 0.05%

N017373 001 May DISC

@ COSETTE 0.05%

A072537 001 Feb 07, 1989 Apr DISC

@ PADAGIS US 0.05%

A209030 001 Jun 19, 2018 Jan CAHN

SOLUTION; TOPICAL

FLUOCINONIDE

@ COSETTE 0.05%

A071535 001 Dec 02, 1988 Apr DISC

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP EUGIA PHARMA SPECLTS 500MG/10ML (50MG/ML)

A202668 001 Jul 17, 2012 Apr CMFD

AP 1GM/20ML (50MG/ML)

A202668 002 Jul 17, 2012 Apr CMFD

AP 2.5GM/50ML (50MG/ML)

A202669 001 Jul 17, 2012 Apr CMFD

AP 5GM/100ML (50MG/ML)

A202669 002 Jul 17, 2012 Apr CMFD



INJECTABLE; INJECTION  
FLUOROURACIL

>A> AP KINDOS 2.5GM/50ML (50MG/ML) A216494 001 Sep 24, 2024 Sep NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>D> @ STRIDES PHARMA EQ 10MG BASE A076922 001 Dec 16, 2004 Sep CMFD  
 >A> AB1 EQ 10MG BASE A076922 001 Dec 16, 2004 Sep CMFD  
 >D> @ EQ 20MG BASE A076922 002 Dec 16, 2004 Sep CMFD  
 >A> AB1 EQ 20MG BASE A076922 002 Dec 16, 2004 Sep CMFD  
 >D> @ EQ 40MG BASE A076922 003 Dec 16, 2004 Sep CMFD  
 >A> AB EQ 40MG BASE A076922 003 Dec 16, 2004 Sep CMFD  
 @ SUN PHARM INDS LTD EQ 40MG BASE A076990 001 Dec 13, 2004 Jan DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

>D> AA APTAPHARMA INC EQ 20MG BASE/5ML A216953 001 Nov 15, 2022 Sep CAHN  
 @ BAJAJ EQ 20MG BASE/5ML A075920 001 Jan 29, 2002 Mar CAHN  
 >A> AA UPSHER SMITH LABS EQ 20MG BASE/5ML A216953 001 Nov 15, 2022 Sep CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 10MG BASE A203836 001 Aug 19, 2016 Apr CAHN  
 AB EQ 20MG BASE A203836 002 Aug 19, 2016 Apr CAHN  
 AB EQ 60MG BASE A209419 001 Nov 16, 2017 Apr CAHN  
 AB STRIDES PHARMA EQ 10MG BASE A212684 001 Apr 05, 2024 Mar NEWA  
 AB EQ 20MG BASE A212684 002 Apr 05, 2024 Mar NEWA  
 >A> AB EQ 60MG BASE A212683 001 Sep 13, 2024 Sep NEWA  
 @ TEVA EQ 10MG BASE A075872 001 Jan 29, 2002 Jan DISC  
 @ EQ 20MG BASE A075872 002 Jan 04, 2019 Jan DISC  
 @ TEVA PHARMS USA EQ 60MG BASE A211051 001 Dec 03, 2018 Jan DISC  
 @ UPSHER SMITH LABS EQ 10MG BASE A211696 001 Jan 30, 2019 Jun DISC  
 @ EQ 20MG BASE A211696 002 Jan 30, 2019 Jun DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 25MG BASE;EQ 3MG BASE A077742 001 Nov 02, 2012 Apr CAHN  
 AB EQ 25MG BASE;EQ 6MG BASE A077742 002 Nov 02, 2012 Apr CAHN  
 AB EQ 25MG BASE;EQ 12MG BASE A077742 003 Nov 02, 2012 Apr CAHN  
 AB EQ 50MG BASE;EQ 6MG BASE A077742 004 Nov 02, 2012 Apr CAHN  
 AB EQ 50MG BASE;EQ 12MG BASE A077742 005 Nov 02, 2012 Apr CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO ENDO OPERATIONS 25MG/ML A203732 001 Jul 03, 2014 Apr CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB ALEMBIC 1MG A218173 001 Jul 23, 2024 Jul NEWA  
 AB 2.5MG A218173 002 Jul 23, 2024 Jul NEWA  
 AB 5MG A218173 003 Jul 23, 2024 Jul NEWA  
 AB 10MG A218173 004 Jul 23, 2024 Jul NEWA  
 >A> AB CHARTWELL RX 1MG A215141 001 Oct 20, 2021 Sep CAHN  
 >A> AB 2.5MG A215141 002 Oct 20, 2021 Sep CAHN  
 >A> AB 5MG A215141 003 Oct 20, 2021 Sep CAHN  
 >A> AB 10MG A215141 004 Oct 20, 2021 Sep CAHN  
 AB RISING 1MG A218283 001 Jun 07, 2024 May NEWA  
 AB 2.5MG A218283 002 Jun 07, 2024 May NEWA  
 AB 5MG A218283 003 Jun 07, 2024 May NEWA  
 AB 10MG A218283 004 Jun 07, 2024 May NEWA  
 >D> AB ZAMEER PHARMS 1MG A215141 001 Oct 20, 2021 Sep CAHN  
 AB 1MG A215141 001 Oct 20, 2021 Feb CAHN  
 >D> AB 2.5MG A215141 002 Oct 20, 2021 Sep CAHN  
 AB 2.5MG A215141 002 Oct 20, 2021 Feb CAHN  
 >D> AB 5MG A215141 003 Oct 20, 2021 Sep CAHN  
 AB 5MG A215141 003 Oct 20, 2021 Feb CAHN  
 >D> AB 10MG A215141 004 Oct 20, 2021 Sep CAHN  
 AB 10MG A215141 004 Oct 20, 2021 Feb CAHN

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

@ NATCO PHARMA	50MG	A 074358	001	Jun 20, 1994	Aug CAHN
@	100MG	A 074358	002	Jun 20, 1994	Aug CAHN

>A> FLURPIRIDAZ F-18

&gt;A&gt; SOLUTION; INTRAVENOUS

&gt;A&gt; FLYRCADO

>A> +! GE HLTHCARE	5-55mCi/ML	N 215168	001	Sep 27, 2024	Sep NEWA
--------------------	------------	----------	-----	--------------	----------

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER

+ @ TEVA PHARM	0.055MG/INH	N 208798	004	Feb 20, 2020	Jun DISC
+ @	0.113MG/INH	N 208798	005	Feb 20, 2020	Jun DISC
+ @	0.232MG/INH	N 208798	006	Feb 20, 2020	Jun DISC

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

@ HIKMA	0.05MG/SPRAY	A 077570	001	Jan 16, 2008	Mar DISC
---------	--------------	----------	-----	--------------	----------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO DIGIHALER

+ @ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N 208799	004	Jul 12, 2019	Jun DISC
+ @	0.113MG/INH;EQ 0.014MG BASE/INH	N 208799	005	Jul 12, 2019	Jun DISC
+ @	0.232MG/INH;EQ 0.014MG BASE/INH	N 208799	006	Jul 12, 2019	Jun DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB ENDO OPERATIONS	100MG	A 091476	001	Mar 13, 2013	Apr CAHN
AB	150MG	A 091476	002	Mar 13, 2013	Apr CAHN

TABLET; ORAL

FLUVOXAMINE MALEATE

AB BIONPHARMA	25MG	A 217917	001	Jan 22, 2024	Jan NEWA
AB	50MG	A 217917	002	Jan 22, 2024	Jan NEWA
AB	100MG	A 217917	003	Jan 22, 2024	Jan NEWA

FOLIC ACID

TABLET; ORAL

FOLIC ACID

@ ENDO OPERATIONS	1MG	A 040756	001	Jun 04, 2010	May CAHN
-------------------	-----	----------	-----	--------------	----------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

FONDAPARINUX SODIUM

AP HANGZHOU ZHONGMEI	2.5MG/0.5ML	A 216493	001	Aug 19, 2024	Aug NEWA
AP	5MG/0.4ML	A 216493	002	Aug 19, 2024	Aug NEWA
AP	7.5MG/0.6ML	A 216493	003	Aug 19, 2024	Aug NEWA
AP	10MG/0.8ML	A 216493	004	Aug 19, 2024	Aug NEWA

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN MICRO LABS	0.02MG/2ML	A 218304	001	Jun 26, 2024	Jun NEWA
AN RITEDOSE CORP	0.02MG/2ML	A 216486	001	Nov 25, 2022	May CAHN
AN WILSHIRE PHARMS INC	0.02MG/2ML	A 215621	001	Dec 13, 2022	Jul CAHN

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB ! MYLAN	EQ 700MG BASE	A 204060	001	Apr 15, 2016	Jan CHRS
LEXIVA					
+ @ VIIV HLTHCARE	EQ 700MG BASE	N 021548	001	Oct 20, 2003	Jan DISC

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

@ ACCORD HLTHCARE EQ 150MG BASE/VIAL A204025 001 Aug 26, 2020 May DISC  
@ GENEYORK PHARMS EQ 150MG BASE/VIAL A211624 001 Sep 05, 2019 Jul CAHN

FOSCARNET SODIUM

INJECTABLE; INJECTION  
FOSCARNET SODIUM

AP AMNEAL 2.4GM/100ML A216602 001 Mar 01, 2024 Feb NEWA

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL  
FOSFOMYCIN TROMETHAMINE

AA AMNEAL EQ 3GM BASE/PACKET A216600 001 Mar 25, 2024 Mar NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION  
FOSPHENYTOIN SODIUM

@ NORVIUM BIOSCIENCE EQ 50MG PHENYTOIN NA/ML A078736 001 Jun 08, 2010 Jul CAHN

FROVATRIPTAN SUCCINATE

TABLET; ORAL  
FROVA

AB +! ENDO OPERATIONS EQ 2.5MG BASE N021006 001 Nov 08, 2001 Apr CAHN

FULVESTRANT

SOLUTION; INTRAMUSCULAR  
FULVESTRANT

AO FRESENIUS KABI USA 250MG/5ML (50MG/ML) N210326 001 May 20, 2019 Aug CTEC

FUROSEMIDE

INJECTABLE; INJECTION  
FUROSEMIDE

AP HIKMA 10MG/ML N018267 001 Aug CMFD  
AP SABA ILAC SANAYIVE 10MG/ML A215856 001 Apr 02, 2024 Mar NEWA

TABLET; ORAL  
FUROSEMIDE

>D> MYLAN 20MG N018487 001 Sep DISC  
>A> @ 20MG N018487 001 Sep DISC  
>D> AB 40MG N018487 002 Sep DISC  
>A> @ 40MG N018487 002 Sep DISC  
>D> AB 80MG A070082 001 Oct 29, 1986 Sep DISC  
>A> @ 80MG A070082 001 Oct 29, 1986 Sep DISC

GABAPENTIN

CAPSULE; ORAL  
GABAPENTIN

AB RISING 100MG A207099 001 Mar 24, 2017 Aug CAHN  
AB 300MG A207099 002 Mar 24, 2017 Aug CAHN  
AB 400MG A207099 003 Mar 24, 2017 Aug CAHN  
@ SUN PHARM INDS LTD 100MG A077242 001 Aug 24, 2006 May DISC  
@ 300MG A077242 002 Aug 24, 2006 May DISC  
@ 400MG A077242 003 Aug 24, 2006 May DISC

SOLUTION; ORAL  
GABAPENTIN

AA ANNORA PHARMA 250MG/5ML A217682 001 Jan 17, 2024 Jan NEWA

TABLET; ORAL  
GABAPENTIN

>A> AB2 ABON PHARMS LLC 600MG A203643 001 Sep 09, 2024 Sep CAHN  
AB1 ACTAVIS ELIZABETH 600MG A075694 001 Oct 21, 2004 Jan CTEC  
AB1 800MG A075694 002 Oct 21, 2004 Jan CTEC  
AB1 ALKEM LABS LTD 600MG A206402 001 Dec 23, 2015 Jan CTEC  
AB1 800MG A206402 002 Dec 23, 2015 Jan CTEC  
AB2 ANNORA PHARMA 300MG A218075 001 Feb 26, 2024 Feb NEWA  
AB2 600MG A218075 002 Feb 26, 2024 Feb NEWA  
AB1 APOTEX 100MG A077894 001 Oct 10, 2006 Jan CTEC  
AB1 300MG A077894 002 Oct 10, 2006 Jan CTEC  
AB1 400MG A077894 003 Oct 10, 2006 Jan CTEC  
AB1 ASCENT PHARMS INC 600MG A214957 001 Oct 01, 2021 Jan CTEC  
AB1 800MG A214957 002 Oct 01, 2021 Jan CTEC

TABLET;ORAL

GABAPENTIN

AB1	AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011	Jan CTEC	
AB1		800MG	A200651	002	Oct 06, 2011	Jan CTEC	
AB1	CSPC OUYI	600MG	A207057	001	Oct 26, 2017	Jan CTEC	
AB1		800MG	A207057	002	Oct 26, 2017	Jan CTEC	
AB1	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	Jan CTEC	
AB1		800MG	A077662	002	Aug 18, 2006	Jan CTEC	
AB1	GRANULES	600MG	A217116	001	Mar 28, 2023	Jan CTEC	
AB1		800MG	A217116	002	Mar 28, 2023	Jan CTEC	
AB2	HUMANWELL	300MG	A216252	001	Feb 26, 2024	Feb NEWA	
AB2		600MG	A216252	002	Feb 26, 2024	Feb NEWA	
>D>	AB2	INCEPTA PHARMS LTD	600MG	A203643	001	Sep 09, 2024	Sep CAHN
AB2		600MG	A203643	001	Sep 09, 2024	Aug NEWA	
	@	INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012	Mar DISC
AB1		600MG	A202764	001	Oct 16, 2012	Jan CTEC	
	@		800MG	A202764	002	Oct 16, 2012	Mar DISC
AB1		800MG	A202764	002	Oct 16, 2012	Jan CTEC	
AB1	IPCA LABS LTD	600MG	A209855	001	May 29, 2024	May NEWA	
AB1		800MG	A209855	002	May 29, 2024	May NEWA	
AB1	IVAX SUB TEVA PHARMS	100MG	A076017	001	Apr 28, 2004	Jan CTEC	
AB1		300MG	A076017	002	Apr 28, 2004	Jan CTEC	
AB1		400MG	A076017	003	Apr 28, 2004	Jan CTEC	
AB1	LAURUS	600MG	A217965	001	Apr 08, 2024	Mar NEWA	
AB1		800MG	A217965	002	Apr 08, 2024	Mar NEWA	
AB1	RISING	600MG	A217995	001	Jul 19, 2023	Jan CTEC	
AB1		800MG	A217995	002	Jul 19, 2023	Jan CTEC	
AB1	RUBICON	600MG	A077661	004	Sep 13, 2006	Jan CTEC	
AB1		800MG	A077661	005	Sep 13, 2006	Jan CTEC	
AB1	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan CTEC	
AB1		800MG	A205101	002	Feb 04, 2016	Jan CTEC	
AB1	STRIDES PHARMA	600MG	A211313	001	Mar 04, 2024	Feb NEWA	
AB1		800MG	A211313	002	Mar 04, 2024	Feb NEWA	
AB1	SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006	Jan CTEC	
AB1		800MG	A077525	002	Aug 24, 2006	Jan CTEC	
AB2	ZYDUS PHARMS	300MG	A203934	001	Jan 24, 2024	Jan NEWA	
AB2		600MG	A203934	002	Jan 24, 2024	Jan NEWA	
AB1	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan CTEC	
AB1		800MG	A078926	002	Feb 11, 2011	Jan CTEC	
	GRALISE						
AB2	+!	ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CTEC
AB2	+		600MG	N022544	002	Jan 28, 2011	Jan CTEC
BX	+		600MG	N022544	002	Jan 28, 2011	Jan CHRS
	+!		900MG	N022544	005	Apr 18, 2023	Jan CHRS
	NEURONTIN						
AB1	+	VIATRIS	600MG	N020882	001	Oct 09, 1998	Jan CTEC
AB1	+!		800MG	N020882	002	Oct 09, 1998	Jan CTEC

GADOBUTROL

SOLUTION;INTRAVENOUS

GADOBUTROL

AP	HENGRUI PHARMA	1.20944GM/2ML (604.72MG/ML)	A216081	003	Nov 17, 2022	Jul CMS1
AP		4.5354GM/7.5ML (604.72MG/ML)	A216081	004	Nov 17, 2022	Jul CMS1
AP		6.0472GM/10ML (604.72MG/ML)	A216081	005	Nov 17, 2022	Jul CMS1
AP		9.0708GM/15ML (604.72MG/ML)	A216081	006	Nov 17, 2022	Jul CMS1

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

+	@	GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar CRLD
+	@		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar DISC

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

GADOTERATE MEGLUMINE

AP	HAINAN POLY	1.8845GM/5ML (376.9MG/ML)	A218073	001	Jun 17, 2024	Jun NEWA
AP		3.769GM/10ML (376.9MG/ML)	A218073	002	Jun 17, 2024	Jun NEWA
AP		5.6535GM/15ML (376.9MG/ML)	A218073	003	Jun 17, 2024	Jun NEWA
AP		7.538GM/20ML (376.9MG/ML)	A218073	004	Jun 17, 2024	Jun NEWA
AP		37.69GM/100ML (376.9MG/ML)	A218073	005	Jun 17, 2024	Jun NEWA

GANCICLOVIR SODIUM

	INJECTABLE; INJECTION						
	GANCICLOVIR SODIUM						
AP	ENDO OPERATIONS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May	CAHN

GATIFLOXACIN

	SOLUTION/DROPS; OPHTHALMIC						
	GATIFLOXACIN						
	@ HIKMA	0.5%	A203189	001	Sep 03, 2014	Mar	DISC

GEMCITABINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	GEMCITABINE HYDROCHLORIDE						
	@ ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Apr	DISC
	@	EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Apr	DISC
	@	EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Apr	DISC

GEPİRONE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL						
	EXXUA						
	+ @ FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Jun	DISC
	+ @	EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Jun	DISC
	+ @	EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Jun	DISC
	+ @	EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Jun	DISC

GIVINOSTAT HYDROCHLORIDE

	SUSPENSION; ORAL						
	DUVYZAT						
	+! ITALFARMACO SPA	EQ 8.86MG BASE/ML	N217865	001	Mar 21, 2024	Mar	NEWA

GLATIRAMER ACETATE

	INJECTABLE; SUBCUTANEOUS							
	GLATIRAMER ACETATE							
>A>	AP	SYNTHON PHARMS INC	20MG/ML	A203857	001	Sep 25, 2024	Sep	NEWA
>A>	AP		40MG/ML	A206873	001	Sep 25, 2024	Sep	NEWA

GLIPIZIDE

	TABLET; ORAL						
	GLIPIZIDE						
	@ ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	May	DISC
	@	10MG	A074550	002	Sep 11, 1997	May	DISC
	@ SANDOZ	5MG	A074305	001	Apr 07, 1995	Jun	DISC
	@	10MG	A074305	002	Apr 07, 1995	Jun	DISC
	TABLET, EXTENDED RELEASE; ORAL						
	GLIPIZIDE						
	@ ENDO OPERATIONS	5MG	A076159	002	Sep 20, 2013	May	CAHN
	@	10MG	A076159	001	Sep 20, 2013	May	CAHN

GLUCAGON HYDROCHLORIDE

	POWDER; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS						
	GLUCAGON						
	+! FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	002	Sep 19, 2019	Apr	CMS1

GLYBURIDE; METFORMIN HYDROCHLORIDE

	TABLET; ORAL						
	GLYBURIDE AND METFORMIN HYDROCHLORIDE						
AB	HERITAGE	1.25MG; 250MG	A079009	001	Jun 03, 2009	Feb	CMFD
AB		2.5MG; 500MG	A079009	002	Jun 03, 2009	Feb	CMFD
AB		5MG; 500MG	A079009	003	Jun 03, 2009	Feb	CMFD

GLYCEROL PHENYLBUTYRATE

	LIQUID; ORAL						
	GLYCEROL PHENYLBUTYRATE						
	@ ENDO OPERATIONS	1.1GM/ML	A205742	001	Dec 02, 2021	May	CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>D>	AP	ASPEN	0.2MG/ML	A212871	001	Nov 29, 2022	Sep CAHN
	AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Feb CAHN
>A>	AP	OMNIVIUM PHARMS	0.2MG/ML	A212871	001	Nov 29, 2022	Sep CAHN
	AP	UMEDICA	0.2MG/ML	A212591	001	Oct 13, 2021	Aug CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

>D>	+!	EXELA PHARMA	0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020	Sep DISC
>A>	+ @		0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020	Sep DISC

SOLUTION; ORAL

GLYCOPYRROLATE

AA		CHARTWELL RX	1MG/5ML	A216368	001	Aug 28, 2024	Aug NEWA
AA		GRANULES	1MG/5ML	A214735	001	Aug 19, 2024	Aug NEWA
>A>	AA	SAPTALIS PHARMS	1MG/5ML	A216297	001	Oct 07, 2024	Sep NEWA

TABLET; ORAL

GLYCOPYRROLATE

AA		ADAPTIS	1MG	A091182	001	Feb 03, 2014	Aug CAHN
AA			2MG	A091182	002	Feb 03, 2014	Aug CAHN
	!	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012	Jul CHRS
AA		QUAGEN	1MG	A212696	001	Jul 10, 2024	Jun NEWA
AA			2MG	A212696	002	Jul 10, 2024	Jun NEWA
AA		VELZEN PHARMA PVT	1MG	A090195	001	Sep 21, 2012	Aug CAHN
AA			2MG	A090195	002	Sep 21, 2012	Aug CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

PREVDUO

+!	AZURITY		0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb CAHN
----	---------	--	--	---------	-----	--------------	----------

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT		NORDIC PHARMA	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Jun CAHN
----	--	---------------	--	---------	-----	--------------	----------

GRANISETRON

INJECTABLE; SUBCUTANEOUS

SUSTOL

+!	HERON THERAPS INC		10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug CMS1
----	-------------------	--	-------------------------	---------	-----	--------------	----------

GRISEOFULVIN, MICROSIZE

TABLET; ORAL

FULVICIN-U/F

AB		CHARTWELL RX	250MG	A060569	002		Jan CTEC
			250MG	A060569	002		Jan CAIN
AB			500MG	A060569	001		Jan CTEC
			500MG	A060569	001		Jan CAIN

GRISEOFULVIN

AB		SANDOZ	250MG	A091592	001	Aug 07, 2013	Jan CTEC
----	--	--------	-------	---------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

FULVICIN P/G

AB		CHARTWELL RX	125MG	A061996	001		Jan CTEC
			125MG	A061996	001		Jan CAIN
AB			250MG	A061996	002		Jan CTEC
			250MG	A061996	002		Jan CAIN

FULVICIN P/G 165

		CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Jan CAIN
--	--	--------------	-------	---------	-----	--------------	----------

FULVICIN P/G 330

		CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Jan CAIN
--	--	--------------	-------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB		XIROMED	EQ 1MG BASE	A218326	001	Feb 23, 2024	Feb NEWA
AB			EQ 2MG BASE	A218326	002	Feb 23, 2024	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL  
GUANFACINE HYDROCHLORIDE

AB	WANBANG BIOPHARMS	EQ 1MG BASE	A217638	001	Jun 12, 2024	May NEWA
AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	May NEWA
AB		EQ 3MG BASE	A217638	003	Jun 12, 2024	May NEWA
AB		EQ 4MG BASE	A217638	004	Jun 12, 2024	May NEWA

HALCINONIDE

OINTMENT;TOPICAL  
HALOG

	+ @ SUN PHARM INDS INC	0.1%	N017824	001		Jan DISC
--	------------------------	------	---------	-----	--	----------

SOLUTION;TOPICAL  
HALCINONIDE

	ENCUBE	0.1%	A217671	001	May 29, 2024	May NFTG
--	--------	------	---------	-----	--------------	----------

HALOG

	+ @ SUN PHARM INDS INC	0.1%	N017823	001		Jan DISC
--	------------------------	------	---------	-----	--	----------

HALOBETASOL PROPIONATE

LOTION;TOPICAL  
ULTRAVATE

	+ @ MICAL PHARMS	0.05%	N208183	001	Nov 06, 2015	May CAHN
--	------------------	-------	---------	-----	--------------	----------

	+ @ SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	May DISC
--	--------------------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL  
HALOPERIDOL

AB	AUROBINDO PHARMA LTD	0.5MG	A218789	001	Apr 19, 2024	Apr NEWA
AB		1MG	A218789	002	Apr 19, 2024	Apr NEWA
AB		2MG	A218789	003	Apr 19, 2024	Apr NEWA
AB		5MG	A218789	004	Apr 19, 2024	Apr NEWA
AB		10MG	A218789	005	Apr 19, 2024	Apr NEWA
AB		20MG	A218789	006	Apr 19, 2024	Apr NEWA
AB	CHARTWELL RX	0.5MG	A071209	002	Nov 17, 1986	Jan CAHN
AB		1MG	A071209	003	Nov 17, 1986	Jan CAHN
	@	2MG	A071209	004	Nov 17, 1986	Jan CAHN
AB		5MG	A071209	001	Nov 17, 1986	Jan CAHN
AB		10MG	A071210	001	Mar 11, 1988	Jan CAHN
AB		20MG	A071211	001	Mar 11, 1988	Jan CAHN
AB	MANKIND PHARMA	0.5MG	A216918	001	Apr 11, 2024	Apr NEWA
AB		1MG	A216918	002	Apr 11, 2024	Apr NEWA
AB		2MG	A216918	003	Apr 11, 2024	Apr NEWA
AB		5MG	A216918	004	Apr 11, 2024	Apr NEWA
AB		10MG	A216918	005	Apr 11, 2024	Apr NEWA
AB		20MG	A216918	006	Apr 11, 2024	Apr NEWA

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION  
HALOPERIDOL DECANOATE

	@ TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan DISC
--	-------------------	-----------------	---------	-----	--------------	----------

	@	EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan DISC
--	---	------------------	---------	-----	--------------	----------

HALOPERIDOL LACTATE

CONCENTRATE;ORAL  
HALOPERIDOL

AA	RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan NEWA
----	---------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION  
HEPARIN SODIUM

	@ ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	008		Jun CAHN
--	--------------------	----------------	---------	-----	--	----------

	@	5,000 UNITS/ML	N000552	009		Jun CAHN
--	---	----------------	---------	-----	--	----------

	@	10,000 UNITS/ML	N000552	010		Jun CAHN
--	---	-----------------	---------	-----	--	----------

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%

>D>	+!	FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017	Sep DISC
-----	----	--------------------	-------------	---------	-----	--------------	----------

>A>	+ @		40 UNITS/ML	N017029	021	Aug 24, 2017	Sep DISC
-----	-----	--	-------------	---------	-----	--------------	----------

	+!		40 UNITS/ML	N017029	021	Aug 24, 2017	Mar NEWA
--	----	--	-------------	---------	-----	--------------	----------

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

	+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar NEWA
--	----	--------------------	-------------	---------	-----	--------------	----------

	+!		100 UNITS/ML	N017029	023	Aug 24, 2017	Mar NEWA
--	----	--	--------------	---------	-----	--------------	----------

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

	+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar NEWA
--	----	--------------------	-------------	---------	-----	--------------	----------

	+!		100 UNITS/ML	N017029	025	Aug 24, 2017	Mar NEWA
--	----	--	--------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

LIQUAEMIN LOCK FLUSH

@ ASPEN GLOBAL INC	100 UNITS/ML	N000552	007			Jun	CAHN
LIQUAEMIN SODIUM							
@ ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	004			Jun	CAHN
@	5,000 UNITS/ML	N000552	003			Jun	CAHN
@	10,000 UNITS/ML	N000552	005			Jun	CAHN
@	20,000 UNITS/ML	N000552	001			Jun	CAHN
@	40,000 UNITS/ML	N000552	002			Jun	CAHN
LIQUAEMIN SODIUM PRESERVATIVE FREE							
@ ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986		Jun	CAHN
@	5,000 UNITS/ML	N000552	012	Apr 11, 1986		Jun	CAHN
@	10,000 UNITS/ML	N000552	013	Apr 11, 1986		Jun	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
VANTAS							
+ @	ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
>D>	@	APOZEAL PHARMS	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN
	@	GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
	@	PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC
>A>	@	SCIEGEN PHARMS INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
AP	!	FRESENIUS KABI USA	20MG/ML	A040388	001	Mar 13, 2001	Aug	CHRS
	@	NORVIUM BIOSCIENCE	20MG/ML	A204680	001	Apr 28, 2016	Jun	CAHN
AP		RISING	20MG/ML	A040730	001	Apr 21, 2009	Aug	CHRS

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		GLENMARK PHARMS LTD	10MG	A090527	001	May 29, 2009	Jul	CMS1
AA			25MG	A090527	002	May 29, 2009	Jul	CMS1
AA			50MG	A090527	003	May 29, 2009	Jul	CMS1
AA			100MG	A090527	004	May 29, 2009	Jul	CMS1
	@	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
	@		25MG	A090255	002	Dec 15, 2008	Mar	DISC
	@		50MG	A090255	003	Dec 15, 2008	Mar	DISC
	@		100MG	A090255	004	Dec 15, 2008	Mar	DISC
AA		MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Aug	NEWA
AA			25MG	A211010	002	Aug 21, 2024	Aug	NEWA
AA			50MG	A211010	003	Aug 21, 2024	Aug	NEWA
AA			100MG	A211010	004	Aug 21, 2024	Aug	NEWA
	@	NORVIUM BIOSCIENCE	10MG	A090413	001	Dec 08, 2010	Jul	CAHN
	@		25MG	A090413	002	Dec 08, 2010	Jul	CAHN
	@		50MG	A090413	003	Dec 08, 2010	Jul	CAHN
	@		100MG	A090413	004	Dec 08, 2010	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Jan	NEWA
----	--	-----------	--------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	IVAX SUB TEVA PHARMS	12.5MG	A083177	003	Sep 19, 2024	Sep	NEWA
	@	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Aug	DISC
	@		50MG	A040412	002	Mar 29, 2002	Aug	DISC



HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

>D>	@ COREPHARMA	12.5MG;10MG	A 076674	001	Oct 05, 2004	Sep	CMFD
>A>	AB	12.5MG;10MG	A 076674	001	Oct 05, 2004	Sep	CMFD
>D>	@	12.5MG;20MG	A 076674	002	Oct 05, 2004	Sep	CMFD
>A>	AB	12.5MG;20MG	A 076674	002	Oct 05, 2004	Sep	CMFD
>D>	@	25MG;20MG	A 076674	003	Oct 05, 2004	Sep	CMFD
>A>	AB	25MG;20MG	A 076674	003	Oct 05, 2004	Sep	CMFD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@	GRANULES	12.5MG;50MG	A 218015	001	Sep 29, 2023	Mar	DISC
@		12.5MG;100MG	A 218015	002	Sep 29, 2023	Mar	DISC
@		25MG;100MG	A 218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

@	SUN PHARM INDS	25MG;50MG	A 090654	001	Jan 19, 2012	May	DISC
@		25MG;100MG	A 090654	002	Jan 19, 2012	May	DISC
@		50MG;100MG	A 090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

HYDROCHLOROTHIAZIDE AND OLMESARTAN MEDOXOMIL

AB	ALKEM LABS LTD	12.5MG;20MG	A 207037	001	Jul 11, 2024	Jul	NEWA
AB		12.5MG;40MG	A 207037	002	Jul 11, 2024	Jul	NEWA
AB		25MG;40MG	A 207037	003	Jul 11, 2024	Jul	NEWA

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS USA	12.5MG;40MG	A 200532	002	Apr 24, 2017	May	DISC
---	-----------------	-------------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A 201356	001	Apr 20, 2011	Mar	DISC
@		12.5MG;EQ 20MG BASE	A 201356	002	Apr 20, 2011	Mar	DISC
@		25MG;EQ 20MG BASE	A 201356	003	Apr 20, 2011	Mar	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	@ APOZEAL PHARMS	5MG/5ML;60MG/5ML	A 206661	001	Jan 23, 2019	Sep	CAHN
>A>	@ SCIEGEN PHARMS INC	5MG/5ML;60MG/5ML	A 206661	001	Jan 23, 2019	Sep	CAHN

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE

AB	! LUPIN LTD	0.1%	A 210209	001	Aug 17, 2018	Aug	CHRS
	LOCOID						
	+ @ BAUSCH	0.1%	N 022076	001	May 18, 2007	Aug	DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

AP	CIPLA	EQ 100MG BASE/VIAL	A 214050	001	Sep 05, 2024	Aug	NFTG
AP	+! PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N 009866	001		Aug	CFTG

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP	+! FRESENIUS KABI USA	0.2MG/ML	N 019034	006	Jan 16, 2020	Feb	CFTG
AP	+!	0.5MG/0.5ML	N 019034	007	Feb 10, 2017	Feb	CFTG
	+!	0.5MG/0.5ML	N 019034	007	Feb 10, 2017	Jan	NEWA
AP	+!	4MG/ML	N 019034	005	Apr 30, 2009	Aug	CMFD

HYDROMORPHONE HYDROCHLORIDE

AP	HIKMA	0.2MG/ML	A 216899	001	Feb 09, 2024	Feb	NFTG
AP		0.5MG/0.5ML	A 216899	002	Feb 09, 2024	Feb	NFTG
AP		1MG/ML	A 216899	003	Feb 09, 2024	Feb	NEWA

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP		2MG/ML	A216899	004	Feb 09, 2024	Feb	NEWA
AP	HOSPIRA INC	4MG/ML	N200403	003	Dec 01, 2011	Aug	CTEC

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

>A>	@ CHARTWELL	5MG/5ML	A207108	001	Apr 22, 2020	Sep	CAHN
>D>	@ GENUS	5MG/5ML	A207108	001	Apr 22, 2020	Sep	CAHN
	@	5MG/5ML	A207108	001	Apr 22, 2020	Jan	CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

>A>	@ CHARTWELL	2MG	A077471	002	Dec 09, 2009	Sep	CAHN
>A>	@	4MG	A077471	003	Dec 09, 2009	Sep	CAHN
>A>	@	8MG	A077471	001	Dec 09, 2009	Sep	CAHN
>D>	@ GENUS	2MG	A077471	002	Dec 09, 2009	Sep	CAHN
	@	2MG	A077471	002	Dec 09, 2009	Jan	CAHN
>D>	@	4MG	A077471	003	Dec 09, 2009	Sep	CAHN
	@	4MG	A077471	003	Dec 09, 2009	Jan	CAHN
>D>	@	8MG	A077471	001	Dec 09, 2009	Sep	CAHN
	@	8MG	A077471	001	Dec 09, 2009	Jan	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	ALLIED	200MG	A040150	001	Jan 27, 1996	Jun	CAHN
AB	! APPCO	100MG	A210441	002	Sep 19, 2022	Jun	CHRS
AB	CREEKWOOD PHARMS	200MG	A040150	001	Jan 27, 1996	Jul	CAHN
AB		200MG	A040150	001	Jan 27, 1996	Apr	CMFD
	@	200MG	A040150	001	Jan 27, 1996	Jan	CAHN
AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Feb	CAHN
AB	TEVA PHARMS	200MG	A040081	001	Sep 30, 1994	Feb	CMFD

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

	+ @ BAUSCH AND LOMB INC	5MG	N018771	001		Jul	DISC
--	-------------------------	-----	---------	-----	--	-----	------

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB	QILU	500MG	A218021	001	Mar 06, 2024	Feb	NEWA
----	------	-------	---------	-----	--------------	-----	------

SOLUTION; ORAL

XROMI

	+! NOVA LABS LTD	100MG/ML	N216593	001	Apr 04, 2024	Apr	NEWA
--	------------------	----------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA	APOZEAL PHARMS	10MG/5ML	A210634	001	Feb 26, 2019	Jun	CMFD
----	----------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ INVAGEN PHARMS 10MG

A040812 001 Mar 12, 2008 Mar DISC

@ 25MG

A040812 002 Mar 12, 2008 Mar DISC

@ 50MG

A040812 003 Mar 12, 2008 Mar DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	! HERITAGE PHARMA	EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jul	CHRS
----	-------------------	-----------------------	---------	-----	--------------	-----	------

AB	SANDOZ	EQ 50MG HYDROCHLORIDE	A086183	001		Jul	CHRS
----	--------	-----------------------	---------	-----	--	-----	------

VISTARIL

	+ @ PFIZER	EQ 100MG HYDROCHLORIDE	N011459	006		Jul	CRLD
--	------------	------------------------	---------	-----	--	-----	------

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

@ SUN PHARM EQ 3MG BASE/3ML

A090853 001 Feb 14, 2014 May DISC

TABLET; ORAL

IBANDRONATE SODIUM

@ WATSON LABS TEVA EQ 150MG BASE

A079003 001 Mar 20, 2012 May DISC

IBRUTINIB

	CAPSULE;ORAL							
	IBRUTINIB							
>D>	@ ZYDUS	70MG	A211344	001	Mar 31, 2021	Sep	CAHN	
>D>	@	140MG	A211344	002	Mar 31, 2021	Sep	CAHN	
>A>	@ ZYDUS LIFESCIENCES	70MG	A211344	001	Mar 31, 2021	Sep	CAHN	
>A>	@	140MG	A211344	002	Mar 31, 2021	Sep	CAHN	
	TABLET;ORAL							
	IMBRUVICA							
	+!	PHARMACYCLICS LLC	420MG	N210563	003	Feb 16, 2018	Jan	CHRS

IBUPROFEN

TABLET;ORAL

IBUPROFEN

	@ ENDO OPERATIONS	300MG	A071230	001	Oct 22, 1986	May	CAHN	
	@	400MG	A071231	001	Oct 22, 1986	May	CAHN	
	@	400MG	A071644	001	Feb 01, 1988	May	CAHN	
	@	600MG	A071232	001	Oct 22, 1986	May	CAHN	
	@	800MG	A072004	001	Nov 18, 1987	May	CAHN	
	SHANDONG XINHUA	300MG	A202413	004	Jul 05, 2024	Jul	NEWA	

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

AP	AVET LIFESCIENCES	0.1MG/ML	A204146	001	Apr 01, 2024	Mar	NEWA	
----	-------------------	----------	---------	-----	--------------	-----	------	--

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

AP	ALEMBIC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213773	001	Jun 14, 2024	Jun	NEWA	
AP	WILSHIRE PHARMS INC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211501	001	Sep 01, 2020	Jul	CAHN	

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB	ASCENT PHARMS INC	1GM	A216811	002	Feb 16, 2024	Feb	NEWA	
AB	ZYDUS LIFESCIENCES	500MG	A217656	001	Apr 20, 2023	Apr	CAHN	
AB		1GM	A217656	002	Apr 20, 2023	Apr	CAHN	

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDARUBICIN HYDROCHLORIDE

	@ RISING	1MG/ML	A200144	001	Oct 11, 2012	Feb	CAHN	
--	----------	--------	---------	-----	--------------	-----	------	--

ILOPROST

SOLUTION;INHALATION

VENTAVIS

	+ @ ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Mar	DISC	
	+ @	20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Mar	DISC	

SOLUTION;INTRAVENOUS

AURLUMYN

	+!	EICOS SCI	100MCG/ML (100MCG/ML)	N217933	001	Feb 13, 2024	Feb	NEWA
--	----	-----------	-----------------------	---------	-----	--------------	-----	------

IMETELSTAT SODIUM

POWDER;INTRAVENOUS

RYTELO

	+!	GERON	EQ 47MG BASE/VIAL	N217779	001	Jun 06, 2024	Jun	NEWA
	+!		EQ 188MG BASE/VIAL	N217779	002	Jun 06, 2024	Jun	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB	!	LEADING	50MG	A040903	003	Oct 24, 2012	Apr	CHRS
	+ @	SPECGX LLC	10MG	A087846	002	May 22, 1984	Apr	DISC
	+ @		25MG	A087846	003	May 22, 1984	Apr	DISC
		TOFRANIL						
	+ @	SPECGX LLC	50MG	A087846	001	May 22, 1984	Apr	DISC

>D>	<u>INDIUM IN-111 CHLORIDE</u>								
>D>	INJECTABLE;INJECTION								
>D>	INDIUM IN 111 CHLORIDE								
>D>	+! CURIUM	5mCi/0.5ML			N019841	001	Sep 27, 1994	Sep	DISC
>A>	+ @	5mCi/0.5ML			N019841	001	Sep 27, 1994	Sep	DISC
	<u>INDIUM IN-111 PENTETREOTIDE KIT</u>								
	INJECTABLE;INJECTION								
	INDIUM IN-111 PENTETREOTIDE KIT								
AP	SUN PHARM INDS INC	3mCi/ML			A212785	001	Jul 01, 2024	Jun	NFTG
	OCTREOSCAN								
AP	+! CURIUM	3mCi/ML			N020314	001	Jun 02, 1994	Jun	CFTG
	<u>INDOMETHACIN</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	INDOMETHACIN								
	@ MYLAN	75MG			A202139	001	Mar 20, 2014	Aug	CAHN
	SUPPOSITORY;RECTAL								
	INDOMETHACIN								
AB	ZYDUS LIFESCIENCES	50MG			A216184	001	Aug 02, 2023	Apr	CAHN
	SUSPENSION;ORAL								
	INDOCIN								
AB	+! ZYLA	25MG/5ML			N018332	001	Oct 10, 1985	Jan	CTEC
	INDOMETHACIN								
AB	NOVITIUM PHARMA	25MG/5ML			A217883	001	Jan 12, 2024	Jan	NEWA
>D>	<u>INOTERSEN SODIUM</u>								
>D>	SOLUTION;SUBCUTANEOUS								
>D>	TEGSEDI								
>D>	+! AKCEA THERAPS	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)			N211172	001	Oct 05, 2018	Sep	DISC
>A>	+ @	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)			N211172	001	Oct 05, 2018	Sep	DISC
	<u>IOBENGUANE I-131</u>								
	SOLUTION;INTRAVENOUS								
	AZEDRA								
	+ @ PROGENICS PHARMS INC	15mCi/ML			N209607	001	Jul 30, 2018	Feb	DISC
	<u>IOPAMIDOL</u>								
	INJECTABLE;INJECTION								
	IOPAMIDOL								
AP	HAINAN POLY	51%			A217134	002	Apr 09, 2024	Mar	NEWA
AP		61%			A217134	003	Apr 09, 2024	Mar	NEWA
AP		76%			A217134	004	Apr 09, 2024	Mar	NEWA
	ISOVUE-250								
AP	+! BRACCO	51%			N018735	007	Jul 06, 1992	Mar	CTEC
	ISOVUE-300								
AP	+! BRACCO	61%			N018735	002	Dec 31, 1985	Mar	CTEC
	ISOVUE-370								
AP	+! BRACCO	76%			N018735	003	Dec 31, 1985	Mar	CTEC
	<u>IPRATROPIUM BROMIDE</u>								
	SOLUTION;INHALATION								
	IPRATROPIUM BROMIDE								
	@ NORVIUM BIOSCIENCE	0.02%			A074755	001	Jan 10, 1997	Jul	CAHN
	<u>IRBESARTAN</u>								
	TABLET;ORAL								
	AVAPRO								
	+ @ SANOFI AVENTIS US	75MG			N020757	001	Sep 30, 1997	Jul	DISC
	IRBESARTAN								
AB	IPCA LABS LTD	75MG			A211056	001	May 22, 2024	May	NEWA
AB		150MG			A211056	002	May 22, 2024	May	NEWA
AB		300MG			A211056	003	May 22, 2024	May	NEWA

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

@ HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Jul	DISC
@	100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Jul	DISC

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

@ CIPLA	0.2MG/ML	A210322	001	Jun 12, 2018	Mar	DISC
@ EUGIA PHARMA	0.2MG/ML	A211864	001	Feb 09, 2021	Jun	DISC
>A> AP GLAND PHARMA LTD	0.2MG/ML	A217648	001	Oct 03, 2024	Sep	NEWA
AP SOMERSET THERAPS LLC	0.2MG/ML	A211590	001	Aug 06, 2024	Jul	NEWA

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL  
DILATRATE-SR

+ @ ENDO OPERATIONS	40MG	N019790	001	Sep 02, 1988	May	CAHN
---------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

ISOSORBIDE DINITRATE

AB ENDO OPERATIONS	40MG	A211290	001	Nov 23, 2021	Apr	CAHN
AB ZYDUS LIFESCIENCES	5MG	A213057	001	Nov 20, 2019	Aug	CAHN
AB	10MG	A213057	002	Nov 20, 2019	Aug	CAHN
AB	20MG	A213057	003	Nov 20, 2019	Aug	CAHN
AB	30MG	A213057	004	Nov 20, 2019	Aug	CAHN
AB	40MG	A213057	005	Nov 20, 2019	Aug	CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL

MONOKET

AB + OMNIVIUM PHARMS	10MG	N020215	002	Jun 30, 1993	Jan	CAHN
AB +!	20MG	N020215	001	Jun 30, 1993	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB CHARTWELL MOLECULAR	120MG	A075155	003	Aug 04, 2000	Mar	CHRS
AB ! RICONPHARMA LLC	120MG	A210918	003	Nov 05, 2018	Mar	CHRS
AB SHANDONG	30MG	A214115	002	Feb 08, 2024	Feb	NEWA
AB	60MG	A214115	003	Feb 08, 2024	Feb	NEWA
AB	120MG	A214115	001	Apr 29, 2022	Mar	CMFD
@ ZYDUS PHARMS	30MG	A218255	001	Feb 15, 2024	Aug	DISC
AB	30MG	A218255	001	Feb 15, 2024	Feb	NEWA
@	60MG	A218255	002	Feb 15, 2024	Aug	DISC
AB	60MG	A218255	002	Feb 15, 2024	Feb	NEWA
@	120MG	A218255	003	Feb 15, 2024	Aug	DISC
AB	120MG	A218255	003	Feb 15, 2024	Feb	NEWA

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS

ISOSULFAN BLUE

AP AM REGENT	1%	A210294	001	May 17, 2023	May	CDFR
AP	50MG/5ML (10MG/ML)	A210294	001	May 17, 2023	May	CPOT
@ BELOTECA	1%	A210714	001	Jan 16, 2019	May	CDFR
@	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	May	CPOT
@ EUGIA PHARMA	1%	A206831	001	Feb 02, 2016	May	CDFR
@	50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016	May	CPOT
@ FRESENIUS KABI USA	1%	A211869	001	Sep 08, 2022	May	CDFR
@	50MG/5ML (10MG/ML)	A211869	001	Sep 08, 2022	May	CPOT
AP MEITHEAL	1%	A213130	001	Nov 03, 2021	May	CDFR
AP	50MG/5ML (10MG/ML)	A213130	001	Nov 03, 2021	May	CPOT
AP MSN	1%	A216090	001	Sep 16, 2022	May	CDFR
AP	50MG/5ML (10MG/ML)	A216090	001	Sep 16, 2022	May	CPOT
AP ! MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	May	CDFR
AP !	50MG/5ML (10MG/ML)	A090874	001	Jul 20, 2010	May	CPOT
@ SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	May	CDFR
@	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May	CPOT
LYMPHAZURIN						
+ @ COVIDIEN	1%	N018310	001		May	CDFR
+ @	50MG/5ML (10MG/ML)	N018310	001		May	CPOT

ISOTRETINOIN

CAPSULE;ORAL		ISOTRETINOIN					
AB2	AUROBINDO PHARMA	10MG		A218194	001	Jan 29, 2024	Jan NEWA
AB2		20MG		A218194	002	Jan 29, 2024	Jan NEWA
AB2		25MG		A218194	003	Jan 29, 2024	Jan NEWA
AB2		30MG		A218194	004	Jan 29, 2024	Jan NEWA
AB2		35MG		A218194	005	Jan 29, 2024	Jan NEWA
AB2		40MG		A218194	006	Jan 29, 2024	Jan NEWA

ITRACONAZOLE

CAPSULE;ORAL		ITRACONAZOLE					
	@ ACCORD HLTHCARE	100MG		A205991	001	May 26, 2016	May DISC
	@ RISING	100MG		A205724	001	Dec 13, 2016	Apr CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL		IVABRADINE HYDROCHLORIDE					
AB	BIONPHARMA	EQ 5MG BASE		A213276	001	Sep 05, 2024	Aug NEWA
AB		EQ 7.5MG BASE		A213276	002	Sep 05, 2024	Aug NEWA
AB	INGENUS PHARMS LLC	EQ 5MG BASE		A214051	001	Dec 30, 2021	May CMFD
AB		EQ 7.5MG BASE		A214051	002	Dec 30, 2021	May CMFD

IVERMECTIN

CREAM;TOPICAL		IVERMECTIN					
AB	ZYDUS LIFESCIENCES	1%		A215210	001	Aug 02, 2022	Mar CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		KETALAR					
AP	+ ENDO OPERATIONS	EQ 50MG BASE/ML		N016812	002		Aug CHRS
AP	+ KETAMINE HYDROCHLORIDE	EQ 100MG BASE/ML		N016812	003		Aug CHRS
>D>	@ FRESENIUS KABI USA	EQ 10MG BASE/ML		A215808	001	Jan 13, 2023	Sep CMFD
>A>	AP	EQ 10MG BASE/ML		A215808	001	Jan 13, 2023	Sep CMFD
>D>	@	EQ 50MG BASE/ML		A215808	002	Jan 13, 2023	Sep CMFD
>A>	AP	EQ 50MG BASE/ML		A215808	002	Jan 13, 2023	Sep CMFD
AP	! HIKMA	EQ 50MG BASE/ML		A074524	001	Mar 22, 1996	Aug CHRS
AP	!	EQ 100MG BASE/ML		A074524	002	Mar 22, 1996	Aug CHRS

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL		KETOCONAZOLE					
AB	! XIROMED	2%		A213601	001	May 21, 2021	Feb CHRS
CREAM;TOPICAL		KETOCONAZOLE					
AB	TRUPHARMA	2%		A215185	001	Nov 17, 2021	Aug CAHN
SHAMPOO;TOPICAL		KETOCONAZOLE					
AB	COSETTE	2%		A076942	001	Apr 11, 2005	Jul CAHN
>A>	AB	NOVITIUM PHARMA	2%	A218498	001	Sep 16, 2024	Sep NEWA
TABLET;ORAL		KETOCONAZOLE					
AB	SENORES PHARMS	200MG		A075912	001	Jan 10, 2002	Feb CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC		KETOROLAC TROMETHAMINE					
AT	CAPLIN	0.5%		A218204	001	Mar 26, 2024	Mar NEWA

L-GLUTAMINE

FOR SOLUTION;ORAL		ENDARI					
AA	+ EMMAUS MEDCL	5GM/PACKET		N208587	001	Jul 07, 2017	Jun CFTG
L-GLUTAMINE							
AA	NOVITIUM PHARMA	5GM/PACKET		A215647	001	Jul 08, 2024	Jun NFTG

LABETALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

LABETALOL HYDROCHLORIDE

>D>	+	HIKMA	10MG/2ML (5MG/ML)	N213330	005	Mar 18, 2022	Sep	DISC
>A>	+	@	10MG/2ML (5MG/ML)	N213330	005	Mar 18, 2022	Sep	DISC
	+		20MG/4ML (5MG/ML)	N213330	006	Aug 19, 2024	Aug	NEWA

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB		ANDAS 5 HOLDING	100MG	A075215	001	Jul 29, 1999	Aug	CAHN
AB			200MG	A075215	002	Jul 29, 1999	Aug	CAHN
AB			300MG	A075215	003	Jul 29, 1999	Aug	CAHN
AB		ENDO OPERATIONS	100MG	A200908	001	Jul 10, 2012	Apr	CAHN
AB	!		200MG	A200908	002	Jul 10, 2012	Apr	CAHN
AB			300MG	A200908	003	Jul 10, 2012	Apr	CAHN
>D>	AB	EYWA	100MG	A207863	001	Feb 04, 2019	Sep	CAHN
>D>	AB		200MG	A207863	002	Feb 04, 2019	Sep	CAHN
>D>	AB		300MG	A207863	003	Feb 04, 2019	Sep	CAHN
>A>	AB	HIBROW HLTHCARE	100MG	A207863	001	Feb 04, 2019	Sep	CAHN
>A>	AB		200MG	A207863	002	Feb 04, 2019	Sep	CAHN
>A>	AB		300MG	A207863	003	Feb 04, 2019	Sep	CAHN

LACOSAMIDE

SOLUTION;INTRAVENOUS

LACOSAMIDE

AP		DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar	NEWA
AP		HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb	NEWA
AP		HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar	NEWA
>A>	AP	SOMERSET THERAPS LLC	200MG/20ML (10MG/ML)	A214960	001	Oct 09, 2024	Sep	NEWA

SOLUTION;ORAL

LACOSAMIDE

	@	AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr	DISC
AA			10MG/ML	A204839	001	Mar 27, 2024	Mar	NEWA
AA		AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan	NEWA
AA		CHARTWELL RX	10MG/ML	A215154	001	May 15, 2024	May	NEWA

TABLET;ORAL

LACOSAMIDE

>A>	AB	KANCHAN HLTHCARE	50MG	A218014	001	Apr 02, 2024	Sep	CAHN
>A>	AB		100MG	A218014	002	Apr 02, 2024	Sep	CAHN
>A>	AB		150MG	A218014	003	Apr 02, 2024	Sep	CAHN
>A>	AB		200MG	A218014	004	Apr 02, 2024	Sep	CAHN
	AB	MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May	NEWA
	AB		100MG	A208466	002	May 24, 2024	May	NEWA
	AB		150MG	A208466	003	May 24, 2024	May	NEWA
	AB		200MG	A208466	004	May 24, 2024	May	NEWA
>D>	AB	MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Sep	CAHN
	AB		50MG	A218014	001	Apr 02, 2024	Mar	NEWA
>D>	AB		100MG	A218014	002	Apr 02, 2024	Sep	CAHN
	AB		100MG	A218014	002	Apr 02, 2024	Mar	NEWA
>D>	AB		150MG	A218014	003	Apr 02, 2024	Sep	CAHN
	AB		150MG	A218014	003	Apr 02, 2024	Mar	NEWA
>D>	AB		200MG	A218014	004	Apr 02, 2024	Sep	CAHN
	AB		200MG	A218014	004	Apr 02, 2024	Mar	NEWA
	AB	UNICHEM	50MG	A213109	001	Sep 04, 2024	Aug	NEWA
	AB		100MG	A213109	002	Sep 04, 2024	Aug	NEWA
	AB		150MG	A213109	003	Sep 04, 2024	Aug	NEWA
	AB		200MG	A213109	004	Sep 04, 2024	Aug	NEWA
		@ ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May	DISC
		@	100MG	A204947	002	Dec 15, 2023	May	DISC
		@	150MG	A204947	003	Dec 15, 2023	May	DISC
		@	200MG	A204947	004	Dec 15, 2023	May	DISC

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA		APOZEAL PHARMS	10GM/15ML	A207786	001	Jun 11, 2018	Jul	CMFD
		@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
AA	!	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS

SOLUTION;ORAL, RECTAL

GENERLAC

AA		CHARTWELL RX	10GM/15ML	A074603	001	Oct 31, 1996	Jun	CAHN
----	--	--------------	-----------	---------	-----	--------------	-----	------

SOLUTION;ORAL, RECTAL  
LACTULOSE

AA	APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul	CMFD
	@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC

LAMIVUDINE

SOLUTION;ORAL

EPIVIR-HBV

	+ @ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998	Apr	DISC
--	---------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

EPIVIR-HBV

	+ @ GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998	Apr	DISC
--	---------------------	-------	---------	-----	--------------	-----	------

LAMIVUDINE

AB	! APOTEX	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
	@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC
	@	300MG	A078545	002	Mar 05, 2019	Jan	DISC
	@ NATCO	150MG	A204528	001	Mar 04, 2016	Jun	CAHN
	@	300MG	A204528	002	Mar 04, 2016	Jun	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

	+ @ VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	Jan	DISC
--	-------------------	-------------	---------	-----	--------------	-----	------

LAMIVUDINE AND ZIDOVUDINE

>D>	AB	ANDA REPOSITORY	150MG;300MG	A206375	001	Apr 10, 2018	Sep	CAHN
>A>	AB	EPIC PHARMA LLC	150MG;300MG	A206375	001	Apr 10, 2018	Sep	CAHN
	AB	! HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan	CHRS
		@ NATCO	150MG;300MG	A204005	001	Aug 28, 2014	Jun	CAHN
		@ NORVIUM BIOSCIENCE	150MG;300MG	A079079	001	Aug 12, 2019	Jul	CAHN

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

	AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 04, 2012	Jul	CMS1
	AB		25MG	A090169	001	May 12, 2012	Mar	CAHN
	AB		100MG	A090169	002	May 04, 2012	Jul	CMS1
	AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
	AB		150MG	A090169	003	May 04, 2012	Jul	CMS1
	AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
	AB		200MG	A090169	004	May 04, 2012	Jul	CMS1
	AB		200MG	A090169	004	May 12, 2012	Mar	CAHN
>A>	AB	IPCA LABS	25MG	A204499	001	Sep 26, 2024	Sep	NEWA
>A>	AB		100MG	A204499	002	Sep 26, 2024	Sep	NEWA
>A>	AB		150MG	A204499	003	Sep 26, 2024	Sep	NEWA
>A>	AB		200MG	A204499	004	Sep 26, 2024	Sep	NEWA
		@ NORVIUM BIOSCIENCE	25MG	A078443	001	Feb 11, 2009	Jul	CAHN
		@	100MG	A078443	002	Feb 11, 2009	Jul	CAHN
		@	150MG	A078443	003	Feb 11, 2009	Jul	CAHN
		@	200MG	A078443	004	Feb 11, 2009	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>A>	AB	ALEMBIC	200MG	A211821	001	Oct 01, 2024	Sep	NEWA
>A>	AB		250MG	A211821	002	Oct 01, 2024	Sep	NEWA
>A>	AB		300MG	A211821	003	Oct 01, 2024	Sep	NEWA
		@ ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb	DISC
		@	50MG	A201374	002	Dec 26, 2012	Feb	DISC
		@	100MG	A201374	003	Dec 26, 2012	Feb	DISC
		@	200MG	A201374	004	Dec 26, 2012	Feb	DISC
		@	250MG	A201374	005	Dec 26, 2012	Feb	DISC
		@	300MG	A201374	006	Dec 26, 2012	Feb	DISC
		@ ENDO OPERATIONS	25MG	A201374	001	Dec 26, 2012	May	CAHN
	AB		25MG	A201791	001	Jan 18, 2013	Apr	CAHN
		@	50MG	A201374	002	Dec 26, 2012	May	CAHN
	AB		50MG	A201791	002	Jan 18, 2013	Apr	CAHN
		@	100MG	A201374	003	Dec 26, 2012	May	CAHN
	AB		100MG	A201791	003	Jan 18, 2013	Apr	CAHN
		@	200MG	A201374	004	Dec 26, 2012	May	CAHN
	AB		200MG	A201791	004	Jan 18, 2013	Apr	CAHN
		@	250MG	A201374	005	Dec 26, 2012	May	CAHN
	AB		250MG	A201791	005	Jan 18, 2013	Apr	CAHN
		@	300MG	A201374	006	Dec 26, 2012	May	CAHN
	AB		300MG	A201791	006	Jan 18, 2013	Apr	CAHN



## TABLET, ORALLY DISINTEGRATING;ORAL

## LAMOTRIGINE

AB	ENDO OPERATIONS	25MG	A204158	001	Oct 27, 2015	Apr	CAHN
AB		50MG	A204158	002	Oct 27, 2015	Apr	CAHN
AB		100MG	A204158	003	Oct 27, 2015	Apr	CAHN
AB		200MG	A204158	004	Oct 27, 2015	Apr	CAHN

LANREOTIDE ACETATE

## SOLUTION;SUBCUTANEOUS

## LANREOTIDE ACETATE

AB	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	A217193	001	May 21, 2024	May	NFTG
AB		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	A217193	002	May 21, 2024	May	NFTG
AB		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	A217193	003	May 21, 2024	May	NFTG

## SOMATULINE DEPOT

AB	+! IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG
AB	+!	EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG
AB	+!	EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG

LANSOPRAZOLE

## CAPSULE, DELAYED REL PELLETS;ORAL

## LANSOPRAZOLE

>D>	AB	SANDOZ	15MG	A090331	001	Apr 23, 2010	Sep	DISC
>A>		@	15MG	A090331	001	Apr 23, 2010	Sep	DISC
>D>	AB		30MG	A090331	002	Apr 23, 2010	Sep	DISC
>A>		@	30MG	A090331	002	Apr 23, 2010	Sep	DISC
		@ SUN PHARM	15MG	A202637	001	Sep 13, 2013	May	DISC
		@	30MG	A091509	001	Sep 13, 2013	May	DISC

LAPATINIB DITOSYLATE

## TABLET;ORAL

## LAPATINIB DITOSYLATE

AB	TEVA PHARMS USA INC	EQ 250MG BASE	A217968	001	Aug 16, 2024	Aug	NEWA
----	---------------------	---------------	---------	-----	--------------	-----	------

LATANOPROST

>D>		EMULSION;OPHTHALMIC						
>D>		XELPROS						
>D>	+!	SUN PHARM	0.005%	N206185	001	Sep 12, 2018	Sep	DISC
>A>	+ @		0.005%	N206185	001	Sep 12, 2018	Sep	DISC
		SOLUTION/DROPS;OPHTHALMIC						
		LATANOPROST						
>D>	AT	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Sep	CAHN
>A>	AT	RYAN LABS	0.005%	A202077	001	Feb 11, 2013	Sep	CAHN

LAZERTINIB MESYLATE

## TABLET;ORAL

## LAZCLUZE

+	JANSSEN BIOTECH	EQ 80MG BASE	N219008	001	Aug 19, 2024	Aug	NEWA
+!		EQ 240MG BASE	N219008	002	Aug 19, 2024	Aug	NEWA

LEFAMULIN ACETATE

## SOLUTION;INTRAVENOUS

## XENLETA

+!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Apr	CMFD
----	---------	---	---------	-----	--------------	-----	------

LENALIDOMIDE

## CAPSULE;ORAL

## LENALIDOMIDE

AB	NOVUGEN	2.5MG	A217281	001	Sep 11, 2024	Aug	NEWA
AB		5MG	A217281	002	Sep 11, 2024	Aug	NEWA
AB		10MG	A217281	003	Sep 11, 2024	Aug	NEWA
AB		15MG	A217281	004	Sep 11, 2024	Aug	NEWA
AB		20MG	A217281	005	Sep 11, 2024	Aug	NEWA
AB		25MG	A217281	006	Sep 11, 2024	Aug	NEWA
	@ QILU	2.5MG	A217265	001	Feb 22, 2024	Jul	DISC
AB		2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
	@	5MG	A217265	002	Feb 22, 2024	Jul	DISC
AB		5MG	A217265	002	Feb 22, 2024	Feb	NEWA

CAPSULE;ORAL  
LENALIDOMIDE

	@	10MG	A217265	003	Feb 22, 2024	Jul	DISC
AB		10MG	A217265	003	Feb 22, 2024	Feb	NEWA
	@	15MG	A217265	004	Feb 22, 2024	Jul	DISC
AB		15MG	A217265	004	Feb 22, 2024	Feb	NEWA
	@	20MG	A217265	005	Feb 22, 2024	Jul	DISC
AB		20MG	A217265	005	Feb 22, 2024	Feb	NEWA
	@	25MG	A217265	006	Feb 22, 2024	Jul	DISC
AB		25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LETERMOVIR

PELLETS;ORAL  
PREVYMIS

+	MSD	20MG/PACKET	N219104	001	Aug 30, 2024	Aug	NEWA
+	!	120MG/PACKET	N219104	002	Aug 30, 2024	Aug	NEWA

LETROZOLE

TABLET;ORAL  
LETROZOLE

>D>	AB	CARNEGIE	2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN
>A>	AB	RYAN LABS	2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION  
LEUCOVORIN CALCIUM

>D>	@	ABIC	EQ 3MG BASE/ML	A089352	001	Jun 01, 1988	Sep	CDFR
>D>	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Sep	CDFR
>D>	!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Sep	CDFR
>D>	+	@ HOSPIRA	EQ 3MG BASE/ML	N008107	001		Sep	CDFR
AP		MEITHEAL	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jun	CAHN
AP			EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jun	CAHN
AP			EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jun	CAHN
AP			EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jun	CAHN
AP			EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jun	CAHN
>D>	@	NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Sep	CDFR
			LEUCOVORIN CALCIUM PRESERVATIVE FREE					
>D>	@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep	CDFR
>D>	@	HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997	Sep	CDFR
>D>	@	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999	Sep	CDFR
			WELLCOVORIN					
>D>	@	GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982	Sep	CDFR

SOLUTION;INTRAMUSCULAR, INTRAVENOUS  
LEUCOVORIN CALCIUM

>A>	@	ABIC	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	A089352	001	Jun 01, 1988	Sep	CPOT
>A>	@		EQ 3MG BASE/ML	A089352	001	Jun 01, 1988	Sep	CDFR
>A>	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Sep	CDFR
>A>	!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Sep	CDFR
>A>	!		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A207241	001	Mar 14, 2018	Sep	CPOT
>A>	!		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A207226	001	Jul 27, 2018	Sep	CPOT
>A>	+	@ HOSPIRA	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	N008107	001		Sep	CPOT
>A>	+	@	EQ 3MG BASE/ML	N008107	001		Sep	CDFR
>A>	@	NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Sep	CDFR
>A>	@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Sep	CPOT
			LEUCOVORIN CALCIUM PRESERVATIVE FREE					
>A>	@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep	CDFR
>A>	@		EQ 300MG BASE/30ML (EQ 10MG BASE/ML)	A040347	001	Apr 25, 2000	Sep	CPOT
>A>	@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040347	002	Apr 25, 2000	Sep	NEWA
>A>	@	HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997	Sep	CDFR
>A>	@		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A040147	001	Jun 25, 1997	Sep	CPOT
>A>	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A040147	002	Jun 25, 1997	Sep	NEWA
>A>	@	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999	Sep	CDFR
>A>	@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040332	001	Jun 28, 1999	Sep	CPOT
			WELLCOVORIN					
>A>	@	GLAXOSMITHKLINE	EQ 5MG BASE/ML (EQ 5MG BASE/ML)	A087439	001	Oct 19, 1982	Sep	CPOT
>A>	@		EQ 5MG BASE/ML	A087439	001	Oct 19, 1982	Sep	CDFR

SOLUTION; INTRAMUSCULAR, INTRAVENOUS  
WELLCOVORIN

>A>	@	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A 087439	002	Oct 19, 1982	Sep	NEWA
-----	---	-----------------------------------	----------	-----	--------------	-----	------

LEUPROLIDE ACETATESOLUTION; SUBCUTANEOUS  
LEUPROLIDE ACETATE

AP	AMNEAL	1MG/0.2ML	A 215336	001	Oct 28, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A 215336	001	Oct 28, 2022	Jul	CPOT
AP	EUGIA PHARMA	1MG/0.2ML	A 212963	001	Jun 06, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A 212963	001	Jun 06, 2022	Jul	CPOT
	@ GENZYME	1MG/0.2ML	A 075721	001	Nov 29, 2001	Jul	CDFR
	@	14MG/2.8ML (1MG/0.2ML)	A 075721	001	Nov 29, 2001	Jul	CPOT
AP	MEITHEAL	1MG/0.2ML	A 075471	001	Oct 25, 2000	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A 075471	001	Oct 25, 2000	Jul	CPOT
AP	RK PHARMA	1MG/0.2ML	A 213829	001	Aug 13, 2021	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A 213829	001	Aug 13, 2021	Jul	CPOT
AP	! SANDOZ	1MG/0.2ML	A 074728	001	Aug 04, 1998	Jul	CDFR
AP	!	14MG/2.8ML (1MG/0.2ML)	A 074728	001	Aug 04, 1998	Jul	CPOT
AP	SUN PHARM	1MG/0.2ML	A 078885	001	Mar 09, 2009	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A 078885	001	Mar 09, 2009	Jul	CPOT
	LUPRON						
	+ @ ABBVIE ENDOCRINE INC	1MG/0.2ML	N 019010	001	Apr 09, 1985	Jul	CDFR
	+ @	14MG/2.8ML (1MG/0.2ML)	N 019010	001	Apr 09, 1985	Jul	CPOT

>A> LEVACETYLLEUCINE

&gt;A&gt; FOR SUSPENSION; ORAL

&gt;A&gt; AQNEURSA

>A>	+!	INTRABIO	1GM/PACKET	N 219132	001	Sep 24, 2024	Sep	NEWA
-----	----	----------	------------	----------	-----	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

## SOLUTION; INHALATION

## LEVALBUTEROL HYDROCHLORIDE

AN	! MYLAN SPECIALITY LP	EQ 0.25% BASE	A 078309	001	Mar 20, 2009	Apr	CHRS
	@ NORVIUM BIOSCIENCE	EQ 0.0103% BASE	A 077800	001	Mar 15, 2013	Jul	CAHN
	@	EQ 0.021% BASE	A 077800	002	Mar 15, 2013	Jul	CAHN
	@	EQ 0.042% BASE	A 077800	003	Mar 15, 2013	Jul	CAHN
	@ SUN PHARM	EQ 0.0103% BASE	A 207820	001	Nov 05, 2018	May	DISC
	@	EQ 0.021% BASE	A 207820	002	Nov 05, 2018	May	DISC
	@	EQ 0.042% BASE	A 207820	003	Nov 05, 2018	May	DISC
AN	! TEVA PHARMS USA	EQ 0.0103% BASE	A 090297	001	Apr 26, 2013	Apr	CHRS
AN	!	EQ 0.021% BASE	A 090297	002	Apr 26, 2013	Apr	CHRS
AN	!	EQ 0.042% BASE	A 090297	003	Apr 26, 2013	Apr	CHRS
	XOPENEX						
	+ @ HIKMA	EQ 0.0103% BASE	N 020837	003	Jan 30, 2002	Apr	DISC
	+ @	EQ 0.021% BASE	N 020837	001	Mar 25, 1999	Apr	DISC
	+ @	EQ 0.042% BASE	N 020837	002	Mar 25, 1999	Apr	DISC
	+ @	EQ 0.25% BASE	N 020837	004	Jul 18, 2003	Apr	DISC

>D> LEVAMLODIPINE MALEATE

&gt;D&gt; TABLET; ORAL

&gt;D&gt; CONJUPRI

>D>	+	CSPC OUYI	EQ 2.5MG BASE	N 212895	002	Dec 19, 2019	Sep	DISC
>A>	+ @		EQ 2.5MG BASE	N 212895	002	Dec 19, 2019	Sep	DISC
	+		EQ 2.5MG BASE	N 212895	002	Dec 19, 2019	Mar	CMFD
>D>	+!		EQ 5MG BASE	N 212895	003	Dec 19, 2019	Sep	DISC
>A>	+ @		EQ 5MG BASE	N 212895	003	Dec 19, 2019	Sep	DISC
	+!		EQ 5MG BASE	N 212895	003	Dec 19, 2019	Mar	CMFD

LEVETIRACETAM

## INJECTABLE; INTRAVENOUS

## LEVETIRACETAM

AP	ADRASTEA PHARMA	500MG/5ML (100MG/ML)	A 091485	001	Aug 05, 2011	Feb	CAHN
	@ SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A 090754	001	Jun 16, 2010	May	DISC
AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A 091485	001	Aug 05, 2011	Jul	CAHN
	LEVETIRACETAM IN SODIUM CHLORIDE						
AP	B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A 209705	001	Feb 27, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A 209705	002	Feb 27, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A 209705	003	Feb 27, 2024	Feb	NEWA
AP	BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A 217059	001	Oct 02, 2023	Feb	CTNA
AP		1GM/100ML (10MG/ML)	A 217059	002	Oct 02, 2023	Feb	CTNA
AP		1.5GM/100ML (15MG/ML)	A 217059	003	Oct 02, 2023	Feb	CTNA
	@ FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A 208619	001	Jan 31, 2023	Mar	DISC

INJECTABLE; INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

	@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
	@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP	HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA

SOLUTION; ORAL

LEVETIRACETAM

	@	HIKMA	100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
	@	STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023	May	DISC

TABLET; ORAL

LEVETIRACETAM

	@	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	May	DISC
	@		500MG	A090843	002	Feb 14, 2011	May	DISC
	@		750MG	A090843	003	Feb 14, 2011	May	DISC
	@		1GM	A090843	004	Feb 14, 2011	May	DISC
	@	GRANULES	250MG	A217878	001	Jun 13, 2023	Mar	DISC
	@		500MG	A217878	002	Jun 13, 2023	Mar	DISC
	@		750MG	A217878	003	Jun 13, 2023	Mar	DISC
	@		1GM	A217878	004	Jun 13, 2023	Mar	DISC
>A>	AB	INGENUS PHARMS LLC	250MG	A079042	001	Jan 15, 2009	Sep	CAHN
>A>	AB		500MG	A079042	002	Jan 15, 2009	Sep	CAHN
>A>	AB		750MG	A079042	003	Jan 15, 2009	Sep	CAHN
>A>	AB		1GM	A079042	004	Jan 15, 2009	Sep	CAHN
	@	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009	Mar	DISC
	@		500MG	A078234	002	Jan 15, 2009	Mar	DISC
	@		750MG	A078234	003	Jan 15, 2009	Mar	DISC
>D>	AB	STALLION LABS	250MG	A079042	001	Jan 15, 2009	Sep	CAHN
>D>	AB		500MG	A079042	002	Jan 15, 2009	Sep	CAHN
>D>	AB		750MG	A079042	003	Jan 15, 2009	Sep	CAHN
>D>	AB		1GM	A079042	004	Jan 15, 2009	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

>A>	@	ADAPTIS	500MG	A202167	001	Sep 04, 2015	Sep	CAHN
>A>	@		750MG	A202167	002	Sep 04, 2015	Sep	CAHN
	@	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
	@		750MG	A091360	002	Oct 04, 2011	Feb	DISC
>D>	@	DEXCEL	500MG	A202167	001	Sep 04, 2015	Sep	CAHN
>D>	@		750MG	A202167	002	Sep 04, 2015	Sep	CAHN
	@	ENDO OPERATIONS	500MG	A091360	001	Oct 04, 2011	May	CAHN
	@		750MG	A091360	002	Oct 04, 2011	May	CAHN
>D>	AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Sep	DISC
>A>	@		500MG	A201464	001	May 25, 2012	Sep	DISC
>D>	AB		750MG	A201464	002	May 25, 2012	Sep	DISC
>A>	@		750MG	A201464	002	May 25, 2012	Sep	DISC
	@	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Aug	DISC
	@		750MG	A202533	002	Jul 20, 2012	Aug	DISC

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@	CHARTWELL RX	0.5%	A074850	001	Oct 28, 1996	Jul	CAHN
--	---	--------------	------	---------	-----	--------------	-----	------

LEVOPUIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

+	@	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999	Jun	CRLD
+	@		EQ 5MG BASE/ML	N020997	002	Aug 05, 1999	Jun	CRLD
+	@		EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999	Jun	CRLD

LEVOCARNITINE

SOLUTION; ORAL

LEVOCARNITINE

	@	HIKMA	1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
>D>	AA	LYNE	1GM/10ML	A076851	001	Aug 10, 2004	Sep	CAHN
>A>	AA	RISING	1GM/10ML	A076851	001	Aug 10, 2004	Sep	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE  
 AB IPCA LABS LTD 5MG A204626 001 May 06, 2024 Apr NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN  
 @ NORVIUM BIOSCIENCE EQ 500MG/20ML (EQ 25MG/ML) A200560 001 Jun 20, 2011 Jun CAHN  
 @ EQ 750MG/30ML (EQ 25MG/ML) A200560 002 Jun 20, 2011 Jun CAHN  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER  
 @ KNACK EQ 250MG/50ML (EQ 5MG/ML) A216164 001 Jan 29, 2024 Jul DISC  
 AP EQ 250MG/50ML (EQ 5MG/ML) A216164 001 Jan 29, 2024 Jan NEWA  
 @ EQ 500MG/100ML (EQ 5MG/ML) A216164 002 Jan 29, 2024 Jul DISC  
 AP EQ 500MG/100ML (EQ 5MG/ML) A216164 002 Jan 29, 2024 Jan NEWA  
 @ EQ 750MG/150ML (EQ 5MG/ML) A216164 003 Jan 29, 2024 Jul DISC  
 AP EQ 750MG/150ML (EQ 5MG/ML) A216164 003 Jan 29, 2024 Jan NEWA

TABLET; ORAL

LEVOFLOXACIN

>A> @ ANDA REPOSITORY 250MG A090367 001 Jun 20, 2011 Sep CAHN  
 >A> @ 500MG A090367 002 Jun 20, 2011 Sep CAHN  
 >A> @ 750MG A090367 003 Jun 20, 2011 Sep CAHN  
 >D> @ CELLTRION 250MG A090367 001 Jun 20, 2011 Sep CAHN  
 @ 250MG A090367 001 Jun 20, 2011 Apr DISC  
 >D> @ 500MG A090367 002 Jun 20, 2011 Sep CAHN  
 @ 500MG A090367 002 Jun 20, 2011 Apr DISC  
 >D> @ 750MG A090367 003 Jun 20, 2011 Sep CAHN  
 @ 750MG A090367 003 Jun 20, 2011 Apr DISC

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

+ @ ACROTECH BIOPHARMA EQ 50MG BASE/VIAL N020140 001 Mar 07, 2008 May DISC  
 +! EQ 50MG BASE/VIAL N020140 001 Mar 07, 2008 Mar CTEC  
 LEVOLEUCOVORIN CALCIUM  
 @ MEITHEAL EQ 50MG BASE/VIAL A211003 001 Aug 22, 2019 Mar DISC

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

@ NORVIUM BIOSCIENCE EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) A203576 001 Oct 20, 2015 Jun CAHN  
 @ EQ 250MG BASE/25ML (EQ 10MG BASE/ML) A203576 002 Oct 20, 2015 Jun CAHN  
 @ PRAXGEN EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) A213797 001 Nov 02, 2021 Jul CAHN

LEVONORGESTREL

SYSTEM; INTRAUTERINE

KYLEENA

+! BAYER HLTHCARE 19.5MG N208224 001 Sep 16, 2016 Jun CDFR  
 LILETTA  
 +! MEDICINES360 52MG N206229 001 Feb 26, 2015 Jun CDFR  
 MIRENA  
 +! BAYER HLTHCARE 52MG N021225 001 Dec 06, 2000 Jun CDFR  
 SKYLA  
 +! BAYER HLTHCARE 13.5MG N203159 001 Jan 09, 2013 Jun CDFR

TABLET; ORAL

LEVONORGESTREL

@ XIROMED 0.75MG A202740 001 Sep 02, 2016 May CAHN

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

@ ENDO OPERATIONS 200MCG/VIAL A205366 001 Dec 07, 2015 May CAHN

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2 AUROBINDO PHARMA 0.137MG A216414 001 Jul 16, 2024 Jul NEWA  
 AB2 0.15MG A216414 002 Jul 16, 2024 Jul NEWA  
 AB2 0.175MG A216414 003 Jul 16, 2024 Jul NEWA

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB2		0.2MG	A216414	004	Jul 16, 2024	Jul	NEWA
AB2		0.3MG	A216414	005	Jul 16, 2024	Jul	NEWA
>D>	AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.025MG	A211417	001	Dec 21, 2022	Sep CTEC
>D>	AB2		0.05MG	A211417	002	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.05MG	A211417	002	Dec 21, 2022	Sep CTEC
>D>	AB2		0.075MG	A211417	003	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.075MG	A211417	003	Dec 21, 2022	Sep CTEC
>D>	AB2		0.088MG	A211417	004	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.088MG	A211417	004	Dec 21, 2022	Sep CTEC
>D>	AB2		0.1MG	A211417	005	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.1MG	A211417	005	Dec 21, 2022	Sep CTEC
>D>	AB2		0.112MG	A211417	006	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.112MG	A211417	006	Dec 21, 2022	Sep CTEC
>D>	AB2		0.125MG	A211417	007	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.125MG	A211417	007	Dec 21, 2022	Sep CTEC
>D>	AB2		0.137MG	A211417	008	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.137MG	A211417	008	Dec 21, 2022	Sep CTEC
>D>	AB2		0.15MG	A211417	009	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.15MG	A211417	009	Dec 21, 2022	Sep CTEC
>D>	AB2		0.175MG	A211417	010	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.175MG	A211417	010	Dec 21, 2022	Sep CTEC
>D>	AB2		0.2MG	A211417	011	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.2MG	A211417	011	Dec 21, 2022	Sep CTEC
>D>	AB2		0.3MG	A211417	012	Dec 21, 2022	Sep CTEC
>A>	AB1, AB2		0.3MG	A211417	012	Dec 21, 2022	Sep CTEC
	AB1,	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.05MG	A207588	002	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.075MG	A207588	003	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.088MG	A207588	004	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.1MG	A207588	005	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.112MG	A207588	006	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.125MG	A207588	007	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.137MG	A207588	008	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.15MG	A207588	009	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						
	AB1,		0.175MG	A207588	010	May 10, 2022	Feb CTEC
	AB2, AB3, AB4						

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB1, AB2, AB3, AB4	0.2MG	A207588	011	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4	0.3MG	A207588	012	May 10, 2022	Feb CTEC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	AUROBINDO PHARMA LTD	5%	A217117	001	Jun 18, 2024	Jun NEWA
	@ COSETTE	5%	A211019	001	Dec 12, 2018	Apr DISC
	@ GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019	Jul CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A088586	002		Apr CMS1
AP		2%	A088586	003		Apr CMS1
AP	+ INTL MEDICATION	1%	A083173	001		Aug CRLD
	LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE				
AP	HIKMA	1%	A084625	001		Jun CAHN
AP		2%	A084625	002		Jun CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb NEWA
----	--------------------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	THE J MOLNER	4%	A218411	001	Apr 29, 2024	Apr NEWA
----	--------------	----	---------	-----	--------------	----------

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

	@ HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar DISC
AB	PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun CMFD
>D> AB	RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Sep DISC
>A>	@	2.5%;2.5%	A213253	001	Sep 21, 2020	Sep DISC
AB		2.5%;2.5%	A213253	001	Sep 21, 2020	Jun CMFD

LIDOCAINE; TETRACAINE

CREAM;TOPICAL

PLIAGLIS

+ @	CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	Jul CAHN
-----	-----------------	-------	---------	-----	--------------	----------

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

LIFITEGRAST

>A> AB	@ EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	May DISC
	INGENUS PHARMS LLC	5%	A215058	001	Oct 03, 2024	Sep NFTG
	@ MICRO LABS	5%	A215081	001	Aug 04, 2023	May DISC
	XIIDRA					
>D>	+! BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016	Sep CFTG
>A> AB	+!	5%	N208073	001	Jul 11, 2016	Sep CFTG
	+!	5%	N208073	001	Jul 11, 2016	May CTEC
AB	+!	5%	N208073	001	Jul 11, 2016	Jan CAHN

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

AB	INVAGEN PHARMS	5MG	A208423	001	Sep 03, 2024	Aug NEWA
----	----------------	-----	---------	-----	--------------	----------

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

AP	ARTHUR GRP	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul CAHN
AP	GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May CMFD
>A>	@ SLAYBACK	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991	Sep CAHN
>D>	@ WATSON LABS	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991	Sep CAHN

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

TRIOSTAT

+ @ ENDO OPERATIONS

EQ 0.01MG BASE/ML

N020105 001 Dec 31, 1991 May CAHN

TABLET; ORAL

LIOTHYRONINE SODIUM

AB	BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar	CAHN
AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb	CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar	CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb	CAHN
AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan	NEWA
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan	NEWA
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan	NEWA
	@ NORVIUM BIOSCIENCE	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Jul	CAHN
	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Jul	CAHN
	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Jul	CAHN
AB	ZYDUS LIFESCIENCES	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Aug	CAHN
AB		EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Aug	CAHN
AB		EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Aug	CAHN

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

SAXENDA

+! NOVO

18MG/3ML (6MG/ML)

N206321 001 Dec 23, 2014 Mar CAIN

VICTOZA

+! NOVO NORDISK INC

18MG/3ML (6MG/ML)

N022341 001 Jan 25, 2010 Mar CAIN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

LISDEXAMFETAMINE DIMESYLATE

	@ ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Feb	DISC
	@	20MG	A202802	002	Aug 25, 2023	Feb	DISC
	@	30MG	A202802	003	Aug 25, 2023	Feb	DISC
	@	40MG	A202802	004	Aug 25, 2023	Feb	DISC
	@	50MG	A202802	005	Aug 25, 2023	Feb	DISC
	@	60MG	A202802	006	Aug 25, 2023	Feb	DISC
	@	70MG	A202802	007	Aug 25, 2023	Feb	DISC
AB	HIKMA	10MG	A202827	007	Jan 17, 2024	Jan	NEWA
	@ SANDOZ	20MG	A202836	001	Jul 26, 2024	Aug	DISC
AB		20MG	A202836	001	Jul 26, 2024	Jul	NEWA
	@	30MG	A202836	002	Jul 26, 2024	Aug	DISC
AB		30MG	A202836	002	Jul 26, 2024	Jul	NEWA
	@	40MG	A202836	003	Jul 26, 2024	Aug	DISC
AB		40MG	A202836	003	Jul 26, 2024	Jul	NEWA
	@	50MG	A202836	004	Jul 26, 2024	Aug	DISC
AB		50MG	A202836	004	Jul 26, 2024	Jul	NEWA
	@	60MG	A202836	005	Jul 26, 2024	Aug	DISC
AB		60MG	A202836	005	Jul 26, 2024	Jul	NEWA
	@	70MG	A202836	006	Jul 26, 2024	Aug	DISC
AB		70MG	A202836	006	Jul 26, 2024	Jul	NEWA

TABLET, CHEWABLE; ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA
AB		20MG	A218306	002	Feb 02, 2024	Jan	NEWA
AB		30MG	A218306	003	Feb 02, 2024	Jan	NEWA
AB		40MG	A218306	004	Feb 02, 2024	Jan	NEWA
AB		50MG	A218306	005	Feb 02, 2024	Jan	NEWA
AB		60MG	A218306	006	Feb 02, 2024	Jan	NEWA
AB	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Aug	CMFD
	@	10MG	A215415	001	Aug 25, 2023	Feb	DISC
AB		20MG	A215415	002	Aug 25, 2023	Aug	CMFD
	@	20MG	A215415	002	Aug 25, 2023	Feb	DISC
AB		30MG	A215415	003	Aug 25, 2023	Aug	CMFD
	@	30MG	A215415	003	Aug 25, 2023	Feb	DISC
AB		40MG	A215415	004	Aug 25, 2023	Aug	CMFD
	@	40MG	A215415	004	Aug 25, 2023	Feb	DISC
AB		50MG	A215415	005	Aug 25, 2023	Aug	CMFD
	@	50MG	A215415	005	Aug 25, 2023	Feb	DISC
AB		60MG	A215415	006	Aug 25, 2023	Aug	CMFD
	@	60MG	A215415	006	Aug 25, 2023	Feb	DISC



LISINOPRIL

TABLET; ORAL

LISINOPRIL

	@ ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May DISC
	@	5MG	A202554	002	Jul 30, 2013	May DISC
	@	10MG	A202554	003	Jul 30, 2013	May DISC
	@	20MG	A202554	004	Jul 30, 2013	May DISC
	@	30MG	A202554	005	Jul 30, 2013	May DISC
	@	40MG	A202554	006	Jul 30, 2013	May DISC

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

	@ PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb DISC
AA	! RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar NEWA
	!	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar CTEC
AA	!	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb CHRS

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LOFEXIDINE HYDROCHLORIDE

AB	INDOCO	EQ 0.18MG BASE	A218613	001	Aug 20, 2024	Aug NFTG
	LUCEMYRA					
AB	+! USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	Aug CFTG

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

+	CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan CAHN
+		EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan CAHN
+		EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CAHN
+		EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan CAHN
+	@	EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan CAHN
+	@	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CAHN

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

+	@ LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb CAHN
+		10MG	N017588	001		Feb CAHN
+	!	40MG	N017588	002		May CHRS
+		40MG	N017588	002		Feb CAHN
+		100MG	N017588	003		May CHRS
+	!	100MG	N017588	003		Feb CAHN

LONAFARNIB

CAPSULE; ORAL

ZOKINVY

+	SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May CAHN
+	!	75MG	N213969	002	Nov 20, 2020	May CAHN

LOPINAVIR; RITONAVIR

TABLET; ORAL

LOPINAVIR AND RITONAVIR

AB	MACLEODS PHARMS LTD	100MG;25MG	A204739	001	Jul 25, 2024	Jul NEWA
AB		200MG;50MG	A204739	002	Jul 25, 2024	Jul NEWA
AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan NEWA
AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan NEWA

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

	@ HIKMA	2MG/ML	A200169	001	Jan 30, 2012	Mar DISC
--	---------	--------	---------	-----	--------------	----------

INJECTABLE; INJECTION

LORAZEPAM

	@ ENDO OPERATIONS	2MG/ML	A074793	001	Mar 16, 2000	Apr CAHN
	@	4MG/ML	A074793	002	Mar 16, 2000	Apr CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM							
	@ AIPING PHARM INC	25MG	A 090544	001	Oct 06, 2010	Feb	CAHN
	@	50MG	A 090544	002	Oct 06, 2010	Feb	CAHN
	@	100MG	A 090544	003	Oct 06, 2010	Feb	CAHN
AB	APOTEX	25MG	A 218551	001	Jun 04, 2024	May	NEWA
AB		50MG	A 218551	002	Jun 04, 2024	May	NEWA
AB		100MG	A 218551	003	Jun 04, 2024	May	NEWA
AB	CHARTWELL RX	25MG	A 077424	001	Oct 06, 2010	Jan	CAHN
AB		50MG	A 077424	002	Oct 06, 2010	Jan	CAHN
AB		100MG	A 077424	003	Oct 06, 2010	Jan	CAHN

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEPREDNOL ETABONATE							
AB	HIKMA	0.5%	A 213956	001	Nov 29, 2023	Apr	CAHN
SUSPENSION/DROPS; OPHTHALMIC							
	LOTEPREDNOL ETABONATE						
AB	LUPIN LTD	0.5%	A 215719	001	Apr 24, 2024	Apr	NEWA
AB	PADAGIS US	0.2%	A 215203	001	Jul 10, 2024	Jun	NEWA

LUBIPROSTONE

CAPSULE; ORAL

LUBIPROSTONE							
	@ ENDO OPERATIONS	8MCG	A 201442	001	Jun 27, 2022	Apr	CAHN
	@	24MCG	A 201442	002	Jun 27, 2022	Apr	CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE							
AB	ANNORA PHARMA	20MG	A 218174	001	Aug 21, 2024	Aug	NEWA
AB		40MG	A 218174	002	Aug 21, 2024	Aug	NEWA
AB		60MG	A 218174	003	Aug 21, 2024	Aug	NEWA
AB		80MG	A 218174	004	Aug 21, 2024	Aug	NEWA
AB		120MG	A 218174	005	Aug 21, 2024	Aug	NEWA
AB	SLATE RUN PHARMA	20MG	A 212091	001	Dec 28, 2020	Feb	CAHN
AB		40MG	A 212091	002	Dec 28, 2020	Feb	CAHN
AB		60MG	A 212091	003	Dec 28, 2020	Feb	CAHN
AB		80MG	A 212091	004	Dec 28, 2020	Feb	CAHN
AB		120MG	A 212091	005	Dec 28, 2020	Feb	CAHN

MACITENTAN

TABLET; ORAL

MACITENTAN							
	@ APOTEX	10MG	A 211195	001	Jan 09, 2024	Apr	DISC
	@ TORRENT	10MG	A 211107	001	Aug 05, 2024	Aug	DISC
AB		10MG	A 211107	001	Aug 05, 2024	Jul	NFTG
	@ ZYDUS LIFESCIENCES	10MG	A 211224	001	Apr 06, 2021	May	CAHN
	OPSUMIT						
	+! ACTELION	10MG	N 204410	001	Oct 18, 2013	Aug	CTEC
AB	+!	10MG	N 204410	001	Oct 18, 2013	Jul	CFTG
	+!	10MG	N 204410	001	Oct 18, 2013	Apr	CTEC

MACITENTAN; TADALAFIL

TABLET; ORAL

OPSYNVI							
+	ACTELION	10MG; 20MG	N 218490	001	Mar 22, 2024	Mar	NEWA
+	!	10MG; 40MG	N 218490	002	Mar 22, 2024	Mar	NEWA

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE							
	@ ENDO OPERATIONS	5%	A 201511	001	Feb 12, 2013	May	CAHN

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE							
	@ EXELA PHARMA	5GM/10ML (500MG/ML)	A 206039	001	Dec 18, 2014	Aug	DISC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Mar	NEWA
AA	BIONPHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A204135	001	Jun 24, 2024	Jun	NEWA
>D>	AA	LANNETT CO INC	A209941	001	Jul 15, 2024	Sep	CAHN
AA		1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024	Jul	NEWA
>A>	AA	PAI HOLDINGS	A209941	001	Jul 15, 2024	Sep	CAHN
AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Jun	CMS1

MANNITOL

INJECTABLE;INJECTION

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	20GM/100ML	N013684	007		Jul	CHRS
AP	+		20GM/100ML	N013684	007		Jul	CRLD

POWDER;INHALATION

ARIDOL KIT

+!	PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May	CAHN
+!	PHARMAXIS EUROPE	40MG	N202049	001	Oct 30, 2020	Aug	CAHN

MARALIXIBAT CHLORIDE

SOLUTION;ORAL

LIVMARLI

+!	MIRUM	EQ 19MG BASE/ML	N214662	002	Jul 24, 2024	Jul	NEWA
----	-------	-----------------	---------	-----	--------------	-----	------

MARAVIROC

TABLET;ORAL

SELZENTRY

+	@	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Jan	DISC
+	@		75MG	N022128	004	Nov 04, 2016	Jan	DISC

MAVORIXAFOR

CAPSULE;ORAL

XOLREMDI

+!	X4 PHARMS	100MG	N218709	001	Apr 26, 2024	Apr	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar	CHRS
AA	!		50MG	A201451	003	Feb 23, 2011	Feb	CMFD
>A>	@	CHARTWELL RX	12.5MG	A205136	001	Feb 22, 2019	Sep	CAHN
>A>	@		25MG	A205136	002	Feb 22, 2019	Sep	CAHN
>A>	@		50MG	A205136	003	Feb 22, 2019	Sep	CAHN
	@	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
	@		25MG	A200432	002	Feb 17, 2022	Mar	DISC
	@		50MG	A200432	003	Feb 17, 2022	Mar	DISC
>D>	@	WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	Sep	CAHN
	@		12.5MG	A205136	001	Feb 22, 2019	Jul	DISC
>D>	@		25MG	A205136	002	Feb 22, 2019	Sep	CAHN
	@		25MG	A205136	002	Feb 22, 2019	Jul	DISC
>D>	@		50MG	A205136	003	Feb 22, 2019	Sep	CAHN
	@		50MG	A205136	003	Feb 22, 2019	Jul	DISC

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

@	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar	DISC
---	----------------	------	---------	-----	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB		HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN
----	--	-----------	----------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+!	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	May	CAHN
	@	CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar	CAHN
	@	HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar	DISC

SUSPENSION; ORAL

MEGESTROL ACETATE  
 AB NOVITIUM PHARMA 40MG/ML A 077404 001 Feb 16, 2006 May CMFD

MELOXICAM

TABLET; ORAL

MELOXICAM  
 AB AIPING PHARM INC 7.5MG A 077920 001 Jul 19, 2006 Jun CAHN  
 AB 15MG A 077920 002 Jul 19, 2006 Jun CAHN  
 AB SCIEGEN PHARMS INC 7.5MG A 077920 001 Jul 19, 2006 Apr CMFD  
 AB 15MG A 077920 002 Jul 19, 2006 Apr CMFD  
 AB ! ZYDUS PHARMS USA 15MG A 077921 002 Jul 19, 2006 Jan CTEC  
 MOBIC  
 + @ BOEHRINGER INGELHEIM 7.5MG N 020938 001 Apr 13, 2000 Jan DISC  
 + @ 15MG N 020938 002 Aug 23, 2000 Jan DISC

MELPHALAN

TABLET; ORAL

MELPHALAN  
 @ ALVOGEN 2MG A 207809 001 Mar 22, 2017 May DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE  
 @ ENDO OPERATIONS EQ 50MG BASE/VIAL A 204773 001 Aug 22, 2016 May CAHN  
 AP HETERO LABS EQ 50MG BASE/VIAL A 215024 001 May 23, 2024 May NEWA  
 SOLUTION; INTRAVENOUS  
 IVRA  
 +! APOTEX EQ 90MG BASE/ML (EQ 90MG BASE/ML) N 217110 001 Aug 18, 2023 Jul CTNA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE  
 @ ENDO OPERATIONS 7MG A 205784 001 Jun 09, 2017 Apr CAHN  
 @ 14MG A 205784 002 Jun 09, 2017 Apr CAHN  
 @ 21MG A 205784 003 Jun 09, 2017 Apr CAHN  
 @ 28MG A 205784 004 Jun 09, 2017 Apr CAHN  
 AB XIAMEN LP PHARM CO 21MG A 213985 004 Feb 06, 2024 Jan NEWA  
 AB ! ZYDUS PHARMS 28MG A 203293 004 Aug 03, 2017 Jul CHRS  
 NAMENDA XR  
 + @ ABBVIE 14MG N 022525 002 Jun 21, 2010 Jul DISC  
 + @ 21MG N 022525 003 Jun 21, 2010 Jul DISC  
 + @ 28MG N 022525 004 Jun 21, 2010 Jul DISC

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE  
 >D> @ APOZEAL PHARMS 2MG/ML A 205446 001 Dec 07, 2015 Sep CAHN  
 >A> @ SCIEGEN PHARMS INC 2MG/ML A 205446 001 Dec 07, 2015 Sep CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE  
 AB ACME LABS 5MG A 209527 001 May 07, 2018 Aug CAHN  
 AB 10MG A 209527 002 May 07, 2018 Aug CAHN  
 AB ALLIED 5MG A 090073 001 Sep 04, 2015 Jul CAHN  
 AB 10MG A 090073 002 Sep 04, 2015 Jul CAHN  
 AB RENATA 5MG A 209527 001 May 07, 2018 Jan CAHN  
 AB 10MG A 209527 002 May 07, 2018 Jan CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL  
 >A> @ QUAGEN 25MG/ML N 005010 007 Sep CAHN  
 >A> @ 50MG/ML N 005010 002 Sep CAHN  
 >A> @ 75MG/ML N 005010 009 Sep CAHN  
 >A> @ 100MG/ML N 005010 003 Sep CAHN  
 >D> @ VALIDUS PHARMS 25MG/ML N 005010 007 Sep CAHN  
 >D> @ 50MG/ML N 005010 002 Sep CAHN  
 >D> @ 75MG/ML N 005010 009 Sep CAHN  
 >D> @ 100MG/ML N 005010 003 Sep CAHN

SYRUP; ORAL

DEMEROL  
 >A> @ QUAGEN 50MG/5ML N 005010 005 Sep CAHN  
 >D> @ VALIDUS PHARMS 50MG/5ML N 005010 005 Sep CAHN

	TABLET; ORAL						
	DEMEROL						
>A>	+ @	QUAGEN	50MG	N005010	001		Sep CAHN
>A>	+ @		100MG	N005010	004		Sep CAHN
>D>	+ @	VALIDUS PHARMS	50MG	N005010	001		Sep CAHN
>D>	+ @		100MG	N005010	004		Sep CAHN
	MEPERIDINE HYDROCHLORIDE						
AA	!	EPIC PHARMA LLC	50MG	A040331	001	May 28, 1999	Feb CTEC
	!		50MG	A040331	001	May 28, 1999	Feb CHRS
AA		GENUS	50MG	A040893	001	Jun 24, 2009	Feb CMFD
	@		50MG	A040893	001	Jun 24, 2009	Jan CAHN
	@		75MG	A040893	002	Jun 24, 2009	Jan CAHN
	@		100MG	A040893	003	Jun 24, 2009	Jan CAHN
	@		150MG	A040893	004	Jun 24, 2009	Jan CAHN
	<u>MEROPENEM</u>						
	INJECTABLE; INJECTION						
	MEROPENEM						
AP		QILU	500MG/VIAL	A216424	001	Jul 22, 2024	Jul NEWA
AP			1GM/VIAL	A216424	002	Jul 22, 2024	Jul NEWA
	<u>MESALAMINE</u>						
	CAPSULE, EXTENDED RELEASE; ORAL						
	MESALAMINE						
AB		NOVAST LABS	375MG	A218410	001	Aug 22, 2024	Aug NEWA
	SUPPOSITORY; RECTAL						
	MESALAMINE						
>D>	AB	PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Sep CAHN
>A>	AB	RISING	1GM	A207448	001	Apr 19, 2019	Sep CAHN
	TABLET, DELAYED RELEASE; ORAL						
	MESALAMINE						
AB		ANNORA PHARMA	1.2GM	A216334	001	Feb 05, 2024	Jan NEWA
AB		TEVA PHARMS INC	800MG	A213191	001	Aug 22, 2024	Aug NEWA
AB	!	ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017	Aug CTEC
	<u>MESNA</u>						
	INJECTABLE; INTRAVENOUS						
	MESNA						
	@	RISING	100MG/ML	A203364	001	Jul 18, 2014	Feb CAHN
	<u>METAPROTERENOL SULFATE</u>						
	SYRUP; ORAL						
	METAPROTERENOL SULFATE						
>A>	!	CHARTWELL	10MG/5ML	A073632	001	Jul 22, 1992	Sep CAHN
>D>	!	GENUS	10MG/5ML	A073632	001	Jul 22, 1992	Sep CAHN
	!		10MG/5ML	A073632	001	Jul 22, 1992	Jan CAHN
	<u>METARAMINOL BITARTRATE</u>						
	INJECTABLE; INJECTION						
	METARAMINOL BITARTRATE						
		AZURITY	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Jul CAHN
	<u>METAXALONE</u>						
	TABLET; ORAL						
	METAXALONE						
>D>	BX	APPCO	800MG	A208774	001	Sep 24, 2018	Sep CAHN
>A>	BX	RISING	800MG	A208774	001	Sep 24, 2018	Sep CAHN
	<u>METFORMIN HYDROCHLORIDE</u>						
	TABLET; ORAL						
	METFORMIN HYDROCHLORIDE						
	@	AMNEAL PHARMS NY	500MG	A077880	001	Jun 05, 2006	Jul DISC
	@		850MG	A077880	002	Jun 05, 2006	Jul DISC
	@		1GM	A077880	003	Jun 05, 2006	Jul DISC
	TABLET, EXTENDED RELEASE; ORAL						
	METFORMIN HYDROCHLORIDE						
>D>	@	AMTA	500MG	A213394	001	Aug 03, 2021	Sep CAHN
>D>	@		1GM	A213394	002	Aug 03, 2021	Sep CAHN
AB1		HARMAN FINOCHEM	500MG	A218673	001	Jul 05, 2024	Jun NEWA
AB			750MG	A218673	002	Jul 05, 2024	Jun NEWA
AB3		MACLEODS PHARMS LTD	1GM	A211163	001	Mar 13, 2024	Mar NEWA
>A>	@	UTOPIIC PHARMS	500MG	A213394	001	Aug 03, 2021	Sep CAHN

	TABLET, EXTENDED RELEASE;ORAL						
	METFORMIN HYDROCHLORIDE						
>A>	@	1GM	A213394	002	Aug 03, 2021	Sep	CAHN
	<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE						
	@	CHARTWELL RX 500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Jan	CAHN
	@	850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Jan	CAHN
	<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	ZITUVIMET XR						
	+	ZYDUS 500MG;50MG	N216778	001	Jul 18, 2024	Jul	NEWA
	+	1GM;50MG	N216778	002	Jul 18, 2024	Jul	NEWA
	+	1GM;100MG	N216778	003	Jul 18, 2024	Jul	NEWA
	+	ZYDUS LIFESCIENCES 500MG;50MG	N216778	001	Jul 18, 2024	Aug	CAHN
	+	1GM;50MG	N216778	002	Jul 18, 2024	Aug	CAHN
	+	1GM;100MG	N216778	003	Jul 18, 2024	Aug	CAHN
	<u>METHADONE HYDROCHLORIDE</u>						
	CONCENTRATE;ORAL						
	METHADONE HYDROCHLORIDE						
AA	VISTAPHARM LLC	10MG/ML	A040088	001	Nov 30, 1994	Apr	CAHN
	SOLUTION;ORAL						
	METHADONE HYDROCHLORIDE						
	@	VISTAPHARM LLC 5MG/5ML	A090707	001	Jun 30, 2010	Jun	DISC
AA		5MG/5ML	A090707	001	Jun 30, 2010	Apr	CAHN
	@	10MG/5ML	A090707	002	Jun 30, 2010	Jun	DISC
AA		10MG/5ML	A090707	002	Jun 30, 2010	Apr	CAHN
	TABLET;ORAL						
	METHADONE HYDROCHLORIDE						
AA	ELITE LABS INC	5MG	A210484	001	Aug 02, 2018	Aug	CMFD
	@	5MG	A210484	001	Aug 02, 2018	Jun	CAHN
AA		10MG	A210484	002	Aug 02, 2018	Aug	CMFD
	@	10MG	A210484	002	Aug 02, 2018	Jun	CAHN
	@	VISTAPHARM LLC 5MG	A040241	001	May 29, 1998	Apr	CAHN
AA		10MG	A040241	002	May 29, 1998	Apr	CAHN
AA		10MG	A204166	001	Mar 16, 2020	Apr	CAHN
	<u>METHENAMINE HIPPURATE</u>						
	TABLET;ORAL						
	METHENAMINE HIPPURATE						
AB	JUBILANT CADISTA	1GM	A217675	001	Dec 01, 2023	Apr	CAHN
	<u>METHOCARBAMOL</u>						
	SOLUTION;IM-IV						
	METHOCARBAMOL						
	@	NORVIUM BIOSCIENCE 1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jul	CAHN
	TABLET;ORAL						
	METHOCARBAMOL						
AA	ALLIED	500MG	A212623	001	Apr 30, 2021	Aug	CAHN
AA		750MG	A212623	002	Apr 30, 2021	Aug	CAHN
>D>	AA	DBL PHARMS 500MG	A203550	001	Feb 08, 2017	Sep	CAHN
	AA	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
>D>	AA	750MG	A203550	002	Feb 08, 2017	Sep	CAHN
	AA	750MG	A203550	002	Feb 08, 2017	Feb	CAHN
	AA	HANGZHOU BINJIANG 500MG	A200958	001	Oct 21, 2011	Mar	CAHN
	AA	750MG	A200958	002	Oct 21, 2011	Mar	CAHN
AB	!	1GM	A200958	003	Dec 06, 2021	Mar	CAHN
>A>	AA	HLTHCARE 500MG	A203550	001	Feb 08, 2017	Sep	CAHN
>A>	AA	750MG	A203550	002	Feb 08, 2017	Sep	CAHN
	ROBAXIN						
	+	@ ENDO OPERATIONS 500MG	N011011	004		May	CAHN
		ROBAXIN-750					
	+	@ ENDO OPERATIONS 750MG	N011011	006		May	CAHN

METHOHEXITAL SODIUMINJECTABLE; INJECTION  
BREVITAL SODIUM

>D>	+	ENDO OPERATIONS	500MG/VIAL	N011559	001		Sep	CFTG
>A>	AP	+	500MG/VIAL	N011559	001		Sep	CFTG
>A>		METHOHEXITAL SODIUM						
>A>	AP	STERISCIENCE	500MG/VIAL	A215488	001	Oct 03, 2024	Sep	NFTG

METHOTREXATE SODIUM

TABLET; ORAL

METHOTREXATE SODIUM

AB		ALEMBIC	EQ 2.5MG BASE	A217552	001	Jun 03, 2024	May	NEWA
>D>	AB	AMNEAL PHARMS	EQ 2.5MG BASE	A210040	001	Dec 22, 2017	Sep	DISC
>A>		@	EQ 2.5MG BASE	A210040	001	Dec 22, 2017	Sep	DISC
AB		ELITE LABS INC	EQ 2.5MG BASE	A216453	001	May 16, 2024	May	NEWA
		@ LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr	DISC

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA		AACE PHARMS	2.5MG	A216786	001	Feb 01, 2024	Jan	NEWA
AA			5MG	A216786	002	Feb 01, 2024	Jan	NEWA
AA		NE RX PHARMA	2.5MG	A216786	001	Feb 01, 2024	May	CAHN
AA			5MG	A216786	002	Feb 01, 2024	May	CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

		@ CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Feb	DISC
			250MG	N018934	001	Jun 29, 1984	Jan	CMFD
		@	500MG	N018934	002	Jun 29, 1984	Feb	DISC
		!	500MG	N018934	002	Jun 29, 1984	Jan	CMFD

METHYLENE BLUE

SOLUTION; INTRAVENOUS

METHYLENE BLUE

AP		ZYDUS LIFESCIENCES	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Apr	CAHN
AP			50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Apr	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

>A>	AB	TRUPHARMA	0.2MG	A212233	001	May 01, 2020	Sep	CAHN
>D>	AB	TULEX PHARMS INC	0.2MG	A212233	001	May 01, 2020	Sep	CAHN

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

AP		ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Aug	NFTG
AP			12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Aug	NFTG
		RELISTOR						
AP	+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Aug	CFTG
AP	+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Aug	CFTG

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

COTEMPLA XR-ODT

>D>	+	NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Sep	DISC
>A>	+	@	34.6MG	N205489	004	Aug 19, 2024	Sep	DISC
	+		34.6MG	N205489	004	Aug 19, 2024	Aug	NEWA

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AA	ANDA REPOSITORY	5MG/5ML	A210764	001	Apr 10, 2020	Sep	CAHN
>A>	AA		10MG/5ML	A210764	002	Apr 10, 2020	Sep	CAHN
		@ BRECKENRIDGE	5MG/5ML	A201466	001	Nov 12, 2013	Mar	DISC
		@	10MG/5ML	A201466	002	Nov 12, 2013	Mar	DISC
>D>	AA	PATRIN	5MG/5ML	A210764	001	Apr 10, 2020	Sep	CAHN
>D>	AA		10MG/5ML	A210764	002	Apr 10, 2020	Sep	CAHN

## TABLET;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

AB	CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Mar	CMFD
AB		10MG	A208737	002	Feb 01, 2019	Mar	CMFD
AB		20MG	A208737	003	Feb 01, 2019	Mar	CMFD

METHYLPREDNISOLONE

## TABLET;ORAL

## METHYLPREDNISOLONE

AB	ENDO OPERATIONS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN
	@ PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	DISC

METHYLPREDNISOLONE ACETATE

## INJECTABLE;INJECTION

## METHYLPREDNISOLONE ACETATE

AB	ENDO OPERATIONS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN
AB		80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN
AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN
AB		80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN
	@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC
	@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC
AB	WILSHIRE PHARMS INC	40MG/ML	A214870	002	May 10, 2023	Jul	CAHN
AB		80MG/ML	A214870	001	Jan 03, 2023	Jul	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

## SOLUTION;ORAL

## METOCLOPRAMIDE HYDROCHLORIDE

AA	! GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN
----	---------	-----------------	---------	-----	--------------	-----	------

METOLAZONE

## TABLET;ORAL

## METOLAZONE

>A>	AB	CHEMISTRY HLTH	2.5MG	A218606	001	Apr 17, 2024	Sep	CAHN
>A>	AB		5MG	A218606	002	Apr 17, 2024	Sep	CAHN
>A>	AB		10MG	A218606	003	Apr 17, 2024	Sep	CAHN
>D>	AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Sep	CAHN
	AB		2.5MG	A218606	001	Apr 17, 2024	Apr	NEWA
>D>	AB		5MG	A218606	002	Apr 17, 2024	Sep	CAHN
	AB		5MG	A218606	002	Apr 17, 2024	Apr	NEWA
>D>	AB		10MG	A218606	003	Apr 17, 2024	Sep	CAHN
	AB		10MG	A218606	003	Apr 17, 2024	Apr	NEWA

METOPROLOL SUCCINATE

## TABLET, EXTENDED RELEASE;ORAL

## METOPROLOL SUCCINATE

	@ GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Mar	DISC
	@	EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Mar	DISC
	@	EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Mar	DISC
	@	EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Mar	DISC
AB	SUNSHINE	EQ 25MG TARTRATE	A214004	004	May 23, 2024	May	NEWA
AB	ZHEJIANG JUTAI PHARM	EQ 50MG TARTRATE	A214110	001	Jul 26, 2024	Jul	NEWA
AB		EQ 100MG TARTRATE	A214110	002	Jul 26, 2024	Jul	NEWA
AB		EQ 200MG TARTRATE	A214110	003	Jul 26, 2024	Jul	NEWA

METRONIDAZOLE

## GEL;TOPICAL

## METROGEL

	+ @ GALDERMA LABS LP	0.75%	N019737	001	Nov 22, 1988	May	DISC
--	----------------------	-------	---------	-----	--------------	-----	------

## METRONIDAZOLE

AB	! COSETTE	0.75%	A078178	001	Jan 19, 2011	May	CHRS
----	-----------	-------	---------	-----	--------------	-----	------

## GEL;VAGINAL

## METRONIDAZOLE

AB	ENCUBE	1.3%	A216795	001	Mar 18, 2024	Mar	NFTG
----	--------	------	---------	-----	--------------	-----	------

## NUVESSA

AB	+! CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Mar	CFTG
----	----------------------	------	---------	-----	--------------	-----	------

## TABLET;ORAL

## METRONIDAZOLE

	@ FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar	DISC
	@	500MG	A207309	002	May 16, 2016	Mar	DISC



METYROSINECAPSULE;ORAL  
METYROSINE

>A>	AB	LEADING	250MG	A215541	001	Sep 17, 2024	Sep NEWA
-----	----	---------	-------	---------	-----	--------------	----------

MEXILETINE HYDROCHLORIDECAPSULE;ORAL  
MEXILETINE HYDROCHLORIDE

AB		LEADING	150MG	A215876	001	Feb 27, 2023	Aug CAHN
AB			200MG	A215876	002	Feb 27, 2023	Aug CAHN
AB			250MG	A215876	003	Feb 27, 2023	Aug CAHN

MICAFUNGIN SODIUMINJECTABLE;INTRAVENOUS  
MICAFUNGIN SODIUM

		@ APOTEX	EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020	Jul DISC
		@	EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020	Jul DISC
AP		BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May NEWA
AP			EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May NEWA

MIDAZOLAMSOLUTION;INTRAVENOUS  
MIDAZOLAM IN 0.8% SODIUM CHLORIDE  
+ @ EXELA PHARMA 50MG/50ML (1MG/ML)

N215868 001 Jul 20, 2022 May DISC

AP		GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A218993	001	Aug 12, 2024	Aug NEWA
AP			100MG/100ML (1MG/ML)	A218993	002	Aug 12, 2024	Aug NEWA

MIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION  
MIDAZOLAM HYDROCHLORIDE

>A>		@ ENDO OPERATIONS	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Sep CAHN
>A>		@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Sep CAHN
>A>		@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Sep CAHN
>A>		@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Sep CAHN
		@ FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan DISC
>D>		@ PAI HOLDINGS	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Sep CAHN
>D>		@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Sep CAHN
>D>		@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Sep CAHN
>D>		@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Sep CAHN

AP		MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE					
		STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Aug CAHN
AP			EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Aug CAHN

AP		MIDOZALAM HYDROCHLORIDE					
		STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Aug CAHN
AP			EQ 5MG BASE/ML	A090316	002	May 04, 2011	Aug CAHN

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE  
@ PAI HOLDINGS

EQ 2MG BASE/ML A075958 001 Sep 04, 2003 Jul CAHN

MIDODRINE HYDROCHLORIDETABLET;ORAL  
MIDODRINE HYDROCHLORIDE

AB		ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr CAHN
AB			5MG	A207169	002	Oct 29, 2018	Apr CAHN
AB			10MG	A207169	003	Oct 29, 2018	Apr CAHN

MIDOSTAURINCAPSULE;ORAL  
MIDOSTAURIN

AB		DR REDDYS	25MG	A215921	001	Jun 28, 2024	Jun NEWA
AB		LUPIN	25MG	A216015	001	May 10, 2024	May NEWA
AB		TEVA PHARMS	25MG	A216076	001	Apr 29, 2024	Apr NFTG
		RYDAPT					
AB		+! NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr CFTG

MILNACIPRAN HYDROCHLORIDE

## TABLET;ORAL

>A>	MILNACIPRAN HYDROCHLORIDE						
>A>	AB	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Sep NFTG
>A>	AB		25MG	A205147	002	Oct 03, 2024	Sep NFTG
>A>	AB		50MG	A205147	003	Oct 03, 2024	Sep NFTG
>A>	AB		100MG	A205147	004	Oct 03, 2024	Sep NFTG
>A>		@ ORYZA	12.5MG	A205071	001	Jan 27, 2016	Sep CAHN
>A>		@	25MG	A205071	002	Jan 27, 2016	Sep CAHN
>A>		@	50MG	A205071	003	Jan 27, 2016	Sep CAHN
>A>		@	100MG	A205071	004	Jan 27, 2016	Sep CAHN
>D>		@ USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Sep CAHN
>D>		@	25MG	A205071	002	Jan 27, 2016	Sep CAHN
>D>		@	50MG	A205071	003	Jan 27, 2016	Sep CAHN
>D>		@	100MG	A205071	004	Jan 27, 2016	Sep CAHN

## SAVELLA

>D>	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Sep CFTG
>A>	AB	+	12.5MG	N022256	001	Jan 14, 2009	Sep CFTG
>D>		+	25MG	N022256	002	Jan 14, 2009	Sep CFTG
>A>	AB	+	25MG	N022256	002	Jan 14, 2009	Sep CFTG
>D>		+	50MG	N022256	003	Jan 14, 2009	Sep CFTG
>A>	AB	+	50MG	N022256	003	Jan 14, 2009	Sep CFTG
>D>		+	100MG	N022256	004	Jan 14, 2009	Sep CFTG
>A>	AB	+	100MG	N022256	004	Jan 14, 2009	Sep CFTG

MILRINONE LACTATE

## INJECTABLE;INJECTION

## MILRINONE LACTATE IN DEXTROSE 5%

		@ WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Jun DISC
--	--	------------	---------------------------------------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

## TABLET;ORAL

## MINOCYCLINE HYDROCHLORIDE

		@ SUN PHARM INDUSTRIES	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jul DISC
		@	EQ 75MG BASE	A090217	002	Jan 29, 2016	Jul DISC
		@	EQ 100MG BASE	A090217	003	Jan 29, 2016	Jul DISC

## TABLET, EXTENDED RELEASE;ORAL

## MINOCYCLINE HYDROCHLORIDE

AB	!	ALKEM LABS LTD	EQ 115MG BASE	A204453	007	Mar 16, 2018	Jul CHRS
AB	!		EQ 135MG BASE	A204453	005	Sep 28, 2016	Jul CHRS
AB		SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Jul CHRS
AB		SUN PHARM	EQ 45MG BASE	A204394	001	Dec 30, 2015	Aug CAHN
AB			EQ 55MG BASE	A204394	002	Oct 07, 2022	Aug CAHN
AB			EQ 65MG BASE	A204394	003	Oct 07, 2022	Aug CAHN
AB			EQ 80MG BASE	A204394	004	Dec 30, 2015	Aug CAHN
AB			EQ 105MG BASE	A204394	005	Dec 30, 2015	Aug CAHN
AB			EQ 115MG BASE	A204394	006	Oct 07, 2022	Aug CAHN
AB			EQ 135MG BASE	A204394	007	Dec 30, 2015	Aug CAHN
		@ SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan DISC
		@	EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan DISC
		@	EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan DISC
		@	EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan DISC
		@	EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan DISC
		@	EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan DISC
		@	EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan DISC
		@ ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan DISC
		@	EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan DISC
		@	EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan DISC
		@	EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan DISC
		@	EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan DISC
		@	EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan DISC
		@	EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan DISC
		@	EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan DISC

## MINOLIRA

		@ EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017	Jul DISC
		@	EQ 135MG BASE	N209269	002	May 08, 2017	Jul DISC

## SOLODYN

	+	@ BAUSCH	EQ 55MG BASE	N050808	008	Aug 27, 2010	Jun DISC
	+	@	EQ 65MG BASE	N050808	004	Jul 23, 2009	Jun DISC
	+	@	EQ 80MG BASE	N050808	007	Aug 27, 2010	Jun DISC
	+	@	EQ 105MG BASE	N050808	006	Aug 27, 2010	Jun DISC

TABLET, EXTENDED RELEASE;ORAL  
SOLODYN

+ @ EQ 115MG BASE N050808 005 Jul 23, 2009 Jun DISC

MINOXIDIL

TABLET;ORAL  
MINOXIDIL

AB ENDO OPERATIONS 2.5MG A071826 001 Nov 14, 1988 Apr CAHN  
AB 10MG A071839 001 Nov 14, 1988 Apr CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL  
MIRABEGRON

AB ALKEM LABS LTD 25MG A215948 001 Feb 12, 2024 Feb NEWA  
AB 50MG A215948 002 Feb 12, 2024 Feb NEWA  
AB ZYDUS PHARMS 25MG A209488 001 Sep 29, 2022 Mar CMFD  
AB 50MG A209488 002 Sep 29, 2022 Mar CMFD

MIRTAZAPINE

TABLET;ORAL  
MIRTAZAPINE

AB AIPING PHARM INC 15MG A076219 001 Jun 19, 2003 Feb CAHN  
AB 30MG A076219 002 Jun 19, 2003 Feb CAHN  
AB 45MG A076219 003 Jun 19, 2003 Feb CAHN  
AB CHARTWELL RX 15MG A076219 001 Jun 19, 2003 Jun CAHN  
AB 30MG A076219 002 Jun 19, 2003 Jun CAHN  
AB 45MG A076219 003 Jun 19, 2003 Jun CAHN

MITOMYCIN

INJECTABLE;INJECTION  
MITOMYCIN

AP FRESENIUS KABI USA 5MG/VIAL A211269 001 Apr 05, 2024 Mar NEWA  
AP 20MG/VIAL A211269 002 Apr 05, 2024 Mar NEWA  
AP 40MG/VIAL A211269 003 Apr 05, 2024 Mar NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION  
MITOXANTRONE HYDROCHLORIDE

@ RISING EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A201014 001 Dec 11, 2012 Mar CAHN

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS  
MIVACURIUM CHLORIDE

@ WOODWARD EQ 10MG BASE/5ML (EQ 2MG BASE/ML) A209708 001 Oct 12, 2021 Jul DISC  
@ EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A209708 002 Oct 12, 2021 Jul DISC

MOMETASONE FUROATE

LOTION;TOPICAL  
MOMETASONE FUROATE

@ COSETTE 0.1% A077678 001 Nov 21, 2007 Apr DISC

SPRAY, METERED;NASAL  
MOMETASONE FUROATE

AB AUROBINDO PHARMA 0.05MG/SPRAY A215878 001 Mar 18, 2024 Mar NEWA

MONTELUKAST SODIUM

GRANULE;ORAL  
MONTELUKAST SODIUM

@ TEVA PHARMS EQ 4MG BASE/PACKET A090955 001 Aug 03, 2012 Jan DISC

TABLET;ORAL  
MONTELUKAST SODIUM

AB RISING EQ 10MG BASE A209012 001 Apr 24, 2017 Aug CAHN  
@ SANDOZ INC EQ 10MG BASE A200889 001 Aug 03, 2012 Jul DISC

TABLET, CHEWABLE;ORAL  
MONTELUKAST SODIUM

>D> AB SANDOZ INC EQ 4MG BASE A091414 001 Aug 03, 2012 Sep DISC  
>A> @ EQ 4MG BASE A091414 001 Aug 03, 2012 Sep DISC  
>D> AB EQ 5MG BASE A091414 002 Aug 03, 2012 Sep DISC  
>A> @ EQ 5MG BASE A091414 002 Aug 03, 2012 Sep DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

>D> ! UPSHER SMITH LABS 10MG A202104 001 Jun 03, 2013 Sep CHRS  
>A> 10MG A202104 001 Jun 03, 2013 Sep CHRS

SOLUTION;INTRAMUSCULAR, INTRAVENOUS  
MORPHINE SULFATE

>D> +! FRESENIUS KABI USA 5MG/ML (5MG/ML) N204223 003 Oct 30, 2013 Sep DISC  
>A> + @ 5MG/ML (5MG/ML) N204223 003 Oct 30, 2013 Sep DISC  
>D> +! 8MG/ML (8MG/ML) N204223 004 Oct 30, 2013 Sep DISC  
>A> + @ 8MG/ML (8MG/ML) N204223 004 Oct 30, 2013 Sep DISC

SOLUTION;ORAL

MORPHINE SULFATE

@ HIKMA 100MG/5ML A208809 001 Jul 06, 2017 Mar DISC  
@ PHARM ASSOC 10MG/5ML A206573 002 Sep 12, 2023 Aug DISC  
@ 100MG/5ML A206573 001 Nov 14, 2016 Aug DISC  
AA WINDER LABS LLC 10MG/5ML A211454 001 Feb 12, 2021 Jan CMFD  
AA 20MG/5ML A211454 002 Feb 12, 2021 Jan CMFD  
AA 100MG/5ML A211454 003 Feb 12, 2021 Jan CMFD

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT1 ADAPTIS EQ 0.5% BASE A202525 001 Mar 06, 2015 Aug CAHN  
VIGAMOX  
AT1 +! HARROW EYE EQ 0.5% BASE N021598 001 Apr 15, 2003 Jan CAHN  
TABLET;ORAL  
MOXIFLOXACIN HYDROCHLORIDE  
@ NATCO EQ 400MG BASE A204635 001 Aug 31, 2015 Jun CAHN

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL  
MYCOPHENOLATE MOFETIL

>A> AB AUROBINDO PHARMA LTD 200MG/ML A218227 001 Sep 26, 2024 Sep NEWA  
SUSPENSION;ORAL  
MYHIBBIN  
+! AZURITY 200MG/ML N216482 001 May 01, 2024 May NEWA  
TABLET;ORAL  
MYCOPHENOLATE MOFETIL  
@ AMNEAL 500MG A090606 001 Jul 16, 2010 Feb DISC  
AB AUROBINDO PHARMA 500MG A217937 001 Feb 20, 2024 Feb NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION  
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP ENDO OPERATIONS 500MG/VIAL A203575 001 Oct 28, 2016 Apr CAHN  
AP STERISCIENCE SPECLTS 500MG/VIAL A216390 001 Dec 23, 2022 Aug CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLIC SODIUM

AB AUROBINDO PHARMA LTD EQ 180MG BASE A218603 001 Feb 27, 2024 Feb NEWA  
AB EQ 360MG BASE A218603 002 Feb 27, 2024 Feb NEWA  
AB BIOCON PHARMA EQ 180MG BASE A217031 001 Nov 29, 2023 Jun CAHN  
AB EQ 360MG BASE A217031 002 Nov 29, 2023 Jun CAHN  
AB NOVUGEN EQ 180MG BASE A216637 001 May 29, 2024 May NEWA  
AB EQ 360MG BASE A216637 002 May 29, 2024 May NEWA  
AB SKG PHARMA EQ 180MG BASE A217031 001 Nov 29, 2023 Apr CAHN  
AB EQ 360MG BASE A217031 002 Nov 29, 2023 Apr CAHN  
AB WANBANG BIOPHARMS EQ 180MG BASE A216637 001 May 29, 2024 Jun CAHN  
AB EQ 360MG BASE A216637 002 May 29, 2024 Jun CAHN

NABILONE

CAPSULE;ORAL  
CESAMET

+ @ BAUSCH 1MG N018677 001 Dec 26, 1985 Aug DISC

NADOLOL

TABLET; ORAL		CORGARD					
	+ @ USWM	20MG	N018063	005	Oct 28, 1986	Aug	DISC
	+ @	40MG	N018063	001		Aug	DISC
	+ @	80MG	N018063	002		Aug	DISC
NADOLOL							
AB	! INVAGEN PHARMS	80MG	A203455	003	Dec 18, 2015	Aug	CHRS

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION		NALBUPHINE HYDROCHLORIDE					
>A>	AP	SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Sep NEWA
>A>	AP		10MG/ML	A216050	001	Sep 19, 2024	Sep NEWA
>A>	AP		20MG/ML	A216049	002	Sep 19, 2024	Sep NEWA
>A>	AP		20MG/ML	A216050	002	Sep 19, 2024	Sep NEWA
NUBAIN							
	+ @ ENDO OPERATIONS	10MG/ML	N018024	001		May	CAHN
	+ @	20MG/ML	N018024	002	May 27, 1982	May	CAHN

NALMEFENE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS		NALMEFENE HYDROCHLORIDE					
	! CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	Jun	CMFD
	@	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	May	DISC
AP	@	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	Jun	CMFD
	@	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	May	DISC
AP	! PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jun	CTEC
	!	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CTEC
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS		ZURNAI (AUTOINJECTOR)					
	+! PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Aug	NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION		NALOXONE HYDROCHLORIDE					
AP	@ EUGIA PHARMA	0.4MG/ML	A212455	001	Oct 15, 2019	Jun	DISC
AP	FRESENIUS KABI USA	0.4MG/ML	A213573	001	Apr 02, 2024	Mar	NEWA
AP		1MG/ML	A213573	002	Apr 02, 2024	Mar	NEWA
AP	HIKMA	0.4MG/ML	A212300	002	Mar 07, 2024	Mar	NEWA
AP	MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024	Feb	NEWA
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS		ZIMHI					
	+! ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	May	CAHN
SPRAY; NASAL		REZENOPY					
	+! SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Apr	NEWA
SPRAY, METERED; NASAL		REXTOVY					
	+! AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Apr	CMFD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR		NALTREXONE					
	@ TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jan	DISC
	VIVITROL						
	+! ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jan	CTEC

NAPROXEN

TABLET; ORAL		NAPROXEN					
>A>	AB	ADAPTIS	250MG	A091416	001	Feb 14, 2011	Sep CAHN
>A>	AB		375MG	A091416	002	Feb 14, 2011	Sep CAHN
>A>	AB		500MG	A091416	003	Feb 14, 2011	Sep CAHN
	@ INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Mar	DISC
	@	375MG	A091305	002	Aug 24, 2011	Mar	DISC
	@	500MG	A091305	003	Aug 24, 2011	Mar	DISC
>D>	AB	MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Sep CAHN

TABLET;ORAL									
NAPROXEN									
>D>	AB		375MG	A091416	002	Feb 14, 2011	Sep	CAHN	
>D>	AB		500MG	A091416	003	Feb 14, 2011	Sep	CAHN	
TABLET, DELAYED RELEASE;ORAL									
NAPROXEN									
	AB	NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024	May	NEWA	
	AB		500MG	A218497	002	Jun 12, 2024	May	NEWA	
>A>	AB	TRUPHARMA	375MG	A216908	001	May 31, 2023	Sep	CAHN	
>A>	AB		500MG	A216908	002	May 31, 2023	Sep	CAHN	
>D>	AB	TULEX PHARMS INC	375MG	A216908	001	May 31, 2023	Sep	CAHN	
>D>	AB		500MG	A216908	002	May 31, 2023	Sep	CAHN	
<u>NARATRIPTAN HYDROCHLORIDE</u>									
TABLET;ORAL									
NARATRIPTAN									
		@ SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May	DISC	
<u>NEBIVOLOL HYDROCHLORIDE</u>									
TABLET;ORAL									
NEBIVOLOL HYDROCHLORIDE									
		@ APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	May	DISC	
AB			EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb	NEWA	
		@	EQ 20MG BASE	A209741	002	Feb 27, 2024	May	DISC	
AB			EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb	NEWA	
AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	Jun	CMFD	
AB			EQ 5MG BASE	A203821	002	May 25, 2017	Jun	CMFD	
AB			EQ 10MG BASE	A203821	003	May 25, 2017	Jun	CMFD	
AB			EQ 20MG BASE	A203821	004	May 25, 2017	Jun	CMFD	
>A>	AB	MSN	EQ 2.5MG BASE	A217397	001	Oct 01, 2024	Sep	NEWA	
>A>	AB		EQ 5MG BASE	A217397	002	Oct 01, 2024	Sep	NEWA	
>A>	AB		EQ 10MG BASE	A217397	003	Oct 01, 2024	Sep	NEWA	
>A>	AB		EQ 20MG BASE	A217397	004	Oct 01, 2024	Sep	NEWA	
AB		UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Aug	CMFD	
AB			EQ 5MG BASE	A213830	002	Mar 15, 2022	Aug	CMFD	
AB			EQ 10MG BASE	A213830	003	Mar 15, 2022	Aug	CMFD	
AB			EQ 20MG BASE	A213830	004	Mar 15, 2022	Aug	CMFD	
<u>NEFAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
NEFAZODONE HYDROCHLORIDE									
		@ CHARTWELL RX	50MG	A076302	001	Sep 16, 2003	Jun	CAHN	
		@	100MG	A076302	002	Sep 16, 2003	Jun	CAHN	
		@	150MG	A076302	003	Sep 16, 2003	Jun	CAHN	
		@	200MG	A076302	004	Sep 16, 2003	Jun	CAHN	
		@	250MG	A076302	005	Sep 16, 2003	Jun	CAHN	
<u>NELARABINE</u>									
INJECTABLE;INTRAVENOUS									
NELARABINE									
AP		ALEMBIC	250MG/50ML (5MG/ML)	A218554	001	Aug 01, 2024	Jul	NEWA	
AP		MEITHEAL	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun	CAHN	
>A>	AP	MSN	250MG/50ML (5MG/ML)	A216948	001	Sep 13, 2024	Sep	NEWA	
AP		XGEN PHARMS	250MG/50ML (5MG/ML)	A216510	001	Sep 05, 2024	Aug	NEWA	
<u>NEOMYCIN SULFATE</u>									
TABLET;ORAL									
NEOMYCIN SULFATE									
>A>	AA	ADRASTEIA PHARMA	500MG	A065220	001	Jul 28, 2006	Sep	CAHN	
>D>	AA	XGEN PHARMS	500MG	A065220	001	Jul 28, 2006	Sep	CAHN	
<u>NEOSTIGMINE METHYLSULFATE</u>									
SOLUTION;INTRAVENOUS									
BLOXIVERZ									
		+ @ EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May	DISC	
NEOSTIGMINE METHYLSULFATE									
AP		ADAPTIS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Aug	CAHN	
AP			10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Aug	CAHN	
AP		ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	CAHN	
AP			10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	CAHN	
		@ EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC	
		@	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC	

SOLUTION; INTRAVENOUS  
NEOSTIGMINE METHYLSULFATE

AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan CAHN
AP	UMEDICA	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug CAHN

NESIRITIDE

FOR SOLUTION; INTRAVENOUS  
NATRECOR

	+ @ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar CAIN
--	---------------	------------	---------	-----	--------------	----------

NEVIRAPINE

SUSPENSION; ORAL  
NEVIRAPINE

AA	! AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	Jun CHRS
	VIRAMUNE					
	+ @ BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	Jun DISC

TABLET; ORAL

NEVIRAPINE

	@ NORVIUM BIOSCIENCE	200MG	A078864	001	May 22, 2012	Jul CAHN
--	----------------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB	! MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Jun CHRS
	VIRAMUNE XR					
	+ @ BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Jun DISC
	+ @	400MG	N201152	001	Mar 25, 2011	Jun DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL  
NIACIN

AB	HIBROW HLTHCARE	500MG	A213090	001	Aug 25, 2023	Jul CAHN
AB		750MG	A213090	002	Aug 25, 2023	Jul CAHN
AB		1GM	A213090	003	Aug 25, 2023	Jul CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB	SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar NEWA
AB		30MG	A218202	002	Apr 10, 2024	Mar NEWA

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP	CHENGDU SHUODE	25MG/10ML (2.5MG/ML)	A217548	001	Sep 06, 2024	Aug NEWA
AP	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb CMFD
AP	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Aug CMFD

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP	+! CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr CFTG
----	-----------	-----------------------	---------	-----	--------------	----------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP	+! CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr CFTG
----	-----------	-----------------------	---------	-----	--------------	----------

NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE

AP	INFORLIFE	40MG/200ML (0.2MG/ML)	A203978	002	Apr 17, 2024	Apr NFTG
----	-----------	-----------------------	---------	-----	--------------	----------

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE

AP	INFORLIFE	20MG/200ML (0.1MG/ML)	A203978	001	Apr 17, 2024	Apr NFTG
----	-----------	-----------------------	---------	-----	--------------	----------

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

>A>	AP	CIPLA	20MG/200ML (0.1MG/ML)	A215592	001	Sep 24, 2024	Sep NFTG
>A>	AP		40MG/200ML (0.2MG/ML)	A215592	002	Sep 24, 2024	Sep NFTG
>D>	+!	HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Sep CFTG
>A>	AP	+!	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Sep CFTG
>D>	+!		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Sep CFTG
>A>	AP	+!	40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Sep CFTG

NICOTINE

>D> INHALANT; ORAL

>D> NICOTROL

>D>	+!	PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997	Sep DISC
>A>	+ @		4MG/CARTRIDGE	N020714	001	May 02, 1997	Sep DISC

NIFEDIPINE

CAPSULE;ORAL		NIFEDIPINE					
	@ ACTAVIS ELIZABETH	20MG	A 072556	001	Sep 20, 1990	Aug	DISC
AB	VELZEN PHARMA PVT	10MG	A 073250	001	Oct 08, 1991	Aug	CAHN
AB		20MG	A 074045	001	Apr 30, 1992	Aug	CAHN
TABLET, EXTENDED RELEASE;ORAL		NIFEDIPINE					
	@ ENDO OPERATIONS	30MG	A 077899	001	Dec 13, 2006	May	CAHN
	@	60MG	A 077899	002	Dec 13, 2006	May	CAHN
	@	90MG	A 077899	003	May 25, 2012	May	CAHN
	@ SWISS PHARM	30MG	A 216019	001	Nov 18, 2022	Jul	CAHN
	@	60MG	A 216019	002	Nov 18, 2022	Jul	CAHN

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL		NILOTINIB HYDROCHLORIDE					
	@ APOTEX	EQ 50MG BASE	A 203640	001	Jan 05, 2024	Apr	DISC
	@	EQ 150MG BASE	A 203640	002	Jan 05, 2024	Apr	DISC
	@	EQ 200MG BASE	A 203640	003	Jan 05, 2024	Apr	DISC
TASIGNA							
+	NOVARTIS	EQ 50MG BASE	N 022068	003	Mar 22, 2018	Apr	CTEC
+		EQ 150MG BASE	N 022068	002	Jun 17, 2010	Apr	CTEC
+	!	EQ 200MG BASE	N 022068	001	Oct 29, 2007	Apr	CTEC

NIMODIPINE

SOLUTION;ORAL		NIMODIPINE					
	ANNORA PHARMA	3MG/ML	A 216937	001	Jul 09, 2024	Jun	NFTG

NIRAPARIB TOSYLATE

CAPSULE;ORAL		ZEJULA					
+	@ GLAXOSMITHKLINE	EQ 100MG BASE	N 208447	001	Mar 27, 2017	Feb	DISC

NIRMATRELVIR; RITONAVIR

TABLET;ORAL		PAXLOVID (COPACKAGED)						
+	!	PFIZER	150MG;100MG	N 217188	001	May 25, 2023	Jul	CHRS

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL		OGSIVEO					
+	SPRINGWORKS	EQ 50MG BASE	N 217677	001	Nov 27, 2023	Apr	CHRS
+		EQ 100MG BASE	N 217677	002	Apr 04, 2024	Apr	NEWA
+	!	EQ 150MG BASE	N 217677	003	Apr 04, 2024	Apr	NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL		NISOLDIPINE						
>D>	AB	AMTA	8.5MG	A 216606	001	Apr 10, 2023	Sep	DISC
>A>		@	8.5MG	A 216606	001	Apr 10, 2023	Sep	DISC
	AB		8.5MG	A 216606	001	Apr 10, 2023	Jun	CMFD

NITAZOXANIDE

FOR SUSPENSION;ORAL		ALINIA								
>D>		+	!	ROMARK	100MG/5ML	N 021498	001	Nov 22, 2002	Sep	DISC
>A>		+	@		100MG/5ML	N 021498	001	Nov 22, 2002	Sep	DISC
TABLET;ORAL		ALINIA								
>D>	AB	+	!	ROMARK	500MG	N 021497	001	Jul 21, 2004	Sep	DISC
>A>		+	@		500MG	N 021497	001	Jul 21, 2004	Sep	DISC
NITAZOXANIDE		RISING								
>D>	AB				500MG	A 213820	001	Nov 27, 2020	Sep	CHRS
>A>		!			500MG	A 213820	001	Nov 27, 2020	Sep	CTEC
>A>	AB	!			500MG	A 213820	001	Nov 27, 2020	Sep	CHRS



NITRIC OXIDE

GAS; INHALATION

INOMAX

+!	MALLINCKRODT HOSP	4880PPM	N020845	004	Jan 17, 2023	May	NEWA
	NOXIVENT						
!	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	May	CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

	@	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Feb	DISC
	@		50MG	A091095	002	Jun 18, 2015	Feb	DISC
	@		100MG	A091095	003	Jun 18, 2015	Feb	DISC
>A>	AB	AUROBINDO PHARMA USA	25MG	A077025	002	Oct 02, 2024	Sep	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>D>	@	AUROBINDO PHARMA USA	75MG;25MG	A076648	001	Mar 22, 2004	Sep	CAHN
>A>	@	CHARTWELL RX	75MG;25MG	A076648	001	Mar 22, 2004	Sep	CAHN
>A>	AB	MICRO LABS	75MG;25MG	A217073	001	Nov 03, 2023	Sep	CAHN
>D>	AB	OMSAV PHARMA	75MG;25MG	A217073	001	Nov 03, 2023	Sep	CAHN

NITROGLYCERIN

OINTMENT; INTRA-ANAL

NITROGLYCERIN

AB		COSETTE	0.4%	A216103	001	Feb 16, 2024	Feb	NFTG
		RECTIV						
AB	+!	ABBVIE	0.4%	N021359	001	Jun 21, 2011	Feb	CFTG

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

	@	NORVIUM BIOSCIENCE	150MG	A075806	001	Jul 05, 2002	Aug	CAHN
	@		300MG	A075806	002	Jul 05, 2002	Aug	CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP		DDREG PHARMA	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	NEWA
AP		RISING	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	CAHN

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

	@	RISING	EQ 10MG BASE	A074234	001	Jul 26, 1993	Feb	CAHN
	@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Feb	CAHN
	@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Feb	CAHN
	@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Feb	CAHN

NYSTATIN

POWDER; TOPICAL

NYSTATIN

AT		ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
----	--	------------------	------------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

NYSTATIN

AA	!	LEADING	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Jul	CHRS
>D>	AA	MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Sep	DISC
>A>		@	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Sep	DISC
		@	PAI HOLDINGS	A064042	001	Feb 28, 1994	Jul	CAHN
AA		WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jul	CHRS

TABLET;ORAL

NYSTATIN

@ SUN PHARM INDUSTRIES 500,000 UNITS A062838 001 Dec 22, 1988 Aug DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

@ COSETTE 100,000 UNITS/GM;0.1% A062367 001 May 28, 1985 Apr DISC

OINTMENT;TOPICAL

MYKACET

@ COSETTE 100,000 UNITS/GM;0.1% A062733 001 Mar 06, 1987 Apr DISC

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP SHUANGCHENG EQ 0.1MG BASE/ML A217860 001 May 02, 2024 Apr NEWA

AB TEVA PHARMS USA INC EQ 10MG BASE/VIAL A210317 001 Dec 05, 2023 Jan CTEC

AB EQ 20MG BASE/VIAL A210317 002 Dec 05, 2023 Jan CTEC

AB EQ 30MG BASE/VIAL A210317 003 Dec 05, 2023 Jan CTEC

SANDOSTATIN LAR

AB + NOVARTIS EQ 10MG BASE/VIAL N021008 001 Nov 25, 1998 Jan CTEC

AB + EQ 20MG BASE/VIAL N021008 002 Nov 25, 1998 Jan CTEC

AB +! EQ 30MG BASE/VIAL N021008 003 Nov 25, 1998 Jan CTEC

>A> SOLUTION;SUBCUTANEOUS

>A> BYNFEZIA PEN

>A> +! SUN PHARM 7MG/2.8ML (2.5MG/ML) N213224 001 Sep 27, 2024 Sep NEWA

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

+ IPSEN 0.4MG N215498 002 Jul 20, 2021 Jan CAHN

+! 1.2MG N215498 004 Jul 20, 2021 Jan CAHN

CAPSULE, PELLETS;ORAL

BYLVAY

+ IPSEN 0.2MG N215498 001 Jul 20, 2021 Jan CAHN

+! 0.6MG N215498 003 Jul 20, 2021 Jan CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT AMNEAL 0.3% A211524 001 Mar 01, 2024 Feb NEWA

AT CAPLIN 0.3% A217904 001 Apr 12, 2024 Apr NEWA

AT SOMERSET 0.3% A213597 001 Aug 01, 2024 Jul NEWA

SOLUTION/DROPS;OTIC

OFLOXACIN

@ HIKMA 0.3% A076616 001 Mar 17, 2008 Mar DISC

TABLET;ORAL

OFLOXACIN

>A> @ CHARTWELL RX 200MG A076093 001 Sep 02, 2003 Sep CAHN

>A> @ 300MG A076093 002 Sep 02, 2003 Sep CAHN

>A> AB 400MG A076093 003 Sep 02, 2003 Sep CAHN

>D> @ LARKEN LABS 200MG A076093 001 Sep 02, 2003 Sep CAHN

>D> @ 300MG A076093 002 Sep 02, 2003 Sep CAHN

>D> AB 400MG A076093 003 Sep 02, 2003 Sep CAHN

OLANZAPINE

TABLET;ORAL

OLANZAPINE

@ INDOCO 2.5MG A206155 001 Jul 31, 2020 Mar DISC

@ 5MG A206155 002 Jul 31, 2020 Mar DISC

@ 7.5MG A206155 003 Jul 31, 2020 Mar DISC

@ 10MG A206155 004 Jul 31, 2020 Mar DISC

@ 15MG A206155 005 Jul 31, 2020 Mar DISC

@ 20MG A206155 006 Jul 31, 2020 Mar DISC

@ NATCO PHARMA 2.5MG A076866 001 Apr 23, 2012 Aug CAHN

@ 5MG A076866 002 Apr 23, 2012 Aug CAHN

@ 7.5MG A076866 003 Apr 23, 2012 Aug CAHN

@ 10MG A076866 004 Apr 23, 2012 Aug CAHN

@ 15MG A076866 005 Apr 23, 2012 Aug CAHN

@ 20MG A076866 006 Apr 23, 2012 Aug CAHN

@ SUN PHARM INDS 2.5MG A091038 001 Apr 23, 2012 May DISC

@ 5MG A091038 002 Apr 23, 2012 May DISC

TABLET;ORAL									
OLANZAPINE									
	@	7.5MG	A091038	003	Apr 23, 2012	May	DISC		
	@	10MG	A091038	004	Apr 23, 2012	May	DISC		
	@	15MG	A091038	005	Apr 23, 2012	May	DISC		
	@	20MG	A091038	006	Apr 23, 2012	May	DISC		
TABLET, ORALLY DISINTEGRATING;ORAL									
OLANZAPINE									
	@ SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	May	DISC		
	@	10MG	A090881	002	Feb 28, 2012	May	DISC		
	@	15MG	A090881	003	Feb 28, 2012	May	DISC		
	@	20MG	A090881	004	Feb 28, 2012	May	DISC		
<u>OLMESARTAN MEDOXOMIL</u>									
TABLET;ORAL									
OLMESARTAN MEDOXOMIL									
AB	BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan	NEWA		
AB		20MG	A206227	002	Jan 25, 2024	Jan	NEWA		
AB		40MG	A206227	003	Jan 25, 2024	Jan	NEWA		
AB	CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar	CAHN		
AB		20MG	A206227	002	Jan 25, 2024	Mar	CAHN		
AB		40MG	A206227	003	Jan 25, 2024	Mar	CAHN		
AB	INVENTIA	5MG	A208659	001	May 18, 2020	May	CMFD		
AB		20MG	A208659	002	May 18, 2020	May	CMFD		
AB		40MG	A208659	003	May 18, 2020	May	CMFD		
<u>OLOPATADINE HYDROCHLORIDE</u>									
SPRAY, METERED;NASAL									
OLOPATADINE HYDROCHLORIDE									
	@ HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar	DISC		
<u>OMACETAXINE MEPESUCCINATE</u>									
POWDER;SUBCUTANEOUS									
SYNRIBO									
	+ @ TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Jun	DISC		
<u>OMEGA-3-ACID ETHYL ESTERS</u>									
CAPSULE;ORAL									
OMEGA-3-ACID ETHYL ESTERS									
AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN		
AB	WILSHIRE PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211345	001	Dec 07, 2023	Jul	CAHN		
<u>OMEPRAZOLE; SODIUM BICARBONATE</u>									
CAPSULE;ORAL									
OMEPRAZOLE AND SODIUM BICARBONATE									
AB	! AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS		
	ZEGERID								
	+ @ SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC		
	+ @	40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC		
FOR SUSPENSION;ORAL									
OMEPRAZOLE AND SODIUM BICARBONATE									
AB	! AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS		
	ZEGERID								
	+ @ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC		
	+ @	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC		
<u>ONDANSETRON</u>									
TABLET, ORALLY DISINTEGRATING;ORAL									
ONDANSETRON									
	@ MYLAN	4MG	A078139	001	Jun 25, 2007	Jun	DISC		
	@	8MG	A078139	002	Jun 25, 2007	Jun	DISC		
	@ SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Jan	DISC		
	@	8MG	A078602	002	Feb 24, 2011	Jan	DISC		

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ ACCORD HLTHCARE EQ 2MG BASE/ML A206845 001 Mar 10, 2016 May DISC

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

@ PHARM ASSOC EQ 4MG BASE/5ML A078127 001 Jun 25, 2007 Feb DISC

@ TARO EQ 4MG BASE/5ML A077009 001 Nov 30, 2007 May DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ CHARTWELL RX EQ 4MG BASE A077517 001 Jun 25, 2007 Jun CAHN

@ EQ 8MG BASE A077517 002 Jun 25, 2007 Jun CAHN

@ EQ 24MG BASE A077517 003 Jun 25, 2007 Jun CAHN

OPICAPONE

CAPSULE; ORAL

ONGENTYS

+ AMNEAL 25MG N212489 001 Apr 24, 2020 Apr CAHN

+! 50MG N212489 002 Apr 24, 2020 Apr CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

@ STEVENS J 100MG A040368 001 Jun 23, 2000 Jun CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB LAURUS EQ 30MG BASE A218565 001 May 01, 2024 Apr NEWA

AB EQ 45MG BASE A218565 002 May 01, 2024 Apr NEWA

AB EQ 75MG BASE A218565 003 May 01, 2024 Apr NEWA

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

&gt;D&gt; AB APTAPharma INC EQ 6MG BASE/ML A212858 001 Aug 30, 2021 Sep CAHN

AB AUROBINDO PHARMA LTD EQ 6MG BASE/ML A218131 001 May 10, 2024 May NEWA

&gt;A&gt; AB INVAGEN PHARMS EQ 6MG BASE/ML A212858 001 Aug 30, 2021 Sep CAHN

@ LEADING EQ 6MG BASE/ML A214949 001 Feb 28, 2022 Aug CAHN

AB ORYZA EQ 6MG BASE/ML A217303 001 Jul 02, 2024 Jun NEWA

OSPEMIFENE

TABLET; ORAL

OSPEMIFENE

AB HETERO LABS LTD V 60MG A215574 001 Feb 13, 2024 Feb NFTG

AB +! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Feb CFTG

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP @ STERISCIENCE SPECLTS EQ 1GM BASE/VIAL A091486 001 Aug 25, 2014 Aug CAHN

EQ 2GM BASE/VIAL A091486 002 Aug 25, 2014 Aug CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+ @ SANOFI AVENTIS US 50MG/10ML (5MG/ML) N021759 001 Jan 31, 2005 Jun DISC

+ @ 100MG/20ML (5MG/ML) N021759 002 Jan 31, 2005 Jun DISC

OXALIPLATIN

&gt;D&gt; AP ! ACTAVIS TOTOWA 50MG/VIAL A078803 001 Aug 08, 2012 Sep DISC

&gt;A&gt; @ 50MG/VIAL A078803 001 Aug 08, 2012 Sep DISC

&gt;D&gt; AP ! 100MG/VIAL A078803 002 Aug 08, 2012 Sep DISC

&gt;A&gt; @ 100MG/VIAL A078803 002 Aug 08, 2012 Sep DISC

AP ! GLAND 50MG/10ML (5MG/ML) A207325 001 Feb 10, 2017 Jun CHRS

AP ! 100MG/20ML (5MG/ML) A207325 002 Feb 10, 2017 Jun CHRS

AP KINDOS 50MG/10ML (5MG/ML) A217348 001 Jan 11, 2024 Jan NEWA

AP 100MG/20ML (5MG/ML) A217348 002 Jan 11, 2024 Jan NEWA

AP MEITHEAL 50MG/10ML (5MG/ML) A217348 001 Jan 11, 2024 Jun CAHN

AP 100MG/20ML (5MG/ML) A217348 002 Jan 11, 2024 Jun CAHN

@ NORVIUM BIOSCIENCE 50MG/VIAL A200979 001 Aug 08, 2012 Jul CAHN

@ 100MG/VIAL A200979 002 Aug 08, 2012 Jul CAHN

OXAPROZIN

## TABLET; ORAL

## OXAPROZIN

>A>	AB	ABRAXEOLUS	600MG	A 075845	001	Jan 31, 2001	Sep CAHN
>D>	AB	PANGEA	600MG	A 075845	001	Jan 31, 2001	Sep CAHN
	AB		600MG	A 075845	001	Jan 31, 2001	Jun CAHN
		@ TEVA	600MG	A 075849	001	Jul 03, 2002	Jan DISC

OXAZEPAM

## CAPSULE; ORAL

## OXAZEPAM

>A>	AB	TRUPHARMA	10MG	A 071026	002	Aug 10, 1987	Sep CAHN
>A>	AB		15MG	A 071026	003	Aug 10, 1987	Sep CAHN
>A>	AB		30MG	A 071026	001	Aug 10, 1987	Sep CAHN
>D>	AB	UNITED RES LABS	10MG	A 071026	002	Aug 10, 1987	Sep CAHN
>D>	AB		15MG	A 071026	003	Aug 10, 1987	Sep CAHN
>D>	AB		30MG	A 071026	001	Aug 10, 1987	Sep CAHN

OXCARBAZEPINE

## SUSPENSION; ORAL

## OXCARBAZEPINE

	AB	ALKEM LABS LTD	300MG/5ML	A 213183	001	Mar 18, 2023	Mar NEWA
	AB	BIOCON PHARMA	300MG/5ML	A 218278	001	Mar 01, 2024	Apr CAHN
	AB	CARNEGIE	300MG/5ML	A 218278	001	Mar 01, 2024	Feb NEWA
>A>	AB	KANCHAN HLTHCARE	300MG/5ML	A 217782	001	Feb 14, 2024	Sep CAHN
>D>	AB	MEDLEY PHARMS	300MG/5ML	A 217782	001	Feb 14, 2024	Sep CAHN
	AB		300MG/5ML	A 217782	001	Feb 14, 2024	Feb NEWA
	AB	RISING	300MG/5ML	A 218278	001	Mar 01, 2024	Mar CAHN

## TABLET; ORAL

## OXCARBAZEPINE

	AB	ANI PHARMS	150MG	A 078005	001	Dec 11, 2007	Jul CMFD
	AB		300MG	A 078005	002	Dec 11, 2007	Jul CMFD
	AB		600MG	A 078005	003	Dec 11, 2007	Jul CMFD
	AB	RUBICON	150MG	A 207717	001	Mar 05, 2024	Feb NEWA
	AB		300MG	A 207717	002	Mar 05, 2024	Feb NEWA
	AB		600MG	A 207717	003	Mar 05, 2024	Feb NEWA
		@ ZYDUS	150MG	A 211747	001	Jul 03, 2023	Jan DISC
		@	300MG	A 211747	002	Jul 03, 2023	Jan DISC
		@	600MG	A 211747	003	Jul 03, 2023	Jan DISC

## TABLET, EXTENDED RELEASE; ORAL

## OXCARBAZEPINE

		@ AJANTA PHARMA LTD	150MG	A 217659	001	Feb 22, 2024	Aug DISC
	AB		150MG	A 217659	001	Feb 22, 2024	Feb NEWA
		@	300MG	A 217659	002	Feb 22, 2024	Aug DISC
	AB		300MG	A 217659	002	Feb 22, 2024	Feb NEWA
		@	600MG	A 217659	003	Feb 22, 2024	Aug DISC
	AB		600MG	A 217659	003	Feb 22, 2024	Feb NEWA
	AB	APOTEX	150MG	A 213369	001	Jul 13, 2023	Aug CMFD
	AB		300MG	A 213369	002	Jul 13, 2023	Aug CMFD
	AB		600MG	A 213369	003	Jul 13, 2023	Aug CMFD
		OXTELLAR XR					
	AB	+ SUPERNUS PHARMS	150MG	N 202810	001	Oct 19, 2012	Feb CTEC
	AB	+	300MG	N 202810	002	Oct 19, 2012	Feb CTEC
	AB	+!	600MG	N 202810	003	Oct 19, 2012	Feb CTEC

OXYBUTYNIN CHLORIDE

## SYRUP; ORAL

## OXYBUTYNIN CHLORIDE

## @ PHARM ASSOC

5MG/5ML

A 075137 001 Dec 18, 1998 Feb DISC

## TABLET; ORAL

## OXYBUTYNIN CHLORIDE

## @ EYWA

5MG

A 211062 001 Feb 06, 2019 Mar DISC

## @ HIBROW HLTHCARE

5MG

A 211062 001 Feb 06, 2019 Jul CAHN

>A>	AB	TRUPHARMA	5MG	A 210125	001	Sep 06, 2018	Sep CAHN
>D>	AB	TULEX PHARMS INC	5MG	A 210125	001	Sep 06, 2018	Sep CAHN

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

	@ HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar	DISC
	@	100MG/5ML	A208795	001	Aug 07, 2017	Mar	DISC
	+ @ VISTAPHARM LLC	5MG/5ML	N201194	001	Jan 12, 2012	Apr	CAHN
	@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar	CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	STRIDES PHARMA	5MG	A077712	003	Mar 02, 2009	Aug	CMFD
AB		10MG	A077712	004	Apr 13, 2015	Aug	CMFD
AB		15MG	A077712	001	Jan 31, 2007	Aug	CMFD
AB		20MG	A077712	005	Apr 13, 2015	Aug	CMFD
AB		30MG	A077712	002	Jan 31, 2007	Aug	CMFD
	@ SUN PHARM INDS INC	5MG	A090659	001	Apr 10, 2009	Jun	DISC
	@	10MG	A090659	005	Nov 06, 2012	Jun	DISC
	@	15MG	A090659	002	Apr 10, 2009	Jun	DISC
	@	20MG	A090659	004	Nov 06, 2012	Jun	DISC
	@	30MG	A090659	003	Apr 10, 2009	Jun	DISC
	ROXYBOND						
>A>	PROTEGA PHARMS	10MG	N209777	004	Sep 05, 2024	Sep	NEWA

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

	+ @ NORVIUM BIOSCIENCE	50MG	N016848	001		Jun	CAHN
--	------------------------	------	---------	-----	--	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

	+ @ ENDO OPERATIONS	5MG	N021610	001	Jun 22, 2006	May	CAHN
	+ @	7.5MG	N021610	005	Feb 29, 2008	May	CAHN
	+ @	10MG	N021610	002	Jun 22, 2006	May	CAHN
	+ @	15MG	N021610	006	Feb 29, 2008	May	CAHN
	+ @	20MG	N021610	003	Jun 22, 2006	May	CAHN
	+ @	30MG	N021610	007	Feb 29, 2008	May	CAHN
	+ @	40MG	N021610	004	Jun 22, 2006	May	CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

	+ BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan	CAHN
	+	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan	CAHN
	+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan	CAHN

PACLITAXEL

POWDER; INTRAVENOUS

ABRAXANE

AB	+! BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan	CTEC
	PACLITAXEL						
AB	+! AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr	CTEC
>A>	AB HENGRUI PHARMA	100MG/VIAL	A212700	001	Oct 08, 2024	Sep	NEWA
AB	+! TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan	CMFD

PALBOCICLIB

TABLET;ORAL

IBRANCE

AB	+ PFIZER	75MG	N212436	001	Nov 01, 2019	May	CFTG
	+	75MG	N212436	001	Nov 01, 2019	Jan	CTEC
AB	+	100MG	N212436	002	Nov 01, 2019	May	CFTG
	+	100MG	N212436	002	Nov 01, 2019	Jan	CTEC
AB	+!	125MG	N212436	003	Nov 01, 2019	May	CFTG
	+!	125MG	N212436	003	Nov 01, 2019	Jan	CTEC

PALBOCICLIB

AB	SYNTHON PHARMS INC	75MG	A215570	001	Jun 05, 2024	May	NFTG
AB		100MG	A215570	002	Jun 05, 2024	May	NFTG
AB		125MG	A215570	003	Jun 05, 2024	May	NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

	@	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul	DISC
	@		3MG	A202645	002	Aug 03, 2015	Jul	DISC
	@		6MG	A202645	003	Aug 03, 2015	Jul	DISC
	@		9MG	A202645	004	Aug 03, 2015	Jul	DISC
AB		AJANTA PHARMA LTD	1.5MG	A218514	001	Jun 26, 2024	Jun	NEWA
AB			3MG	A218514	002	Jun 26, 2024	Jun	NEWA
AB			6MG	A218514	003	Jun 26, 2024	Jun	NEWA
AB			9MG	A218514	004	Jun 26, 2024	Jun	NEWA
>A>	AB	ALEMBIC	1.5MG	A218330	001	Sep 26, 2024	Sep	NEWA
>A>	AB		3MG	A218330	002	Sep 26, 2024	Sep	NEWA
>A>	AB		6MG	A218330	003	Sep 26, 2024	Sep	NEWA
>A>	AB		9MG	A218330	004	Sep 26, 2024	Sep	NEWA
BX		LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun	CTEC
BX			3MG	A208643	002	Jun 29, 2022	Jun	CTEC
BX			6MG	A208643	003	Jun 29, 2022	Jun	CTEC
BX			9MG	A208643	004	Jun 29, 2022	Jun	CTEC
>A>	AB	ZYDUS PHARMS	1.5MG	A217445	001	Oct 08, 2024	Sep	NEWA
>A>	AB		3MG	A217445	002	Oct 08, 2024	Sep	NEWA
>A>	AB		6MG	A217445	003	Oct 08, 2024	Sep	NEWA
>A>	AB		9MG	A217445	004	Oct 08, 2024	Sep	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ERZOFRI

+	!	LUYE INNOMIND PHARMA	39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Aug	CHRS
+			39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Jul	NEWA
+	!		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Aug	CHRS
+			78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Jul	NEWA
+	!		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Aug	CHRS
+			117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Jul	NEWA
+	!		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Aug	CHRS
+			156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Jul	NEWA
+	!		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Aug	CHRS
+			234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Jul	NEWA
+	!		351MG/2.25ML (156MG/ML)	N216352	006	Jul 26, 2024	Jul	NEWA
		INVEGA SUSTENNA						
AB	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
AB	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
AB	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
AB	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
AB	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC
		INVEGA TRINZA						
+	!	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	Aug	CHRS
+	!		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	Aug	CHRS
+	!		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	Aug	CHRS
		PALIPERIDONE PALMITATE						
AB		TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
AB			78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
AB			117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
AB			156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
AB			234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		MEITHEAL	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun	CAHN
		SOLUTION;INTRAVENOUS						
		POSFREA						
+	@	AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CTNA
+	@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CRLD
	@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
+	!		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CTNA
+	!		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CMFD
	@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN

SOLUTION; INTRAVENOUS									
POSFREA									
		BASE/ML)							
<u>PALOPEGTERIPARATIDE</u>									
SOLUTION; SUBCUTANEOUS									
YORVIPATH									
+	ASCENDIS PHARMA BONE	EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	N216490	001	Aug 09, 2024	Aug	NEWA		
+		EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	Aug	NEWA		
+		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	Aug	NEWA		
<u>PANCURONIUM BROMIDE</u>									
INJECTABLE; INJECTION									
PANCURONIUM BROMIDE									
!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CTEC		
@	HOSPIRA	1MG/ML	A072320	001	Jan 19, 1989	May	DISC		
<u>PANTOPRAZOLE SODIUM</u>									
INJECTABLE; INTRAVENOUS									
PANTOPRAZOLE SODIUM									
AP	HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN		
	@ SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC		
POWDER; INTRAVENOUS									
PANTOPRAZOLE SODIUM									
AP	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Jul	NEWA		
AP	+	HIKMA	N209463	001	Jun 30, 2017	Jul	CFTG		
SOLUTION; INTRAVENOUS									
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE									
+	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA		
+		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA		
+		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA		
TABLET, DELAYED RELEASE; ORAL									
PANTOPRAZOLE SODIUM									
AB	MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024	Apr	NEWA		
<u>PARICALCITOL</u>									
SOLUTION; INTRAVENOUS									
PARICALCITOL									
@	HOSPIRA	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	May	DISC		
@		0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	May	DISC		
@		0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	May	DISC		
<u>PATIROMER SORBITE X CALCIUM</u>									
POWDER; ORAL									
VELTASSA									
+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Aug	CMFD		
+	@	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC		
+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jul	CHRS		
+	@	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jul	DISC		
<u>PAZOPANIB HYDROCHLORIDE</u>									
TABLET; ORAL									
PAZOPANIB HYDROCHLORIDE									
AB	NOVUGEN	EQ 200MG BASE	A218231	001	Apr 23, 2024	Apr	NEWA		
<u>PEGULICIANINE ACETATE</u>									
POWDER; INTRAVENOUS									
LUMISIGHT									
+	LUMICELL	EQ 40MG BASE/VIAL	N214511	001	Apr 17, 2024	Apr	NEWA		
<u>PEMETREXED DIPOTASSIUM</u>									
POWDER; INTRAVENOUS									
PEMETREXED									
+	AVYXA HOLDINGS	EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024	Jun	NEWA		
+		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024	Jun	NEWA		



PEMETREXED DISODIUMPOWDER; INTRAVENOUS  
PEMETREXED DISODIUM

AP	HETERO LABS LTD VI	EQ 100MG BASE/VIAL	A215460	001	Jun 14, 2024	Jun	NEWA
AP		EQ 500MG BASE/VIAL	A215460	002	Jun 14, 2024	Jun	NEWA
AP	RELIANCE LIFE	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	Jun	CAHN
AP		EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	Jun	CAHN

PENBUTOLOL SULFATETABLET; ORAL  
LEVATOL

+ @	ENDO OPERATIONS	10MG	N018976	001	Dec 30, 1987	May	CAHN
+ @		20MG	N018976	004	Jan 05, 1989	May	CAHN

PENCICLOVIRCREAM; TOPICAL  
PENCICLOVIR

>A>	AB	PADAGIS ISRAEL	1%	A212368	001	Sep 27, 2024	Sep	NEWA
-----	----	----------------	----	---------	-----	--------------	-----	------

PENICILLAMINECAPSULE; ORAL  
LUXZYLA

AB	@ ANI PHARMS	250MG	A209921	001	May 07, 2019	Aug	CTNA
		250MG	A209921	001	May 07, 2019	Aug	CTNA

AB	PENICILLAMINE						
	ENDO OPERATIONS	250MG	A211231	001	Dec 23, 2019	Apr	CAHN

TABLET; ORAL

AB	PENICILLAMINE						
	ENDO OPERATIONS	250MG	A211196	001	Dec 23, 2019	Apr	CAHN

PENICILLIN V POTASSIUMTABLET; ORAL  
PENICILLIN V POTASSIUM

AB	! AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
	@ SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
	@	EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL  
PENTOXIFYLLINE

AB	ANI PHARMS	400MG	A074878	001	Jul 09, 1997	Jan	CMFD
AB	RISING	400MG	A074425	001	Jul 08, 1997	Jun	CMFD

PERMETHRINCREAM; TOPICAL  
PERMETHRIN

@	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jan	DISC
---	-------------------	----	---------	-----	--------------	-----	------

PERPHENAZINETABLET; ORAL  
PERPHENAZINE

AB	ENDO OPERATIONS	2MG	A040226	001	Dec 31, 1998	Apr	CAHN
AB		4MG	A040226	002	Dec 31, 1998	Apr	CAHN
AB		8MG	A040226	003	Dec 31, 1998	Apr	CAHN
AB		16MG	A040226	004	Dec 31, 1998	Apr	CAHN
AB	MACLEODS PHARMS LTD	2MG	A212545	001	May 06, 2024	Apr	NEWA
AB		4MG	A212545	002	May 06, 2024	Apr	NEWA
AB		8MG	A212545	003	May 06, 2024	Apr	NEWA
AB		16MG	A212545	004	May 06, 2024	Apr	NEWA

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE; ORAL  
PHENOXYBENZAMINE HYDROCHLORIDE

AB	! ENDO OPERATIONS	10MG	A204522	001	Jan 24, 2017	May	CAHN
----	-------------------	------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

	CAPSULE;ORAL						
	ADIPEX-P						
	+ @	TEVA	37.5MG	A088023	001	Aug 02, 1983	Feb DISC
	PHENTERMINE HYDROCHLORIDE						
	@	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Mar DISC
	@		30MG	A202858	002	Feb 14, 2014	Mar DISC
	@		30MG	A204414	001	May 05, 2014	Mar DISC
	@		37.5MG	A202846	001	Feb 05, 2014	Mar DISC
AA	!	NUVO PHARM	37.5MG	A205017	001	Sep 25, 2014	Feb CHRS
	TABLET;ORAL						
	PHENTERMINE HYDROCHLORIDE						
>A>	AA	AUROBINDO PHARMA LTD	37.5MG	A203068	001	Aug 06, 2014	Sep CAHN
>D>	AA	AUROLIFE PHARMA LLC	37.5MG	A203068	001	Aug 06, 2014	Sep CAHN
	@	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Mar DISC

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

	CAPSULE, EXTENDED RELEASE;ORAL						
	PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE						
AB		ACTAVIS LABS FL INC	EQ 3.75MG BASE;23MG	A204982	001	Jun 25, 2024	Jun NFTG
AB			EQ 7.5MG BASE;46MG	A204982	002	Jun 25, 2024	Jun NFTG
AB			EQ 11.25MG BASE;69MG	A204982	003	Jun 25, 2024	Jun NFTG
AB			EQ 15MG BASE;92MG	A204982	004	Jun 25, 2024	Jun NFTG
	QSYMIA						
AB	+	VIVUS LLC	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jun CFTG
	+		EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	May CAHN
AB	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jun CFTG
	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	May CAHN
AB	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jun CFTG
	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	May CAHN
AB	+	!	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jun CFTG
	+	!	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	May CAHN

PHENTOLAMINE MESYLATE

	SOLUTION;OPHTHALMIC						
	RYZUMVI						
	+	FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Jan CAHN

PHENYLBUTAZONE

	CAPSULE;ORAL						
	PHENYLBUTAZONE						
	@	CHARTWELL RX	100MG	A087774	001	Jun 16, 1982	Aug CAHN

PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION;INTRAVENOUS						
	PHENYLEPHRINE HYDROCHLORIDE						
	@	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	May DISC
	@		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	May DISC
	@		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	May DISC
AP1		ASPIRO	10MG/ML (10MG/ML)	A218110	001	May 10, 2024	May NEWA
AP1			50MG/5ML (10MG/ML)	A218110	002	May 10, 2024	May NEWA
AP1			100MG/10ML (10MG/ML)	A218110	003	May 10, 2024	May NEWA
	@	ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr CAHN
AP1			50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr CAHN
AP1			100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr CAHN
>D>	AP1	HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Sep DISC
>A>	@		10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Sep DISC
AP1			10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar NEWA
>D>	AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Sep DISC
>A>	@		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Sep DISC
AP1			50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar NEWA
>D>	AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Sep DISC
>A>	@		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Sep DISC
AP1			100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar NEWA
	SOLUTION/DROPS;OPHTHALMIC						
	PHENYLEPHRINE HYDROCHLORIDE						
AT		CAPLIN	2.5%	A215183	001	May 23, 2024	May NEWA
AT			10%	A215183	002	May 23, 2024	May NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	GENUS	5MG/5ML; 6.25MG/5ML	A 040654	001	Dec 07, 2006	Apr	CAHN
	@	HIKMA	5MG/5ML; 6.25MG/5ML	A 040675	001	Dec 23, 2014	Mar	DISC

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

@ PAI HOLDINGS PHARM

125MG/5ML

A 040420 001 Apr 19, 2002 Feb DISC

@ VISTAPHARM

125MG/5ML

A 040342 001 Jan 31, 2001 Apr DISC

@

125MG/5ML

A 040342 002 Aug 18, 2005 Apr DISC

TABLET, CHEWABLE; ORAL

PHENYTOIN

AB		TARO	50MG	A 200565	001	Apr 17, 2014	Apr	CAHN
----	--	------	------	----------	-----	--------------	-----	------

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	!	HIKMA	50MG/ML	A 084307	001		Jun	CAHN
----	---	---	-------	---------	----------	-----	--	-----	------

PHYTONADIONE

TABLET; ORAL

PHYTONADIONE

AB	!	ZYDUS LIFESCIENCES	5MG	A 210189	001	Feb 20, 2019	Jul	CAHN
----	---	--------------------	-----	----------	-----	--------------	-----	------

PIMAVANSERIN TARTRATE

CAPSULE; ORAL

NUPLAZID

AB	+	!	ACADIA PHARMS INC	EQ 34MG BASE	N 210793	001	Jun 28, 2018	Jul	CTEC
				EQ 34MG BASE	N 210793	001	Jun 28, 2018	Jan	CFTG

PIMAVANSERIN

AB		@	MSN	EQ 34MG BASE	A 214925	001	Jan 16, 2024	Feb	DISC
		@	ZYDUS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	NEWA
		@	ZYDUS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jul	DISC
		@	ZYDUS PHARMS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	CAHN
		@	ZYDUS PHARMS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	NEWA

TABLET; ORAL

NUPLAZID

AB	+	!	ACADIA PHARMS INC	EQ 10MG BASE	N 207318	002	Jun 28, 2018	Jul	CTEC
				EQ 10MG BASE	N 207318	002	Jun 28, 2018	Jan	CFTG

PIMAVANSERIN

AB		@	ZYDUS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jul	DISC
		@	ZYDUS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	CAHN
		@	ZYDUS PHARMS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	NEWA

PIMOZIDE

TABLET; ORAL

PIMOZIDE

			ENDO OPERATIONS	1MG	A 204521	001	Sep 28, 2015	Apr	CAHN
	!			2MG	A 204521	002	Sep 28, 2015	Apr	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB			COREPHARMA	EQ 15MG BASE	A 210165	001	Jan 22, 2021	Jul	CAHN
AB				EQ 30MG BASE	A 210165	002	Jan 22, 2021	Jul	CAHN
AB				EQ 45MG BASE	A 210165	003	Jan 22, 2021	Jul	CAHN
>D>		@	MYLAN PHARMS INC	EQ 15MG BASE	A 076801	001	Aug 17, 2012	Sep	CAHN
>D>		@		EQ 30MG BASE	A 076801	002	Aug 17, 2012	Sep	CAHN
>D>		@		EQ 45MG BASE	A 076801	003	Aug 17, 2012	Sep	CAHN
>A>		@	NORVIUM BIOSCIENCE	EQ 15MG BASE	A 076801	001	Aug 17, 2012	Sep	CAHN
>A>		@		EQ 30MG BASE	A 076801	002	Aug 17, 2012	Sep	CAHN
>A>		@		EQ 45MG BASE	A 076801	003	Aug 17, 2012	Sep	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

@ EUGIA PHARMA

EQ 12GM BASE/VIAL; EQ 1.5GM  
BASE/VIAL

A 217409 002 Oct 12, 2023 Apr DISC

@

EQ 36GM BASE/VIAL; EQ 4.5GM

A 217409 001 Oct 12, 2023 Apr DISC

## INJECTABLE; INJECTION

## PIPERACILLIN AND TAZOBACTAM

		BASE/VIAL					
	@ FRESenius KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM	A206204	001	May 11, 2018	Feb	DISC
		BASE/VIAL					
AP	STERISCIENCE SPECLTS	EQ 2GM BASE/VIAL;EQ 250MG	A065458	001	Aug 15, 2014	Aug	CAHN
		BASE/VIAL					
AP		EQ 3GM BASE/VIAL;EQ 375MG	A065458	002	Aug 15, 2014	Aug	CAHN
		BASE/VIAL					
AP		EQ 4GM BASE/VIAL;EQ 500MG	A065458	003	Aug 15, 2014	Aug	CAHN
		BASE/VIAL					

PIROXICAM

## CAPSULE; ORAL

## PIROXICAM

	@ FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar	DISC
	@	20MG	A207938	002	Sep 09, 2016	Mar	DISC

PITAVASTATIN CALCIUM

## TABLET; ORAL

## PITAVASTATIN CALCIUM

AB	AMNEAL PHARMS NY	EQ 1MG BASE	A205961	001	Aug 20, 2024	Aug	NEWA
AB		EQ 2MG BASE	A205961	002	Aug 20, 2024	Aug	NEWA
AB		EQ 4MG BASE	A205961	003	Aug 20, 2024	Aug	NEWA
AB	HETERO LABS LTD V	EQ 1MG BASE	A205977	001	Apr 30, 2024	Apr	NEWA
AB		EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr	NEWA
AB		EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr	NEWA

PIVMECILLINAM HYDROCHLORIDE

## TABLET; ORAL

## PIVYA

	+ @ UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Aug	DISC
	+!	EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr	NEWA

PLERIXAFOR

## SOLUTION; SUBCUTANEOUS

## PLERIXAFOR

AP	GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr	NEWA
AP	MEITHEAL	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jun	CAHN
	@ ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

## FOR SOLUTION; ORAL

## PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA	NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A090019	001	May 27, 2009	Jun	CMFD
		.2GM/BOT					

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

## FOR SOLUTION; ORAL

## COLYTE

## @ NORVIUM BIOSCIENCE

		120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jul	CAHN
--	--	---	---------	-----	--------------	-----	------

	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul	CAHN
--	---	--	---------	-----	--------------	-----	------

	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul	CAHN
--	---	---	---------	-----	--------------	-----	------

	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul	CAHN
--	---	--	---------	-----	--------------	-----	------

	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jul	CAHN
--	---	--	---------	-----	--------------	-----	------

## COLYTE WITH FLAVOR PACKS

	@ MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC
--	-----------------------	--	---------	-----	--------------	-----	------

	@ NORVIUM BIOSCIENCE	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CAHN
--	----------------------	--	---------	-----	--------------	-----	------

## COLYTE-FLAVORED

	@ NORVIUM BIOSCIENCE	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul	CAHN
--	----------------------	---	---------	-----	--------------	-----	------

	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul	CAHN
--	---	--	---------	-----	--------------	-----	------

FOR SOLUTION;ORAL  
PEG 3350 AND ELECTROLYTES

NOVEL LABS INC 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT A 090186 001 Jun 01, 2009 Apr CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION  
POLYMYXIN B SULFATE

AP ADRASTEIA PHARMA EQ 500,000 UNITS BASE/VIAL A 063000 001 Sep 30, 1994 Feb CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC  
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT SOMERSET THERAPS LLC 10,000 UNITS/ML;EQ 1MG BASE/ML A 211572 001 Aug 05, 2024 Jul NEWA

POMALIDOMIDE

CAPSULE;ORAL  
POMALIDOMIDE

AB APOTEX 1MG A 210164 001 Jun 11, 2024 May NEWA  
 AB 2MG A 210164 002 Jun 11, 2024 May NEWA  
 AB 3MG A 210164 003 Jun 11, 2024 May NEWA  
 AB 4MG A 210164 004 Jun 11, 2024 May NEWA  
 >A> AB HETERO LABS LTD V 1MG A 210236 001 Sep 26, 2024 Sep NEWA  
 >A> AB 2MG A 210236 002 Sep 26, 2024 Sep NEWA  
 >A> AB 3MG A 210236 003 Sep 26, 2024 Sep NEWA  
 >A> AB 4MG A 210236 004 Sep 26, 2024 Sep NEWA  
 POMALYST  
 AB + BRISTOL 1MG N 204026 001 Feb 08, 2013 May CTEC  
 AB + 2MG N 204026 002 Feb 08, 2013 May CTEC  
 AB + 3MG N 204026 003 Feb 08, 2013 May CTEC  
 AB +! 4MG N 204026 004 Feb 08, 2013 May CTEC

PONESIMOD

TABLET;ORAL  
PONVORY

+! VANDA PHARMS INC 2MG N 213498 001 Mar 18, 2021 May CAHN  
 + 3MG N 213498 002 Mar 18, 2021 May CAHN  
 + 4MG N 213498 003 Mar 18, 2021 May CAHN  
 + 5MG N 213498 004 Mar 18, 2021 May CAHN  
 + 6MG N 213498 005 Mar 18, 2021 May CAHN  
 + 7MG N 213498 006 Mar 18, 2021 May CAHN  
 + 8MG N 213498 007 Mar 18, 2021 May CAHN  
 + 9MG N 213498 008 Mar 18, 2021 May CAHN  
 + 10MG N 213498 009 Mar 18, 2021 May CAHN  
 + 20MG N 213498 010 Mar 18, 2021 May CAHN

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL  
NOXAFIL

+ @ MERCK SHARP DOHME 100MG N 205053 001 Nov 25, 2013 Aug DISC  
 POSACONAZOLE  
 AB ! AET PHARMA 100MG A 213454 001 Feb 01, 2021 Aug CHRS  
 AB AUROBINDO PHARMA 100MG A 217119 001 Jul 18, 2024 Jul NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

@ ANCHEN PHARMS 8MEQ A 202886 001 Dec 26, 2013 Feb DISC  
 @ 10MEQ A 202886 002 Dec 26, 2013 Feb DISC  
 @ ENDO OPERATIONS 8MEQ A 202886 001 Dec 26, 2013 May CAHN  
 @ 10MEQ A 202886 002 Dec 26, 2013 May CAHN  
 >D> AB GLENMARK PHARMS LTD 10MEQ A 202868 001 Jan 19, 2016 Sep DISC  
 >A> @ 10MEQ A 202868 001 Jan 19, 2016 Sep DISC  
 FOR SOLUTION;ORAL  
 POKONZA  
 + GENUS 10MEQ N 208019 002 Aug 25, 2023 Jun CAHN  
 POTASSIUM CHLORIDE  
 AA + GENUS 20MEQ N 208019 001 Aug 19, 2015 Jun CAHN  
 +! 40MEQ N 208019 003 Aug 25, 2023 Jun CAHN  
 SOLUTION;ORAL  
 POTASSIUM CHLORIDE  
 AA STRIDES PHARMA 20MEQ/15ML A 211665 002 Jan 16, 2024 Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE							
	@ CHARTWELL RX	10MEQ	A206630	001	Mar 29, 2019	May	CAHN
	@	15MEQ	A206630	002	Mar 29, 2019	May	CAHN
	@	20MEQ	A206630	003	Mar 29, 2019	May	CAHN
AB2	MACLEODS PHARMS LTD	8MEQ	A212987	001	Sep 06, 2024	Aug	NEWA
AB2		10MEQ	A212987	002	Sep 06, 2024	Aug	NEWA
AB1		10MEQ	A216269	001	May 09, 2024	May	NEWA
AB1		15MEQ	A216269	002	May 09, 2024	May	NEWA
AB1		20MEQ	A216269	003	May 09, 2024	May	NEWA
	! RUBICON	15MEQ	A215725	003	Aug 22, 2024	Aug	NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE							
AB	HIBROW HLTHCARE	5MEQ	A214426	001	Feb 19, 2021	Jul	CAHN
AB		10MEQ	A214426	002	Feb 19, 2021	Jul	CAHN
AB		15MEQ	A214426	003	Feb 19, 2021	Jul	CAHN
	@ TORRENT	5MEQ	A213986	001	Feb 06, 2024	Feb	DISC
AB		5MEQ	A213986	001	Feb 06, 2024	Jan	NEWA
	@	10MEQ	A213986	002	Feb 06, 2024	Feb	DISC
AB		10MEQ	A213986	002	Feb 06, 2024	Jan	NEWA
	@	15MEQ	A213986	003	Feb 06, 2024	Feb	DISC
AB		15MEQ	A213986	003	Feb 06, 2024	Jan	NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES							
AP	SOMERSET THERAPS LLC	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	A217726	001	Jul 11, 2024	Jun	NEWA
AP		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	A217726	002	Jul 11, 2024	Jun	NEWA
	POTASSIUM PHOSPHATES IN	0.9% SODIUM CHLORIDE					
+!	AMNEAL	1.18GM/250ML (4.72MG/ML);1.12GM/250ML	N218343	001	Jul 26, 2024	Jul	NEWA

PRALSETINIB

CAPSULE;ORAL

GAVRETO							
+!	BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Feb	CAHN
+!	RIGEL PHARMS	100MG	N213721	001	Sep 04, 2020	Jun	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE							
AB	GLENMARK PHARMS LTD	0.125MG	A090781	001	Oct 08, 2010	Mar	CAHN
AB	!	0.25MG	A090781	002	Oct 08, 2010	Mar	CAHN
AB		0.5MG	A090781	003	Oct 08, 2010	Mar	CAHN
AB		0.75MG	A090781	006	Sep 11, 2015	Mar	CAHN
AB		1MG	A090781	004	Oct 08, 2010	Mar	CAHN
AB		1.5MG	A090781	005	Oct 08, 2010	Mar	CAHN
	@ NATCO	0.125MG	A077854	001	Oct 08, 2010	Aug	CAHN
	@	0.25MG	A077854	002	Oct 08, 2010	Aug	CAHN
	@	0.5MG	A077854	003	Oct 08, 2010	Aug	CAHN
	@	1MG	A077854	004	Oct 08, 2010	Aug	CAHN
	@	1.5MG	A077854	005	Oct 08, 2010	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER							
+ @	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Aug	DISC
+ @		0.75MG	N022421	002	Feb 19, 2010	Aug	DISC
+ @		1.5MG	N022421	003	Feb 19, 2010	Aug	DISC
+ @		2.25MG	N022421	006	Jun 17, 2011	Aug	DISC
+ @		3MG	N022421	004	Feb 19, 2010	Aug	DISC
+ @		3.75MG	N022421	007	Jun 17, 2011	Aug	DISC
+ @		4.5MG	N022421	005	Feb 19, 2010	Aug	DISC
	PRAPIPEXOLE DIHYDROCHLORIDE						
AB	! DR REDDYS	0.375MG	A203354	001	Aug 07, 2015	Aug	CHRS
	@ ENDO OPERATIONS	0.375MG	A202206	001	Feb 06, 2014	May	CAHN
	@	0.75MG	A202206	002	Feb 06, 2014	May	CAHN
	@	1.5MG	A202206	003	Feb 06, 2014	May	CAHN
	@	2.25MG	A202206	004	Feb 06, 2014	May	CAHN
	@	3MG	A202206	005	Feb 06, 2014	May	CAHN
	@	3.75MG	A202206	006	Feb 06, 2014	May	CAHN

TABLET, EXTENDED RELEASE;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

@ 4.5MG A202206 007 Feb 06, 2014 May CAHN

PRAZIQUANTEL

TABLET;ORAL

>D> BILTRICIDE  
>D> AB + BAYER HLTHCARE 600MG N018714 001 Dec 29, 1982 Sep DISC  
>A> + @ 600MG N018714 001 Dec 29, 1982 Sep DISC  
AB + 600MG N018714 001 Dec 29, 1982 Jun CHRS  
PRAZIQUANTEL  
>D> AB ! ENDO OPERATIONS 600MG A208820 001 Nov 27, 2017 Sep CTEC  
>A> ! 600MG A208820 001 Nov 27, 2017 Sep CTEC  
AB ! 600MG A208820 001 Nov 27, 2017 Jun CHRS  
AB 600MG A208820 001 Nov 27, 2017 Apr CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

@ LANNETT CO INC EQ 1MG BASE A214083 001 Jan 03, 2024 Jul DISC  
@ EQ 2MG BASE A214083 002 Jan 03, 2024 Jul DISC  
@ EQ 5MG BASE A214083 003 Jan 03, 2024 Jul DISC  
>A> AB MSN EQ 1MG BASE A216727 001 Sep 17, 2024 Sep NEWA  
>A> AB EQ 2MG BASE A216727 002 Sep 17, 2024 Sep NEWA  
>A> AB EQ 5MG BASE A216727 003 Sep 17, 2024 Sep NEWA

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@ HIKMA 15MG/5ML A040401 001 Feb 27, 2003 Mar DISC  
@ PHARM ASSOC 15MG/5ML A040399 001 Mar 05, 2003 Feb DISC

TABLET;ORAL

PREDNISOLONE

AB ZHEJIANG XIANJU 5MG A218083 001 May 02, 2024 Apr NEWA

PREDNISOLONE ACETATE

SUSPENSION;ORAL

FLO-PRED

@ TARO EQ 5MG BASE/5ML N022067 001 Jan 17, 2008 Aug CAHN  
@ EQ 15MG BASE/5ML N022067 002 Jan 17, 2008 Aug CAHN

SUSPENSION/DROPS;OPHTHALMIC

PREDNISOLONE ACETATE

AB LUPIN LTD 1% A216935 001 Aug 02, 2024 Jul NFTG

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ ENDO OPERATIONS EQ 15MG BASE/5ML A079010 001 May 26, 2009 May CAHN  
@ HIKMA EQ 5MG BASE/5ML A075183 001 Mar 26, 2003 Mar DISC  
@ PHARM ASSOC EQ 30MG BASE/5ML A204962 001 Mar 11, 2020 Mar DISC  
>A> @ PHARMOBEDIANT EQ 15MG BASE/5ML A076895 001 Oct 04, 2004 Sep CAHN  
>D> @ XTTRIUM LABS INC EQ 15MG BASE/5ML A076895 001 Oct 04, 2004 Sep CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

@ GENUS EQ 0.23% PHOSPHATE;10% A073630 001 May 27, 1993 Aug CAHN

PREDNISONE

SOLUTION;ORAL

PREDNISONE INTENSOL

+! HIKMA 5MG/ML A088810 001 Feb 20, 1985 Jan CRLD

TABLET;ORAL

PREDNISONE

@ ALLIED 5MG A212629 001 Dec 05, 2023 Aug CAHN  
@ 10MG A212629 002 Dec 05, 2023 Aug CAHN  
@ 20MG A212629 003 Dec 05, 2023 Aug CAHN  
BX CHARTWELL MOLECULAR 20MG A084275 001 Jul CMFD  
AB ENDO OPERATIONS 1MG A040584 001 Dec 21, 2004 Apr CAHN  
AB 2.5MG A040581 001 Dec 21, 2004 Apr CAHN  
AB 5MG A040256 001 Jul 12, 2002 Apr CAHN  
AB 10MG A040256 002 Jul 12, 2002 Apr CAHN

TABLET;ORAL  
PREDNISONE

AB		20MG	A040392	001	Feb 12, 2003	Apr	CAHN
	@ GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Feb	DISC
	@	2.5MG	A210525	004	Dec 07, 2018	Feb	DISC
	@	5MG	A210525	005	Dec 07, 2018	Feb	DISC
	@	10MG	A210525	001	Dec 04, 2018	Feb	DISC
	@	20MG	A210525	002	Dec 04, 2018	Feb	DISC
	@	50MG	A210525	003	Dec 04, 2018	Feb	DISC
	@ GRANULATION TECH	5MG	A212629	001	Dec 05, 2023	Jul	DISC
	@	10MG	A212629	002	Dec 05, 2023	Jul	DISC
	@	20MG	A212629	003	Dec 05, 2023	Jul	DISC
AB	STRIDES PHARMA	2.5MG	A208412	004	Nov 20, 2020	Jun	CMS1
AB		5MG	A208412	005	Nov 20, 2020	Jun	CMS1

PREGABALIN

CAPSULE;ORAL  
PREGABALIN

AB	ACME LABS	50MG	A210585	001	Dec 26, 2019	Aug	CAHN
AB		75MG	A210585	002	Dec 26, 2019	Aug	CAHN
AB		100MG	A210585	003	Dec 26, 2019	Aug	CAHN
AB		150MG	A210585	004	Dec 26, 2019	Aug	CAHN
AB		200MG	A210585	005	Dec 26, 2019	Aug	CAHN
AB		300MG	A210585	006	Dec 26, 2019	Aug	CAHN
AB	ADAPTIS	25MG	A208113	001	May 17, 2024	Aug	CAHN
AB		50MG	A208113	002	May 17, 2024	Aug	CAHN
AB		75MG	A208113	004	May 17, 2024	Aug	CAHN
AB		100MG	A208113	005	May 17, 2024	Aug	CAHN
AB		150MG	A208113	003	May 17, 2024	Aug	CAHN
AB		200MG	A208113	006	May 17, 2024	Aug	CAHN
AB		225MG	A208113	007	May 17, 2024	Aug	CAHN
AB		300MG	A208113	008	May 17, 2024	Aug	CAHN
	@ CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jan	DISC
	@	50MG	A206452	002	Jul 12, 2023	Jan	DISC
	@	75MG	A206452	003	Jul 12, 2023	Jan	DISC
	@	100MG	A206452	004	Jul 12, 2023	Jan	DISC
	@	150MG	A206452	005	Jul 12, 2023	Jan	DISC
	@	200MG	A206452	006	Jul 12, 2023	Jan	DISC
	@	225MG	A206452	007	Jul 12, 2023	Jan	DISC
	@	300MG	A206452	008	Jul 12, 2023	Jan	DISC
>A> AB	CHANGZHOU PHARM	25MG	A214322	008	Sep 26, 2024	Sep	NEWA
	@ CIPLA	25MG	A212280	001	Jan 10, 2020	May	DISC
	@	50MG	A212280	002	Jan 10, 2020	May	DISC
	@	75MG	A212280	003	Jan 10, 2020	May	DISC
	@	100MG	A212280	004	Jan 10, 2020	May	DISC
	@	150MG	A212280	005	Jan 10, 2020	May	DISC
	@	200MG	A212280	006	Jan 10, 2020	May	DISC
	@	225MG	A212280	007	Jan 10, 2020	May	DISC
	@	300MG	A212280	008	Jan 10, 2020	May	DISC
AB	INDOCO	25MG	A208113	001	May 17, 2024	May	NEWA
AB		50MG	A208113	002	May 17, 2024	May	NEWA
AB		75MG	A208113	004	May 17, 2024	May	NEWA
AB		100MG	A208113	005	May 17, 2024	May	NEWA
AB		150MG	A208113	003	May 17, 2024	May	NEWA
AB		200MG	A208113	006	May 17, 2024	May	NEWA
AB		225MG	A208113	007	May 17, 2024	May	NEWA
AB		300MG	A208113	008	May 17, 2024	May	NEWA
	@ STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jul	DISC
AB		25MG	A209883	001	Jan 24, 2024	Jan	NEWA
	@	50MG	A209883	002	Jan 24, 2024	Jul	DISC
AB		50MG	A209883	002	Jan 24, 2024	Jan	NEWA
	@	75MG	A209883	003	Jan 24, 2024	Jul	DISC
AB		75MG	A209883	003	Jan 24, 2024	Jan	NEWA
	@	100MG	A209883	004	Jan 24, 2024	Jul	DISC
AB		100MG	A209883	004	Jan 24, 2024	Jan	NEWA
	@	150MG	A209883	005	Jan 24, 2024	Jul	DISC
AB		150MG	A209883	005	Jan 24, 2024	Jan	NEWA
	@	200MG	A209883	006	Jan 24, 2024	Jul	DISC
AB		200MG	A209883	006	Jan 24, 2024	Jan	NEWA
	@	225MG	A209883	007	Jan 24, 2024	Jul	DISC
AB		225MG	A209883	007	Jan 24, 2024	Jan	NEWA
	@	300MG	A209883	008	Jan 24, 2024	Jul	DISC
AB		300MG	A209883	008	Jan 24, 2024	Jan	NEWA
	@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC



		CAPSULE;ORAL							
		PREGABALIN							
	@	50MG	A091157	002	Nov 29, 2019	Jan	DISC		
	@	75MG	A091157	003	Nov 29, 2019	Jan	DISC		
	@	100MG	A091157	004	Nov 29, 2019	Jan	DISC		
	@	150MG	A091157	005	Nov 29, 2019	Jan	DISC		
	@	200MG	A091157	006	Nov 29, 2019	Jan	DISC		
	@	225MG	A091157	007	Nov 29, 2019	Jan	DISC		
	@	300MG	A091157	008	Nov 29, 2019	Jan	DISC		
	@ TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Aug	DISC		
	@	50MG	A091219	002	Jul 19, 2019	Aug	DISC		
	@	75MG	A091224	001	Jul 19, 2019	Aug	DISC		
	@	100MG	A091224	002	Jul 19, 2019	Aug	DISC		
	@	150MG	A091224	003	Jul 19, 2019	Aug	DISC		
	@	200MG	A091224	004	Jul 19, 2019	Aug	DISC		
	@	225MG	A091224	005	Jul 19, 2019	Aug	DISC		
	@	300MG	A091224	006	Jul 19, 2019	Aug	DISC		
		SOLUTION;ORAL							
		PREGABALIN							
>A>	AA	ANDA REPOSITORY	20MG/ML	A212604	001	Feb 18, 2022	Sep	CAHN	
>D>	AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Sep	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		PREGABALIN							
	@	NORVIUM BIOSCIENCE	330MG	A211431	001	Jul 02, 2021	Jun	CAHN	
		<u>PRIMIDONE</u>							
		SUSPENSION;ORAL							
		MYSOLINE							
	+ @	FHTA	250MG/5ML	N010401	001		Jan	CAHN	
		TABLET;ORAL							
		PRIMIDONE							
AB		CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA	
AB			250MG	A218366	002	Jan 23, 2024	Jan	NEWA	
		<u>PROCAINAMIDE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		PROCAINAMIDE HYDROCHLORIDE							
AP		GLAND PHARMA LTD	100MG/ML	A218135	001	Jul 22, 2024	Jul	NEWA	
AP			500MG/ML	A218135	002	Jul 22, 2024	Jul	NEWA	
	@	HIKMA	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN	
		<u>PROCHLORPERAZINE EDISYLATE</u>							
		INJECTABLE;INJECTION							
		PROCHLORPERAZINE EDISYLATE							
	@	HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Jul	DISC	
>A>	AP	SOMERSET THERAPS LLC	EQ 5MG BASE/ML	A212257	001	Sep 13, 2024	Sep	NEWA	
		<u>PROCHLORPERAZINE MALEATE</u>							
		TABLET;ORAL							
		PROCHLORPERAZINE MALEATE							
AB		AJANTA PHARMA LTD	EQ 5MG BASE	A218515	001	May 09, 2024	Apr	NEWA	
AB			EQ 10MG BASE	A218515	002	May 09, 2024	Apr	NEWA	
>A>	AB	LEADING	EQ 5MG BASE	A218912	001	Sep 30, 2024	Sep	NEWA	
>A>	AB		EQ 10MG BASE	A218912	002	Sep 30, 2024	Sep	NEWA	
		<u>PROGESTERONE</u>							
		INJECTABLE;INJECTION							
		PROGESTERONE							
	@	ACCORD HLTHCARE	50MG/ML	A217707	001	Nov 21, 2023	Jul	DISC	
		<u>PROMETHAZINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		PROMETHAZINE HYDROCHLORIDE							
AP	+!	HIKMA	25MG/ML	A083312	001		Jun	CAHN	
AP	+!		50MG/ML	A083312	002		Jun	CAHN	
		<u>PROPAFENONE HYDROCHLORIDE</u>							
		CAPSULE, EXTENDED RELEASE;ORAL							
		PROPAFENONE HYDROCHLORIDE							
AB		SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	May	CTEC	
AB			325MG	A210339	002	Jan 04, 2019	May	CTEC	
AB			425MG	A210339	003	Jan 04, 2019	May	CTEC	

## CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE							
	@ TWI PHARMS	225MG	A212928	001	Jun 18, 2020	Aug	DISC
AB		225MG	A212928	001	Jun 18, 2020	Mar	CAHN
	@	325MG	A212928	002	Jun 18, 2020	Aug	DISC
AB		325MG	A212928	002	Jun 18, 2020	Mar	CAHN
	@	425MG	A212928	003	Jun 18, 2020	Aug	DISC
AB		425MG	A212928	003	Jun 18, 2020	Mar	CAHN

## TABLET;ORAL

PROPAFENONE HYDROCHLORIDE							
	@ SUN PHARM INDUSTRIES	150MG	A075998	001	Nov 29, 2001	Jul	DISC
	@	225MG	A075998	002	Nov 29, 2001	Jul	DISC
	@	300MG	A075998	003	Nov 29, 2001	Jul	DISC

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC							
PROPARACAINE HYDROCHLORIDE							
AT	SOMERSET THERAPS LLC	0.5%	A215816	001	Aug 09, 2024	Aug	NEWA

PROPOFOL

INJECTABLE;INJECTION							
PROPOFOL							
AB	AMNEAL	10MG/ML	A217525	001	Aug 15, 2024	Aug	NEWA
AB	ASPIRO	10MG/ML	A217013	001	Jun 20, 2024	Jun	NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
PROPRANOLOL HYDROCHLORIDE							
	@ LUPIN LTD	60MG	A204349	001	Jan 12, 2024	Apr	DISC
AB		60MG	A204349	001	Jan 12, 2024	Jan	NEWA
	@	80MG	A204349	002	Jan 12, 2024	Apr	DISC
AB		80MG	A204349	002	Jan 12, 2024	Jan	NEWA
	@	120MG	A204349	003	Jan 12, 2024	Apr	DISC
AB		120MG	A204349	003	Jan 12, 2024	Jan	NEWA
	@	160MG	A204349	004	Jan 12, 2024	Apr	DISC
AB		160MG	A204349	004	Jan 12, 2024	Jan	NEWA
SOLUTION;ORAL							
HEMANGEOL							
+!	PIERRE FABRE	4.28MG/ML	N205410	001	Mar 14, 2014	May	CAHN
TABLET;ORAL							
PROPRANOLOL HYDROCHLORIDE							
	@ AIPING PHARM INC	90MG	A071288	001	Oct 22, 1986	Jul	CAHN
AB	ENDO OPERATIONS	10MG	A070221	002	Aug 01, 1986	Apr	CAHN
AB		20MG	A070221	003	Aug 01, 1986	Apr	CAHN
AB		40MG	A070221	004	Aug 01, 1986	Apr	CAHN
AB		60MG	A070221	005	Sep 24, 1986	Apr	CAHN
AB		80MG	A070221	001	Apr 14, 1986	Apr	CAHN

PROPYLTHIOURACIL

TABLET;ORAL							
PROPYLTHIOURACIL							
AB	+! ENDO OPERATIONS	50MG	N006188	001		Apr	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL							
CORPHED							
	@ CHARTWELL RX	60MG;2.5MG	A088602	001	Apr 11, 1985	Aug	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL							
PYRIDOSTIGMINE BROMIDE							
AB	ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD
AB	MLV	30MG	A211181	002	May 14, 2019	Mar	CAHN
AB		60MG	A211181	001	Jul 20, 2018	Mar	CAHN

PYRIMETHAMINE

TABLET;ORAL							
PYRIMETHAMINE							
>D>	AB CEROVENE INC	25MG	A207127	001	Feb 28, 2020	Sep	CAHN
>A>	AB SANALUZ	25MG	A207127	001	Feb 28, 2020	Sep	CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	IPCA LABS LTD	EQ 25MG BASE	A 205983	001	May 20, 2024	May	NEWA
AB		EQ 50MG BASE	A 205983	002	May 20, 2024	May	NEWA
AB		EQ 100MG BASE	A 205983	003	May 20, 2024	May	NEWA
AB		EQ 200MG BASE	A 205983	004	May 20, 2024	May	NEWA
AB		EQ 300MG BASE	A 205983	005	May 20, 2024	May	NEWA
AB		EQ 400MG BASE	A 205983	006	May 20, 2024	May	NEWA
>D>	SANDOZ	EQ 25MG BASE	A 078679	001	Dec 14, 2012	Sep	DISC
>A>	@	EQ 25MG BASE	A 078679	001	Dec 14, 2012	Sep	DISC
>D>	AB	EQ 50MG BASE	A 078679	002	Dec 14, 2012	Sep	DISC
>A>	@	EQ 50MG BASE	A 078679	002	Dec 14, 2012	Sep	DISC
>D>	AB	EQ 100MG BASE	A 078679	003	Dec 14, 2012	Sep	DISC
>A>	@	EQ 100MG BASE	A 078679	003	Dec 14, 2012	Sep	DISC
>D>	AB	EQ 150MG BASE	A 078679	004	Dec 14, 2012	Sep	DISC
>A>	@	EQ 150MG BASE	A 078679	004	Dec 14, 2012	Sep	DISC
>D>	AB	EQ 200MG BASE	A 078679	005	Dec 14, 2012	Sep	DISC
>A>	@	EQ 200MG BASE	A 078679	005	Dec 14, 2012	Sep	DISC
>D>	AB	EQ 300MG BASE	A 078679	006	Dec 14, 2012	Sep	DISC
>A>	@	EQ 300MG BASE	A 078679	006	Dec 14, 2012	Sep	DISC
>D>	AB	EQ 400MG BASE	A 078679	007	Dec 14, 2012	Sep	DISC
>A>	@	EQ 400MG BASE	A 078679	007	Dec 14, 2012	Sep	DISC
>A>	AB	EQ 25MG BASE	A 090960	001	Mar 27, 2012	Sep	CAHN
>A>	AB	EQ 50MG BASE	A 090960	002	Mar 27, 2012	Sep	CAHN
>A>	AB	EQ 100MG BASE	A 090960	003	Mar 27, 2012	Sep	CAHN
>A>	AB	EQ 200MG BASE	A 090960	004	Mar 27, 2012	Sep	CAHN
>A>	AB	EQ 300MG BASE	A 090960	005	Mar 27, 2012	Sep	CAHN
>A>	AB	EQ 400MG BASE	A 090960	006	Mar 27, 2012	Sep	CAHN
>D>	AB	EQ 25MG BASE	A 090960	001	Mar 27, 2012	Sep	CAHN
>D>	AB	EQ 50MG BASE	A 090960	002	Mar 27, 2012	Sep	CAHN
>D>	AB	EQ 100MG BASE	A 090960	003	Mar 27, 2012	Sep	CAHN
>D>	AB	EQ 200MG BASE	A 090960	004	Mar 27, 2012	Sep	CAHN
>D>	AB	EQ 300MG BASE	A 090960	005	Mar 27, 2012	Sep	CAHN
>D>	AB	EQ 400MG BASE	A 090960	006	Mar 27, 2012	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

@	ENDO OPERATIONS	EQ 50MG BASE	A 090482	001	May 09, 2017	May	CAHN
@		EQ 150MG BASE	A 090482	002	May 09, 2017	May	CAHN
@		EQ 150MG BASE	A 090757	001	Dec 01, 2017	May	CAHN
@		EQ 200MG BASE	A 090482	003	May 09, 2017	May	CAHN
@		EQ 200MG BASE	A 090757	002	Dec 01, 2017	May	CAHN
@		EQ 300MG BASE	A 090482	004	May 09, 2017	May	CAHN
@		EQ 300MG BASE	A 090757	003	Dec 01, 2017	May	CAHN
@		EQ 400MG BASE	A 090482	005	May 09, 2017	May	CAHN
@		EQ 400MG BASE	A 090757	004	Dec 01, 2017	May	CAHN
@	PAR PHARM	EQ 50MG BASE	A 090482	001	May 09, 2017	Feb	DISC
@		EQ 150MG BASE	A 090482	002	May 09, 2017	Feb	DISC
@		EQ 200MG BASE	A 090482	003	May 09, 2017	Feb	DISC
@		EQ 300MG BASE	A 090482	004	May 09, 2017	Feb	DISC
@		EQ 400MG BASE	A 090482	005	May 09, 2017	Feb	DISC
AB	PRINSTON INC	EQ 400MG BASE	A 208781	005	Mar 11, 2024	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB	CHARTWELL RX	EQ 5MG BASE	A 076803	001	Mar 02, 2005	Jul	CMFD
AB		EQ 10MG BASE	A 076803	002	Mar 02, 2005	Jul	CMFD
AB		EQ 20MG BASE	A 076803	003	Mar 02, 2005	Jul	CMFD
AB		EQ 40MG BASE	A 076803	004	Mar 02, 2005	Jul	CMFD
@	INVAGEN PHARMS	EQ 5MG BASE	A 078457	001	Aug 24, 2007	Mar	DISC
@		EQ 10MG BASE	A 078457	002	Aug 24, 2007	Mar	DISC
@		EQ 20MG BASE	A 078457	003	Aug 24, 2007	Mar	DISC
@		EQ 40MG BASE	A 078457	004	Aug 24, 2007	Mar	DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

>D>	AB	EYWA	324MG	A 212589	001	Sep 17, 2021	Sep	CAHN
>A>	AB	HIBROW HLTHCARE	324MG	A 212589	001	Sep 17, 2021	Sep	CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

@ CHARTWELL RX 300MG A089839 001 Sep 29, 1988 Jul CAHN

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

+ @ SUN PHARM INDUSTRIES 324MG N021799 001 Aug 12, 2005 Aug DISC

AB ! QUININE SULFATE

NOVAST LABS 324MG A204372 001 Jul 22, 2015 Aug CHRS

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

+ @ WAYLIS THERAP 10MG N020973 001 May 29, 2002 Apr CAHN

AB +! 20MG N020973 002 Aug 19, 1999 Apr CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

AB ANDAS 5 HOLDING 8MG A215435 001 Aug 24, 2022 Aug CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ ACCORD HLTHCARE 1.25MG A202392 001 Apr 15, 2014 May DISC

@ 2.5MG A202392 002 Apr 15, 2014 May DISC

@ 5MG A202392 003 Apr 15, 2014 May DISC

@ 10MG A202392 004 Apr 15, 2014 May DISC

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ LANNETT CO INC EQ 15MG BASE/ML A091288 001 Dec 09, 2010 Mar DISC

@ PHARM ASSOC EQ 15MG BASE/ML A077405 001 Sep 21, 2007 Mar DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ ENDO OPERATIONS EQ 150MG BASE A075180 001 Jan 28, 1999 May CAHN

@ EQ 300MG BASE A075180 002 Jan 28, 1999 May CAHN

@ PAR PHARM EQ 150MG BASE A075180 001 Jan 28, 1999 Feb DISC

@ EQ 300MG BASE A075180 002 Jan 28, 1999 Feb DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

+ @ SPIL 500MG N216018 001 Feb 28, 2022 Aug DISC

+ @ 1GM N216018 002 Feb 28, 2022 Aug DISC

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

>A> AB ALLIED 500MG A213517 001 Apr 27, 2022 Sep CAHN

>A> AB 1GM A213517 002 Apr 27, 2022 Sep CAHN

>D> AB I3 PHARMS 500MG A213517 001 Apr 27, 2022 Sep CAHN

>D> AB 1GM A213517 002 Apr 27, 2022 Sep CAHN

@ PIRAMAL 500MG A213085 001 Jul 25, 2023 Jan DISC

@ 1GM A213085 002 Jul 25, 2023 Jan DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>D> @ CARNEGIE EQ 0.5MG BASE A201942 001 Nov 18, 2021 Sep CAHN

>D> @ EQ 1MG BASE A201942 002 Nov 18, 2021 Sep CAHN

AB MACLEODS PHARMS LTD EQ 0.5MG BASE A208866 001 Jun 28, 2024 Jun NEWA

AB EQ 1MG BASE A208866 002 Jun 28, 2024 Jun NEWA

>A> @ RYAN LABS EQ 0.5MG BASE A201942 001 Nov 18, 2021 Sep CAHN

>A> @ EQ 1MG BASE A201942 002 Nov 18, 2021 Sep CAHN

AB SKG PHARMA EQ 0.5MG BASE A218163 001 Apr 09, 2024 Mar NEWA

AB EQ 1MG BASE A218163 002 Apr 09, 2024 Mar NEWA

REGADENOSONSOLUTION; INTRAVENOUS  
REGADENOSON

AP	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Jul	NEWA
AP	INDIES PHARMA	0.4MG/5ML (0.08MG/ML)	A218054	001	Aug 22, 2024	Aug	NEWA

REMIFENTANIL HYDROCHLORIDEINJECTABLE; INJECTION  
REMIFENTANIL HYDROCHLORIDE

AP	NIVAGEN PHARMS INC	EQ 1MG BASE/VIAL	A215635	001	Jun 28, 2024	Jun	NEWA
AP		EQ 2MG BASE/VIAL	A215635	002	Jun 28, 2024	Jun	NEWA
AP		EQ 5MG BASE/VIAL	A215635	003	Jun 28, 2024	Jun	NEWA

REPOTRECTINIBCAPSULE; ORAL  
AUGTYRO

+	BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul	NEWA
---	---------	-------	---------	-----	--------------	-----	------

RESMETIROMTABLET; ORAL  
REZDIFFRA

+	MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA
+		80MG	N217785	002	Mar 14, 2024	Mar	NEWA
+	!	100MG	N217785	003	Mar 14, 2024	Mar	NEWA

RETAPAMULINOINTMENT; TOPICAL  
ALTABAX

+	@ ALMIRALL	1%	N022055	001	Apr 12, 2007	May	DISC
---	------------	----	---------	-----	--------------	-----	------

REZAFUNGIN ACETATEPOWDER; INTRAVENOUS  
REZZAYO

+	!	MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN
---	---	-------------	--------------------	---------	-----	--------------	-----	------

RIFAMPINCAPSULE; ORAL  
RIFAMPIN

@	HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC
@		300MG	A065028	002	Mar 14, 2001	Mar	DISC

RILPIVIRINE HYDROCHLORIDETABLET, FOR SUSPENSION; ORAL  
EDURANT PED

+	@	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Aug	DISC
+	!		EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA

>D> RILUZOLE>D> FILM; ORAL  
>D> EXSERVAN

>D>	+	!	AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Sep	DISC
>A>	+	@		50MG	N212640	001	Nov 22, 2019	Sep	DISC

SUSPENSION; ORAL  
RILUZOLE

AB	ALKEM LABS LTD	50MG/10ML	A216035	001	Aug 22, 2024	Aug	NFTG
----	----------------	-----------	---------	-----	--------------	-----	------

AB	+	!	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Aug	CFTG
----	---	---	----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL  
RILUTEK

+	@	COVIS	50MG	N020599	001	Dec 12, 1995	May	DISC
---	---	-------	------	---------	-----	--------------	-----	------

AB	!	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	May	CHRS
----	---	----------------	------	---------	-----	--------------	-----	------

RISEDRONATE SODIUMTABLET; ORAL  
RISEDRONATE SODIUM

BX	AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Jun	CTEC
----	------------------	-------	---------	-----	--------------	-----	------

RISPERIDONEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
RYKINDO

>D>	+	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Sep CHRS
>A>	+		12.5MG	N212849	001	Jan 13, 2023	Sep CHRS
>D>	+		37.5MG	N212849	003	Jan 13, 2023	Sep CHRS
>A>	+		37.5MG	N212849	003	Jan 13, 2023	Sep CHRS
>D>	+		50MG	N212849	004	Jan 13, 2023	Sep CHRS
>A>	+		50MG	N212849	004	Jan 13, 2023	Sep CHRS

INJECTABLE; INTRAMUSCULAR  
RISPERDAL CONSTA

AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan CMS1
AB	+		25MG/VIAL	N021346	001	Oct 29, 2003	Jan CMS1
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan CMS1
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan CMS1

RISPERIDONE

AB		TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan CMS1
AB			25MG/VIAL	A214068	002	Dec 05, 2023	Jan CMS1
AB			37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan CMS1
AB			50MG/VIAL	A214068	004	Dec 05, 2023	Jan CMS1

SOLUTION; ORAL

RISPERIDONE

>D>	@	APOZEAL PHARMS	1MG/ML	A078909	001	Jul 29, 2009	Sep CAHN
	@	HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar DISC
	@	PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb DISC
>A>	@	SCIEGEN PHARMS INC	1MG/ML	A078909	001	Jul 29, 2009	Sep CAHN

TABLET; ORAL

RISPERIDONE

AB		ALLIED	0.25MG	A078871	001	Oct 09, 2008	Jul CAHN
AB			0.5MG	A078871	002	Oct 09, 2008	Jul CAHN
AB			1MG	A078871	003	Oct 09, 2008	Jul CAHN
AB			2MG	A078871	004	Oct 09, 2008	Jul CAHN
AB			3MG	A078871	005	Oct 09, 2008	Jul CAHN
AB			4MG	A078871	006	Oct 09, 2008	Jul CAHN
AB		IPCA LABS LTD	0.25MG	A205104	001	Jun 26, 2024	Jun NEWA
AB			0.5MG	A205104	002	Jun 26, 2024	Jun NEWA
AB			1MG	A205104	003	Jun 26, 2024	Jun NEWA
AB			2MG	A205104	004	Jun 26, 2024	Jun NEWA
AB			3MG	A205104	005	Jun 26, 2024	Jun NEWA
AB			4MG	A205104	006	Jun 26, 2024	Jun NEWA
AB		NOVITIUM PHARMA	0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
AB			0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
AB			1MG	A078871	003	Oct 09, 2008	Aug CAHN
AB			2MG	A078871	004	Oct 09, 2008	Aug CAHN
AB			3MG	A078871	005	Oct 09, 2008	Aug CAHN
AB			4MG	A078871	006	Oct 09, 2008	Aug CAHN
AB		RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
AB			0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
AB			1MG	A078707	003	Dec 29, 2008	Feb CAHN
AB			2MG	A078707	004	Dec 29, 2008	Feb CAHN
AB			3MG	A078707	005	Dec 29, 2008	Feb CAHN
AB			4MG	A078707	006	Dec 29, 2008	Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

		ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr CAHN
AB			0.5MG	A077494	002	Apr 30, 2009	Apr CAHN
AB			1MG	A077494	003	Oct 26, 2009	Apr CAHN
AB			2MG	A077494	004	Apr 30, 2009	Apr CAHN
AB			3MG	A077494	005	Apr 30, 2009	Apr CAHN
AB			4MG	A077494	006	Apr 30, 2009	Apr CAHN

RIVASTIGMINE TARTRATE

SOLUTION; ORAL

EXELON

+	@	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr CRLD
---	---	----------	----------------	---------	-----	--------------	----------

RIZATRIPTAN BENZOATE

FILM; ORAL

RIZAFILM

+ @ GENSCO EQ 10MG BASE N205394 001 Apr 14, 2023 Jun DISC

TABLET; ORAL

RIZATRIPTAN BENZOATE

@ GLENMARK PHARMS LTD EQ 5MG BASE A201967 001 Dec 31, 2012 Aug DISC

@ EQ 10MG BASE A201967 002 Dec 31, 2012 Aug DISC

@ INVAGEN PHARMS EQ 5MG BASE A204339 001 Jul 01, 2013 Apr DISC

@ EQ 10MG BASE A204339 002 Jul 01, 2013 Apr DISC

@ NATCO PHARMA LTD EQ 5MG BASE A200482 001 Dec 31, 2012 Aug DISC

@ EQ 10MG BASE A200482 002 Dec 31, 2012 Aug DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RIZATRIPTAN BENZOATE

@ GLENMARK PHARMS LTD EQ 5MG BASE A201914 001 Jul 01, 2013 Aug DISC

@ EQ 10MG BASE A201914 002 Jul 01, 2013 Aug DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP @ HIKMA 50MG/5ML (10MG/ML) A217034 001 May 24, 2023 Jul DISC

AP SHANDONG 50MG/5ML (10MG/ML) A215684 001 Jul 12, 2024 Jul NEWA

AP 100MG/10ML (10MG/ML) A215684 002 Jul 12, 2024 Jul NEWA

AP STERISCIENCE 50MG/5ML (10MG/ML) A217092 001 Jul 22, 2024 Jul NEWA

ROFLUMILAST

CREAM; TOPICAL

ZORYVE

+! ARCUTIS 0.15% N215985 002 Jul 09, 2024 Jul NEWA

TABLET; ORAL

ROFLUMILAST

@ BRECKENRIDGE 250MCG A208236 002 Oct 19, 2023 Jul DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP CAPLIN 200MG/100ML (2MG/ML) A212808 005 May 23, 2024 May NEWA

AP 400MG/200ML (2MG/ML) A212808 006 May 23, 2024 May NEWA

AP HIKMA 200MG/100ML (2MG/ML) A211907 001 Aug 15, 2024 Aug NEWA

AP 400MG/200ML (2MG/ML) A211907 002 Aug 15, 2024 Aug NEWA

AP 500MG/100ML (5MG/ML) A211907 003 Aug 15, 2024 Aug NEWA

@ HOSPIRA 20MG/10ML (2MG/ML) A090194 001 Sep 23, 2014 May DISC

@ 40MG/20ML (2MG/ML) A090194 005 Sep 23, 2014 May DISC

@ 100MG/10ML (10MG/ML) A090194 004 Sep 23, 2014 May DISC

@ 150MG/30ML (5MG/ML) A090194 002 Sep 23, 2014 May DISC

@ 150MG/20ML (7.5MG/ML) A090194 003 Sep 23, 2014 May DISC

@ 200MG/20ML (10MG/ML) A090194 006 Sep 23, 2014 May DISC

AP KINDOS 20MG/10ML (2MG/ML) A218713 001 Jul 30, 2024 Jul NEWA

AP 40MG/20ML (2MG/ML) A218713 002 Jul 30, 2024 Jul NEWA

AP 100MG/20ML (5MG/ML) A218713 003 Jul 30, 2024 Jul NEWA

AP 100MG/10ML (10MG/ML) A218713 004 Jul 30, 2024 Jul NEWA

AP 150MG/30ML (5MG/ML) A218713 005 Jul 30, 2024 Jul NEWA

AP 150MG/20ML (7.5MG/ML) A218713 006 Jul 30, 2024 Jul NEWA

AP 200MG/20ML (10MG/ML) A218713 007 Jul 30, 2024 Jul NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

@ SANDOZ EQ 5MG BASE A079171 001 Jul 19, 2016 Jan DISC

@ EQ 10MG BASE A079171 002 Jul 19, 2016 Jan DISC

@ EQ 20MG BASE A079171 003 Jul 19, 2016 Jan DISC

@ EQ 40MG BASE A079171 004 Jul 19, 2016 Jan DISC

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+ PHARMAAND EQ 200MG BASE N209115 001 Dec 19, 2016 Jul CAHN

+ EQ 250MG BASE N209115 003 May 01, 2017 Jul CAHN

+! EQ 300MG BASE N209115 002 Dec 19, 2016 Jul CAHN

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL  
ENTRESTO SPRINKLE

	+	NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr	NEWA
	+	!	15MG; 16MG	N218591	002	Apr 12, 2024	Apr	NEWA

TABLET; ORAL  
ENTRESTO

AB	+	NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
AB	+		49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
AB	+	!	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG

SACUBITRIL AND VALSARTAN

AB		ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213682	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213682	003	May 28, 2024	May	NFTG
>A>	AB	ALKEM LABS LTD	24MG; 26MG	A213764	001	Sep 16, 2024	Sep	NEWA
>A>	AB		49MG; 51MG	A213764	002	Sep 16, 2024	Sep	NEWA
>A>	AB		97MG; 103MG	A213764	003	Sep 16, 2024	Sep	NEWA
AB		BIOCON PHARMA	24MG; 26MG	A213680	001	Aug 30, 2024	Aug	NEWA
AB			49MG; 51MG	A213680	002	Aug 30, 2024	Aug	NEWA
AB			97MG; 103MG	A213680	003	Aug 30, 2024	Aug	NEWA
AB		CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213605	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213605	003	May 28, 2024	May	NFTG
AB		LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213676	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213676	003	May 28, 2024	May	NFTG
AB		MSN	24MG; 26MG	A213748	001	Jul 24, 2024	Jul	NEWA
AB			49MG; 51MG	A213748	002	Jul 24, 2024	Jul	NEWA
AB			97MG; 103MG	A213748	003	Jul 24, 2024	Jul	NEWA
>D>	AB	TORRENT	24MG; 26MG	A213604	001	Aug 22, 2024	Sep	DISC
>A>		@	24MG; 26MG	A213604	001	Aug 22, 2024	Sep	DISC
AB			24MG; 26MG	A213604	001	Aug 22, 2024	Aug	NEWA
>D>	AB		49MG; 51MG	A213604	002	Aug 22, 2024	Sep	DISC
>A>		@	49MG; 51MG	A213604	002	Aug 22, 2024	Sep	DISC
AB			49MG; 51MG	A213604	002	Aug 22, 2024	Aug	NEWA
>D>	AB		97MG; 103MG	A213604	003	Aug 22, 2024	Sep	DISC
>A>		@	97MG; 103MG	A213604	003	Aug 22, 2024	Sep	DISC
AB			97MG; 103MG	A213604	003	Aug 22, 2024	Aug	NEWA
AB		ZYDUS PHARMS	24MG; 26MG	A213719	001	Jul 09, 2024	Jun	NEWA
AB			49MG; 51MG	A213719	002	Jul 09, 2024	Jun	NEWA
AB			97MG; 103MG	A213719	003	Jul 09, 2024	Jun	NEWA

SAFINAMIDE MESYLATE

TABLET; ORAL  
SAFINAMIDE MESYLATE

AB		PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr	NEWA
AB			EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr	NEWA
		XADAGO						
AB	+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC
AB	+	!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL  
SAXAGLIPTIN

	@	AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb	DISC
	@		EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb	DISC

SCOPOLAMINE

SYSTEM; TRANSDERMAL  
SCOPOLAMINE

AB		RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr	NEWA
AB		ZYDUS PHARMS	1MG/72HR	A217893	001	Aug 29, 2024	Aug	NEWA

SECNIDAZOLE

GRANULE; ORAL  
SOLOSEC

>A>	+	EVOFEM INC	2GM/PACKET	N209363	001	Sep 15, 2017	Sep	CAHN
>D>	+	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017	Sep	CAHN



SELADELPAR LYSINE

CAPSULE;ORAL

LIVDELZI

>D>	+	CYMABAY	EQ 10MG BASE	N217899	001	Aug 14, 2024	Sep CAHN
	+		EQ 10MG BASE	N217899	001	Aug 14, 2024	Aug NEWA
>A>	+	GILEAD SCIENCES INC	EQ 10MG BASE	N217899	001	Aug 14, 2024	Sep CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

ELDEPRYL

	+	@ NORVIUM BIOSCIENCE	5MG	N020647	001	May 15, 1996	Aug CAHN
--	---	----------------------	-----	---------	-----	--------------	----------

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

>D>	AB	I3 PHARMS	5MG	A074672	001	Apr 01, 1997	Sep CAHN
		@ KENTON	5MG	A074912	001	Apr 30, 1998	May CAHN
>A>	AB	MLV	5MG	A074672	001	Apr 01, 1997	Sep CAHN
		+ @ NORVIUM BIOSCIENCE	5MG	N019334	001	Jun 05, 1989	Aug CAHN

SELEXIPAG

TABLET;ORAL

SELEXIPAG

	@	ZYDUS LIFESCIENCES	0.2MG	A214302	001	Dec 21, 2022	May CAHN
	@		0.4MG	A214302	002	Dec 21, 2022	May CAHN
	@		0.6MG	A214302	003	Dec 21, 2022	May CAHN
	@		0.8MG	A214302	004	Dec 21, 2022	May CAHN
	@		1MG	A214302	005	Dec 21, 2022	May CAHN
	@		1.2MG	A214302	006	Dec 21, 2022	May CAHN
	@		1.4MG	A214302	007	Dec 21, 2022	May CAHN
	@		1.6MG	A214302	008	Dec 21, 2022	May CAHN

SELPERCATINIB

TABLET;ORAL

RETEVMO

	+	LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr NEWA
	+		80MG	N218160	002	Apr 10, 2024	Apr NEWA
	+		120MG	N218160	003	Apr 10, 2024	Apr NEWA
	+		160MG	N218160	004	Apr 10, 2024	Apr NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	May CAHN
	@		EQ 50MG BASE	A077713	002	Feb 06, 2007	May CAHN
	@		EQ 100MG BASE	A077713	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB		INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jul NEWA
AB			2.4GM/PACKET	A206234	002	Jul 12, 2024	Jul NEWA
AB		MACLEODS PHARMS LTD	800MG/PACKET	A207291	001	Apr 25, 2024	Apr NEWA
AB			2.4GM/PACKET	A207291	002	Apr 25, 2024	Apr NEWA

TABLET;ORAL

SEVELAMER CARBONATE

	@	ANXIN	800MG	A212970	001	Apr 09, 2020	Apr DISC
	@	SINOTHERAPEUTICS INC	800MG	A212970	001	Apr 09, 2020	Aug CAHN
AB		STRIDES PHARMA	800MG	A211915	001	May 09, 2024	May NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

>D>	AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Sep CAHN
>D>	AB	APTAPHARMA INC	EQ 10MG BASE/ML	A213041	001	Aug 06, 2020	Sep CAHN
>A>	AB	INVAGEN PHARMS	EQ 10MG BASE/ML	A213041	001	Aug 06, 2020	Sep CAHN
>A>	AB	SOMERSET THERAPS LLC	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Sep CAHN

SUSPENSION;ORAL

LIQREV

	+	@ CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023	Jul DISC
--	---	---------------	-----------------	---------	-----	--------------	----------

## TABLET;ORAL

SILDENAFIL CITRATE							
	@ MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012	Apr	DISC
BX	UMEDICA	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun	CTEC
BX		EQ 50MG BASE	A209302	001	Aug 25, 2020	Jun	CTEC
BX		EQ 100MG BASE	A209302	002	Aug 25, 2020	Jun	CTEC

SILODOSIN

SILODOSIN							
AB	CHARTWELL RX	4MG	A204726	001	Mar 31, 2017	Mar	CAHN
AB		8MG	A204726	002	Mar 31, 2017	Mar	CAHN

SILVER SULFADIAZINE

SSD							
AB	+! DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan	CRLD
AB	!	1%	N018578	001	Feb 25, 1982	Jan	CHRS

SIMVASTATIN

FLOLIPID							
	+ SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN
	+!	40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN

SINCALIDE

KINEVAC							
AP	+! BRACCO	0.005MG/VIAL	N017697	001		May	CTEC
POWDER; INTRAVENOUS							
KINEVAC							
AP	+! BRACCO	0.005MG/VIAL	N017697	001		May	CDFR
SINCALIDE							
AP	+! MAIA PHARMS INC	0.005MG/VIAL	N210850	001	Nov 22, 2022	May	CTEC

SIROLIMUS

SIROLIMUS							
>A> AA	HETERO LABS LTD V	1MG/ML	A215080	001	Sep 16, 2024	Sep	NEWA

SODIUM ACETATE

SODIUM ACETATE							
AP	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CPOT
AP	MILLA PHARMS	400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CPOT
SOLUTION; INTRAVENOUS							
SODIUM ACETATE							
AP	! FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CDFR
AP	HIKMA	40MEQ/20ML (2MEQ/ML)	A216920	001	Mar 15, 2024	Mar	NEWA
AP		100MEQ/50ML (2MEQ/ML)	A216920	002	Mar 15, 2024	Mar	NEWA
AP		200MEQ/100ML (2MEQ/ML)	A216920	003	Mar 15, 2024	Mar	NEWA
AP	+! HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar	CDFR
AP	+!	40MEQ/20ML (2MEQ/ML)	N018893	001	May 04, 1983	Mar	CPOT
AP	+!	100MEQ/50ML (2MEQ/ML)	N018893	002	Sep 02, 2014	Mar	CMS1
AP	+!	200MEQ/100ML (2MEQ/ML)	N018893	003	Sep 02, 2014	Mar	CMS1
AP	MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar	CDFR
AP		40MEQ/20ML (2MEQ/ML)	A214805	004	Jan 22, 2024	Mar	CMS1
AP		100MEQ/50ML (2MEQ/ML)	A214805	001	May 04, 2021	Mar	CPOT
AP		200MEQ/100ML (2MEQ/ML)	A214805	003	May 04, 2021	Mar	CMS1
AP		400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CDFR

SODIUM BENZOATE; SODIUM PHENYLACETATE

AMMONUL							
	+ @ BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul	DISC
SODIUM PHENYLACETATE AND SODIUM BENZOATE							
AP	! AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CHRS

SODIUM BICARBONATEINJECTABLE; INJECTION  
SODIUM BICARBONATE

AP	LONG GROVE PHARMS	1MEQ/ML	A216042	001	Feb 27, 2024	Jun	CAHN
AP	NIVAGEN PHARMS INC	1MEQ/ML	A216042	001	Feb 27, 2024	Feb	NEWA
AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Apr	CMFD
	@	1MEQ/ML	A217594	001	Jun 28, 2023	Jan	DISC

SODIUM CHLORIDESOLUTION; INJECTION  
SODIUM CHLORIDE 0.9%  
@ HIKMA

90MG/10ML (9MG/ML)

A201850 001 Jan 20, 2012 Mar DISC

SOLUTION; IRRIGATION  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	FRESENIUS KABI USA	900MG/100ML	A213688	001	Jun 24, 2024	Jun	NEWA
----	--------------------	-------------	---------	-----	--------------	-----	------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS  
SODIUM FLUORIDE F-18

AP	! PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015	Jan	CHRS
----	----------	--------------	---------	-----	--------------	-----	------

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION  
SODIUM NITROPRUSSIDE

>D>	AP	HAINAN POLY PHARM	25MG/ML	A214199	001	Aug 25, 2020	Sep	CAHN
>A>	AP	SLATE RUN PHARMA	25MG/ML	A214199	001	Aug 25, 2020	Sep	CAHN

SOLUTION; INTRAVENOUS  
SODIUM NITROPRUSSIDE

>D>		HAINAN POLY	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Sep	CAHN
>D>	AP		20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Sep	CAHN
>D>	AP		50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Sep	CAHN
>A>		SLATE RUN PHARMA	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Sep	CAHN
>A>	AP		20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Sep	CAHN
>A>	AP		50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Sep	CAHN

SODIUM PHENYL BUTYRATEPOWDER; ORAL  
SODIUM PHENYL BUTYRATE

AB	ENDO OPERATIONS	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Apr	CAHN
----	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL  
SODIUM PHENYL BUTYRATE

AB	ENDO OPERATIONS	500MG	A204395	001	Apr 15, 2016	Apr	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

>D>		INJECTABLE; INJECTION					
>D>		SODIUM PHOSPHATES					

>D>	AP	AM REGENT	142MG/ML; 276MG/ML	A218314	001	Jun 21, 2024	Sep	CPOT
	AP		142MG/ML; 276MG/ML	A218314	001	Jun 21, 2024	Jun	NEWA

>D>	AP	! FRESENIUS KABI USA	142MG/ML; 276MG/ML	A209997	001	Mar 30, 2022	Sep	CPOT
>D>		SODIUM PHOSPHATES IN PLASTIC CONTAINER						

>D>	AP	+! HOSPIRA	142MG/ML; 276MG/ML	N018892	001	May 10, 1983	Sep	CPOT
-----	----	------------	--------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS  
SODIUM PHOSPHATES

>A>	AP	AM REGENT	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A218314	001	Jun 21, 2024	Sep	CPOT
>A>	AP	! FRESENIUS KABI USA	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A209997	001	Mar 30, 2022	Sep	CPOT

SODIUM PHOSPHATES IN PLASTIC CONTAINER

>A>	AP	+! HOSPIRA	4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	N018892	001	May 10, 1983	Sep	CPOT
-----	----	------------	--	---------	-----	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

>A>		SOLUTION; INTRAVENOUS					
>A>		SODIUM PHOSPHATES					

>A>	AP	AM REGENT	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A218314	001	Jun 21, 2024	Sep	CAIN
-----	----	-----------	--	---------	-----	--------------	-----	------

>A>	AP		4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	A218314	002	Jun 21, 2024	Sep	NEWA
-----	----	--	--	---------	-----	--------------	-----	------

>A>	AP		13.4GM/50ML; 13.8GM/50ML (268MG/ML; 276MG/ML)	A218314	003	Jun 21, 2024	Sep	NEWA
-----	----	--	--	---------	-----	--------------	-----	------

>A>	AP	! FRESENIUS KABI USA	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A209997	001	Mar 30, 2022	Sep	CAIN
-----	----	----------------------	--	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS  
SODIUM PHOSPHATES

>A>	AP		4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)	A209997	002	Mar 30, 2022	Sep	NEWA
>A>	AP	!	13.4GM/50ML;13.8GM/50ML (268MG/ML;276MG/ML)	A209997	003	Mar 30, 2022	Sep	NEWA
>A>			SODIUM PHOSPHATES IN PLASTIC CONTAINER					
>A>	AP	+!	HOSPIRA 4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)	N018892	001	May 10, 1983	Sep	CAIN

SOPFIRONIUM BROMIDE

GEL, METERED;TOPICAL  
SOFDRA

+!	BOTANIX SB		EQ 12.45% BASE (EQ 72MG BASE/ACTUATION)	N217347	001	Jun 18, 2024	Jun	NEWA
----	------------	--	--	---------	-----	--------------	-----	------

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

>A>	AB		JUBILANT GENERICS	5MG	A205484	001	Oct 02, 2024	Sep	NEWA
>A>	AB			10MG	A205484	002	Oct 02, 2024	Sep	NEWA
	AB		MACLEODS PHARMS LTD	5MG	A204374	001	Feb 20, 2024	Feb	NEWA
	AB			10MG	A204374	002	Feb 20, 2024	Feb	NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

@	RISING			80MG	A075725	001	Dec 19, 2000	Feb	CAHN
@				120MG	A075725	002	Dec 19, 2000	Feb	CAHN
@				160MG	A075725	003	Dec 19, 2000	Feb	CAHN
@				240MG	A075725	004	Dec 19, 2000	Feb	CAHN

SOTORASIB

TABLET;ORAL

LUMAKRAS

+	AMGEN INC			240MG	N214665	003	Jun 26, 2024	Jul	NEWA
---	-----------	--	--	-------	---------	-----	--------------	-----	------

SOYBEAN OIL

INJECTABLE;INJECTION

NUTRILIPID 10%

+	@ B BRAUN			10%	N019531	001	May 28, 1993	Jul	DISC
---	-----------	--	--	-----	---------	-----	--------------	-----	------

SPINOSAD

SUSPENSION;TOPICAL

NATROBA

+!	CIPHER			0.9%	N022408	001	Jan 18, 2011	Aug	CAHN
----	--------	--	--	------	---------	-----	--------------	-----	------

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	AM REGENT			100% (5ML)	A217341	003	Feb 09, 2024	Feb	NEWA
----	-----------	--	--	------------	---------	-----	--------------	-----	------

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER FOR IRRIGATION

AT	FRESENIUS KABI USA			100%	A216123	001	Aug 12, 2024	Aug	NFTG
----	--------------------	--	--	------	---------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

	@	ACCORD HLTHCARE		20MG/ML	A213705	001	May 20, 2020	May	DISC
AP		ADAPTIS		20MG/ML	A214308	001	May 22, 2020	Aug	CAHN
>A>	AP	BAXTER HLTHCARE CORP		20MG/ML	A218878	001	Sep 24, 2024	Sep	NEWA
	@	EUGIA PHARMA		20MG/ML	A217808	001	Oct 16, 2023	Apr	DISC
AP		NIVAGEN PHARMS INC		20MG/ML	A211625	001	May 19, 2020	Jan	CAHN
AP		UMEDICA		20MG/ML	A211625	001	May 19, 2020	Aug	CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

AP		DR REDDYS		100MG/5ML (20MG/ML)	A218467	001	Jan 17, 2024	Jan	NEWA
AP	+!	HIKMA		100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Jan	CFTG
AP		STERISCIENCE		100MG/5ML (20MG/ML)	A217873	001	Jul 09, 2024	Jun	NEWA

SUCRALFATESUSPENSION; ORAL  
SUCRALFATE

AB	ABON PHARMS LLC	1GM/10ML	A216726	001	Mar 21, 2024	Mar	NEWA
AB	HIKMA	1GM/10ML	A212769	001	Jul 23, 2024	Jul	NEWA
AB	PD PARTNERS	1GM/10ML	A213549	001	Jan 17, 2024	Jan	NEWA
AB	STRIDES PHARMA	1GM/10ML	A216474	001	May 21, 2024	May	NEWA
AB	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Apr	CAHN

SUGAMMADEX SODIUMSOLUTION; INTRAVENOUS  
SUGAMMADEX SODIUM

	@ ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Mar	DISC
	@	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Mar	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIMSUSPENSION; ORAL  
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	! AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	A091348	001	Jun 08, 2010	Mar	CHRS
	@ HIKMA	200MG/5ML; 40MG/5ML	A074650	001	Dec 29, 1997	Mar	DISC

SULFANILAMIDECREAM; VAGINAL  
AVC

+ @ NORVIUM BIOSCIENCE 15% N006530 003 Jan 27, 1987 Jun CAHN

SUPPOSITORY; VAGINAL  
AVC

@ NORVIUM BIOSCIENCE 1.05GM N006530 004 Jan 27, 1987 Jun CAHN

SUMATRIPTANSPRAY; NASAL  
SUMATRIPTAN

>A>	AB	ADAPTIS	20MG/SPRAY	A208967	001	Feb 17, 2021	Sep	CAHN
>D>	AB	FLORIDA	20MG/SPRAY	A208967	001	Feb 17, 2021	Sep	CAHN

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

AP	CAPLIN	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213998	001	Jul 13, 2021	Jun	CAHN
	@ ENDO OPERATIONS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	May	CAHN
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	May	CAHN
AP	! EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Jan	CHRS
	@ PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb	DISC
	SUMAVEL DOSEPRO						
	+ @ ENDO OPERATIONS	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May	CAHN
	+ @	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	May	CAHN

SUNITINIB MALATECAPSULE; ORAL  
SUNITINIB MALATE

AB	EUGIA PHARMA	EQ 12.5MG BASE	A218615	001	Mar 14, 2024	Mar	NEWA
AB		EQ 25MG BASE	A218615	002	Mar 14, 2024	Mar	NEWA
AB		EQ 37.5MG BASE	A218615	003	Mar 14, 2024	Mar	NEWA
AB		EQ 50MG BASE	A218615	004	Mar 14, 2024	Mar	NEWA
AB	NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	May	CMFD
	@	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb	DISC
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	May	CMFD
	@	EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb	DISC
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	May	CMFD
	@	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb	DISC
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	May	CMFD
	@	EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb	DISC
AB	WANBANG BIOPHARMS	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Aug	CAHN
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Aug	CAHN
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Aug	CAHN

CAPSULE;ORAL  
SUNITINIB MALATE

AB EQ 50MG BASE A218012 004 Aug 21, 2023 Aug CAHN

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL  
ASTAGRAF XL

AB + ASTELLAS EQ 0.5MG BASE N204096 001 Jul 19, 2013 Jan CFTG  
 AB + EQ 1MG BASE N204096 002 Jul 19, 2013 Jan CFTG  
 AB +! EQ 5MG BASE N204096 003 Jul 19, 2013 Jan CFTG

TACROLIMUS  
 AB CHENGDU EQ 0.5MG BASE A215012 001 Jan 25, 2024 Jan NFTG  
 AB EQ 1MG BASE A215012 002 Jan 25, 2024 Jan NFTG  
 AB EQ 5MG BASE A215012 003 Jan 25, 2024 Jan NFTG

TADALAFIL

TABLET;ORAL  
CIALIS

>D> AB1 + LILLY 2.5MG N021368 004 Jan 07, 2008 Sep DISC  
 >A> + @ 2.5MG N021368 004 Jan 07, 2008 Sep DISC

TADALAFIL

>D> AB1 FOURRTS LABS 2.5MG A217606 001 Aug 13, 2024 Sep CAHN  
 AB1 2.5MG A217606 001 Aug 13, 2024 Aug NEWA  
 >D> AB1 5MG A217606 002 Aug 13, 2024 Sep CAHN  
 AB1 5MG A217606 002 Aug 13, 2024 Aug NEWA  
 >D> AB1 10MG A217606 003 Aug 13, 2024 Sep CAHN  
 AB1 10MG A217606 003 Aug 13, 2024 Aug NEWA  
 >D> AB1 20MG A217606 004 Aug 13, 2024 Sep CAHN  
 AB1 20MG A217606 004 Aug 13, 2024 Aug NEWA  
 AB1 HANGZHOU BINJIANG 2.5MG A208824 001 Oct 27, 2020 Mar CAHN  
 AB1 5MG A208824 002 Oct 27, 2020 Mar CAHN  
 AB1 10MG A208824 003 Oct 27, 2020 Mar CAHN  
 AB1 20MG A208824 004 Oct 27, 2020 Mar CAHN  
 >A> AB1 HIBROW HLTHCARE 2.5MG A217606 001 Aug 13, 2024 Sep CAHN  
 >A> AB1 5MG A217606 002 Aug 13, 2024 Sep CAHN  
 >A> AB1 10MG A217606 003 Aug 13, 2024 Sep CAHN  
 >A> AB1 20MG A217606 004 Aug 13, 2024 Sep CAHN  
 AB1 SHANDONG 20MG A216279 001 Mar 04, 2024 Feb NEWA  
 BX UMEDICA 2.5MG A211298 001 Oct 23, 2020 Jun CTEC  
 BX 5MG A211298 002 Oct 23, 2020 Jun CTEC  
 BX 10MG A211298 003 Oct 23, 2020 Jun CTEC  
 BX 20MG A211298 004 Oct 23, 2020 Jun CTEC

TABLET, CHEWABLE;ORAL  
CHEWTADZY

+ @ B BETTER 5MG N218527 001 Jun 28, 2024 Aug DISC  
 + 5MG N218527 001 Jun 28, 2024 Jun NEWA  
 + @ 10MG N218527 002 Jun 28, 2024 Aug DISC  
 + 10MG N218527 002 Jun 28, 2024 Jun NEWA  
 + @ 20MG N218527 003 Jun 28, 2024 Aug DISC  
 +! 20MG N218527 003 Jun 28, 2024 Jun NEWA

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC  
TAFLUPROST

@ INGENUS PHARMS LLC 0.0015% A218002 001 Apr 05, 2024 May DISC  
 AT 0.0015% A218002 001 Apr 05, 2024 Mar NEWA

TALAZOPARIB TOSYLATE

CAPSULE;ORAL  
TALZENNA

+ PFIZER EQ 0.1MG BASE N217439 001 Mar 07, 2024 Mar NEWA  
 + EQ 0.25MG BASE N217439 002 Mar 07, 2024 Mar NEWA  
 + EQ 0.35MG BASE N217439 003 Mar 07, 2024 Mar NEWA  
 + EQ 0.5MG BASE N217439 004 Mar 07, 2024 Mar NEWA  
 + EQ 0.75MG BASE N217439 005 Mar 07, 2024 Mar NEWA  
 +! EQ 1MG BASE N217439 006 Mar 07, 2024 Mar NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

@ ENDO OPERATIONS 0.4MG

A202010 001 Jan 04, 2013 May CAHN

@ NORVIUM BIOSCIENCE 0.4MG

A090408 001 Apr 27, 2010 Jul CAHN

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN

+ @ ANACOR PHARMS INC 5%

N204427 001 Jul 07, 2014 Mar DISC

TAVABOROLE

AB ! ENCUBE 5%

A211297 001 Oct 13, 2020 Mar CHRS

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

AB PADAGIS ISRAEL 0.05%

A217075 001 Jul 15, 2024 Jul NFTG

TAZORAC

AB +! ALLERGAN 0.05%

N021184 001 Sep 29, 2000 Jul CFTG

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVIEW

+! MEDI-PHYSICS N/A

N020372 001 Feb 09, 1996 Jun CAHN

MYOVIEW 30ML

+! MEDI-PHYSICS N/A

N020372 002 Jul 07, 2005 Jun CAHN

TEDUGLUTIDE

POWDER;SUBCUTANEOUS

GATTEX KIT

+! TAKEDA PHARMS USA 5MG/VIAL

N203441 001 Dec 21, 2012 Mar CAIN

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB CHARTWELL RX 15MG

A071427 001 Jan 12, 1988 Jan CAHN

AB 30MG

A071428 001 Jan 12, 1988 Jan CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB HETERO LABS LTD V 5MG

A210030 001 Aug 23, 2024 Aug NEWA

AB 20MG

A210030 002 Aug 23, 2024 Aug NEWA

AB 100MG

A210030 003 Aug 23, 2024 Aug NEWA

AB 140MG

A210030 004 Aug 23, 2024 Aug NEWA

AB 180MG

A210030 005 Aug 23, 2024 Aug NEWA

AB 250MG

A210030 006 Aug 23, 2024 Aug NEWA

>D> AB NIVAGEN PHARMS INC 5MG

A213328 001 Nov 23, 2021 Sep DISC

>A> @ 5MG

A213328 001 Nov 23, 2021 Sep DISC

>D> AB 20MG

A213328 002 Nov 23, 2021 Sep DISC

>A> @ 20MG

A213328 002 Nov 23, 2021 Sep DISC

>D> AB 100MG

A213328 003 Nov 23, 2021 Sep DISC

>A> @ 100MG

A213328 003 Nov 23, 2021 Sep DISC

>D> AB 140MG

A213328 004 Nov 23, 2021 Sep DISC

>A> @ 140MG

A213328 004 Nov 23, 2021 Sep DISC

>D> AB 180MG

A213328 005 Nov 23, 2021 Sep DISC

>A> @ 180MG

A213328 005 Nov 23, 2021 Sep DISC

>D> AB 250MG

A213328 006 Nov 23, 2021 Sep DISC

>A> @ 250MG

A213328 006 Nov 23, 2021 Sep DISC

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

XPHOZAH

+ @ ARDELYX INC EQ 10MG BASE

N213931 001 Oct 17, 2023 Apr DISC

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE FUMARATE

AB @ APOTEX EQ 25MG BASE

A213867 001 Mar 21, 2024 May DISC

AB EQ 25MG BASE

A213867 001 Mar 21, 2024 Mar NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

>D>	AB	MYLAN LABS LTD	300MG	A 079071	001	Feb 29, 2024	Sep CAHN
	AB		300MG	A 079071	001	Feb 29, 2024	Feb NEWA
>A>	AB	NORVIUM BIOSCIENCE	300MG	A 079071	001	Feb 29, 2024	Sep CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB		BIONPHARMA	EQ 1MG BASE	A 075667	001	Jul 28, 2000	Jan CMFD
AB			EQ 2MG BASE	A 075667	002	Jul 28, 2000	Jan CMFD
AB			EQ 5MG BASE	A 075667	003	Jul 28, 2000	Jan CMFD
AB			EQ 10MG BASE	A 075667	004	Jul 28, 2000	Jan CMFD

SOLUTION;ORAL

TEZRULY

+	@	NOVITIUM PHARMA	EQ 1MG BASE/ML	N 218139	001	Jul 29, 2024	Aug DISC
+	!		EQ 1MG BASE/ML	N 218139	001	Jul 29, 2024	Jul NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL

@	KARO HLTHCARE	1%	N 020846	001	Apr 29, 1998	Feb CAHN
---	---------------	----	----------	-----	--------------	----------

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL

@	KARO HLTHCARE	1%	N 020749	001	Oct 17, 1997	Feb CAHN
---	---------------	----	----------	-----	--------------	----------

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@	CIPLA	EQ 250MG BASE	A 077137	001	Jul 02, 2007	Mar DISC
---	-------	---------------	----------	-----	--------------	----------

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP		AREVA PHARMS	1MG/ML	A 200122	001	Nov 08, 2013	Apr CAHN
----	--	--------------	--------	----------	-----	--------------	----------

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

	@	AMNEAL PHARMS CO	7MG	A 209613	001	Sep 28, 2018	May DISC
	@		14MG	A 209613	002	Sep 28, 2018	May DISC
>A>	@	MYLAN	7MG	A 209702	001	Feb 28, 2020	Sep CAHN
	@		7MG	A 209702	001	Feb 28, 2020	Apr DISC
>A>	@		14MG	A 209702	002	Feb 28, 2020	Sep CAHN
	@		14MG	A 209702	002	Feb 28, 2020	Apr DISC
>D>	@	NORVIUM BIOSCIENCE	7MG	A 209702	001	Feb 28, 2020	Sep CAHN
>D>	@		14MG	A 209702	002	Feb 28, 2020	Sep CAHN

TERIPARATIDE

SOLUTION;SUBCUTANEOUS

TERIPARATIDE

+	!	ALMAJECT	0.6MG/2.4ML (0.25MG/ML)	N 218771	001	Jun 04, 2024	Jun NEWA
---	---	----------	-------------------------	----------	-----	--------------	----------

TESTOSTERONE

GEL;TRANSDERMAL

TESTIM

AB2	+	!	ENDO OPERATIONS	50MG/5GM PACKET	N 021454	001	Oct 31, 2002	Apr CAHN
-----	---	---	-----------------	-----------------	----------	-----	--------------	----------

GEL, METERED;TRANSDERMAL

FORTESTA

+	@	ENDO OPERATIONS	10MG/0.5GM ACTUATION	N 021463	001	Dec 29, 2010	Apr CAHN
+	@	ENDO PHARMS	10MG/0.5GM ACTUATION	N 021463	001	Dec 29, 2010	Jan DISC

TESTOSTERONE

!	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A 204571	001	Aug 05, 2015	Jan CTEC
AB	!	10MG/0.5GM ACTUATION	A 204571	001	Aug 05, 2015	Jan CHRS
AB1	!	12.5MG/1.25GM ACTUATION	A 076737	003	Mar 09, 2015	Apr CTEC
AB1		ENCUBE	A 212984	002	Feb 09, 2024	Apr NEWA

PELLET;IMPLANTATION

TESTOPEL

!	ENDO OPERATIONS	75MG	A 080911	001		Apr CAHN
---	-----------------	------	----------	-----	--	----------



SOLUTION, METERED;TRANSDERMAL  
TESTOSTERONE

AT	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Apr	CAHN
AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION  
TESTOSTERONE CYPIONATE

>D>	AO	WATSON PHARMS INC	200MG/ML	A086030	001		Sep	DISC
>A>		@	200MG/ML	A086030	001		Sep	DISC
SOLUTION; INTRAMUSCULAR								
TESTOSTERONE CYPIONATE								
>D>		+ @ AZURITY	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep	CMFD
>A>		+!	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep	CMFD
>A>		+ @	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jul	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION  
TESTOSTERONE ENANTHATE

AO	EUGIA PHARMA	200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA	
AO		200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA	
>D>	AO	HIKMA FARMACEUTICA	200MG/ML	A091120	001	Sep 18, 2012	Sep	CHRS
>A>	AO	!	200MG/ML	A091120	001	Sep 18, 2012	Sep	CHRS
>D>	AO	! WATSON PHARMS INC	200MG/ML	A085598	001		Sep	DISC
>A>		@	200MG/ML	A085598	001		Sep	DISC

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL  
TLANDO

+!	VERITY	112.5MG	N208088	001	Mar 28, 2022	Jan	CAHN	
INJECTABLE; INTRAMUSCULAR								
AVEED								
+!	ENDO OPERATIONS	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014	Apr	CAHN	

TETRABENAZINE

TABLET; ORAL  
TETRABENAZINE

AB	SLATE RUN PHARMA	12.5MG	A213316	001	Jan 22, 2020	Feb	CAHN
AB		25MG	A213316	002	Jan 22, 2020	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL  
SUMYCIN

@	ENDO OPERATIONS	125MG/5ML	A060400	001		May	CAHN	
TABLET; ORAL								
SUMYCIN								
	STRIDES PHARMA	250MG	A061147	001		Jan	CMFD	
!		500MG	A061147	004		Jan	CMFD	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL  
THEO-24

	ENDO OPERATIONS	100MG	A087943	002	Aug 22, 1983	Apr	CAHN
+		200MG	A087943	001	Aug 22, 1983	Apr	CAHN
		300MG	A087943	003	Aug 22, 1983	Apr	CAHN
!		400MG	A087943	004	Feb 28, 1992	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL  
THEOPHYLLINE

@	RHODES PHARMS	600MG	A040086	001	Apr 15, 1996	Jul	DISC
AB	STRIDES PHARMA	300MG	A215312	001	Sep 05, 2024	Aug	NEWA
AB		450MG	A215312	002	Sep 05, 2024	Aug	NEWA
AB	VELZEN PHARMA PVT	300MG	A214950	001	Jan 30, 2023	Aug	CAHN
AB		450MG	A214950	002	Jan 30, 2023	Aug	CAHN
AB	ZYDUS LIFESCIENCES	300MG	A218063	001	May 21, 2024	May	CAHN
AB		450MG	A218063	002	May 21, 2024	May	CAHN
AB	ZYDUS PHARMS	300MG	A218063	001	May 21, 2024	May	NEWA
AB		450MG	A218063	002	May 21, 2024	May	NEWA

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA							
AP	BELOTECA	15MG/VIAL	A217559	001	Aug 20, 2024	Aug	NEWA
AP	MEITHEAL	15MG/VIAL	A216037	001	Dec 26, 2023	Jun	CAHN
AP		100MG/VIAL	A216037	002	Dec 26, 2023	Jun	CAHN

SOLUTION; INTRAVENOUS

TEPYLUTE							
+!	SHORLA	15MG/1.5ML (10MG/ML)	N216984	001	Jun 25, 2024	Jun	NEWA

TICAGRELOR

TABLET; ORAL

TICAGRELOR							
AB	PRINSTON INC	90MG	A208599	001	Aug 16, 2024	Aug	NEWA

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE							
@	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	May	DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE							
@	AMNEAL	EQ 0.25% BASE	A216343	001	May 23, 2024	Jun	DISC
AB		EQ 0.25% BASE	A216343	001	May 23, 2024	May	NEWA
@		EQ 0.5% BASE	A216343	002	May 23, 2024	Jun	DISC
AB		EQ 0.5% BASE	A216343	002	May 23, 2024	May	NEWA
>A>	AB	SOMERSET THERAPS LLC	A210640	001	Sep 16, 2024	Sep	NEWA
>A>	AB		A210640	002	Sep 16, 2024	Sep	NEWA

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE							
AT1	CAPLIN	EQ 0.5% BASE	A218460	001	Aug 07, 2024	Jul	NEWA
AT1	SOMERSET	EQ 0.25% BASE	A217764	002	Jul 03, 2024	Jun	NEWA
AT1		EQ 0.5% BASE	A217764	001	Jul 03, 2024	Jun	NEWA
AT2	SOMERSET THERAPS LLC	EQ 0.5% BASE	A216653	001	Jul 03, 2024	Jun	NEWA

TIOPRONIN

TABLET, DELAYED RELEASE; ORAL

THIOLA EC							
AB	+ MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan	CFTG
TIOPRONIN							
AB	ENDO OPERATIONS	100MG	A217219	001	Feb 24, 2023	Jun	CMFD
AB		300MG	A217219	002	Feb 24, 2023	Jun	CMFD
AB	TEVA PHARMS INC	100MG	A216456	001	Jul 22, 2024	Jul	NEWA
AB		300MG	A216456	002	Jul 22, 2024	Jul	NEWA
AB	TORRENT	100MG	A216990	001	Jan 30, 2024	Jan	NFTG
AB		300MG	A216990	002	Jan 30, 2024	Jan	NEWA

TIRZEPATIDE

SOLUTION; SUBCUTANEOUS

MOUNJARO							
+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan	NEWA
+!		5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan	NEWA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan	NEWA
+!		10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan	NEWA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan	NEWA
+!		15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan	NEWA
MOUNJARO (AUTOINJECTOR)							
+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan	CTNA
+!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan	CTNA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan	CTNA
+!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan	CTNA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan	CTNA
+!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan	CTNA
ZEPBOUND							
+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar	NEWA
+!		5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar	NEWA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar	NEWA
+!		10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar	NEWA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar	NEWA
+!		15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar	NEWA

SOLUTION;SUBCUTANEOUS  
ZEPBOUND (AUTOINJECTOR)

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar	CTNA
+!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar	CTNA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar	CTNA
+!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar	CTNA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar	CTNA
+!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar	CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL  
TIZANIDINE HYDROCHLORIDE

>D>	AB	APPCO	EQ 4MG BASE	A213365	001	May 13, 2024	Sep	CAHN
	AB		EQ 4MG BASE	A213365	001	May 13, 2024	May	NEWA
>D>	AB		EQ 6MG BASE	A213365	002	May 13, 2024	Sep	CAHN
	AB		EQ 6MG BASE	A213365	002	May 13, 2024	May	NEWA
		@ ENDO OPERATIONS	EQ 2MG BASE	A207199	001	Mar 14, 2017	May	CAHN
		@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May	CAHN
		@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May	CAHN
>A>	AB	SOMERSET THERAPS LLC	EQ 4MG BASE	A213365	001	May 13, 2024	Sep	CAHN
>A>	AB		EQ 6MG BASE	A213365	002	May 13, 2024	Sep	CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

		@ ENDO OPERATIONS	EQ 2MG BASE	A207170	001	Jan 26, 2017	May	CAHN
		@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May	CAHN
AB		GRAVITI PHARMS	EQ 4MG BASE	A218920	002	Aug 07, 2024	Jul	NEWA
AB			EQ 2MG BASE	A218920	001	Aug 07, 2024	Jul	NEWA

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC  
TOBRAMYCIN

AT	!	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr	CHRS
		TOBREX						
	+	@ NOVARTIS	0.3%	N050541	001		Apr	DISC

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION  
TOBRAMYCIN SULFATE

>D>	AP	HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Sep	CAHN
>A>	AP	SLATE RUN PHARMA	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Sep	CAHN

TOFACITINIB CITRATE

SOLUTION;ORAL  
TOFACITINIB CITRATE

AA		HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr	CAHN
----	--	-------	----------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB

		@ AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Jun	DISC
AB			EQ 11MG BASE	A218462	001	Jun 03, 2024	May	NEWA
		XELJANZ XR						
	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jun	CTEC
AB	+		EQ 11MG BASE	N208246	001	Feb 23, 2016	May	CTEC

TOLAZAMIDE

TABLET;ORAL  
TOLAZAMIDE

		@ NATCO	250MG	A070259	001	Jan 02, 1986	Aug	CAHN
		@	500MG	A070259	003	Mar 17, 1986	Aug	CAHN

TOLCAPONE

TABLET;ORAL  
TOLCAPONE

		@ ENDO OPERATIONS	100MG	A204584	001	Mar 26, 2015	May	CAHN
		@ PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	DISC

TOLMETIN SODIUM

CAPSULE;ORAL  
TOLMETIN SODIUM

		@ CHARTWELL RX	EQ 400MG BASE	A073462	001	Apr 30, 1992	Aug	CAHN
--	--	----------------	---------------	---------	-----	--------------	-----	------

## TABLET;ORAL

## TOLMETIN SODIUM

@ CHARTWELL RX

EQ 200MG BASE

A 073588 001 Jul 31, 1992

Aug CAHN

@

EQ 600MG BASE

A 074002 001 Sep 27, 1993

Aug CAHN

TOLTERODINE TARTRATE

## CAPSULE, EXTENDED RELEASE;ORAL

## TOLTERODINE TARTRATE

>D>	AB	AMTA	2MG	A 213858	001	Feb 02, 2021	Sep	CAHN
>D>	AB		4MG	A 213858	002	Feb 02, 2021	Sep	CAHN
	AB	UNICHEM	2MG	A 216917	001	Aug 27, 2024	Aug	NEWA
	AB		4MG	A 216917	002	Aug 27, 2024	Aug	NEWA
>A>	AB	UTOPIC PHARMS	2MG	A 213858	001	Feb 02, 2021	Sep	CAHN
>A>	AB		4MG	A 213858	002	Feb 02, 2021	Sep	CAHN

TOPIRAMATE

## CAPSULE;ORAL

## TOPIRAMATE

AB		ALKEM LABS LTD	15MG	A 218482	001	Jun 13, 2024	Jun	NEWA
AB			25MG	A 218482	002	Jun 13, 2024	Jun	NEWA
		@ CHARTWELL RX	15MG	A 079206	001	Oct 14, 2009	Aug	CAHN
		@	25MG	A 079206	002	Oct 14, 2009	Aug	CAHN
AB		GLENMARK PHARMS LTD	15MG	A 217869	001	Jul 16, 2024	Jul	NEWA
AB			25MG	A 217869	002	Jul 16, 2024	Jul	NEWA
AB		STRIDES PHARMA	15MG	A 078418	001	Oct 14, 2009	Apr	CMFD
AB			25MG	A 078418	002	Oct 14, 2009	Apr	CMFD

## CAPSULE, EXTENDED RELEASE;ORAL

## TOPIRAMATE

		@ AJANTA PHARMA LTD	25MG	A 215663	001	Aug 15, 2023	Feb	DISC
		@	50MG	A 215663	002	Aug 15, 2023	Feb	DISC
		@	100MG	A 215663	003	Aug 15, 2023	Feb	DISC
		@	200MG	A 215663	004	Aug 15, 2023	Feb	DISC
AB1		LUPIN LTD	25MG	A 215561	001	Jul 11, 2024	Jul	NEWA
AB1			50MG	A 215561	002	Jul 11, 2024	Jul	NEWA
AB1			100MG	A 215561	003	Jul 11, 2024	Jul	NEWA
AB1			200MG	A 215561	004	Jul 11, 2024	Jul	NEWA

## TABLET;ORAL

## TOPIRAMATE

@ AIPING PHARM INC

25MG

A 078499 001 Jan 07, 2010

Feb CAHN

@

50MG

A 078499 002 Jan 07, 2010

Feb CAHN

@

100MG

A 078499 003 Jan 07, 2010

Feb CAHN

@

200MG

A 078499 004 Jan 07, 2010

Feb CAHN

@ SUN PHARM INDS LTD

25MG

A 076327 001 Mar 27, 2009

Jan DISC

@

100MG

A 076327 002 Mar 27, 2009

Jan DISC

@

200MG

A 076327 003 Mar 27, 2009

Jan DISC

TOPOTECAN HYDROCHLORIDE

## INJECTABLE; INJECTION

## TOPOTECAN HYDROCHLORIDE

@ RISING

EQ 4MG BASE/VIAL

A 091542 001 Aug 28, 2012

Mar CAHN

## SOLUTION; INTRAVENOUS

## TOPOTECAN HYDROCHLORIDE

>D>	AP	MEITHEAL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N 022453	001	Dec 20, 2012	Sep	DISC
>A>		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N 022453	001	Dec 20, 2012	Sep	DISC

TOREMIFENE CITRATE

## TABLET;ORAL

## FARESTON

+ @ KYOWA KIRIN

EQ 60MG BASE

N 020497 001 May 29, 1997

Aug DISC

## TOREMIFENE CITRATE

AB	!	RISING	EQ 60MG BASE	A 208813	001	Dec 04, 2018	Aug	CHRS
----	---	--------	--------------	----------	-----	--------------	-----	------

TORSEMIDE

## SOLUTION; INTRAVENOUS

## DEMADEX

+ @ ROCHE

50MG/5ML (10MG/ML)

N 020137 002 Aug 23, 1993

Mar CFR

+ @

20MG/2ML (10MG/ML)

N 020137 001 Aug 23, 1993

Mar CFR

## TORSEMIDE

@ AM REGENT

20MG/2ML (10MG/ML)

A 090656 001 Apr 21, 2010

Mar CFR

@

50MG/5ML (10MG/ML)

A 090656 002 Apr 21, 2010

Mar CFR

@ WEST-WARD PHARMS INT

20MG/2ML (10MG/ML)

A 078007 001 Jun 11, 2008

Mar CFR

@

50MG/5ML (10MG/ML)

A 078007 002 Jun 11, 2008

Mar CFR

TABLET;ORAL									
DEMADEX									
	+ @	NORVIUM BIOSCIENCE	5MG	N020136	001	Aug 23, 1993	Jul	CAHN	
	+ @		10MG	N020136	002	Aug 23, 1993	Jul	CAHN	
	+ @		20MG	N020136	003	Aug 23, 1993	Jul	CAHN	
	+ @		100MG	N020136	004	Aug 23, 1993	Jul	CAHN	
TORSEMIDE									
>D>	AB	COREPHARMA	5MG	A076894	001	May 31, 2005	Sep	CAHN	
>D>	AB		10MG	A076894	002	May 31, 2005	Sep	CAHN	
>D>	AB		20MG	A076894	003	May 31, 2005	Sep	CAHN	
>D>	AB		100MG	A076894	004	May 31, 2005	Sep	CAHN	
>A>	AB	HERITAGE	5MG	A076894	001	May 31, 2005	Sep	CAHN	
>A>	AB		10MG	A076894	002	May 31, 2005	Sep	CAHN	
>A>	AB		20MG	A076894	003	May 31, 2005	Sep	CAHN	
>A>	AB		100MG	A076894	004	May 31, 2005	Sep	CAHN	
<u>TOVORAFENIB</u>									
FOR SUSPENSION;ORAL									
OJEMDA									
	+!	DAY ONE BIOPHARMS	25MG/ML	N218033	001	Apr 23, 2024	Apr	NEWA	
TABLET;ORAL									
OJEMDA									
	+!	DAY ONE BIOPHARMS	100MG	N217700	001	Apr 23, 2024	Apr	NEWA	
<u>TRAMADOL HYDROCHLORIDE</u>									
TABLET;ORAL									
TRAMADOL HYDROCHLORIDE									
AB		GRAVITI PHARMS	100MG	A075968	002	Aug 02, 2024	Jul	NEWA	
		RUBICON	75MG	A208708	004	Apr 04, 2024	Mar	NFTG	
AB			100MG	A208708	002	Jun 28, 2019	Jul	CTEC	
TABLET, EXTENDED RELEASE;ORAL									
TRAMADOL HYDROCHLORIDE									
	@	ENDO OPERATIONS	100MG	A200491	001	Jun 27, 2012	Apr	CAHN	
	@		200MG	A200491	002	Jun 27, 2012	Apr	CAHN	
	@		300MG	A200491	003	Jun 27, 2012	Apr	CAHN	
	@	SUN PHARM	100MG	A091607	001	Dec 30, 2011	May	DISC	
	@		300MG	A091607	003	Dec 30, 2011	May	DISC	
<u>TRAMETINIB DIMETHYL SULFOXIDE</u>									
TABLET;ORAL									
MEKINIST									
	+	NOVARTIS	EQ 0.5MG	N204114	001	May 29, 2013	Aug	CTEC	
AB	+		EQ 0.5MG	N204114	001	May 29, 2013	Jul	CFTG	
	+!		EQ 2MG	N204114	003	May 29, 2013	Aug	CTEC	
AB	+!		EQ 2MG	N204114	003	May 29, 2013	Jul	CFTG	
TRAMETINIB DIMETHYL SULFOXIDE									
	@	NOVUGEN	EQ 0.5MG	A219002	001	Aug 06, 2024	Aug	DISC	
AB			EQ 0.5MG	A219002	001	Aug 06, 2024	Jul	NFTG	
	@		EQ 2MG	A219002	002	Aug 06, 2024	Aug	DISC	
AB			EQ 2MG	A219002	002	Aug 06, 2024	Jul	NFTG	
<u>TRANEXAMIC ACID</u>									
INJECTABLE;INJECTION									
TRANEXAMIC ACID									
>D>	AP	ACIC PHARMS	100MG/ML	A202436	001	Feb 11, 2014	Sep	CAHN	
>A>	AP	HERITAGE	100MG/ML	A202436	001	Feb 11, 2014	Sep	CAHN	
SOLUTION;INTRAVENOUS									
TRANEXAMIC ACID									
AP		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	A218242	001	Aug 15, 2024	Aug	NEWA	
AP		GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A218599	001	Apr 16, 2024	Apr	NEWA	
AP		NEXUS	1GM/100ML (10MG/ML)	A216877	001	Apr 16, 2024	Apr	NEWA	
TABLET;ORAL									
TRANEXAMIC ACID									
AB		RUBICON	650MG	A218320	001	Jun 11, 2024	May	NEWA	
<u>TRAVOPROST</u>									
SOLUTION/DROPS;OPHTHALMIC									
TRAVOPROST									
AT		GLAND PHARMA LTD	0.004%	A218159	001	Jul 12, 2024	Jul	NEWA	
AT		LUPIN LTD	0.004%	A207040	001	May 03, 2024	Apr	NEWA	
>A>	AT	SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Sep	NEWA	

TRAZODONE HYDROCHLORIDE

## TABLET; ORAL

## TRAZODONE HYDROCHLORIDE

>A>	@ AIPING PHARM INC	100MG	A072483	001	Apr 30, 1990	Sep	CAHN
AB	CROSSMEDIKA SA	50MG	A211116	001	May 20, 2024	May	NEWA
AB		100MG	A211116	002	May 20, 2024	May	NEWA
AB		150MG	A211116	003	May 20, 2024	May	NEWA
AB		300MG	A211116	004	May 20, 2024	May	NEWA
>D>	@ FOSUN PHARMA	100MG	A072483	001	Apr 30, 1990	Sep	CAHN
AB	GRANULES	50MG	A218988	001	Aug 08, 2024	Aug	NEWA
AB		100MG	A218988	002	Aug 08, 2024	Aug	NEWA
AB		150MG	A218988	003	Aug 08, 2024	Aug	NEWA
AB		300MG	A218988	004	Aug 08, 2024	Aug	NEWA
AB	GRAVITI PHARMS	50MG	A217740	001	Aug 27, 2024	Aug	NEWA
AB		100MG	A217740	002	Aug 27, 2024	Aug	NEWA
AB		150MG	A217740	003	Aug 27, 2024	Aug	NEWA
AB		300MG	A217740	004	Aug 27, 2024	Aug	NEWA

TRETINOIN

## CAPSULE; ORAL

## TRETINOIN

AB	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Apr	CAHN
	CREAM; TOPICAL						
	TRETINOIN						
AB	ALEMBIC	0.1%	A217804	001	Apr 29, 2024	Apr	NEWA
AB	ZYDUS LIFESCIENCES	0.1%	A218561	001	Apr 25, 2024	Apr	NEWA
	GEL; TOPICAL						
	TRETINOIN						
	@ NORVIUM BIOSCIENCE	0.1%	A202026	001	Jul 17, 2013	Aug	CAHN

TRIAMCINOLONE ACETONIDE

## OINTMENT; TOPICAL

## TRIAMCINOLONE ACETONIDE

	@ AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN
	@	0.5%	A211315	002	Mar 18, 2020	Jan	CAHN
	@ COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr	DISC
	PASTE; DENTAL						
	TRIAMCINOLONE ACETONIDE						
>D> AT	LYNE	0.1%	A040771	001	Jul 01, 2010	Sep	CAHN
>A> AT	RISING	0.1%	A040771	001	Jul 01, 2010	Sep	CAHN

TRIAMTERENE

## CAPSULE; ORAL

## TRIAMTERENE

>D>	@ EYWA	50MG	A214768	001	Jul 06, 2022	Sep	CAHN
>D>	@	100MG	A214768	002	Jul 06, 2022	Sep	CAHN
>A>	@ HIBROW HLTHCARE	50MG	A214768	001	Jul 06, 2022	Sep	CAHN
>A>	@	100MG	A214768	002	Jul 06, 2022	Sep	CAHN

TRIAZOLAM

## TABLET; ORAL

## TRIAZOLAM

	@ HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb	DISC
	@	0.25MG	A074224	002	Jun 01, 1994	Feb	DISC

TRIENTINE HYDROCHLORIDE

## CAPSULE; ORAL

## TRIENTINE HYDROCHLORIDE

AB	ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

TRIFLUOPERAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## TRIFLUOPERAZINE HYDROCHLORIDE

	@ CHARTWELL RX	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Aug	CAHN
--	----------------	-----------------	---------	-----	--------------	-----	------

TRILACICLIB DIHYDROCHLORIDE

## POWDER; INTRAVENOUS

## COSELA

>D>	+! G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Sep	CAHN
>A>	+! PHARMACOSMOS	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Sep	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

@ SUN PHARM INDUSTRIES 300MG

A076570 001 Aug 28, 2003 Aug DISC

INJECTABLE;INJECTION

TIGAN

+! ENDO OPERATIONS 100MG/ML

N017530 001 Apr CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB BRECKENRIDGE EQ 25MG BASE  
 AB ! EQ 50MG BASE  
 AB EQ 100MG BASE

A208127 001 Apr 15, 2016 Mar CAHN  
 A208127 002 Apr 15, 2016 Mar CAHN  
 A208127 003 Apr 15, 2016 Mar CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

&gt;D&gt; AB AMTA 60MG

A214760 001 Apr 30, 2021 Sep CAHN

&gt;A&gt; AB UTOPIC PHARMS 60MG

A214760 001 Apr 30, 2021 Sep CAHN

TABLET;ORAL

TROSPIUM CHLORIDE

&gt;A&gt; AB CHARTWELL RX 20MG

A215781 001 Feb 16, 2022 Sep CAHN

AB MACLEODS PHARMS LTD 20MG

A206472 001 Jun 18, 2024 Jun NEWA

&gt;D&gt; AB ZAMEER PHARMS 20MG

A215781 001 Feb 16, 2022 Sep CAHN

AB 20MG

A215781 001 Feb 16, 2022 Feb CAHN

>A> TROSPIUM CHLORIDE; XANOMELINE TARTRATE

&gt;A&gt; CAPSULE;ORAL

&gt;A&gt; COBENFY

&gt;A&gt; + BRISTOL-MYERS 20MG;EQ 50MG BASE

N216158 001 Sep 26, 2024 Sep NEWA

&gt;A&gt; + 20MG;EQ 100MG BASE

N216158 002 Sep 26, 2024 Sep NEWA

&gt;A&gt; +! 30MG;EQ 125MG BASE

N216158 003 Sep 26, 2024 Sep NEWA

UMECLIDINIUM BROMIDE

POWDER;INHALATION

INCRUSE ELLIPTA

+! GLAXO GRP ENGLAND EQ 0.0625MG BASE/INH

N205382 001 Apr 30, 2014 Jan CPOT

UPADACITINIB

SOLUTION;ORAL

RINVOQ LQ

+! ABBVIE 1MG/ML

N218347 001 Apr 26, 2024 Apr NEWA

>D> UREA, C-14

&gt;D&gt; CAPSULE;ORAL

&gt;D&gt; PYTEST

&gt;D&gt; +! AVENT 1uCi

N020617 001 May 09, 1997 Sep DISC

&gt;A&gt; + @ 1uCi

N020617 001 May 09, 1997 Sep DISC

URSODIOL

CAPSULE;ORAL

URSODIOL

AB HIBROW HLTHCARE 300MG

A212452 001 Oct 30, 2019 Jul CAHN

! LGM PHARMA 200MG

A205789 001 May 08, 2020 Aug CHRS

TABLET;ORAL

URSODIOL

AB ENDO OPERATIONS 250MG

A202540 001 Feb 14, 2013 Apr CAHN

AB 500MG

A202540 002 Feb 14, 2013 Apr CAHN

AB EPIC PHARMA LLC 250MG

A214717 001 Aug 14, 2024 Aug NEWA

AB 500MG

A214717 002 Aug 14, 2024 Aug NEWA

VADADUSTAT

TABLET;ORAL

VAFSEO

+ AKEBIA 150MG

N215192 001 Mar 27, 2024 Mar NEWA

+ 300MG

N215192 002 Mar 27, 2024 Mar NEWA

+! 450MG

N215192 003 Mar 27, 2024 Mar NEWA

VALACYCLOVIR HYDROCHLORIDE

## TABLET; ORAL

## VALACYCLOVIR HYDROCHLORIDE

	@	CIPLA	EQ 500MG BASE	A077135	001	May 24, 2010	Apr	DISC
	@		EQ 1GM BASE	A077135	002	May 24, 2010	Apr	DISC
AB		GRAVITI PHARMS	EQ 500MG BASE	A079012	001	May 24, 2010	Jun	CAHN
AB			EQ 1GM BASE	A079012	002	May 24, 2010	Jun	CAHN
>D>	AB	SANDOZ	EQ 500MG BASE	A077478	001	May 24, 2010	Sep	DISC
>A>		@	EQ 500MG BASE	A077478	001	May 24, 2010	Sep	DISC
>D>	AB		EQ 1GM BASE	A077478	002	May 24, 2010	Sep	DISC
>A>		@	EQ 1GM BASE	A077478	002	May 24, 2010	Sep	DISC

VALBENAZINE TOSYLATE

## CAPSULE; ORAL

## INGREZZA

AB	+	NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017	Mar	CFTG
AB	+		EQ 60MG BASE	N209241	003	Apr 23, 2021	Jul	CFTG
AB	+	!	EQ 80MG BASE	N209241	002	Oct 04, 2017	Mar	CFTG

## INGREZZA SPRINKLE

	+	NEUROCRINE	EQ 40MG BASE	N218390	001	Apr 30, 2024	Apr	NEWA
	+		EQ 60MG BASE	N218390	002	Apr 30, 2024	Apr	NEWA
	+	!	EQ 80MG BASE	N218390	003	Apr 30, 2024	Apr	NEWA

## VALBENAZINE TOSYLATE

AB		LUPIN LTD	EQ 40MG BASE	A216064	001	Apr 05, 2024	Mar	NFTG
AB			EQ 80MG BASE	A216064	002	Apr 05, 2024	Mar	NFTG
AB		ZYDUS	EQ 40MG BASE	A216137	001	Aug 07, 2024	Jul	NEWA
AB			EQ 60MG BASE	A216137	002	Aug 07, 2024	Jul	NFTG
AB			EQ 80MG BASE	A216137	003	Aug 07, 2024	Jul	NEWA

VALGANCICLOVIR HYDROCHLORIDE

## TABLET; ORAL

## VALGANCICLOVIR HYDROCHLORIDE

>D>	AB	GPP	EQ 450MG BASE	A212876	001	Jun 11, 2024	Sep	CAHN
	AB		EQ 450MG BASE	A212876	001	Jun 11, 2024	May	NEWA
>A>	AB	SOMERSET THERAPS LLC	EQ 450MG BASE	A212876	001	Jun 11, 2024	Sep	CAHN

VALPROIC ACID

## CAPSULE; ORAL

## VALPROIC ACID

	@	EYWA	250MG	A207611	001	Aug 05, 2019	Mar	DISC
	@	HIBROW HLTHCARE	250MG	A207611	001	Aug 05, 2019	Jul	CAHN
	@	SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	May	DISC

## SYRUP; ORAL

## VALPROIC ACID

	@	HIKMA	250MG/5ML	A074060	001	Jan 13, 1995	Mar	DISC
AA		QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Jan	CAHN

VALRUBICIN

## SOLUTION; INTRAVESICAL

## VALSTAR PRESERVATIVE FREE

AO	+	!	ENDO OPERATIONS	40MG/ML	N020892	001	Sep 25, 1998	Apr	CAHN
----	---	---	-----------------	---------	---------	-----	--------------	-----	------

VALSARTAN

## TABLET; ORAL

## VALSARTAN

AB		ZENARA	40MG	A218169	001	Aug 05, 2024	Jul	NEWA
AB			80MG	A218169	002	Aug 05, 2024	Jul	NEWA
AB			160MG	A218169	003	Aug 05, 2024	Jul	NEWA
AB			320MG	A218169	004	Aug 05, 2024	Jul	NEWA
AB		ZYDUS LIFESCIENCES	40MG	A218991	001	Jul 22, 2024	Jul	NEWA
AB			80MG	A218991	002	Jul 22, 2024	Jul	NEWA
AB			160MG	A218991	003	Jul 22, 2024	Jul	NEWA
AB			320MG	A218991	004	Jul 22, 2024	Jul	NEWA

VANCOMYCIN HYDROCHLORIDE

## CAPSULE; ORAL

## VANCOMYCIN HYDROCHLORIDE

	@	PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb	DISC
	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb	DISC



## INJECTABLE; INJECTION

## VANCOMYCIN HYDROCHLORIDE

>D>	AP	HAINAN POLY	EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Sep CAHN
>D>	AP		EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Sep CAHN
>D>	AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Sep CAHN
>D>	AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Sep CAHN
>A>	AP	HIKMA	EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Sep CAHN
>A>	AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Sep CAHN
		@ MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug CAHN
		@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug CAHN
		@ PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb DISC
		@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb DISC
		@ SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Apr DISC
		@	EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Apr DISC
>A>	AP	SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Sep CAHN
>A>	AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Sep CAHN
>A>	AP		EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Sep CAHN
>A>	AP		EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Sep CAHN
>D>	AP	XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Sep CAHN
>D>	AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Sep CAHN

## VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb CTNA
+	!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb CTNA
+	!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb CTNA

## POWDER; INTRAVENOUS

## VANCOMYCIN HYDROCHLORIDE

+	!	MYLAN LABS LTD	EQ 1.75GM BASE/VIAL	N209481	005	Jun 26, 2024	Jul NEWA
+	!		EQ 2GM BASE/VIAL	N209481	006	Jun 26, 2024	Jul NEWA

## SOLUTION; INTRAVENOUS

## VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb CPOT
+	!		EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb CDFR
+	!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb CPOT
+	!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb CDFR
+	!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb CPOT
+	!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb CDFR
+	!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb NEWA
+	!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb NEWA

VARENICLINE TARTRATE

## TABLET; ORAL

## VARENICLINE TARTRATE

AB		AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar NEWA
AB			EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar NEWA
>A>	AB	DR REDDYS	EQ 0.5MG BASE	A215931	001	Oct 01, 2024	Sep NEWA
>A>	AB		EQ 1MG BASE	A215931	002	Oct 01, 2024	Sep NEWA
AB		MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb NEWA
AB			EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb NEWA
>A>	AB	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Sep CAHN
>A>	AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Sep CAHN
>D>	AB	SLATE RUN PHARMA	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Sep CAHN
AB			EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jul NEWA
>D>	AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Sep CAHN
AB			EQ 1MG BASE	A217115	002	Jul 23, 2024	Jul NEWA

VASOPRESSIN

## SOLUTION; INTRAVENOUS

## VASOPRESSIN

AP		DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr NEWA
AP		GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb NEWA
			VASOPRESSIN IN SODIUM CHLORIDE 0.9%				
+	!	LONG GROVE PHARMS	20UNITS/100ML (0.2UNITS/ML)	N217766	001	Jul 11, 2024	Jul NEWA
+	!		40UNITS/100ML (0.4UNITS/ML)	N217766	002	Jul 11, 2024	Jul NEWA
+	!		50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	Jul NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May	NEWA
AB		EQ 75MG BASE	A217767	002	Jun 06, 2024	May	NEWA
AB		EQ 150MG BASE	A217767	003	Jun 06, 2024	May	NEWA
	@ ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May	CAHN
	@	EQ 75MG BASE	A078087	002	Mar 16, 2012	May	CAHN
	@	EQ 150MG BASE	A078087	003	Mar 16, 2012	May	CAHN
	@ NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
	@	EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
	@	EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

	@ AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010	Jun	DISC
	@	EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun	DISC
	@	EQ 50MG BASE	A079098	003	May 11, 2010	Jun	DISC
	@	EQ 75MG BASE	A079098	004	May 11, 2010	Jun	DISC
	@	EQ 100MG BASE	A079098	005	May 11, 2010	Jun	DISC
>D>	@ MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
>D>	@	EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
>D>	@	EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
>D>	@	EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
>D>	@	EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN
>A>	@ NORVIUM BIOSCIENCE	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
>A>	@	EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
>A>	@	EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
>A>	@	EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
>A>	@	EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

	@ SWISS PHARM	EQ 75MG BASE	A214423	001	Jan 04, 2022	Aug	CAHN
	@	EQ 150MG BASE	A214423	002	Jan 04, 2022	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	+ AZURITY	120MG	N019614	001	May 29, 1990	Aug	CAHN
AB	+	180MG	N019614	003	Jan 09, 1992	Aug	CAHN
AB	+	240MG	N019614	002	May 29, 1990	Aug	CAHN
	+!	360MG	N019614	004	May 10, 1996	Aug	CAHN
	VERELAN PM						
	+ AZURITY	100MG	N020943	001	Nov 25, 1998	Aug	CAHN
	+	200MG	N020943	002	Nov 25, 1998	Aug	CAHN
	+!	300MG	N020943	003	Nov 25, 1998	Aug	CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

>D>	AP	ACIC PHARMS	2.5MG/ML	A215829	001	Mar 17, 2022	Sep	CAHN
		@ FRESENIUS KABI USA	2.5MG/ML	A216471	001	Apr 23, 2024	May	DISC
	AP		2.5MG/ML	A216471	001	Apr 23, 2024	Apr	NEWA
>A>	AP	HERITAGE	2.5MG/ML	A215829	001	Mar 17, 2022	Sep	CAHN

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	NEPHRON	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Apr	CAHN
AP		10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Apr	CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+!	BAUSCH LOMB IRELAND	15MG/VIAL	N021119	001	Apr 12, 2000	Jul	CAHN
--	----	---------------------	-----------	---------	-----	--------------	-----	------

VIGABATRIN

SOLUTION;ORAL

VIGAFYDE

	+!	PYROS PHARMS	100MG/ML	N217684	001	Jun 17, 2024	Jun	NEWA
--	----	--------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

VIGABATRIN

>D>	AB	PROPEL PHARMA	500MG	A215519	001	Apr 28, 2023	Sep	CAHN
>A>	AB	RYAN LABS	500MG	A215519	001	Apr 28, 2023	Sep	CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
VINORELBINE TARTRATE  
@ RISING

EQ 10MG BASE/ML

A200148 001 Aug 31, 2012 Mar CAHN

VORAPAXAR SULFATE

TABLET; ORAL  
ZONTIVITY  
+ @ KEY THERAP  
+!

EQ 2.08MG BASE  
EQ 2.08MG BASE

N204886 001 May 08, 2014 May DISC  
N204886 001 May 08, 2014 Apr CAHN

VORASIDENIB

TABLET; ORAL  
VORANIGO  
+ SERVIER  
+!

10MG  
40MG

N218784 001 Aug 06, 2024 Aug NEWA  
N218784 002 Aug 06, 2024 Aug NEWA

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
VORICONAZOLE

AP ASPIRO  
>A> AP CHARTWELL RX  
@ NORVIUM BIOSCIENCE  
>D> AP XELLIA PHARMS APS

200MG/VIAL  
200MG/VIAL  
200MG/VIAL  
200MG/VIAL

A218533 001 Apr 03, 2024 Mar NEWA  
N208562 001 Mar 09, 2017 Sep CAHN  
A210849 001 Oct 11, 2022 Jul CAHN  
N208562 001 Mar 09, 2017 Sep CAHN

WARFARIN SODIUM

TABLET; ORAL  
WARFARIN SODIUM

@ BARR  
@  
@  
@  
@  
@  
@  
@  
@

1MG  
2MG  
2.5MG  
3MG  
4MG  
5MG  
6MG  
7.5MG  
10MG

A040145 001 Mar 26, 1997 Jun DISC  
A040145 002 Mar 26, 1997 Jun DISC  
A040145 003 Mar 26, 1997 Jun DISC  
A040145 008 Nov 05, 1998 Jun DISC  
A040145 004 Mar 26, 1997 Jun DISC  
A040145 005 Mar 26, 1997 Jun DISC  
A040145 009 Nov 05, 1998 Jun DISC  
A040145 006 Mar 26, 1997 Jun DISC  
A040145 007 Mar 26, 1997 Jun DISC

ZINC SULFATE

SOLUTION; INTRAVENOUS  
ZINC SULFATE

AP APOTEX  
AP NIVAGEN PHARMS INC  
AP  
AP  
AP SOMERSET THERAPS LLC  
AP

EQ 25MG BASE/5ML (EQ 5MG BASE/ML)  
EQ 10MG BASE/10ML (EQ 1MG BASE/ML)  
EQ 25MG BASE/5ML (EQ 5MG BASE/ML)  
EQ 30MG BASE/10ML (EQ 3MG BASE/ML)  
EQ 25MG BASE/5ML (EQ 5MG BASE/ML)  
EQ 30MG BASE/10ML (EQ 3MG BASE/ML)

A218059 001 Jun 10, 2024 May NEWA  
A214597 001 Jul 05, 2024 Jun NEWA  
A214597 002 Jul 05, 2024 Jun NEWA  
A214597 003 Jul 05, 2024 Jun NEWA  
A216135 001 Jul 17, 2024 Jul NEWA  
A216135 002 Jul 17, 2024 Jul NEWA

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID  
@ HOSPIRA

EQ 4MG BASE/5ML

A090621 001 Mar 19, 2015 May DISC

ZOLMITRIPTAN

SPRAY; NASAL  
ZOLMITRIPTAN

AB ! PADAGIS ISRAEL

5MG/SPRAY

A212469 002 Sep 30, 2021 Feb CHRS

TABLET; ORAL  
ZOLMITRIPTAN

>D> AB APPCO  
>D> AB  
@ INVAGEN PHARMS  
@  
>A> AB SOMERSET THERAPS LLC  
>A> AB

2.5MG  
5MG  
2.5MG  
5MG  
2.5MG  
5MG

A206973 001 Jun 30, 2017 Sep CAHN  
A206973 002 Jun 30, 2017 Sep CAHN  
A204284 001 Apr 09, 2014 Mar DISC  
A204284 002 Apr 09, 2014 Mar DISC  
A206973 001 Jun 30, 2017 Sep CAHN  
A206973 002 Jun 30, 2017 Sep CAHN

ZOLPIDEM TARTRATE

	TABLET;ORAL						
	ZOLPIDEM TARTRATE						
	@ INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007	Mar	DISC
	@	10MG	A078184	002	Sep 07, 2007	Mar	DISC
	TABLET;SUBLINGUAL						
	ZOLPIDEM TARTRATE						
AB	ENDO OPERATIONS	1.75MG	A204229	001	Sep 11, 2017	Apr	CAHN
AB		3.5MG	A204229	002	Sep 11, 2017	Apr	CAHN
AB		5MG	A201509	001	Aug 01, 2016	May	CAHN
AB		10MG	A201509	002	Aug 01, 2016	May	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	ZOLPIDEM TARTRATE						
	@ ENDO OPERATIONS	6.25MG	A078148	002	Apr 14, 2011	May	CAHN
	@	12.5MG	A078148	001	Dec 03, 2010	May	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

>D>	AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Sep	DISC
>A>	@	250MG;125MG	A218359	001	Mar 26, 2024	Sep	DISC
		250MG;125MG	A218359	001	Mar 26, 2024	Apr	CTNA
		250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
	DR REDDYS	250MG;125MG	A218247	001	Aug 23, 2024	Aug	NEWA
	GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

>A>	ALEMBIC	0.25%	A209290	001	Oct 02, 2024	Sep	NEWA
	GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	May	NEWA
@	PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
		0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr	NEWA
	AZELASTINE HYDROCHLORIDE ALLERGY						
	APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024	May	NEWA
	AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY						
	APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024	May	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

	DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
	LUMIFY PRESERVATIVE FREE						
+!	BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@	APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@	CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
		5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@	PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
	TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
		5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@	TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@	APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
@	CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR
@	PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR

SOLUTION;ORAL									
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF									
	@ RANBAXY LABS LTD	5MG/5ML		A090183	001	Apr 24, 2008	Feb	CDFR	
	TARO	5MG/5ML		A090182	001	Apr 22, 2008	Feb	CDFR	
		5MG/5ML		A201546	002	May 20, 2011	Feb	CDFR	
	@ TRIS PHARMA INC	5MG/5ML		A090572	002	Nov 16, 2012	Feb	CDFR	
CHILDREN'S ZYRTEC ALLERGY									
+!	J AND J CONSUMER INC	5MG/5ML		N022155	002	Nov 16, 2007	Feb	CDFR	
CHILDREN'S ZYRTEC HIVES RELIEF									
+!	J AND J CONSUMER INC	5MG/5ML		N022155	001	Nov 16, 2007	Feb	CDFR	
TABLET;ORAL									
CETIRIZINE HYDROCHLORIDE									
>A>	INDOCO	10MG		A218895	001	Oct 03, 2024	Sep	NEWA	
TABLET, CHEWABLE;ORAL									
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY									
	@ SUN PHARM	5MG		A090142	001	Aug 30, 2011	Mar	DISC	
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF									
	@ SUN PHARM	5MG		A090142	003	Aug 30, 2011	Mar	DISC	
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE									
	PPI-DAC	5MG;120MG		A210719	001	Nov 16, 2018	Jun	CAHN	
	UNICHEM	5MG;120MG		A210507	001	Sep 10, 2024	Aug	NEWA	
<u>CLOTRIMAZOLE</u>									
CREAM;VAGINAL									
TRIVAGIZOLE 3									
	TARO	2%		N021143	001	Apr 12, 2000	Mar	CAHN	
<u>DICLOFENAC SODIUM</u>									
GEL;TOPICAL									
DICLOFENAC SODIUM									
	CIPLA	1%		A209903	001	Aug 03, 2018	Jul	CMKT	
	@ HIKMA	1%		A209484	001	Nov 21, 2018	Mar	DISC	
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN</u>									
TABLET;ORAL									
IBUPROFEN AND DIPHENHYDRAMINE CITRATE									
	PLD ACQUISITIONS LLC	38MG;200MG		A211404	001	Apr 11, 2024	Apr	NEWA	
<u>DOCOSANOL</u>									
CREAM;TOPICAL									
DOCOSANOL									
	AUROBINDO PHARMA LTD	10%		A217090	001	Mar 01, 2024	Feb	NEWA	
	P AND L DEVELOPMENT	10%		A212385	001	Oct 07, 2022	Mar	CAHN	
<u>ESOMEPRAZOLE MAGNESIUM</u>									
CAPSULE, DELAYED RELEASE;ORAL									
ESOMEPRAZOLE MAGNESIUM									
>A>	ANDA REPOSITORY	EQ 20MG BASE		A216149	001	Mar 15, 2023	Sep	CAHN	
	DR REDDYS	EQ 20MG BASE		A207198	001	Apr 30, 2024	Apr	NEWA	
	GLENMARK SPECLT	EQ 20MG BASE		A218092	001	Jun 11, 2024	May	NEWA	
>D>	GUARDIAN DRUG	EQ 20MG BASE		A216149	001	Mar 15, 2023	Sep	CAHN	
		EQ 20MG BASE		A216149	001	Mar 15, 2023	Feb	CAHN	
TABLET, DELAYED RELEASE;ORAL									
ESOMEPRAZOLE MAGNESIUM									
	AUROBINDO PHARMA LTD	EQ 20MG BASE		A214473	001	Jul 12, 2023	Apr	CMFD	
	@	EQ 20MG BASE		A214473	001	Jul 12, 2023	Jan	DISC	
<u>FAMOTIDINE</u>									
TABLET;ORAL									
FAMOTIDINE									
	CONTRACT PHARMACAL	10MG		A218003	001	May 28, 2024	May	NEWA	
		20MG		A218003	002	May 28, 2024	May	NEWA	
	GRAVITI PHARMS	10MG		A218461	001	Mar 14, 2024	Mar	NEWA	
		20MG		A218461	002	Mar 14, 2024	Mar	NEWA	
	@ SUN PHARM INDS LTD	10MG		A090283	001	Nov 17, 2009	Apr	DISC	
	@	20MG		A090283	002	Nov 17, 2009	Apr	DISC	

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

AUROBINDO PHARMA LTD 0.05MG/SPRAY

A217088 001 May 10, 2024 May NEWA

@ HIKMA 0.05MG/SPRAY

A208024 001 Apr 17, 2019 Mar DISC

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

@ AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM SALT

A215777 001 Sep 14, 2023 Mar DISC

PATHEON SOFTGELS EQ 200MG FREE ACID AND POTASSIUM SALT

A217236 001 Feb 13, 2024 Mar CAHN

EQ 200MG FREE ACID AND POTASSIUM SALT

A217236 001 Feb 13, 2024 Feb NEWA

SUSPENSION;ORAL

IBUPROFEN

&gt;A&gt; ANNORA PHARMA 100MG/5ML

A210602 001 Nov 23, 2018 Sep CAHN

&gt;D&gt; APTAPHARMA INC 100MG/5ML

A210602 001 Nov 23, 2018 Sep CAHN

SUSPENSION/DROPS;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD 40MG/ML

A213506 001 Apr 08, 2024 Mar NEWA

TABLET;ORAL

IBUPROFEN

&gt;A&gt; @ ADAPTIS 200MG

A071265 001 Oct 15, 1986 Sep CAHN

&gt;A&gt; @ 200MG

A071265 002 Sep 10, 1987 Sep CAHN

&gt;A&gt; 200MG

A072299 001 Jul 01, 1988 Sep CAHN

&gt;D&gt; @ CONTRACT PHARMACAL 200MG

A071265 001 Oct 15, 1986 Sep CAHN

&gt;D&gt; @ 200MG

A071265 002 Sep 10, 1987 Sep CAHN

&gt;D&gt; 200MG

A072299 001 Jul 01, 1988 Sep CAHN

ENDO OPERATIONS 200MG

A071229 001 Apr 01, 1987 May CAHN

@ 200MG

A071639 001 Feb 02, 1988 May CAHN

@ 200MG

A072249 001 Jan 10, 1989 May CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

NAARI PTE LTD 1.5MG

A207660 001 May 02, 2019 Apr CMFD

@ XIROMED 0.75MG

A202740 001 Sep 02, 2016 May CAHN

1.5MG

A202739 001 Oct 31, 2014 May CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006 May DISC

LORATADINE

SUSPENSION;ORAL

LORATADINE

+! TARO 1MG/ML

N021734 001 Oct 04, 2005 Aug CAHN

TABLET;ORAL

LORATADINE

&gt;A&gt; ANDA REPOSITORY 10MG

A207569 001 Mar 12, 2019 Sep CAHN

&gt;D&gt; GUARDIAN DRUG 10MG

A207569 001 Mar 12, 2019 Sep CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

BIONPHARMA 10MG;240MG

A218017 001 May 14, 2024 May NEWA

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

@ COSETTE 2%

A074366 001 Feb 22, 1996 Apr DISC

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

COSETTE 2%,200MG

A074926 001 Apr 16, 1999 Jun CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

COSETTE 100MG

A073507 001 Nov 19, 1993 Jun CAHN

@ 100MG

A074414 001 Apr 30, 1997 Apr DISC

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

AUROBINDO PHARMA 5%

A218616 001 Apr 22, 2024 Apr NEWA

MINOXIDIL (FOR WOMEN)

AUROBINDO PHARMA 5%

A218616 002 Apr 22, 2024 Apr NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

&gt;D&gt; APOTEX 0.05MG/SPRAY

A217438 001 Apr 23, 2024 Sep DISC

&gt;A&gt; @ 0.05MG/SPRAY

A217438 001 Apr 23, 2024 Sep DISC

0.05MG/SPRAY

A217438 001 Apr 23, 2024 Apr NEWA

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

AMNEAL 4MG/SPRAY

A217992 001 Apr 23, 2024 Apr NEWA

TEVA PHARMS USA 4MG/SPRAY

A209522 001 Apr 19, 2019 Jun CMKT

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ SUN PHARM INDS LTD 220MG

A091183 001 May 20, 2011 Jan DISC

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA 220MG;120MG

A211360 001 Jun 01, 2022 Jul CMFD

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICOTINE

&gt;D&gt; AVEVA 7MG/24HR

A074612 002 Jul 28, 2003 Sep CAHN

&gt;D&gt; 14MG/24HR

A074612 003 Oct 20, 1997 Sep CAHN

&gt;D&gt; 21MG/24HR

A074612 001 Oct 20, 1997 Sep CAHN

&gt;A&gt; DIFGEN PHARMS 7MG/24HR

A074612 002 Jul 28, 2003 Sep CAHN

&gt;A&gt; 14MG/24HR

A074612 003 Oct 20, 1997 Sep CAHN

&gt;A&gt; 21MG/24HR

A074612 001 Oct 20, 1997 Sep CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ HALEON US HOLDINGS EQ 2MG BASE

N022360 001 May 18, 2009 Jan CAHN

+! EQ 4MG BASE

N022360 002 May 18, 2009 Jan CAHN

NICOTINE POLACRILEX

PPI-DAC EQ 2MG BASE

A090711 001 Jul 10, 2009 Jun CAHN

EQ 2MG BASE

A203690 001 Oct 09, 2012 Jun CAHN

EQ 4MG BASE

A090711 002 Jul 10, 2009 Jun CAHN

EQ 4MG BASE

A203690 002 Oct 09, 2012 Jun CAHN

NORGESTREL

TABLET;ORAL

OPILL

+! LABORATOIRE HRA 0.075MG

N017031 001 Feb CMFD

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

GLENMARK PHARMS INC EQ 0.1% BASE

A200810 001 Jun 28, 2017 Aug CMFD

SOMERSET THERAPS LLC EQ 0.1% BASE

A206306 001 Dec 07, 2015 Apr CMKT

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

DR REDDYS 20MG/PACKET;1.68GM/PACKET

A217784 001 May 09, 2024 May NFTG



POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

PPI-DAC

17GM/PACKET

A090685 001 Oct 06, 2009 Jun CAHN

17GM/SCOOPFUL

A090685 002 Oct 06, 2009 Jun CAHN

POVIDONE-IODINE

SPONGE;TOPICAL

E-Z SCRUB 201

+ @ BECTON DICKINSON 20%

N019240 001 Nov 29, 1985 Feb DISC

E-Z SCRUB 241

+ @ BECTON DICKINSON 10%

N019476 001 Jan 07, 1987 Feb DISC

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1%

N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+! KARO HLTHCARE 1%

N020980 001 Mar 09, 1999 Feb CAHN

SOLUTION;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1%

N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1%

N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2024**

NO SEPTEMBER 2024 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11977067	Apr 30, 2038	DP			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Sep 28, 2031	DS DP U-1981			
	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
	>A> 12083087	Jul 17, 2035	U-3744			
	>A> 12083087	Jul 17, 2035	U-3745			
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					NP	Feb 13, 2027
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-947 ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	8227462	Apr 29, 2033	DS DP			
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034			U-3822	
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034			U-3822	
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038			U-2497	
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038			U-2497	
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12016873	May 15, 2035			U-2414	
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037			U-3447	
	11918685	Oct 06, 2037			U-3448	
	12053461	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIQVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042			U-3816	
	11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 001					>A> NCE	Sep 20, 2029
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 002					>A> NCE	Sep 20, 2029
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 003					>A> NCE	Sep 20, 2029
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 004					>A> NCE	Sep 20, 2029
<u>ARIPIPIRAZOLE - ABILIFY ASIMTUFLII</u>						
N 217006 001	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARIPIPIRAZOLE - ABILIFY ASIMTUFLII</u>						
N 217006 002	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	11407735	May 14, 2040	DS		NCE	Oct 29, 2026
	8829195	May 13, 2033	DS U-1374		ODE*	Oct 29, 2028
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	>A> 12083179	Sep 10, 2033	DP U-2310			
<u>ATORVASTATIN CALCIUM - ATORVALIQ</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					CGT	Dec 04, 2024
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	>A> 12016875	Jul 11, 2034	U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980	Apr 10, 2040	DS DP			
	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	11999744	Apr 10, 2040	U-3506			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035			U-2844	
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037			U-3044	
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035			U-2844	
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037			U-3044	
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	12053482	May 14, 2029			U-2950	
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	12053482	May 14, 2029			U-2950	
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001 >A>	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002 >A>	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003 >A>	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					M-306	Jun 21, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					M-306	Jun 21, 2027
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	RE49948	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11744816	Mar 14, 2036		U-3883	I-943	Mar 22, 2027
	11926584	Jun 19, 2040		U-3873	I-944	Mar 22, 2027
	7335799	Dec 03, 2030	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036		U-3224	I-943	Mar 22, 2027
	10912751	Mar 14, 2036		U-3884	I-945	Mar 22, 2027
	11744816	Mar 14, 2036		U-3692		
	11744816	Mar 14, 2036		U-3883		
	11926584	Jun 19, 2040		U-3873		
	7335799	Dec 03, 2030	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	11795176	Jan 13, 2042	DS	U-713		
	9763953	May 16, 2027		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	11795176	Jan 13, 2042	DS	U-713		
	9763953	May 16, 2027		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	11795176	Jan 13, 2042	DS	U-713		
	9763953	May 16, 2027		U-713		
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040		U-3357		
	11877997	Feb 19, 2040		U-3356		
	11986456	Feb 19, 2040		U-3947		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
	11986456	Feb 19, 2040	U-3947			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12053546	Jun 29, 2032	DP			
	>A> 12070629	Dec 30, 2030	DP U-3987			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					I-942	Feb 23, 2027
					M-305	Apr 24, 2027
					ODE-468	Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942	Feb 23, 2027
	7390791*PED	Oct 17, 2025			ODE-468	Feb 23, 2031
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUEVZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	11992514	May 20, 2039	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	12005069	Sep 23, 2042	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	12005069	Sep 23, 2042	DP			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026			U-3281	
	8618109	Apr 12, 2026			U-543	
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026			U-3281	
	8618109	Apr 12, 2026			U-543	
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028			U-3820	
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039			U-3820	
	8324192	Aug 03, 2029			U-3820	
	8497258	Nov 09, 2026			U-3820	
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026			U-3820	
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026			U-3820	
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	11925636	Jan 20, 2043	U-3419			
	11969421	Nov 05, 2034	U-3419			
	11986444	Feb 15, 2043	U-3419			
	12036191	Feb 15, 2043	U-3419			
	12042473	Feb 23, 2043	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11998542	Jul 02, 2034	U-1583			
	12048769	Nov 08, 2027	U-1585			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11986446	Mar 15, 2033	U-3017		ODE-361	Jul 21, 2027
	11986446	Mar 15, 2033	U-3324		PED	Jan 21, 2028
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
	11963937	Jun 17, 2035	U-2780			
	11963937	Jun 17, 2035	U-2781			
	>A> 12064399	Jun 17, 2035	U-3988			
	>A> 12064399	Jun 17, 2035	U-3989			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	>A> 12084449	Nov 19, 2027	U-2813			
	7767675	Nov 19, 2032	DS DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	>A> 12084449	Nov 19, 2027	U-2813			
	7767675	Nov 19, 2032	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	11963971	Feb 24, 2041	DP			
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					NCE	Apr 03, 2029
					GAIN	Apr 03, 2034
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Mar 21, 2033	DS DP U-2586			
	8487093	Mar 21, 2033	DS DP U-2587			
	8487093	Mar 21, 2033	DS DP U-2840			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	11992472	Mar 15, 2033	U-1			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11938141	Jul 24, 2028	DP			
	8865690	Jul 24, 2025	U-2942			
	9211295	May 31, 2025	DP			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	11918689	Jul 28, 2041	DP U-3944			
	8062667	Mar 29, 2029	DP			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			
	9744144	Nov 01, 2033	U-3643			
<u>COPPER - PARAGARD T 380A</u>						
N 018680 001					D-193	Jun 28, 2027
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 001	>A> 12102662	Oct 27, 2043	U-3904			
	>A> 12102662	Oct 27, 2043	U-3905			
	>A> 12102662	Oct 27, 2043	U-3906			
	>A> 12102662	Oct 27, 2043	U-3907			
	>A> 12102662	Oct 27, 2043	U-3908			
	>A> 12102662	Oct 27, 2043	U-3909			
	>A> 12102662	Oct 27, 2043	U-3910			
	>A> 12102662	Oct 27, 2043	U-3911			
	>A> 12102662	Oct 27, 2043	U-3912			
	>A> 12102662	Oct 27, 2043	U-3913			
	>A> 12102662	Oct 27, 2043	U-3914			
	>A> 12102662	Oct 27, 2043	U-3915			
	>A> 12102662	Oct 27, 2043	U-3916			
	>A> 12102662	Oct 27, 2043	U-3917			
	>A> 12102662	Oct 27, 2043	U-3918			
	>A> 12102662	Oct 27, 2043	U-3919			
	>A> 12102662	Oct 27, 2043	U-3920			
	>A> 12102662	Oct 27, 2043	U-3921			
	>A> 12102662	Oct 27, 2043	U-3922			
	>A> 12102662	Oct 27, 2043	U-3923			
	>A> 12102662	Oct 27, 2043	U-3924			
	>A> 12102662	Oct 27, 2043	U-3925			
	>A> 12102662	Oct 27, 2043	U-3926			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 001	>A> 12102662	Oct 27, 2043	U-3904			
	>A> 12102662	Oct 27, 2043	U-3905			
	>A> 12102662	Oct 27, 2043	U-3906			
	>A> 12102662	Oct 27, 2043	U-3907			
	>A> 12102662	Oct 27, 2043	U-3908			
	>A> 12102662	Oct 27, 2043	U-3909			
	>A> 12102662	Oct 27, 2043	U-3910			
	>A> 12102662	Oct 27, 2043	U-3911			
	>A> 12102662	Oct 27, 2043	U-3912			
	>A> 12102662	Oct 27, 2043	U-3913			
	>A> 12102662	Oct 27, 2043	U-3914			
	>A> 12102662	Oct 27, 2043	U-3915			
	>A> 12102662	Oct 27, 2043	U-3916			
	>A> 12102662	Oct 27, 2043	U-3917			
	>A> 12102662	Oct 27, 2043	U-3918			
	>A> 12102662	Oct 27, 2043	U-3919			
	>A> 12102662	Oct 27, 2043	U-3920			
	>A> 12102662	Oct 27, 2043	U-3921			
	>A> 12102662	Oct 27, 2043	U-3922			
	>A> 12102662	Oct 27, 2043	U-3923			
	>A> 12102662	Oct 27, 2043	U-3924			
	>A> 12102662	Oct 27, 2043	U-3925			
	>A> 12102662	Oct 27, 2043	U-3926			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			
	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			
	11975047	Oct 27, 2043	U-3925			
	11975047	Oct 27, 2043	U-3926			
	>A> 12102662	Oct 27, 2043	U-3904			
	>A> 12102662	Oct 27, 2043	U-3905			
	>A> 12102662	Oct 27, 2043	U-3906			
	>A> 12102662	Oct 27, 2043	U-3907			
	>A> 12102662	Oct 27, 2043	U-3908			
	>A> 12102662	Oct 27, 2043	U-3909			
	>A> 12102662	Oct 27, 2043	U-3910			
	>A> 12102662	Oct 27, 2043	U-3911			
	>A> 12102662	Oct 27, 2043	U-3912			
	>A> 12102662	Oct 27, 2043	U-3913			
	>A> 12102662	Oct 27, 2043	U-3914			
	>A> 12102662	Oct 27, 2043	U-3915			
	>A> 12102662	Oct 27, 2043	U-3916			
	>A> 12102662	Oct 27, 2043	U-3917			
	>A> 12102662	Oct 27, 2043	U-3918			
	>A> 12102662	Oct 27, 2043	U-3919			
	>A> 12102662	Oct 27, 2043	U-3920			
	>A> 12102662	Oct 27, 2043	U-3921			
	>A> 12102662	Oct 27, 2043	U-3922			
	>A> 12102662	Oct 27, 2043	U-3923			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	>A> 12102662	Oct 27, 2043	U-3924			
	>A> 12102662	Oct 27, 2043	U-3925			
	>A> 12102662	Oct 27, 2043	U-3926			
<u>CUPRIC CHLORIDE - CUPRIC CHLORIDE</u>						
A 216113 001					CGT	Dec 21, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP		Y	
	8633162	Aug 27, 2024	U-1479		Y	
	8642556	Aug 27, 2024	DP		Y	
	8648048	Aug 27, 2024	U-1483		Y	
	8685930	Aug 27, 2024	DP		Y	
	9248191	Aug 27, 2024	U-1479		Y	
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYCLOSPORINE - VEVYE</u>						
N 217469 001	>A> 12059449	Apr 01, 2042	DP U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11969439	Jan 15, 2039	U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	8835443	Jun 10, 2025	U-3565			
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001 >A>	12076319	Aug 02, 2038	U-3933		NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS U-3933		ODE-476	Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002 >A>	12076319	Aug 02, 2038	U-3933		NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS U-3933		ODE-476	Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Nov 08, 2026
	7456254	Jun 30, 2025	U-2139		PED	Dec 12, 2027
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7456254	Jun 30, 2025	U-2139			
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 001	12053502	Aug 28, 2038	U-3981			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 002	12053502	Aug 28, 2038	U-3981			
<u>DASATINIB - DASATINIB</u>						
A 202103 001					>A> PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 002					>A> PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 003					>A> PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 004					>A> PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 203180 001					>A> PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 203180 002					>A> PC	Mar 02, 2025
<u>DASATINIB - PHYRAGO</u>						
N 216099 001					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 002					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 003					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 004					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 005					M-307	Dec 05, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099 006					M-307	Dec 05, 2026
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	12036219	Jun 02, 2034	U-3967			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	11963995	May 21, 2029	U-2327			
<u>DEURUXOLITINIB PHOSPHATE - LEQSELVI</u>						
N 217900 001	10561659	May 04, 2037	U-3976		>A> NCE	Jul 25, 2029
	11919907	May 21, 2041	DP U-3976			
	>A> 12076323	May 04, 2037	U-3976			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 001					>A> CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 002					>A> CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
>A>	12090140	Jan 12, 2043	U-3986			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
>A>	12090140	Jan 12, 2043	U-3986			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
>A>	12090140	Jan 12, 2043	U-3986			
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					NPP	Apr 05, 2027
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	12011506	Sep 05, 2038	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641	Y		
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP	Y		
	8598233*PED	May 22, 2026				
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
	>A> 12090231	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			
	>A> 12090231	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	11185519	Mar 30, 2037	U-3955		NCE	Jun 10, 2029
	11331292	Mar 30, 2037	U-1854		ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037	U-1854			
	11857523	Mar 30, 2037	U-3955			
	7632870	Sep 09, 2024	DP			
	7943661	Sep 09, 2024	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	>A> 12083227	Aug 20, 2038	DP U-2842			
	7419983	Jul 06, 2029	DS DP			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	10945950	Sep 15, 2035	DP		NCE	Jun 26, 2029
	9062047	Aug 21, 2031	DS U-3962			
	9956171	Sep 15, 2035	DP U-3962			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	12029710	Jan 22, 2040	U-3963			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 001	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039	U-3979			
	11173209	Feb 06, 2038	U-3979			
	11191838	Feb 06, 2039	DP U-3979			
	11717571	Feb 06, 2039	U-3979			
	11744895	Feb 06, 2039	U-3979			
	11918655	Feb 06, 2039	DP U-3979			
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001					CGT	Oct 23, 2024
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001					>A> NP	Jul 22, 2027
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001					NPP PED	Jul 01, 2027 Jan 01, 2028
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	12036290	Nov 27, 2041	DP U-3614			
	12036290	Nov 27, 2041	DP U-3615			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	11980674	Apr 23, 2042	U-2450			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 12083270	Apr 04, 2031	U-2133		I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FOSAPREPITANT DIMEGLUMINE - FOCINVEZ</u>						
N 216686 001	12042504	Jan 11, 2039	DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 08, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 08, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FUROSEMIDE - FUROSCIX</u>						
N 209988 001					>A> NP	Oct 07, 2025
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001	>A> 12109277	Mar 09, 2036	U-4002			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2025	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032				
	9867799	Feb 03, 2032				
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036	U-3254			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036	U-3254			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383		Y	
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	RE47691	Jun 28, 2028	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	>A> 12076403	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	>A> 12076403	Nov 02, 2031	DP			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROCORTISONE SODIUM SUCCINATE - HYDROCORTISONE SODIUM SUCCINATE</u>						
A 214050 001					>A> CGT	Mar 25, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>							
A 216899	002				PC	Nov 11, 2024	
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>							
A 216899	003				PC	Dec 02, 2024	
<u>HYDROXYUREA - XROMI</u>							
N 216593	001				NP ODE-470	Apr 04, 2027 Apr 04, 2031	
<u>IBRUTINIB - IMBRUVICA</u>							
N 205552	001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
		8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>							
N 205552	002	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
		8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>							
N 210563	001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
		8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>							
N 210563	002	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
		8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>							
N 210563	003	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
		8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>							
N 210563	004				M-14	Aug 24, 2025	
<u>IBRUTINIB - IMBRUVICA</u>							
N 217003	001	10004746	Jun 03, 2031	U-3846			
		10004746	Jun 03, 2031	U-3847			
		10004746	Jun 03, 2031	U-3848			
		10004746	Jun 03, 2031	U-3849			
		10016435	Jun 03, 2031	U-3845			
		10463668	Oct 24, 2034	U-2970			
		10478439	Jun 03, 2031	U-2666			
		10478439	Jun 03, 2031	U-2970			
		10478439	Jun 03, 2031	U-3422			
		10478439	Jun 03, 2031	U-3842			
		10478439	Jun 03, 2031	U-3843			
		10478439	Jun 03, 2031	U-3844			
		10478439	Jun 03, 2031	U-3845			
		10478439*PED	Dec 03, 2031				
		10695350	Oct 24, 2034	U-2970			
		10751342	Jun 03, 2031	U-2666			
		10751342	Jun 03, 2031	U-3842			
		10751342	Jun 03, 2031	U-3843			
		10751342	Jun 03, 2031	U-3844			
		11672803	Jun 03, 2031	U-2666			
		11672803	Jun 03, 2031	U-3842			
		11672803	Jun 03, 2031	U-3843			
		11672803	Jun 03, 2031	U-3844			
		8476284	Dec 28, 2026	U-3843			
		8476284	Dec 28, 2026	U-3844			
		8476284	Dec 28, 2026	U-3845			
		8497277	Dec 28, 2026	U-2666			
		8497277	Dec 28, 2026	U-2970			
		8497277	Dec 28, 2026	U-3422			
		8497277	Dec 28, 2026	U-3842			
		8497277	Dec 28, 2026	U-3843			
		8497277	Dec 28, 2026	U-3844			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933 001					NP ODE-465	Feb 13, 2027 Feb 13, 2031

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2024	U-3956			
	9388416	Sep 09, 2024	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2024	U-3956			
	9388416	Sep 09, 2024	U-3956			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11850245	Apr 30, 2030		U-1455		
	11850245	Apr 30, 2030		U-172		
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883 001					CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	10093663	Jul 14, 2034		U-3980	I-949	Aug 07, 2027
	11723901	Aug 30, 2038		U-3980	NCE	Dec 05, 2028
	11951101	Jul 15, 2041		U-3895	ODE-456	Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11344552	Aug 19, 2036		U-3824	I-932	Feb 13, 2027
	12059497	Oct 15, 2036	DP		ODE-463	Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					NPP	Dec 08, 2026
					ODE-453	Dec 08, 2030
					ODE-459	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051 001					>A> PC	Jan 11, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051 002					>A> PC	Jan 11, 2025
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11951212	Apr 14, 2035	DP	U-3894		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	>A> 12065432	Dec 04, 2028		U-3984		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	>A> 12065432	Dec 04, 2028	U-3984			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	>A> 12065432	Dec 04, 2028	U-3983			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	>A> 12065432	Dec 04, 2028	U-3983			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	>A> 12065432	Dec 04, 2028	U-3983			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11986554	Apr 21, 2036	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	>A> 12071423	Jul 06, 2040	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	>A> 12071423	Jul 06, 2040	DP			
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11020385	Mar 14, 2034	U-1524			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	>A> 11453656	Apr 18, 2038	DS DP		>A> NCE	Aug 19, 2029
	>A> 11850248	Aug 01, 2041	U-3985			
	>A> 11879013	May 21, 2040	U-3985			
	>A> 11981659	Apr 18, 2038	U-3985			
	>A> 9593098	Oct 13, 2035	DS DP U-3985			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	>A> 11453656	Apr 18, 2038	DS DP		>A> NCE	Aug 19, 2029
	>A> 11850248	Aug 01, 2041		U-3985		
	>A> 11879013	May 21, 2040		U-3985		
	>A> 11981659	Apr 18, 2038		U-3985		
	>A> 9593098	Oct 13, 2035	DS DP	U-3985		
<u>LEMBorexant - DAYVIGO</u>						
N 212028 001	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LEMBorexant - DAYVIGO</u>						
N 212028 002	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	11944611	Jun 04, 2041		U-3507		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	11944611	Jun 04, 2041	DS DP	U-3507		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	>A> 12083112	Mar 03, 2036		U-3996		
	>A> 12083112	Mar 03, 2036		U-3997		
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	>A> 12083112	Mar 03, 2036		U-3996		
	>A> 12083112	Mar 03, 2036		U-3997		
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP		>A> NPP	Aug 30, 2027
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP		>A> NPP	Aug 30, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP		>A> NPP	Aug 30, 2027
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP		>A> NPP	Aug 30, 2027
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 001	>A> RE46791	Jan 18, 2029	DS DP		>A> NP >A> ODE* >A> ODE*	Aug 30, 2027 Nov 08, 2024 Jun 05, 2030
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 002	>A> RE46791	Jan 18, 2029	DS DP		>A> NP >A> ODE* >A> ODE*	Aug 30, 2027 Nov 08, 2024 Jun 05, 2030
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	>A> 12064434	Apr 14, 2036	DP		>A> I-951	Sep 17, 2027
	>A> 8962630	Dec 09, 2029	U-2505			
	>A> 8962630	Dec 09, 2029	U-3264			
	>A> 8962630	Dec 09, 2029	U-3998			
	>A> 9416136	Aug 20, 2029	U-2505			
	>A> 9416136	Aug 20, 2029	U-3264			
	>A> 9416136	Aug 20, 2029	U-3998			
	>A> 9868739	Nov 09, 2031	U-2505			
	>A> 9868739	Nov 09, 2031	U-3264			
	>A> 9868739	Nov 09, 2031	U-3998			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	>A> 9617303	Mar 22, 2028	U-4001			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEVACETYLLUCINE - AONEURSA</u>						
N 219132 001					>A> NCE	Sep 24, 2029
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040	U-3821			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	12004992	Oct 06, 2033	DS			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LOFEXIDINE HYDROCHLORIDE - LOFEXIDINE HYDROCHLORIDE</u>						
A 218613 001					CGT	Feb 24, 2025
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	>A> 7838531	Jul 26, 2025	U-3070			
	>A> 8828356	Oct 17, 2025	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	>A> 7838531	Jul 26, 2025	U-3070			
	>A> 8828356	Oct 17, 2025	U-3070			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11980617	Oct 27, 2039	U-3940			
	12070459	Aug 30, 2039	DP U-3362			
	12070459	Aug 30, 2039	DP U-3363			
	>A> 12090155	Jul 07, 2040	DP U-4000			
	8598119	Dec 28, 2029	U-543	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11980617	Oct 27, 2039	U-3940			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11980617	Oct 27, 2039	U-3940			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP		ODE-479	Apr 23, 2031
	10596278*PED	Jan 25, 2039			PED	Jul 26, 2025
	11904027	Jul 25, 2038	DP		PED	Oct 23, 2027
	11904027*PED	Jan 25, 2039			PED	Oct 23, 2031
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-3290		ODE-471	Mar 13, 2031
	11229647	Feb 12, 2040	U-3974			
	11229661	Oct 26, 2032	U-3850			
	11260053	May 26, 2031	U-3290			
	11260053	May 26, 2031	U-3974			
	11376251	Oct 26, 2032	U-3290			
	11376251	Oct 26, 2032	U-3974			
	11497745	Feb 12, 2040	U-3290			
	11497745	Feb 12, 2040	U-3974			
	11918578	Feb 12, 2040	U-3290			
	11918578	Feb 12, 2040	U-3974			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 002	10512657	Oct 26, 2032	U-3973		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-3973		>A> ODE*	Sep 29, 2028
					>A> ODE*	Mar 13, 2030
					>A> ODE*	Mar 13, 2031
					>A> ODE-490	Jul 24, 2031
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	RE50050	Jun 19, 2034	DS DP			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	11969435	Jun 19, 2037	U-1643			
	>A> 12097210	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS	U-2371		
	12042488	May 30, 2038	DS			
	12042489	May 30, 2038	DS	U-2371		
	12042490	May 30, 2038		U-2371		
	RE48608	Oct 20, 2031		U-2371		
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	12059409	Sep 28, 2029	DP			
	>A> 12097189	Sep 28, 2029		U-2996		
	>A> 12097189	Sep 28, 2029		U-3670		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	12059409	Sep 28, 2029	DP			
	>A> 12097189	Sep 28, 2029		U-2996		
	>A> 12097189	Sep 28, 2029		U-3670		
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	11963962	Dec 02, 2040	U-3928			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001 >A>	12064442	Sep 04, 2034	U-3297			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
	>A> 12097284	Aug 16, 2039	DP			
	>A> 12097285	Aug 16, 2039	DP U-1752			
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 001				>A> CGT		Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 002				>A> CGT		Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 001				>A> CGT		Mar 24, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 002				>A> CGT		Mar 24, 2025
<u>NALMEFENE HYDROCHLORIDE - ZURNAI (AUTOINJECTOR)</u>						
N 218590 001	10279131	Jul 31, 2031	DP	>A> NP		Aug 07, 2027
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	11185642	Aug 28, 2031	DP			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11813435	Feb 25, 2035	DP			
	11857547	Nov 05, 2039	DP			
	11865112	Nov 05, 2039	DP U-3630			
	8021335	Oct 04, 2026	DP			
	8496619	Aug 21, 2031	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9364610	Aug 21, 2031	DP			
	9364611	Aug 21, 2031	DP			
	9446195	Aug 21, 2031	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001					NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001					NP	Apr 19, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11020385	Mar 14, 2034	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	12042494	Nov 18, 2030	DP U-3522			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	11931377	Jun 03, 2029	DS DP U-3903			
	11931377*PED	Dec 03, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	11931377	Jun 03, 2029	DS DP U-3903			
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 001 >A>	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 002 >A>	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 003 >A>	12097170	Mar 08, 2041	DP U-3995			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	12013403	Mar 04, 2036	U-1941			
	12013403	Mar 04, 2036	U-1942			
	12013403	Mar 04, 2036	U-1943			
	12013403	Mar 04, 2036	U-1944			
	12013403	Mar 04, 2036	U-2093			
	12013403	Mar 04, 2036	U-2094			
	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784		ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
	11986529	Sep 17, 2029	U-2857			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS U-2986			
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001					NPP	Apr 24, 2027
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12053463	May 16, 2039	DS DP			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
	12042539	Jul 16, 2039	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534	001				M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535	001				M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535	002				M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194	001				M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777	004	>A> 10314788	Aug 12, 2028	DP		
		>A> 7955619	Aug 12, 2028	DP		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	001	10239846	Nov 15, 2030		U-3740	
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	002	10239846	Nov 15, 2030		U-3740	
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899	003	10239846	Nov 15, 2030		U-3740	
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352	001	11666573	Sep 24, 2039		U-3968	
		11666573	Sep 24, 2039		U-3969	
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352	002	11666573	Sep 24, 2039		U-3968	
		11666573	Sep 24, 2039		U-3969	
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352	003	11666573	Sep 24, 2039		U-3968	
		11666573	Sep 24, 2039		U-3969	
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352	004	11666573	Sep 24, 2039		U-3968	
		11666573	Sep 24, 2039		U-3969	
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352	005	11666573	Sep 24, 2039		U-3968	
		11666573	Sep 24, 2039		U-3969	
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352	006	11666573	Sep 24, 2039		U-3968	
		11666573	Sep 24, 2039		U-3969	
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490	001	>A> 11590207	Sep 28, 2037		U-3982	
		>A> 11759504	Sep 28, 2037	DP		>A> NP
		>A> 11857603	Sep 28, 2037		U-3982	ODE-492
		>A> 11890326	Sep 28, 2037	DS DP		
		>A> 11918628	Sep 28, 2037	DS DP		
		>A> 8906847	Apr 30, 2031	DS DP	U-3982	
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490	002	>A> 11590207	Sep 28, 2037		U-3982	
		>A> 11759504	Sep 28, 2037	DP		>A> NP
		>A> 11857603	Sep 28, 2037		U-3982	ODE-492
		>A> 11890326	Sep 28, 2037	DS DP		
		>A> 11918628	Sep 28, 2037	DS DP		
		>A> 8906847	Apr 30, 2031	DS DP	U-3982	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	>A> 11590207	Sep 28, 2037	U-3982		>A> NP	Aug 09, 2027
	>A> 11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	>A> 11857603	Sep 28, 2037	U-3982			
	>A> 11890326	Sep 28, 2037	DS DP			
	>A> 11918628	Sep 28, 2037	DS DP			
	>A> 8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	>A> 11590207	Sep 28, 2037	U-3982		>A> NP	Aug 09, 2027
	>A> 11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	>A> 11857603	Sep 28, 2037	U-3982			
	>A> 11890326	Sep 28, 2037	DS DP			
	>A> 11918628	Sep 28, 2037	DS DP			
	>A> 8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12023312	Aug 31, 2031	U-3966			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001					>A> NPP	Aug 12, 2027
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001					M-270	Jan 13, 2026
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	10285759	Dec 08, 2031	U-3890		NCE	Apr 17, 2029
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	11400077	Oct 25, 2039	U-3804			
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031	U-3685			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PILOCARPINE HYDROCHLORIDE - QLOSI</u>						
N 217836 001	11974986	Aug 18, 2037	U-3741			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRTOBRUTINIB - JAYPIRCA</u> N 216059 001					ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u> N 216059 002					ODE-451	Dec 01, 2030
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u> N 211150 001					NPP ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u> N 211150 002					NPP ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u> N 213498 001	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 002	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 003	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 004	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 005	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 006	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 007	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 008	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 009	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 010	11951097	Oct 10, 2042	U-3891			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192	Apr 03, 2039	U-2952			
	11963958	Apr 03, 2039	U-2828			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001 >A>	12097198	Sep 29, 2037	U-3020			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3835			
	11975012	May 28, 2041	U-3836			
	11975012*PED	Nov 28, 2041				
	11975017	Jul 10, 2038	DP			
	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3833			
	11903953	May 28, 2041	U-3834			
	11903953*PED	Nov 28, 2041				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMEDESIVIR - VEKLURY</u>						
N 214787 002	11975012	May 28, 2041	U-3833			
	11975012	May 28, 2041	U-3834			
	11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	11452725	Jul 24, 2036	U-3755		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3961		ODE-455	Nov 15, 2030
					ODE-483	Jun 13, 2031
					ODE-488	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	10294242	Jul 05, 2036	DS		NCE	Nov 15, 2028
	11452725	Jul 24, 2036		U-3755	ODE*	Nov 15, 2030
	11452725	Jul 24, 2036		U-3961	ODE-488	Jun 13, 2031
	9714258	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033		U-3861	NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP	U-3861		
	11986481	Sep 17, 2033		U-3861		
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033		U-3861	NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP	U-3861		
	11986481	Sep 17, 2033		U-3861		
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033		U-3861	NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP	U-3861		
	11986481	Sep 17, 2033		U-3861		
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12048692	Aug 29, 2039		U-2440		
	7288657	Oct 31, 2028	DS			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	>A> 12064434	Apr 14, 2036	DP		>A> I-950	Sep 17, 2027
	>A> 8962630	Dec 09, 2029		U-1981		
	>A> 8962630	Dec 09, 2029		U-2355		
	>A> 8962630	Dec 09, 2029		U-2356		
	>A> 8962630	Dec 09, 2029		U-3265		
	>A> 8962630	Dec 09, 2029		U-3266		
	>A> 8962630	Dec 09, 2029		U-3975		
	>A> 8962630	Dec 09, 2029		U-3999		
	>A> 9416136	Aug 20, 2029		U-1981		
	>A> 9416136	Aug 20, 2029		U-2355		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	>A> 9416136	Aug 20, 2029	U-2356			
	>A> 9416136	Aug 20, 2029	U-3265			
	>A> 9416136	Aug 20, 2029	U-3266			
	>A> 9416136	Aug 20, 2029	U-3975			
	>A> 9416136	Aug 20, 2029	U-3999			
	>A> 9868739	Nov 09, 2031	U-1981			
	>A> 9868739	Nov 09, 2031	U-2355			
	>A> 9868739	Nov 09, 2031	U-2356			
	>A> 9868739	Nov 09, 2031	U-3265			
	>A> 9868739	Nov 09, 2031	U-3266			
	>A> 9868739	Nov 09, 2031	U-3975			
	>A> 9868739	Nov 09, 2031	U-3999			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879	Apr 21, 2025	DS DP U-3874			
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037	DP			
	7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			
	11969415	Dec 30, 2040	U-3219			
	12023325	Aug 12, 2040	U-3960			
	12023326	Aug 12, 2040	U-3959			
	12023327	Aug 12, 2040	U-3958			
	12023328	Dec 30, 2040	U-3957			
	12059410	Aug 12, 2040	U-3153			
	12059411	Aug 12, 2040	U-3971			
	12064422	Dec 30, 2040	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RITILECITINIB TOSYLATE - LITFULO</u>						
N 215830 001 >A>	12077533	Dec 03, 2034	U-3994			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	11992480	Jun 07, 2037	U-3748			
	12005051	Jun 07, 2037	U-3748			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	10940142	Jun 07, 2037	DP		NS	Jul 09, 2027
	11129818	Aug 25, 2037	U-3970			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3970			
	11992480	Jun 07, 2037	U-3970			
	12005051	Jun 07, 2037	U-3970			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3970			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11992480	Jun 07, 2037	U-3773		NP	Dec 15, 2026
	12005051	Jun 07, 2037	U-3773			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	10272058	Mar 19, 2035	U-1854		NCE	Aug 14, 2029
	11406611	Mar 19, 2035	U-1854		>A> ODE-486	Aug 14, 2031
	11596614	Mar 19, 2035	U-1854			
	7301050	Aug 02, 2025	DS DP			
	7709682	Sep 13, 2026	DS			
	9486428	Mar 19, 2035	U-1854			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	10272058	Mar 19, 2035	U-1854		NCE	Aug 14, 2029
	11406611	Mar 19, 2035	U-1854		>A> ODE-486	Aug 14, 2031
	11596614	Mar 19, 2035	U-1854			
	7301050	Aug 02, 2025	DS DP			
	7709682	Sep 13, 2026	DS			
	9486428	Mar 19, 2035	U-1854			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	11998565	Jul 01, 2041	DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10137124	Oct 10, 2037	U-2826		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-2827		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-2828		ODE-485	May 29, 2031
	10137124	Oct 10, 2037	U-3450		ODE-487	May 29, 2031
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10584124	Oct 10, 2038	DS U-3949			
	10584124	Oct 10, 2038	DS U-3950			
	10584124	Oct 10, 2038	DS U-3951			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
	10786489	Oct 10, 2038	DP U-3949			
	10786489	Oct 10, 2038	DP U-3950			
	10786489	Oct 10, 2038	DP U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10137124	Oct 10, 2037	U-2826		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-2827		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-2828		ODE-485	May 29, 2031
	10137124	Oct 10, 2037	U-3450		ODE-487	May 29, 2031



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12029779	Oct 10, 2038	U-3162		I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12005062	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Jul 24, 2036	U-3889			
	>A> 12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
	>A> 12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Jul 24, 2036	U-3889			
	>A> 12071402	Jan 05, 2032	DP			
<u>SIROLIMUS - FYARRO</u>						
N 213312 001	12061183	Mar 05, 2036	DP			
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920 001					CGT	Nov 16, 2024



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	11986446	Mar 15, 2033	U-3324			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11964018	Jul 01, 2039	U-3898			
	11992530	Jul 01, 2039	U-3948			
	11998604	Jul 01, 2039	U-3952			
<u>SOFPIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	>A> 11566000	May 22, 2040	DS DP		NCE	Jun 20, 2029
	>A> 11584715	May 22, 2040	DS DP			
	>A> 8147809	Mar 26, 2027	DS DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	>A> 12090126	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	>A> 12090126	Dec 30, 2042	U-3693			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE*	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	11827635	May 20, 2040	DS DP U-3306			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	>A> 9993461	Mar 29, 2030	U-3269		>A> ODE-493	Sep 05, 2031
	>A> 9993461	Mar 29, 2030	U-3993			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	>A> 9993461	Mar 29, 2030	U-3269		>A> ODE-493	Sep 05, 2031
	>A> 9993461	Mar 29, 2030	U-3993			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	12033733	Mar 16, 2030	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	11980623	May 29, 2033	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	>A> 12083103	May 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	>A> 12083103	May 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	>A> 12083103	May 30, 2028	U-2678			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11975006	Dec 24, 2038	DP U-3397			
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	>A> 7214695	Dec 19, 2025	DS DP			
	>A> 7214696	Dec 19, 2025	U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	>A> 7214695	Dec 19, 2025	DS DP			
	>A> 7214696	Dec 19, 2025	U-2524			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 203794 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Apr 07, 2033	U-3342			
	11918556	Apr 07, 2033	U-3343			
	11918557	Jan 25, 2033	U-3003			
	11918557	Jan 25, 2033	U-3865			
	12049457	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			
	11918557	Jan 25, 2033	U-3003			
	12049457	Feb 12, 2035	DS DP			
<u>TAZAROTENE - TAZAROTENE</u>						
A 217075 001					>A> CGT	Mar 08, 2025
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12016856	Dec 30, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12016856	Dec 30, 2029	DS DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TERAZOSIN HYDROCHLORIDE - TEZRULY</u>						
N 218139 001	>A> 11224572	Jan 18, 2042	DP U-3990			
	>A> 11224572	Jan 18, 2042	DP U-3991			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12011503	Oct 16, 2040	DP U-3964			
	12011503	Oct 16, 2040	DP U-3965			
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 215312 001				>A> CGT		Mar 26, 2025
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	11975013	Aug 16, 2041	DP			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001					D-192	Jun 07, 2027
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039	U-3855			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	7378423*PED	Nov 29, 2027			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP	U-3564	PED	Sep 16, 2026
	8703781*PED	Apr 15, 2031			PED	Sep 16, 2030
	8835443	Jun 10, 2025		U-3564		
	8835443*PED	Dec 10, 2025				
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 006	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 007	>A> 9604901	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 008	>A> 9604901	Dec 15, 2028	DS		Y	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042	U-3749			
	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 001	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 002	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 003	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 004	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	>A> 9604901	Dec 15, 2028	DS	Y		
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11040042	Oct 25, 2031	DP			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11827600	Jul 12, 2042	DS DP U-3556			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	12048698	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	12048698	Apr 27, 2038	U-3783			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	12048698	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	11925709	Jan 30, 2035	DP			
	>A> 12070450	Dec 22, 2041	U-3992			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11365198	Oct 17, 2036	U-3275		I-946	Apr 26, 2027
	11365198	Oct 17, 2036	U-3946		NPP	Apr 26, 2027
	11512092	Oct 17, 2036	U-3275		ODE-481	Apr 26, 2031
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	11512092	Oct 17, 2036	U-3946			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11773106	Oct 17, 2036	U-3946			
	11976077	Oct 17, 2036	U-3298			
	11993605	Oct 17, 2036	U-3275			
	11993605	Oct 17, 2036	U-3946			
	11993606	Oct 17, 2036	U-3487			
	>A> 12077545	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	>A> 12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
	RE47221	Aug 16, 2033	DS		NPP	Apr 26, 2027
					ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	>A> 12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
	RE47221	Aug 16, 2033	DS		NPP	Apr 26, 2027
					ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO LO</u>						
N 218347 001	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	11439629	Oct 10, 2037				
	11654142	Nov 14, 2038				
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027			U-1995	
	8357697	Nov 08, 2027			U-3055	
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10065952	Oct 28, 2036	DS DP		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP			
	10844058	Oct 28, 2036	DS DP			
	10844058	Oct 28, 2036	DS DP			
	10851103	Oct 28, 2036	DS DP			
	10851103	Oct 28, 2036	DS DP			
	10851104	Oct 28, 2036	DS		U-1995	
	10851104	Oct 28, 2036	DS		U-3055	
	10857137	Oct 10, 2037			U-1995	
	10857148	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-3046	
	10874648	Oct 10, 2037			U-3055	
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037			U-1995	
	10912771	Oct 10, 2037			U-3055	
	10912771	Oct 10, 2037			U-3076	
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040			U-1995	
	10952997	Oct 10, 2037			U-1995	
	10993941	Oct 10, 2037			U-1995	
	11026931	Aug 14, 2039			U-1995	
	11026939	Sep 18, 2038	DP		U-1995	
	11026939	Sep 18, 2038	DP		U-3055	
	11040029	Oct 10, 2037			U-1995	
	11311532	Sep 18, 2038	DP		U-1995	
	11311532	Sep 18, 2038	DP		U-3055	
	11439629	Oct 10, 2037			U-3055	
	11654142	Nov 14, 2038			U-3055	
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027			U-1995	
	8357697	Nov 08, 2027			U-3055	
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10065952	Oct 28, 2036	DS DP		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP			
	10844058	Oct 28, 2036	DS DP			
	10844058	Oct 28, 2036	DS DP			
	10851103	Oct 28, 2036	DS DP			
	10851103	Oct 28, 2036	DS DP			
	10851104	Oct 28, 2036	DS		U-1995	
	10851104	Oct 28, 2036	DS		U-3055	
	10857137	Oct 10, 2037			U-1995	
	10857148	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-1995	
	10874648	Oct 10, 2037			U-3046	
	10874648	Oct 10, 2037			U-3055	
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037			U-1995	
	10912771	Oct 10, 2037			U-3055	
	10912771	Oct 10, 2037			U-3076	
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040			U-1995	
	10952997	Oct 10, 2037			U-1995	
	10993941	Oct 10, 2037			U-1995	
	11026931	Aug 14, 2039			U-1995	
	11026939	Sep 18, 2038	DP		U-1995	
	11026939	Sep 18, 2038	DP		U-3055	
	11040029	Oct 10, 2037			U-1995	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001 >A>	12102638	Mar 22, 2040	U-3045			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12016857	Aug 16, 2039	DP			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001 >A>	7332472	Oct 17, 2025	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					I-948	Jul 17, 2027
<u>VORASIDENIB - VORANIGO</u>						
N 218784 001	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VORASIDENIB - VORANIGO</u>						
N 218784 002	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001	12049628	Jul 28, 2036	DS DP U-3396			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	11965040	Jun 12, 2035	DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)